hydroxychloroquine has been researched along with Lupus Erythematosus, Systemic in 1003 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 9.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 9.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| "We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety." | 9.09 | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. ( Albuquerque, EM; Cataldo, MJ; Duarte, JL; Jesús, NR; Levy, RA; Ramos, RC; Tura, BR; Vilela, VS, 2001) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 9.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 8.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "This review examines the pharmacokinetics, modes of action and therapeutic properties of the anti-malarial drugs, hydroxychloroquine (HCQ) and chloroquine (CQ), in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and related conditions, as well as osteoarthritis (OA)." | 8.91 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. ( Clifford-Rashotte, M; Kean, WF; Parke, AL; Rainsford, KD, 2015) |
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 8.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "We assessed the association between hydroxychloroquine (HCQ) initiation and risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident systemic lupus erythematosus (SLE)." | 8.31 | Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study. ( Aviña-Zubieta, JA; Daftarian, N; Esdaile, JM; Hoque, MR; Lu, L; Xie, H, 2023) |
| "Hydroxychloroquine combined with low-dose aspirin can effectively improve the pregnancy outcomes of pregnant women with SLE by affecting the levels of T helper (Th) 2 and Th1 cytokines." | 8.31 | Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. ( Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 8.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "Hydroxychloroquine (HCQ) is used in the treatment of inflammatory rheumatic diseases and is considered a safe drug." | 8.31 | Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study. ( Costa, L; Macedo, F; Madureira, P; Martins Carvalho, M; Pinheiro, FO; Seabra Rato, M, 2023) |
| "Hydroxychloroquine (HCQ) therapy decreased immunoglobulin (Ig) levels in patients with Sjögren syndrome (SS) and rheumatoid arthritis (RA) in previous studies." | 8.12 | Hydroxychloroquine Therapy and Serum Immunoglobulin Levels in Women with IgG Subclass Deficiency and Systemic Lupus Erythematosus, Sjögren Syndrome, and Rheumatoid Arthritis: A Retrospective Study. ( Barton, JC; Bertoli, LF, 2022) |
| "To study the relationship between hydroxychloroquine (HCQ) use and new-onset atrial fibrillation in patients with systemic lupus erythematosus (SLE)." | 8.02 | Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus. ( Gupta, A; Manzi, S; Sharma, TS; Shields, KJ; Wasko, MC, 2021) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 8.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| " A conditional logistic regression model was used to analyse differences in the risk of arrhythmia between systemic lupus erythematosus patients with and without hydroxychloroquine treatment after controlling for related variables." | 8.02 | Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 7.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| "Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss." | 7.85 | The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. ( Ahn, SJ; Hong, EH; Lee, BR; Lim, HW, 2017) |
| "To compare the retinal toxicity due to hydroxychloroquine (HCQ) use in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) using multifocal electroretinography (mfERG), fundus autofluorescence (FAF) and optical coherence tomography (OCT)." | 7.85 | Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis. ( Ornek, F; Ozdemir, Y; Sungur, G; Telek, HH; Yesil, NK; Yesilirmak, N, 2017) |
| "Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated." | 7.85 | [Hydroxychloroquine-induced hearing loss: First case of positive rechallenge and analysis of the French pharmacovigilance database]. ( Auffret, M; Bondon-Guitton, E; Chatelet, JN; Combret, S; Gautier, S; Lambert, M, 2017) |
| "This observational, retrospective, single-center cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibodies who were treated with hydroxychloroquine in addition to conventional treatment during pregnancy." | 7.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 7.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| " This study aimed to estimate the rate of false positive proteinuria with the dipstick in patients with systemic lupus erythematosus (SLE) taking hydroxychloroquine." | 7.81 | Confirmed False Positive Proteinuria in Patients with Systemic Lupus Erythematosus Taking Hydroxychloroquine: a Spot Sample Measurement. ( Huang, WC; Lee, CH; Li, JY; Wang, JM; Wen, CY; Wu, MF; Yang, CY, 2015) |
| " We report the case of a male patient with SLE who presented with an exacerbation of bipolar disorder triggered by chloroquine." | 7.80 | Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report. ( Bienkowski, P; Bogaczewicz, A; Bogaczewicz, J; Robak, E; Sobów, T; Sysa-Jedrzejowska, A; Wozniacka, A, 2014) |
| " We report a case of old-onset lupus peritonitis treated successfully by Hydroxychloroquine." | 7.80 | Successful treatment of massive ascites due to lupus peritonitis with hydroxychloroquine in old- onset lupus erythematosus. ( Bdioui, F; Hammami, S; Loghmari, H; Mahjoub, S; Ouaz, A; Saffar, H, 2014) |
| "To evaluate pregnancy safety of hydroxychloroquine (HCQ) for rheumatologic diseases." | 7.79 | Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. ( Blyakhman, S; Diav-Citrin, O; Ornoy, A; Shechtman, S, 2013) |
| "Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus and rheumatoid arthritis treatment for many years." | 7.79 | Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. ( Dantas, AT; Duarte, AL; Galdino, SL; Mariz, HA; Oliveira, PS; Pitta, Ida R; Pitta, MG; Rocha, LF; Silva, JC, 2013) |
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 7.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| " We examined medical records of patients with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA(1c) after starting HCQ or methotrexate (MTX)." | 7.76 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. ( Bhatia, R; Garg, R; Gleeson, T; Lu, B; Massarotti, E; Rekedal, LR; Solomon, DH, 2010) |
| "Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients." | 7.76 | [Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. ( Ankri, A; Darnige, L; Fischer, AM; Szymezak, J, 2010) |
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 7.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| "The antimalarial agents chloroquine (CQ) and hydroxychloroquine (HCQ) are used in long-term treatment of connective tissue diseases (CTDs)." | 7.74 | Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. ( Amoura, Z; Costedoat-Chalumeau, N; Funck-Brentano, C; Hulot, JS; Lechat, P; Leroux, G; Piette, JC, 2007) |
| "To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ)." | 7.69 | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. ( Buchanan, NM; Hughes, GR; Kerslake, S; Khamashta, MA; Lima, F; Toubi, E, 1996) |
| "Hydroxychloroquine is used for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)." | 7.68 | Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. ( Littlejohn, GO; McCloud, PI; Morand, EF, 1992) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 7.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE)." | 7.30 | Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. ( Abdelnabi, HH; Dawoud, HE; El-Shahaby, WA; Elrifaey, SM; Gheet, FS, 2023) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 6.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality." | 6.58 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. ( Bortoluzzi, A; Cauli, A; Erre, GL; Floris, A; Mangoni, AA; Piga, M, 2018) |
| "Hydroxychloroquine treatment appears to be safe in this setting." | 6.48 | The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. ( Amoura, Z; Benveniste, O; Cacoub, P; Chapelon, C; Costedoat-Chalumeau, N; De Gennes, C; Eymard, B; Haroche, J; Jallouli, M; Le Thi Huong, D; Leroux, G; Piette, JC; Saadoun, D; Wechsler, B, 2012) |
| "Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus." | 6.47 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. ( Petri, M, 2011) |
| " Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy." | 6.47 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. ( Abarientos, C; Aronow, WS; Ash, JY; Chao, CP; Shapiro, DL; Sperber, K, 2011) |
| " HCQ is generally safe and may be prescribed to pregnant women." | 5.91 | Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Kaneko, K; Murashima, A; Sago, H; Tanaka, R; Tsurane, K; Yoshida, K, 2023) |
| "Hydroxychloroquine (HCQ) has been used during the coronavirus disease 2019 (COVID-19) pandemic because of its reported anti-viral activity." | 5.72 | Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. ( Al Maimouni, HM; Al-Najjar, AH; Alajra, RK; Alali, AS; Alanazi, DS; Albadi, MA; Albarqi, HA; Alghanim, NS; Alkahtani, SA; Alqahtani, F; Alqhtani, H; Alsaweed, OS; Alshabi, AM; Hazzazi, MA; Sabei, AA; Walbi, IA, 2022) |
| "Hydroxychloroquine (HQ) is an antimalarial drug that is widely used in many autoimmune rheumatic diseases, mainly in systemic lupus erythematosus (SLE)." | 5.72 | A case of palmoplantar pustular psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Akkuzu, G; Bes, C; Karaalioğlu, B; Mutlu, MY; Özgür, DS; Yıldırım, F, 2022) |
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 5.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| "03 per 100000 person-month for high and low dosage respectively." | 5.62 | Hydroxychloroquine might reduce risk of incident endometriosis in patients with systemic lupus erythematosus: A retrospective population-based cohort study. ( Chen, FY; Chen, SW; Chen, X; Huang, JY; Wei, JC; Ye, Z, 2021) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 5.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| "Hydroxychloroquine is an antimalarial agent, most commonly prescribed in the treatment of several rheumatic diseases." | 5.51 | Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. ( Cai, L; Liu, X; Zhang, J; Zhang, S; Zhou, C, 2019) |
| "Hydroxychloroquine (HCQ) has been used to treat systemic lupus erythematosus (SLE) in Japan since 2015." | 5.51 | A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Hashimoto, Y; Kawazoe, M; Kusunoki, N; Nanki, T; Shikano, K; Shindo, E; Yamamoto, T, 2019) |
| "Admission Systemic Lupus Erythematosus Disease Activity Index scores (30 vs." | 5.48 | Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( Cohen, EM; Costenbader, KH; D'Silva, K; Kreps, D; Son, MB, 2018) |
| "However, the effect of HCQ on UC-MSCs in lupus nephritis (LN) has not been investigated." | 5.48 | Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice. ( Chen, Q; Han, X; Kuang, S; Liao, X; Luan, Y; Ma, J; Mai, S; Tian, X; Wei, Y; Wu, Y; Yang, J; Yang, Y; Zou, L, 2018) |
| "The hydroxychloroquine was indicated for systemic lupus erythematosus in 73." | 5.46 | Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. ( Bahloul, E; Bahloul, Z; Garbaa, S; Jallouli, M; Marzouk, S; Masmoudi, A; Turki, H, 2017) |
| " The HCQ group showed a trend towards lower dosage of prednisone (OR 0." | 5.46 | Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. ( de Hair, MJH; Derksen, RHWM; Fritsch-Stork, RDE; Kroese, SJ; Lely, AT; Limper, M; van Laar, JM, 2017) |
| " Hydroxychloroquine (HCQ) is an immunomodulator used to treat rheumatoid arthritis and systemic lupus erythematosus." | 5.41 | Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial. ( Boll, L; Cadaval Gonçalves, S; Cortes, A; Eibel, B; Irigoyen, MC; Martinez, D; Rossi, B; Tedesco Silva, LM; Waclawovsky, G, 2021) |
| "Here we report a case of a 22-year-old systemic lupus erythematosus (SLE) patient with three years' disease duration, stable on prednisone and hydroxychloroquine, who was found to have prolactinoma and recurrent GM after she discontinued medication on her own accord." | 5.40 | An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine. ( Shi, TY; Yang, YJ; Zhang, FC; Zhang, LN, 2014) |
| "Hydroxychloroquine (HCQ) is a valuable and possibly underused agent in treating mild lupus." | 5.29 | The use of hydroxychloroquine in lupus pregnancy: the British experience. ( Buchanan, NM; Hughes, GR; Khamashta, MA, 1996) |
| "Multiple guidelines recommend continuing hydroxychloroquine (HCQ) for SLE during pregnancy based on observational data." | 5.22 | Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. ( Balevic, S; Bay, C; Clowse, MEB; Eudy, AM; Fischer-Betz, R; Gladman, DD; Kosinski, A; Mokbel, A; Molad, Y; Nalli, C; Petri, M; Sanders-Schmidler, G; Tincani, A; Urowitz, M; van Noord, M, 2022) |
| "Hydroxychloroquine, when used to treat patients with rheumatoid arthritis or systemic lupus erythematosus, has been found to reduce cardiovascular disease (CVD)." | 5.22 | The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases. ( Porter, M; Weidman-Evans, E, 2022) |
| " Despite these challenges, belimumab, voclosporin, and anifromulab, approved by the United States Food and Drug Administration (FDA) to treat SLE or lupus nephritis (LN), enhanced our armamentarium of traditional therapies, such as hydroxychloroquine, corticosteroids, and immunosuppressives." | 5.22 | B cell-targeted therapies in systemic lupus erythematosus. ( Arbitman, L; Furie, R; Vashistha, H, 2022) |
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 5.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 5.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| "The use of hydroxychloroquine (HCQ) in pregnancy remains controversial." | 5.10 | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. ( Amoura, Z; Costedoat-Chalumeau, N; Denjoy, I; Duhaut, P; Huong, DL; Lupoglazoff, JM; Piette, JC; Sebbough, D; Vauthier, D; Wechsler, B, 2003) |
| "We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety." | 5.09 | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. ( Albuquerque, EM; Cataldo, MJ; Duarte, JL; Jesús, NR; Levy, RA; Ramos, RC; Tura, BR; Vilela, VS, 2001) |
| ", chloroquine and hydroxychloroquine, in pregnant patients with lupus who continued antimalarial drugs throughout pregnancy." | 5.08 | Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. ( Parke, A; West, B, 1996) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 5.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| "Current research in the field of systemic lupus erythematosus (SLE) and pregnancy focuses on predictors of adverse pregnancy outcomes, the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy and the importance of preconception counselling." | 5.05 | [Pregnancy with lupus erythematosus-an update]. ( Fischer-Betz, R; Haase, I, 2020) |
| "Despite the large burden of infection, effective and safe preventative care such as universal hydroxychloroquine use and vaccination are underutilized." | 5.05 | Systemic lupus erythematosus and risk of infection. ( Barber, MRW; Clarke, AE, 2020) |
| "Hydroxychloroquine (HCQ) is used in the treatment of rheumatologic diseases including systemic lupus erythematosus, rheumatoid arthritis and other conditions." | 5.05 | [Hydroxychloroquine treatment rarely causes eye damage when used correctly]. ( Andersen, J; Bay-Laurberg, T; Clemmensen, K; Deleuran, B; Troldborg, A, 2020) |
| "This review summarizes recent research in the field of systemic lupus erythematosus (SLE) and pregnancy with focus on clinical and biochemical predictors of adverse pregnancy outcomes (APOs), accumulating evidence for the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy, and the importance of preconception counseling." | 5.01 | Update on pregnancy complications in systemic lupus erythematosus. ( Marder, W, 2019) |
| " Hydroxychloroquine (HCQ) appears protective against flares in pregnancy, neonatal congenital heart block and preterm birth." | 5.01 | Systemic lupus erythematosus in pregnancy: high risk, high reward. ( Do, SC; Druzin, ML, 2019) |
| " Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple's disease, fungal infections), rheumatological (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren's syndrome), and other immunological diseases." | 4.98 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. ( Koudriavtseva, T; Plantone, D, 2018) |
| "Despite advances in therapy for rheumatic diseases, hydroxychloroquine remains almost universally recommended for the treatment of systemic lupus erythematosus (SLE), and is often used in the management of other rheumatic diseases such as rheumatoid arthritis (RA)." | 4.98 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. ( Choi, HK; Jorge, A; Melles, RB; Ung, C; Young, LH, 2018) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 4.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "This review examines the pharmacokinetics, modes of action and therapeutic properties of the anti-malarial drugs, hydroxychloroquine (HCQ) and chloroquine (CQ), in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and related conditions, as well as osteoarthritis (OA)." | 4.91 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. ( Clifford-Rashotte, M; Kean, WF; Parke, AL; Rainsford, KD, 2015) |
| " A prospective study found great success in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients with quiet lupus nephritis." | 4.90 | Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. ( Clowse, ME; Peart, E, 2014) |
| "Hydroxychloroquine (HCQ) is a widely used medication for the treatment of rheumatoid arthritis and systemic lupus erythematosus." | 4.89 | Multifaceted effects of hydroxychloroquine in human disease. ( Karp, DR; Olsen, NJ; Schleich, MA, 2013) |
| "The use of Hydroxychloroquine (HCQ) during pregnancy has remained controversial for a long time." | 4.82 | [Pleading to maintain hydroxychloroquine throughout Lupus pregnancies]. ( Amoura, Z; Costedoat-Chalumeau, N; Le Thi Huong, D; Piette, JC; Wechsler, B, 2005) |
| " Treatment of the patient with prednisone, colchicine and hydroxychloroquine led to the improvement of the cutaneous vasculitis and a drop in ESR, serum gamma globulins and IgM and IgG rheumatoid factors." | 4.79 | Hypergammaglobulinemic purpura of Waldenstrom associated with systemic lupus erythematosus: report of a case and review of the literature. ( Habib, GS; Quismorio, FP; Stimmer, MM, 1995) |
| "In the United States, hydroxychloroquine (Plaquenil) is one of the most commonly prescribed medications for mild to moderately severe rheumatoid arthritis." | 4.78 | Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity. ( Aylward, JM, 1993) |
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 4.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "We assessed the association between hydroxychloroquine (HCQ) initiation and risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident systemic lupus erythematosus (SLE)." | 4.31 | Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study. ( Aviña-Zubieta, JA; Daftarian, N; Esdaile, JM; Hoque, MR; Lu, L; Xie, H, 2023) |
| "Hydroxychloroquine combined with low-dose aspirin can effectively improve the pregnancy outcomes of pregnant women with SLE by affecting the levels of T helper (Th) 2 and Th1 cytokines." | 4.31 | Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. ( Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 4.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "Hydroxychloroquine (HCQ) is used in the treatment of inflammatory rheumatic diseases and is considered a safe drug." | 4.31 | Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study. ( Costa, L; Macedo, F; Madureira, P; Martins Carvalho, M; Pinheiro, FO; Seabra Rato, M, 2023) |
| "To investigate the clinical efficacy of plasma exchange (PE) with or without prednisone and hydroxychloroquine (HCQ) for the treatment of systemic lupus erythematosus (SLE) during pregnancy." | 4.31 | Clinical efficacy of plasma exchange in systemic lupus erythematosus during pregnancy. ( Bu, YJ; Cao, JP; Cen, X; Chen, FW; Chen, JW; Cheng, T; Fan, R; Hu, XR; Liu, YQ; Zhang, BY; Zhang, F, 2023) |
| "Evaluate the impact of pregnancy physiology and medication non-adherence on serum hydroxychloroquine (HCQ) pharmacokinetics (PK) and exposure-response in SLE." | 4.12 | Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Gonzalez, D; Hornik, CP; Maharaj, AR; Weiner, D, 2022) |
| "Hydroxychloroquine (HCQ) is an important medication for patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases." | 4.12 | RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study. ( Adante, B; Aviña-Zubieta, JA; Bhui, RD; Bhui, SB; Butler, M; Chui, L; Daftarian, N; Dawes, M; Erasmus, M; Esdaile, J; Etminan, M; Godinho, D; Hay, E; Hoens, A; Hollands, H; Hoonjan, M; Joe, A; Levasseur, SD; Lima, A; Lukaris, A; Maberley, DAL; Mammo, Z; Marozoff, S; Navajas, E; Ojo, D; Pakzad-Vaezi, K; Sanmugasunderam, S; Shojania, K, 2022) |
| "Hydroxychloroquine (HCQ) therapy decreased immunoglobulin (Ig) levels in patients with Sjögren syndrome (SS) and rheumatoid arthritis (RA) in previous studies." | 4.12 | Hydroxychloroquine Therapy and Serum Immunoglobulin Levels in Women with IgG Subclass Deficiency and Systemic Lupus Erythematosus, Sjögren Syndrome, and Rheumatoid Arthritis: A Retrospective Study. ( Barton, JC; Bertoli, LF, 2022) |
| "The aim of this study was to assess whether long-term administration of hydroxychloroquine (HCQ) is protective from influenza in patients with rheumatoid arthritis and systemic lupus erythematosus." | 4.12 | Effect of Hydroxychloroquine on Influenza Prevention. ( Finkelstein, J; Huo, X, 2022) |
| "Hydroxychloroquine (HCQ) is an autophagy inhibitor that has been used for the treatment of many diseases, such as malaria, rheumatoid arthritis, systemic lupus erythematosus, and cancer." | 4.12 | Quantitative Proteomics Explore the Potential Targets and Action Mechanisms of Hydroxychloroquine. ( Chen, K; Hou, W; Huang, H; Jiang, Y; Liu, G; Liu, H; Liu, K; Ren, X; Zhao, J; Zhao, Z, 2022) |
| " The treatment of prednisone plus HCQ may improve implantation rate, biochemical pregnancy rate, and clinical pregnancy rate, and reduce pregnancy loss rate in frozen embryo transfer outcomes for ANA-positive women." | 4.02 | Combined treatment of prednisone and hydroxychloroquine may improve outcomes of frozen embryo transfer in antinuclear antibody-positive patients undergoing IVF/ICSI treatment. ( Cheng, K; Deng, W; Gao, R; Meng, C; Qin, L; Zeng, X, 2021) |
| "To study the relationship between hydroxychloroquine (HCQ) use and new-onset atrial fibrillation in patients with systemic lupus erythematosus (SLE)." | 4.02 | Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus. ( Gupta, A; Manzi, S; Sharma, TS; Shields, KJ; Wasko, MC, 2021) |
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 4.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| " A conditional logistic regression model was used to analyse differences in the risk of arrhythmia between systemic lupus erythematosus patients with and without hydroxychloroquine treatment after controlling for related variables." | 4.02 | Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| "Two patients aged 31 and 42 years were treated with hydroxychloroquine for systemic lupus and Sjogren's syndrome, respectively." | 3.96 | [Drug-induced Sweet's syndrome related to hydroxychloroquine: About 2 cases]. ( Bodard, Q; Carre, D; Chenal, P; Litrowski, N; Midhat, M; Zarnitsky, C, 2020) |
| " Hydroxychloroquine prevented atherosclerosis progression mainly by reversing immune status abnormality caused by SLE." | 3.96 | Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. ( Duan, XW; Liu, T; Niu, H; Shi, N; Silverman, GJ; Zhang, S, 2020) |
| "A 59-year-old man with a history of ischemic-labeled heart disease revealed by conduction disorders and cutaneous lupus treated initially with hydroxychloroquine followed by chloroquine consulted for asthenia and weight loss." | 3.96 | [A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials]. ( Costedoat-Chalumeau, N; Dion, J; Lenfant, T; Maisonobe, T, 2020) |
| " The prolonged use of chloroquine and hydroxychloroquine can cause hyperpigmentation in the skin, oral mucosa and retinal pigment epithelium, which in turn can trigger toxicity in this epithelium, which in some cases causes vision loss." | 3.96 | Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus. ( Chacón-Dulcey, V; Frías, J; González, N; López-Labady, J; Pérez Alfonzo, R; Tirado, W; Villarroel-Dorrego, M, 2020) |
| " To determine pregnancy outcomes in women with systemic lupus erythematosus (SLE) who were treated with hydroxychloroquine in a tertiary center." | 3.96 | New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre. ( Abd Rahman, R; Kamisan Atan, I; Min Tun, K; Mohamed Said, MS; Mustafar, R; Zainuddin, AA, 2020) |
| " Hydroxychloroquine (HCQ) reduces disease activity and flares; however, pregnancy causes significant physiologic changes that may alter HCQ levels and lead to therapeutic failure." | 3.91 | Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 3.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| "Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing." | 3.88 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. ( Aranow, C; Askanase, A; Choi, H; Clarke, AE; Costenbader, KH; Esdaile, JM; Jorge, AM; Lim, SS; Lu, N; Melles, RB; Petri, M; Rai, SK; Ramsey-Goldman, R; Urowitz, MB; Young, LH; Zhang, Y, 2018) |
| "Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss." | 3.85 | The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. ( Ahn, SJ; Hong, EH; Lee, BR; Lim, HW, 2017) |
| "To compare the retinal toxicity due to hydroxychloroquine (HCQ) use in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) using multifocal electroretinography (mfERG), fundus autofluorescence (FAF) and optical coherence tomography (OCT)." | 3.85 | Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis. ( Ornek, F; Ozdemir, Y; Sungur, G; Telek, HH; Yesil, NK; Yesilirmak, N, 2017) |
| "Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated." | 3.85 | [Hydroxychloroquine-induced hearing loss: First case of positive rechallenge and analysis of the French pharmacovigilance database]. ( Auffret, M; Bondon-Guitton, E; Chatelet, JN; Combret, S; Gautier, S; Lambert, M, 2017) |
| "This observational, retrospective, single-center cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibodies who were treated with hydroxychloroquine in addition to conventional treatment during pregnancy." | 3.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| "Steroids and hydroxychloroquine remain the most widely prescribed treatment options in pregnancy, but the use of biologic agents is becoming increasingly common." | 3.83 | Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. ( Bateman, BT; Desai, RJ; Gopalakrishnan, C; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Mogun, H; Patorno, E, 2016) |
| " Univariate and multivariate analysis showed that higher numbers of system or organ involvement in SLE, abdominal obesity, hypertriglyceridemia and daily prednisolone of ≥ 1 mg/kg/day were the important associated factors of SDM (P ≤ 0." | 3.81 | Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort. ( Gafor, AH; Kong, NC; Said, MS; Shaharir, SS, 2015) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 3.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "Optical coherence tomography retinal thickness and 10-2 VFMD are objective measures demonstrating clinically useful sensitivity and specificity for the detection of hydroxychloroquine toxicity as identified by mfERG, and thus may be suitable surrogate tests." | 3.81 | Subjective and objective screening tests for hydroxychloroquine toxicity. ( Cukras, C; Ferris, FL; Huynh, N; Sieving, PA; Vitale, S; Wong, WT, 2015) |
| " This study aimed to estimate the rate of false positive proteinuria with the dipstick in patients with systemic lupus erythematosus (SLE) taking hydroxychloroquine." | 3.81 | Confirmed False Positive Proteinuria in Patients with Systemic Lupus Erythematosus Taking Hydroxychloroquine: a Spot Sample Measurement. ( Huang, WC; Lee, CH; Li, JY; Wang, JM; Wen, CY; Wu, MF; Yang, CY, 2015) |
| " An 8-year-old girl was treated with albendazole therapy for common toxocariasis, but she developed two weeks later, asthenia, fever, infiltrated maculopapular eruption of the face, peripheral vascular disease with necrosis of the fingers and inflammatory anemia with proteinuria." | 3.81 | Toxocara canis infection: Unusual trigger of systemic lupus erythematosus. ( Baudouin, V; Bourrat, E; Deschênes, G; Fila, M; Guillem, C; Levy, M; Peuchmaur, M, 2015) |
| " We report the case of a male patient with SLE who presented with an exacerbation of bipolar disorder triggered by chloroquine." | 3.80 | Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report. ( Bienkowski, P; Bogaczewicz, A; Bogaczewicz, J; Robak, E; Sobów, T; Sysa-Jedrzejowska, A; Wozniacka, A, 2014) |
| "To determine whether patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) taking chloroquine or hydroxychloroquine are regularly visiting eye care providers and being screened for maculopathy." | 3.80 | Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. ( Blachley, TS; Edwards, P; Lee, PP; Nika, M; Stein, JD, 2014) |
| " We report a case of old-onset lupus peritonitis treated successfully by Hydroxychloroquine." | 3.80 | Successful treatment of massive ascites due to lupus peritonitis with hydroxychloroquine in old- onset lupus erythematosus. ( Bdioui, F; Hammami, S; Loghmari, H; Mahjoub, S; Ouaz, A; Saffar, H, 2014) |
| "A 30 year old lady patient of SLE on steroid and hydroxychloroquine therapy presented with lupus nephritis and later developed cardiac symptoms." | 3.79 | Hydroxychloroquine-induced phospholipidosis in a case of SLE: the wolf in zebra clothing. ( Bichle, LS; Khubchandani, SR, 2013) |
| "To evaluate pregnancy safety of hydroxychloroquine (HCQ) for rheumatologic diseases." | 3.79 | Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. ( Blyakhman, S; Diav-Citrin, O; Ornoy, A; Shechtman, S, 2013) |
| "Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus and rheumatoid arthritis treatment for many years." | 3.79 | Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. ( Dantas, AT; Duarte, AL; Galdino, SL; Mariz, HA; Oliveira, PS; Pitta, Ida R; Pitta, MG; Rocha, LF; Silva, JC, 2013) |
| "A 57-year-old woman with systemic lupus erythematosus and Sjögren syndrome presented with blue-grey hyperpigmentation of the face, upper back, and dorsal aspects of the feet after seven years of therapy with hydroxychloroquine." | 3.79 | Hydroxycholoroquine-induced hyperpigmentation. ( Boyd, KP; McLellan, B; Meehan, SA; Mir, A, 2013) |
| "In conclusion, prednisolone and TLR antagonist (hydroxychloroquine) may down-regulate protein levels of TLR7 and TLR9 in lupus patients, thereby decreasing the innate immune response against HPV infection." | 3.78 | Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. ( Chan, PK; Cheung, JL; Cheung, TH; Ho, SC; Li, EK; So, K; Szeto, CC; Tam, LS; Wong, CK; Wong, MC; Yeung, AC; Yim, SF; Yu, MM; Yu, SL, 2012) |
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 3.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| " We examined medical records of patients with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA(1c) after starting HCQ or methotrexate (MTX)." | 3.76 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. ( Bhatia, R; Garg, R; Gleeson, T; Lu, B; Massarotti, E; Rekedal, LR; Solomon, DH, 2010) |
| "Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients." | 3.76 | [Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. ( Ankri, A; Darnige, L; Fischer, AM; Szymezak, J, 2010) |
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 3.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| "The antimalarial agents chloroquine (CQ) and hydroxychloroquine (HCQ) are used in long-term treatment of connective tissue diseases (CTDs)." | 3.74 | Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. ( Amoura, Z; Costedoat-Chalumeau, N; Funck-Brentano, C; Hulot, JS; Lechat, P; Leroux, G; Piette, JC, 2007) |
| "To define the risk of hydroxychloroquine (HCQ)-related retinal toxicity in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) who are receiving recommended dosages of the drug (< or =6." | 3.72 | The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. ( Kostopoulos, C; Mavrikakis, E; Mavrikakis, I; Mavrikakis, M; Nikolaou, A; Rougas, K; Sfikakis, PP, 2003) |
| "Multifocal ERG with 103-hexagon stimulation was performed on 19 patients (36 eyes) treated with hydroxychloroquine for systemic lupus erythematosus, rheumatoid arthritis, or localized atypical scleroderma." | 3.72 | Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. ( Maturi, RK; Weleber, RG; Yu, M, 2004) |
| "Growing interest in aggressive early management of rheumatoid arthritis (RA) with hydroxychloroquine (alone or in combination with other immunomodulating drugs) is reason to review current practices for monitoring ocular toxicity in patients who take antimalarial therapy." | 3.69 | Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. ( Brandt, KD; Katz, BP; Mazzuca, SA; Yee, RD; Yung, R, 1994) |
| "To report clinical experience from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) who were receiving recommended doses of hydroxychloroquine for more than six years, and were monitored for evidence of hydroxychloroquine related retinopathy every six months." | 3.69 | Retinal toxicity in long term hydroxychloroquine treatment. ( Mavrikakis, M; Papazoglou, S; Rougas, K; Sfikakis, PP; Vaiopoulos, G, 1996) |
| "To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ)." | 3.69 | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. ( Buchanan, NM; Hughes, GR; Kerslake, S; Khamashta, MA; Lima, F; Toubi, E, 1996) |
| " Hydroxychloroquine therapy induced simultaneous resolution of lupus and angioedema." | 3.68 | Acquired C1 inhibitor deficiency revealing systemic lupus erythematosus. ( Bagot, M; Intrator, L; Ochonisky, S; Revuz, J; Wechsler, J, 1993) |
| "A female patient from the French Antilles developed renal failure due to pure chronic interstitial nephritis six months after the onset of systemic lupus erythematosus (SLE) for which she was taking hydroxychloroquine." | 3.68 | [Lupus, sicca syndrome and chronic interstitial nephritis. Apropos of a case]. ( Blanche, P; Sicard, D, 1992) |
| "Hydroxychloroquine is used for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)." | 3.68 | Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. ( Littlejohn, GO; McCloud, PI; Morand, EF, 1992) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 3.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "The effects of hydroxychloroquine (HCQ) on serum levels of cholesterol, triglycerides, and high- (HDL) and low-density lipoprotein (LDL) were studied in patients with rheumatoid arthritis or systemic lupus erythematosus." | 3.68 | Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. ( Kern, PA; Metzger, AL; Stecher, VJ; Turnbull, BA; Wallace, DJ, 1990) |
| "The authors report their comparative experience of the treatment of proliferative lupus glomerulonephritis using prednisone (16 patients) or the indomethacin-hydroxychloroquine association (12 patients)." | 3.65 | [Lupus nephropathy. Treatment with the indomethacin-hydroxychloroquine combination and comparison with corticoids]. ( Conte, JJ; Fournie, GJ; Mignon-Conte, MA, 1975) |
| "Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE)." | 3.30 | Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. ( Abdelnabi, HH; Dawoud, HE; El-Shahaby, WA; Elrifaey, SM; Gheet, FS, 2023) |
| " We observed high interindividual variability in HCQ PK and found that weight-based dosing for HCQ is poorly correlated with drug concentrations, suggesting the need to use therapeutic drug monitoring to individualise dosing." | 3.11 | Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial. ( Balevic, SJ; Beard, C; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CP; Randell, R; Schanberg, LE; Weiner, D, 2022) |
| " Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice." | 3.01 | How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. ( Brosnan, M; Fairley, JL; Mack, HG; Nikpour, M; Pellegrini, M; Saracino, AM; Wicks, IP, 2023) |
| " The main outcome indicators included clinical total effective rate, adverse reactions, SLE disease activity index (SLEDAI) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complement 3 (C3)." | 3.01 | Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash. ( Fang, H; Guan, T; Liang, S; Wei, Z, 2023) |
| "In the treatment of lupus nephritis, conservative therapeutic measures for nephroprotection play a crucial role in renal prognosis." | 3.01 | [What is proven in the treatment of systemic lupus erythematosus?] ( Gödecke, V; Witte, T, 2023) |
| " Additionally, the data collected remotely in this trial will provide critical information regarding the accuracy of teleresearch in lupus, the impact of adherence to hydroxychloroquine on disease activity and a pharmacokinetic analysis to inform paediatric-specific dosing of hydroxychloroquine." | 3.01 | Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial. ( Balevic, SJ; Cohen-Wolkowiez, M; Cunningham, A; Hornik, CP; Randell, RL; Schanberg, LE; Singler, L, 2021) |
| "Hydroxychloroquine is a treatment for lupus that is widely used based on longstanding experience and a very good safety profile." | 2.87 | Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. ( Arriens, C; Chinchilli, VM; Chong, BF; Ishimori, ML; James, JA; Kamen, DL; Karp, DR; Liao, D; Olsen, NJ; Wallace, DJ, 2018) |
| "Recurrent attacks of painful brachial plexopathy may warrant careful evaluation for underlying SLE with a premise of therapeutic benefit." | 2.82 | Recurrent brachial plexopathy as initial presentation of systemic lupus erythematosus: A case report and review of the literature. ( Ali, S; Bonilla, E; El-Dokla, AM; Perl, A, 2022) |
| "We report the full recovery of dilated cardiomyopathy in a girl with juvenile lupus." | 2.82 | Dilated cardiomyopathy: An unusual and severe condition in juvenile systemic lupus erythematosus. ( Bouayed, K; Boutaleb, AM; Drighil, A; Faid, T; Sakhi, A, 2022) |
| "Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic." | 2.82 | COVID-19 in patients with systemic lupus erythematosus: A systematic review. ( Chen, HL; Du, L; Fu, XL; Jin, XH; Qian, Y; Shi, YQ; Wu, H; Yu, HR, 2022) |
| "There is no clear correlation between weight-based dosing of hydroxychloroquine and the resulting blood levels of the medication." | 2.82 | Advances in the clinical use of hydroxychloroquine levels. ( Chakrabarti, K; McCune, WJ, 2022) |
| "Pregnancy was formerly discouraged in patients with SLE because of unstable disease activity during the gestation period, increased thrombosis risk, severe organ damage, and inevitable side effects of immunosuppressive agents." | 2.82 | Pregnancy-related complications in systemic lupus erythematosus. ( Cui, L; Li, Z; Liu, Q; Mu, R; Qiao, J; Tan, Y; Yang, S, 2022) |
| "Pseudotumor cerebri is a disease that involves an idiopathic rise in intracranial pressure in association with papilledema." | 2.82 | Lupus Anticoagulant-Hypoprothrombinemia Syndrome and Pseudotumor Cerebri as an Initial Presentation of Systemic Lupus Erythematosus in a 16-Year-Old Male Patient: A Case Report and Literature Review. ( Alghaythi, AM; Alharbi, AA; AlJohani, G; Omer, MH; Salama, H, 2022) |
| "Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE)." | 2.78 | Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). ( Ackermann, F; Amoura, Z; Asli, B; Aumaître, O; Boutin, du LT; Cacoub, P; Cohen-Bittan, J; Costedoat-Chalumeau, N; Desmurs-Clavel, H; Fain, O; Francès, C; Galicier, L; Hulot, JS; Jallouli, M; Kahn, JE; Le Guern, V; Lechat, P; Leroux, G; Limal, N; Lioté, F; Musset, L; Papo, T; Perard, L; Piette, JC; Pourrat, J; Sacré, K; Sailler, L; Smail, A; Stirnemann, J; Tanguy, ML, 2013) |
| "Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and mortality." | 2.77 | QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity. ( Ghahartars, M; Kojuri, J; Liaghat, L; Mahmoody, Y; Nazarinia, MA; Rezaian, Gr, 2012) |
| "Antimalarials might reduce the risk of cancer in SLE among the Asian population (RR = 0." | 2.72 | Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies. ( Cao, NW; Chu, XJ; Li, BZ; Li, XB; Wang, H; Ye, DQ; Yu, SJ; Zhou, HY, 2021) |
| "Hydroxychloroquine and steroid treatments were started after the operation." | 2.72 | Systemic lupus erythematosus complicated with Castleman disease: a case-based review. ( Aktay Ayaz, N; Demirkan, FG; Doğan, S; Kalyoncu Uçar, A; Sönmez, HE, 2021) |
| "Chloroquine may increase complete clinical response at 12 months' follow-up compared with placebo (absence of skin lesions) (risk ratio (RR) 1." | 2.72 | Interventions for cutaneous disease in systemic lupus erythematosus. ( Bennett, C; Chen, S; Hannon, CW; Lima, HC; McCourt, C, 2021) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 2.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "Acute acalculous cholecystitis (AAC) is an extremely rare manifestation of systemic lupus erythematous (SLE)." | 2.72 | Acute acalculous cholecystitis as the initial manifestation of systemic lupus erythematous: A case report. ( Kim, Y; Lee, J; Lee, YJ, 2021) |
| "Nineteen patients identified scotomata on red Amsler grid." | 2.71 | Utility of red amsler grid screening in a rheumatology clinic. ( Blomquist, PH; Pluenneke, AC, 2004) |
| "Eleven children with various forms of lupus nephritis were treated with oral MMF at a mean dose of 22 mg/kg/day (range 17-42) for a mean of 9." | 2.70 | Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. ( Bartosh, S; Buratti, S; Reiff, A; Spencer, CH; Szer, IS, 2001) |
| "Oral prednisone alone was used in 50 of the 59 patients (mean initial dose 1 mg/kg body weight/day)." | 2.70 | Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. ( Arnal, C; Bierling, P; Godeau, B; Hachulla, E; Léone, J; Papo, T; Piette, JC; Roudot-Thoraval, F; Schaeffer, A; Taillan, B, 2002) |
| " The primary outcome was time to a major flare of SLE which resulted in either the institution of or an increase in the current dosage of prednisone of 10 mg/day or more, or institution of therapy with immunosuppressive agents." | 2.69 | A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. ( Choquette, D; Cividino, A; Danoff, D; Esdaile, JM; Joseph, L; Osterland, CK; Senécal, JL; Smith, CD; Tsakonas, E; Yeadon, C, 1998) |
| " No correlation could be found between indices of visual field function and total drug usage, average daily dose, dosage in mg/kg body weight or duration of treatment." | 2.67 | Hydroxychloroquine, dosage parameters and retinopathy. ( Hughes, GR; Spalton, DJ; Verdon Roe, GM, 1993) |
| "Patients with quiescent systemic lupus erythematosus who are taking hydroxychloroquine are less likely to have a clinical flare-up if they are maintained on the drug." | 2.67 | A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. ( , 1991) |
| "Hydroxychloroquine was preventively suspended and the patient improved notably within a few days." | 2.66 | Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. ( Alijotas-Reig, J; Esteve-Valverde, E; Ruiz, D; Tapiz-Reula, A, 2020) |
| " An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus." | 2.66 | [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. ( Detert, J; Fiehn, C; Hadjiski, D; Krüger, K; Ness, T; Specker, C; Weseloh, C, 2020) |
| "After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy." | 2.66 | Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. ( Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N, 2020) |
| "The rapid spread of the new Coronavirus Disease 2019 (COVID-19) has actually become the newest challenge for the healthcare system since, to date, there is not an effective treatment." | 2.66 | Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. ( De Tommasi, N; Faraone, I; Labanca, F; Milella, L; Ponticelli, M, 2020) |
| "Dyslipidemia is a common disorder in systemic lupus erythematosus (SLE) patients." | 2.61 | Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. ( Chen, T; Cheng, GY; Jiang, YM; Liu, D; Shang, J; Tao, CY; Xiao, J; Yu, D; Zhao, ZZ, 2019) |
| "Hydroxychloroquine (HCQ) has shown to have significant immunomodulatory effects in the treatment of systemic lupus erythematosus (SLE)." | 2.58 | Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis. ( Ayatollahi, Y; Babary, H; Chen, XP; Doo, L; Kulaga, C; Kwak, MK; Liu, X; Modjinou, D; Olech, E; Uppaluru, LK; Yoo, JW, 2018) |
| "Hydroxychloroquine (HCQ) is an effective treatment of lupus erythematosus." | 2.58 | Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work. ( Kambe, N; Ly, NTM; Matsuda, T; Nguyen, CTH; Okamoto, H; Son, Y; Ueda-Hayakawa, I, 2018) |
| "Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality." | 2.58 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. ( Bortoluzzi, A; Cauli, A; Erre, GL; Floris, A; Mangoni, AA; Piga, M, 2018) |
| "Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis, and potential new uses and benefits continue to emerge." | 2.58 | Hydroxychloroquine: An old drug with new relevance. ( Collamer, AN; Shippey, EA; Wagler, VD, 2018) |
| "The patient was diagnosed with systemic lupus erythematosus with the presence of polyarthralgia, angioedema, leucopenia, and positivity of immunologic criteria." | 2.58 | Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. ( Tekin, ZE; Yener, GO; Yüksel, S, 2018) |
| "Background Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease." | 2.55 | Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. ( Afeltra, A; Fasano, S; Margiotta, DP; Navarini, L; Pantano, I; Pierro, L; Riccardi, A; Valentini, G, 2017) |
| "Hydroxychloroquine was discontinued, and follow-up echocardiogram 57 days after discontinuation showed normalization of her left ventricular ejection fraction." | 2.55 | Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus. ( Cox, ZL; Mendes, LA; Sabato, LA, 2017) |
| " While the mechanisms for the differential responses to drug therapy are unclear, variation in drug exposure with the same dosing protocol related to pharmacogenetic and pharmacokinetic factors may contribute." | 2.55 | Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. ( Mok, CC, 2017) |
| "Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH." | 2.55 | Hydroxychloroquine in systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2017) |
| " These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes." | 2.55 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. ( Apostolopoulos, D; Morand, EF, 2017) |
| "Her quadriparesis was found to be secondary to biopsy-proven hydroxychloroquine-induced myopathy with concomitant inflammatory myopathy." | 2.55 | Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review. ( Bucknor, MD; Chaganti, RK; Jafri, K; Nolan, AL; Patterson, S; Wysham, KD; Zahed, H, 2017) |
| " For this reason, the key question is weather these drugs are absolutely safe and can be long term used in all lupus patients as a background therapy? Potential non-specific side effects occur very rare and are usually minor and last for short period." | 2.53 | [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects]. ( Gaca-Wysocka, M; Grzybowski, A; Leszczyński, P; Pawlak-Buś, K, 2016) |
| "Hydroxychloroquine is a crucial background medication in SLE with actions in many molecular pathways." | 2.53 | Immunomodulators in SLE: Clinical evidence and immunologic actions. ( Durcan, L; Petri, M, 2016) |
| "Systemic lupus erythematosus is an autoimmune disease that affects many systems, including the skin, musculoskeletal, renal, neuropsychiatric, hematologic, cardiovascular, pulmonary, and reproductive systems." | 2.53 | Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management. ( Bieniek, ML; Ghetu, MV; Lam, NC, 2016) |
| " The current goal is to stop all disease activity without long-term use of more than 5 mg prednisolone per day." | 2.53 | [Management of systemic lupus erythematosus]. ( Aringer, M; Schneider, M, 2016) |
| " A new study indicates that toxicity is not as rare as once believed, but depends critically on daily dosage and duration of use, as well as other risk factors." | 2.52 | A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. ( Brézin, AP; Costedoat-Chalumeau, N; Dunogué, B; Jallouli, M; Le Guern, V; Leroux, G; Marmor, MF; Melles, RB; Morel, N; Piette, JC, 2015) |
| " These agents are generally used in fixed, weight-based dosing regimens, and both incomplete response and adverse effects are common." | 2.52 | Optimizing the use of existing therapies in lupus. ( Croyle, L; Morand, EF, 2015) |
| "Hydroxychloroquine treatment appears to be safe in this setting." | 2.48 | The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. ( Amoura, Z; Benveniste, O; Cacoub, P; Chapelon, C; Costedoat-Chalumeau, N; De Gennes, C; Eymard, B; Haroche, J; Jallouli, M; Le Thi Huong, D; Leroux, G; Piette, JC; Saadoun, D; Wechsler, B, 2012) |
| "Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus." | 2.47 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. ( Petri, M, 2011) |
| "Adequate pregnancy care of women with systemic lupus erythematosus (SLE) rests on three pillars: a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit." | 2.47 | Lupus and pregnancy: integrating clues from the bench and bedside. ( Khamashta, MA; Ruiz-Irastorza, G, 2011) |
| " Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy." | 2.47 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. ( Abarientos, C; Aronow, WS; Ash, JY; Chao, CP; Shapiro, DL; Sperber, K, 2011) |
| "Treatment of patients with Systemic Lupus Erythematosus (SLE) who have active disease refractory to current therapeutic strategies continues to be a real challenge." | 2.47 | The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. ( Amoura, Z; Arnaud, L; Costedoat-Chalumeau, N; Zahr, N, 2011) |
| "Systemic lupus erythematosus is an autoimmune inflammatory disorder that frequently affects women of childbearing age." | 2.46 | Systemic lupus erythematosus: safe and effective management in primary care. ( Kodner, C; Michalski, JP, 2010) |
| "Hydroxychloroquine, a common treatment for SLE, can improve lipid profiles and should be considered for all patients with SLE." | 2.44 | Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. ( Ardoin, SP; Sandborg, C; Schanberg, LE, 2007) |
| "Sjogren syndrome (SS) and systemic lupus erythematosus (SLE) are both collagen vascular diseases that can be accompanied by Ro antibodies." | 2.43 | Sjögren syndrome and systemic lupus erythematosus are distinct conditions. ( Scheinfeld, N, 2006) |
| "Histiocytic necrotizing lymphadenitis (Kikuchi's disease) is an uncommon disease of the cervical lymph nodes occurring in young women, commonly associated with various auto-immune or infectious diseases." | 2.39 | [Kikuchi syndrome, Hashimoto thyroiditis and lupus serology. Apropos of a case]. ( Anzieu, B; Bousquet, E; Brousset, P; Dubarry, B; Duffaut, M; Massip, P; Tubéry, M, 1996) |
| "(1) Hydroxychloroquine has a possible anti-thrombotic action." | 2.38 | The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. ( Linker-Israeli, M; Metzger, AL; Stecher, VJ; Wallace, DJ, 1993) |
| "Hydroxychloroquine was continued throughout the duration of therapy." | 2.38 | Transverse myelitis complicating systemic lupus erythematosus: treatment including hydroxychloroquine. Case report. ( Klaiman, MD; Miller, SD, 1993) |
| " Many of these reviews, while generally excellent, have propagated some apparent misconceptions by disregarding or de-emphasizing data suggesting that irreversible retinal toxicity due to antimalarials can be easily avoided by judicious daily dosage and regular ophthalmologic follow-up." | 2.36 | Antimalarials and ophthalmologic safety. ( Olansky, AJ, 1982) |
| "Common complications of systemic lupus erythematosus include nephritis, hematologic complications such as thrombocytopenia, and a variety of neurologic abnormalities." | 1.91 | Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. ( Craigo, S; Kuller, JA; Norton, ME; Osmundson, SS; Porter, F; Silver, R, 2023) |
| "Reduction of the hydroxychloroquine (HCQ) dosage is recommended in systemic lupus erythematosus (SLE) patients with renal impairment, but a pharmacokinetics (PK) study of patients with renal impairment has not yet been performed." | 1.91 | Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment. ( Furudate, S; Hashiguchi, M; Nagai, Y; Ohshima, M; Setoguchi, K; Shimada, K; Shimizu, M; Yokogawa, N, 2023) |
| " Any adverse events that required dose reduction or cessation of hydroxychloroquine, indicating intolerance to the drug, were recorded for up to 26 weeks after initiation of hydroxychloroquine." | 1.91 | Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus. ( Araki, K; Hirata, S; Ishitoku, M; Kohno, H; Masuda, S; Mokuda, S; Oka, N; Sugimoto, T; Watanabe, H; Yorishima, A; Yoshida, Y, 2023) |
| " HCQ is generally safe and may be prescribed to pregnant women." | 1.91 | Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Kaneko, K; Murashima, A; Sago, H; Tanaka, R; Tsurane, K; Yoshida, K, 2023) |
| "Lupus mastitis is a rare clinical manifestation associated with systemic lupus erythematosus or discoid lupus erythematosus." | 1.91 | Unilateral lupus mastitis. ( Jiménez-Antón, A; Jiménez-Gallo, D; Linares-Barrios, M; Millán-Cayetano, JF; Navarro-Navarro, I, 2023) |
| "Patients with low oral HCQ dosage tend to have more flares, although the difference was not statistically significant." | 1.91 | Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. ( Ciccia, F; Coscia, MA; Fasano, S; Iudici, M; Messiniti, V, 2023) |
| "Hydroxychloroquine dose was assessed from pharmacy dispensing records." | 1.91 | Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. ( Choi, HK; Conell, C; Jorge, AM; Marmor, MF; McCormick, N; Melles, RB; Niu, J; Zhang, Y; Zhou, B, 2023) |
| "Recently, due to the coronavirus disease 2019 (COVID-19) pandemic, much concern has been raised about patients with chronic diseases who may become more susceptible to the disease." | 1.91 | The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report. ( Abdolahi, N; Aghaie, M; Damirchi, M; Hassani, M; Roshandel, G; Sedighi, S; Tavassoli, S, 2023) |
| " Patients with low eGFR need to adjust the HCQ dosage according to the monitoring results of HCQ blood concentrations." | 1.91 | Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration. ( He, J; Jin, YB; Liu, SL; Zhang, Q; Zhong, X, 2023) |
| "The main determinants of infection in SLE are disease activity, organ damage, and often inevitable medication." | 1.91 | Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. ( He, J; Li, Z, 2023) |
| " Study results indicated that HCQ dosing management was adequate based on the revised guidelines." | 1.91 | Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus. ( Jung, SY; Kim, YJ; Lee, JE; Nam, DR; Sung, YK, 2023) |
| "Systemic lupus erythematosus is an autoimmune disease associated with serious complications and high costs." | 1.91 | Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study. ( Duarte-Rey, C; Gaviria-Mendoza, A; González-Rangel, A; Machado-Alba, JE; Machado-Duque, ME, 2023) |
| "Renal biopsy revealed Class V lupus nephritis." | 1.91 | Systemic lupus erythematosus presenting as lupus erythematosus tumidus and lupus nephritis: a case report. ( Abderrahim, E; Badrouchi, S; Ben Hamida, F; Gorsane, I; Hajji, M; Litaiem, N; Rammeh, S, 2023) |
| "Drug therapy for patients with systemic lupus erythematosus (SLE) aims to decrease symptom severity." | 1.91 | Systemic lupus erythematosus: An approach to pharmacologic interventions. ( El Hussein, MT; Wong, C, 2023) |
| "This study aimed to understand the profile of hydroxychloroquine-treated patients, referral patterns, and dosing and to assess the adherence of eye care providers to the latest 2016 screening guidelines provided by the American Academy of Ophthalmology." | 1.91 | Trends and practices following the 2016 hydroxychloroquine screening guidelines. ( Arnett, J; Baxter, SL; Borooah, S; Kalaw, FGP; Pedersen, B; Walker, E, 2023) |
| "Initial hospitalization and treatment for fever of unknown origin did not yield improvement." | 1.91 | The co-occurrence of Kikuchi-Fujimoto disease and systemic lupus erythematosus: a case report. ( Binafar, H; Kaveh, R; Mirkamali, H; Pourzand, P; Rukerd, MRZ; Shoaie, S; Yousefi, M, 2023) |
| "Our results suggest that the optimal blood concentration of HCQ measured approximately 12-18 hours after the last dosage may be between 500 and 600 ng/mL in Chinese patients with SLE." | 1.91 | Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE. ( Ge, W; Geng, L; Huang, X; Jin, Z; Shen, W; Shu, Q; Sun, L; Wang, D; Wang, Y; Wen, X; Xie, H; Zhu, Y, 2023) |
| "To investigate the risk of gestational diabetes mellitus (GDM) associated with systemic lupus erythematosus (SLE) by comparing pregnancies in women with SLE to general population controls." | 1.72 | Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus. ( Arkema, EV; Gernaat, SAM; Simard, JF; Svenungsson, E; Wikström, AK, 2022) |
| "To evaluate systemic lupus erythematosus (SLE) flares following hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance." | 1.72 | Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. ( Abrahamowicz, M; Alarcón, GS; Almeida-Brasil, CC; Aranow, C; Askanase, A; Bae, SC; Bernatsky, S; Bruce, IN; Clarke, AE; Dooley, MA; Fortin, PR; Ginzler, EM; Gladman, DD; Gordon, C; Hanly, JG; Inanc, M; Isenberg, D; Jacobsen, S; Jönsen, A; Kalunian, K; Kamen, DL; Khamashta, MA; Lim, S; Manzi, S; Merrill, JT; Nived, O; Peschken, C; Petri, M; Rahman, A; Ramos-Casals, M; Ramsey-Goldman, R; Romero-Diaz, J; Ruiz-Irastorza, G; Sanchez-Guerrero, J; Steinsson, K; Urowitz, M; van Vollenhoven, RF; Wallace, DJ; Zoma, A, 2022) |
| " A positive correlation was found between HCQ dosage (ideal bodyweight) and WBHCQ (r = 0." | 1.72 | Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia. ( Beh, PJ; How, KN; Lim, AL; Peh, D; Stanslas, J; Tan, WC; Thevarajah, S; Wan Ahmad Kammal, WSL; Yong, ACH, 2022) |
| "Neurological complications of systemic lupus erythematosus (SLE) are wide and may rarely involve the peripheral nervous system." | 1.72 | Broadening the spectrum of the neurological complications in systemic lupus erythematosus: A patient with meningoradiculitis. ( Bardel, B; Gendre, T; Limal, N; Matthys, A; Megdiche, I; Planté-Bordeneuve, V; Remy, P, 2022) |
| "Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)." | 1.72 | Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions. ( Cao, X; Gao, B; Pan, M; Shuai, Z; Tan, T; Wang, J; Xia, Q; Yang, C, 2022) |
| "001), mean daily prednisolone dosage 7." | 1.72 | Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study. ( Chang, JW; Liu, CS; Lu, JH; Tsai, HL, 2022) |
| "Antimalarials have been associated with QT prolongation in COVID-19 patients but are generally safe in systemic lupus erythematosus (SLE)." | 1.72 | Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus. ( Agati, L; Ciardi, MR; Conti, F; Garufi, C; Mancuso, S; Mastroianni, CM; Molteni, E; Natalucci, F; Priori, R; Riccieri, V; Spinelli, FR; Truglia, S, 2022) |
| "Hydroxychloroquine (HCQ) has been used during the coronavirus disease 2019 (COVID-19) pandemic because of its reported anti-viral activity." | 1.72 | Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. ( Al Maimouni, HM; Al-Najjar, AH; Alajra, RK; Alali, AS; Alanazi, DS; Albadi, MA; Albarqi, HA; Alghanim, NS; Alkahtani, SA; Alqahtani, F; Alqhtani, H; Alsaweed, OS; Alshabi, AM; Hazzazi, MA; Sabei, AA; Walbi, IA, 2022) |
| " The protective effect of HCQ was dosage related." | 1.72 | Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. ( Deng, X; Gao, D; Geng, Y; Hao, Y; Huang, H; Ji, L; Wang, Y; Zhang, Z, 2022) |
| "Catastrophic antiphospholipid antibody syndrome (CAPS) is an accelerated form of disease with rapid involvement of multiple organ systems often posing a diagnostic challenge." | 1.72 | Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean. ( Asturkar, V; Bhanu, K; Dorji, T; Hegde, A; Yangzom, S, 2022) |
| "Hydroxychloroquine (HCQ) has been used clinically to treat SLE, while its exact mechanism has still remained elusive." | 1.72 | Hydroxychloroquine induces apoptosis of myeloid-derived suppressor cells via up-regulation of CD81 contributing to alleviate lupus symptoms. ( Dou, H; Hou, Y; Jiang, J; Lu, L; Ma, Y; Ni, J; Wang, Y; Yang, Z; You, X; Zhao, Z; Zhu, H, 2022) |
| "Hydroxychloroquine adherence is an imperfect proxy for adherence to other lupus medications among children with SLE, and therefore assessing immunosuppressant adherence concurrently adds value to hydroxychloroquine adherence assessments." | 1.72 | Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus. ( Chang, JC; Costenbader, KH, 2022) |
| "Hydroxychloroquine (HCQ) has been reported to improve the lifespan and the prognosis of dyslipidaemia in patients with SLE, but the mechanism is unclear." | 1.72 | Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease. ( Dobashi, H; Kadowaki, N; Kameda, T; Kato, M; Mino, R; Miyagi, T; Miyatake, N; Mizusaki, M; Nakashima, S; Shimada, H; Sugihara, K; Ueeda, K; Wakiya, R, 2022) |
| "Hydroxychloroquine (HQ) is an antimalarial drug that is widely used in many autoimmune rheumatic diseases, mainly in systemic lupus erythematosus (SLE)." | 1.72 | A case of palmoplantar pustular psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Akkuzu, G; Bes, C; Karaalioğlu, B; Mutlu, MY; Özgür, DS; Yıldırım, F, 2022) |
| "A 69-year-old female patient with breast cancer experienced severe skin itching and rashes on the face, anterior chest wall, back, and trunk for two days before admission." | 1.72 | A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article. ( Chen, PH; Huang, KP; Lin, CH; Lin, CY; Ni, YL; Tung, HH, 2022) |
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 1.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| "Hydroxychloroquine (HCQ) is a key systemic lupus erythematosus (SLE) drug, making concerns of drug shortages grave." | 1.72 | Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision-Making in Systemic Lupus Erythematosus Treatment? ( Abrahamowicz, M; Almeida-Brasil, CC; Bernatsky, S; Clarke, AE; Fortin, PR; Hanly, JG; Peschken, CA; Pineau, CA; Vinet, E, 2022) |
| "001), and average oral dosage of >7." | 1.72 | Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan. ( Chang, YS; Chen, WS; Huang, YF; Lai, CC; Li, TH; Tsao, YP; Wang, WH, 2022) |
| "We identified incident ESRD patients age ≥18 years with SLE as a primary cause of ESRD between January 2006 and June 2013." | 1.72 | Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New-Onset End-Stage Renal Disease. ( Broder, A; Costenbader, KH; Feldman, CH; Kim, M; Mowrey, WB; Valle, A; Yoshida, K, 2022) |
| "BACKGROUND Patients with late-onset systemic lupus erythematosus (SLE) do not present with typical SLE symptoms or serology, and this can lead to a major delay in diagnosis." | 1.62 | Late-Onset Systemic Lupus Erythematosus Associated with Autoimmune Hemolytic Anemia and Sixth Cranial Nerve Palsy. ( Itagane, M; Kinjo, M; Kuroda, K, 2021) |
| "Lupus nephritis was present in 20." | 1.62 | Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal. ( Barros, T; Braga, A; Braga, J; Carvalheira, G; Faria, R; Farinha, F; Marinho, A; Neves, E; Rocha, G; Vasconcelos, C, 2021) |
| "Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients." | 1.62 | Utilization of glucocorticoids among White and Black patients with systemic lupus erythematosus: Observations from the enrollment visit of a prospective registry. ( Littlejohn, EA; Sullivan, JK, 2021) |
| "Ocular manifestations in systemic lupus erythematosus (SLE) can be the presenting symptom of the disease or a sight-threatening complication." | 1.62 | Structural Retinal Assessment Using Optical Coherence Tomography and Fundus Fluorescein Angiography in Systemic Lupus Erythematosus Patients. ( El-Gendy, H; Esmat Mahmoud Ali, SM; Essam, M; Fouad, SA; Mahfouz, S; Rezk Alnaggar, ARL, 2021) |
| "Hydroxychloroquine (HCQ) has been associated with improved survival among patients with systemic lupus erythematosus (SLE) from tertiary referral centers." | 1.62 | Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population. ( Aviña-Zubieta, JA; Choi, H; De Vera, M; Esdaile, J; Jorge, A; Lu, N; McCormick, N; Zheng, Y, 2021) |
| "In the absence of a commonly agreed dosing protocol based on pharmacokinetic (PK) considerations, the dose and treatment duration for hydroxychloroquine (HCQ) in COVID-19 disease currently vary across national guidelines and clinical study protocols." | 1.62 | Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps. ( Dauby, N; Delforge, M; Dogné, JM; Hamdani, J; Konopnicki, D; Lebout, F; Lescrainier, C; Libois, A; Musuamba, FT; Nasreddine, R; Payen, MC; Schrooyen, L; Thémans, P; Verlinden, V; Wuillaume, F, 2021) |
| "SLE patients had more sensorineural hearing loss than controls (23." | 1.62 | Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients. ( Barros, H; Chuchene, AG; Miguel, PTG; Polanski, JF; Skare, TL; Tanaka, EA, 2021) |
| "She had a pyramidal and rigid-akinetic parkinsonian syndrome, with signs of polyneuropathy." | 1.62 | Lentiform fork sign in a patient with systemic lupus erythematosus. ( Constantinides, VC; Deligianni, C; Dimitrakopoulos, A; Kapaki, E; Paraskevas, GP, 2021) |
| "To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study." | 1.62 | Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. ( Bajocchi, G; Boiardi, L; Carrozzi, G; Cassone, G; Costantini, M; Croci, S; Galli, E; Giorgi Rossi, P; Gradellini, F; Mancuso, P; Marata, AM; Muratore, F; Pandolfi, P; Pipitone, N; Reta, M; Salvarani, C; Sandri, G; Viani, N, 2021) |
| "Among 873 subjects, 20% had a psychiatric diagnosis, most commonly depression." | 1.62 | Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth With Systemic Lupus Erythematosus. ( Chang, JC; Cidav, Z; Davis, AM; Klein-Gitelman, MS; Knight, AM; Mandell, DS, 2021) |
| "After two months, a systemic lupus erythematosus was diagnosed." | 1.62 | Pediatric catastrophic antiphospholipid syndrome patient evolving to systemic lupus erythematosus. ( Carvalho, JF; Shoenfeld, Y; Silva, FF, 2021) |
| "To evaluate the association and dose-response pattern between antimalarial drugs and overall and cause specific mortality in SLE patients." | 1.62 | Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. ( Da, Z; Ding, X; Feng, X; Hu, H; Jin, Z; Li, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, F; Wang, M; Wei, H; Wu, J; Wu, M; Zhang, M; Zou, Y, 2021) |
| "The aim of this study was to examine the effects of long-term use of hydroxychloroquine (HQ) on the pachymetric, aberrometric, and densitometric values of the cornea and corneal endothelium in lupus patients." | 1.62 | Evaluation of corneal safety in systemic lupus erythematosus patients undergoing long-term hydroxychloroquine treatment. ( Akyol, L; Alakuş, MF; Balcı, MA; Çağlayan, M; Dağ, U; Öncül, H, 2021) |
| "Proteinuria is one of the most typical manifestations of kidney involvement in Systemic Lupus Erythematosus (SLE)." | 1.62 | "Protenuria in SLE: Is it always lupus?" ( Alessandri, C; Celia, AI; Cerbelli, B; Conti, F; d'Amati, G; Diomedi-Camassei, F; Leuzzi, V; Priori, R; Scrivo, R, 2021) |
| "A 72-year-old woman with systemic lupus erythematosus treated for 24 years by HCQ received a kidney allograft." | 1.62 | [Toxic hydroxychloroquine-induced cardiomyopathy complicating systemic lupus treatment]. ( Bories, MC; Bruneval, P; Gibault, L; Tharaux, PL, 2021) |
| "A 47-year-old woman with history of seizure disorder (semiology of seizure unknown), not well controlled with antiepileptic drugs since last 30 years presented with 1-year history of intermittent throbbing headache." | 1.62 | Moyamoya angiopathy unmasking systemic lupus erythematosus. ( Das, S; Dubey, S; Pandit, A; Ray, BK, 2021) |
| "Treatment with hydroxychloroquine (HCQ) without daily GCs may benefit patients by minimising the cumulative dose of GCs, but clinical experience with HCQ monotherapy is limited." | 1.62 | Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases. ( Ichikawa, K; Kirino, Y; Kishimoto, D; Kunishita, Y; Nakajima, H; Takase-Minegishi, K; Yoshimi, R, 2021) |
| "Hydroxychloroquine retinopathy was prevalent in the study cohort and significantly associated with a higher daily dose of HCQ (mg/kg real body weight)." | 1.62 | Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases. ( Bafna, P; Hazarika, K; Kaur, A; Manoj, M; Sahoo, RR; Singh, A; Wakhlu, A, 2021) |
| "Hydroxychloroquine (HCQ) has received much attention in the treatment of coronavirus disease 2019 recently." | 1.62 | Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review. ( Huang, Y; Li, Z; Lu, J; Ming, M; Shang, F; Xu, H; Ye, Q, 2021) |
| "Hydroxychloroquine (HCQ) is a mainstay of therapy in the treatment of SLE." | 1.62 | Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. ( Belmont, HM; Berger, JS; Buyon, JP; Clancy, R; Cornwell, MG; El Bannoudi, H; Engel, A; Golpanian, M; Izmirly, P; Katz, S; Luttrell-Williams, ES; Myndzar, K; Ruggles, K; Smilowitz, NR, 2021) |
| " Advances in our understanding of HCQ retinopathy have led to changes in the recommendations for HCQ dosing and retinopathy screening." | 1.62 | Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. ( Andersen, J; Bultink, IEM; Cornet, A; Frankel, S; Osmani, Z; Schrama, TJ; van Vollenhoven, RF; Zacouris-Verweij, W, 2021) |
| "To assess the impact of mild-moderate systemic lupus erythematosus (SLE) disease activity during a 12-month period on the risk of death or subsequent organ system damage." | 1.62 | Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre. ( Egger, PJ; Eudy, AM; Fu, Q; Hill, DD; Petri, MA, 2021) |
| "Hydroxychloroquine and steroids were less utilised in the cases than in the controls (70% vs 100% in hydroxychloroquine, 30% vs 82% in steroids)." | 1.62 | Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy-a tertiary centre experience in an Appalachian state. ( Abdel-Latif, A; Batool, A; Kazzaz, NM; McVeigh, ED; Stromberg, A, 2021) |
| "Hydroxychloroquine (HCQ) has been positioned as an anchor drug for systemic lupus erythematosus (SLE)." | 1.62 | Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus. ( Amano, H; Asai, Y; Minowa, K; Tamura, N; Yamaji, K; Yoshida, M, 2021) |
| "Hydroxychloroquine has excellent anti-inflammatory and immunomodulatory effects as one of the antimalarial drugs." | 1.62 | Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report. ( Li, J; Liao, Z; Qi, W; Tian, F; Wang, G; Wen, Z; Zhuo, N, 2021) |
| "Hydroxychloroquine (HCQ) has been proven to be effective against a variety of autoimmune diseases and is an essential drug for the treatment of SLE." | 1.62 | Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies. ( Yang, P; Zhao, X, 2021) |
| "03 per 100000 person-month for high and low dosage respectively." | 1.62 | Hydroxychloroquine might reduce risk of incident endometriosis in patients with systemic lupus erythematosus: A retrospective population-based cohort study. ( Chen, FY; Chen, SW; Chen, X; Huang, JY; Wei, JC; Ye, Z, 2021) |
| "The patient was diagnosed to have systemic lupus erythematosus and immune-mediated intravascular haemolysis and was treated with prednisolone and hydroxychloroquine." | 1.62 | Immune-mediated Coombs negative intravascular haemolysis in systemic lupus erythematosus (SLE). ( Bammigatti, C; Jose, A; Kolar Vishwanath, V; Magendiran, B, 2021) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 1.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| "Hydroxychloroquine (HCQ) has become the rheumatologists's "Swiss army knife" when it comes to managing the rheumatologic manifestations of SLE and other auto-immune disorders." | 1.56 | What every nephrologist needs to know about hydroxychloroquine toxicity . ( Ardoin, S; Ayoub, I; Brodsky, S; Hebert, L; Singh, P, 2020) |
| "A total of 69 cancer patients were identified, and the clinical characteristics and previous treatment were analyzed." | 1.56 | [Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer]. ( Guo, JY; Li, JY; Li, TF; Liu, SY; Liu, XJ; Niu, CZ; Ren, ZG; Xuan, YY, 2020) |
| "Few cases of systemic lupus erythematosus (SLE) pregnancy complicated by PA have been reported, and the background pathophysiology remains elusive." | 1.56 | Placenta accrete after a frozen-thawed embryo transfer in a systemic lupus erythematosus patient treated with hydroxychloroquine. ( Hiramitsu, S; Ishikawa, T; Iwahara, Y; Mano, C; Miyasaka, N; Saito, K; Sekiguchi, M; Tatsumi, T, 2020) |
| "Hydroxychloroquine treatment partially improved symptoms; however, the addition of prednisolone was required for complete resolution." | 1.56 | Lupus Erythematosus Tumidus with Pseudolymphomatous Infiltrates: A Case Report. ( Ansai, S; Hoashi, T; Ito, K; Kanda, N; Saeki, H; Umeda, Y, 2020) |
| "Disease activity (per Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)), SLE exacerbations, emergency room visits, hospitalisations, disease damage (per Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), corticosteroids exposure, prednisone dose and immunosuppressive drugs exposure were determined before and after HCQ dose change." | 1.56 | Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. ( Arroyo-Ávila, M; González-Sepúlveda, L; Medina-Cintrón, N; Vázquez-Otero, I; Vilá, LM, 2020) |
| "Hydroxychloroquine (HCQ) is an anchor drug in the treatment of systemic lupus erythematosus (SLE)." | 1.56 | Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools. ( Allorge, D; Azar, R; Balquet, MH; Bataille, P; Boldron, A; Buchdahl, AL; Clerson, P; Hachulla, E; Hatron, PY; Hennart, B; Lambert, M; Launay, D; Le Gouellec, N; Maillard, H; Morell-Dubois, S; Sobanski, V, 2020) |
| " Safety was evaluated via the frequency of adverse events over a period of three months." | 1.56 | Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose. ( Dobashi, H; Fahmy Mansour, MM; Kadowaki, N; Kameda, T; Kato, M; Miyagi, T; Nakashima, S; Shimada, H; Wakiya, R, 2020) |
| "Of the 51 SLE patients, thyroid cancer (14/51, 27." | 1.56 | The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. ( Guo, J; Li, J; Li, T; Liu, S; Ren, Z; Yu, Z, 2020) |
| "Reticular erythematous mucinosis (REM syndrome) is a rare skin disease that predominantly affects women." | 1.56 | [Reticular erythematous mucinosis-A special subtype of cutaneous lupus erythematosus?] ( Gruber, R; Kreuter, A; Kuntz, T; Oellig, F; Paschos, A; Tigges, C, 2020) |
| " Our primary outcomes were the continuation rate of HCQ treatment for 1 year and adverse events (AEs) during the treatment." | 1.56 | Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital. ( Hosokawa, Y; Oiwa, H, 2020) |
| "Hydroxychloroquine use was associated with lower APOs including pre-eclampsia, prematurity and IUGR in the univariate analyses but it was no longer significant in the GEE analysis." | 1.56 | Adverse pregnancy outcomes among multi-ethnic systemic lupus erythematosus patients in Malaysia. ( Maulana, SA; Mohd, R; Mustafar, R; Rahman, RA; Said, MSM; Shaharir, SS; Shahril, NS, 2020) |
| "New markers of systemic lupus erythematosus (SLE) activity are under investigation." | 1.56 | Differential approach to peripheral blood cell ratios in patients with systemic lupus erythematosus and various manifestations. ( Górak, A; Majdan, M; Suszek, D, 2020) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "Rowell's syndrome is a rare disorder characterised by an association of lupus erythematosus with erythema multiforme (EM)-like skin lesions." | 1.56 | Rowell's syndrome: a rare but distinct entity in rheumatology. ( Chandra, A; Karmakar, P; Ray, AK; Saha, SK, 2020) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug with immunomodulatory effects used to treat systemic lupus erythematosus (SLE) and scleroderma." | 1.56 | Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. ( Alhamad, T; Axelrod, D; Brennan, DC; Caliskan, Y; Chang, SH; Hess, GP; Kasiske, BL; Lam, NN; Lentine, KL; McAdams-DeMarco, M; Schnitzler, MA; Segev, DL; Xiao, H, 2020) |
| "SLE manifestations after ESRD may be underdiagnosed and undertreated, contributing to increased morbidity and mortality." | 1.56 | Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease. ( Broder, A; Dobrowolski, C; Goilav, B; Londono Jimenez, A; Mowrey, WB; Salgado Guerrero, M; Wang, S, 2020) |
| "Hydroxychloroquine was associated with significantly lower BPV." | 1.56 | Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. ( Magder, LS; Petri, M; Stojan, G, 2020) |
| "Hydroxychloroquine (HCQ) is a well-established and effective immunomodulatory therapy for systemic lupus erythematosus and other autoimmune diseases." | 1.51 | Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity. ( Baas, AS; Chang, A; Cruz, D; Fan, J; Fishbein, GA; Larreta, BR; Stolin, G; Wallace, WD; Wang, J, 2019) |
| "Early recognition and treatment of lupus myocarditis is needed to avoid fatal consequences." | 1.51 | Myocarditis as a lupus challenge: two case reports. ( Al Shehhi, MA; Al-Nokhatha, SA; Jassim, IT; Khogali, HI, 2019) |
| "Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease." | 1.51 | Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019) |
| "The results of this study suggested that, with attention paid to possible adverse events immediately after initiation, HCQ may be initiated as a mainstay of SLE therapy in Japanese patients, either as a concomitant medication in the remission induction phase, as a maintenance therapy, or as a monotherapy." | 1.51 | Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. ( Fukuyo, S; Hanami, K; Inoue, Y; Iwata, S; Kubo, S; Miyagawa, I; Nakano, K; Nakayamada, S; Tanaka, Y; Ueno, M, 2019) |
| "Hydroxychloroquine is an antimalarial agent, most commonly prescribed in the treatment of several rheumatic diseases." | 1.51 | Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. ( Cai, L; Liu, X; Zhang, J; Zhang, S; Zhou, C, 2019) |
| "Autoimmune myelofibrosis is a distinct clinicopathological entity that occurs with autoimmune disorders." | 1.51 | Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus. ( Belfeki, N; Declerck, D; Diamantis, S; Shankarasivam, G, 2019) |
| "Hydroxychloroquine (HCQ) is a cornerstone to managing systemic lupus erythematosus (SLE), yet adherence to medication is poor." | 1.51 | Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus. ( Fevrier, HB; Goldfien, R; Hemmerling, A; Herrinton, LJ; Liu, LH, 2019) |
| "Hydroxychloroquine (HCQ) is a key therapy in systemic lupus erythematosus (SLE)." | 1.51 | Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. ( Askanase, A; Danias, G; Dervieux, T; Geraldino-Pardilla, L; Giles, J; Kapoor, T; Miceli, J; Neville, K; Nguyen, S; Perel-Winkler, A, 2019) |
| "Hydroxychloroquine (HCQ) has been used to treat systemic lupus erythematosus (SLE) in Japan since 2015." | 1.51 | A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus. ( Hashimoto, Y; Kawazoe, M; Kusunoki, N; Nanki, T; Shikano, K; Shindo, E; Yamamoto, T, 2019) |
| "We hypothesized that patients with systemic lupus erythematosus (SLE) have greater blood pressure visit-to-visit variability than control subjects and that blood pressure visit-to-visit variability is associated with a higher comorbidity burden." | 1.51 | Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden. ( Barker, KA; Barnado, A; Chung, CP; Dickson, AL; Dupont, WD; Gandelman, JS; Khan, OA; Neal, JE; Reese, T; Shuey, MM; Stein, CM, 2019) |
| "The leading diagnoses were systemic lupus erythematosus (32%), rheumatoid arthritis (29%), and inflammatory arthritis (14%)." | 1.48 | Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients. ( Clowse, MEB; Criscione-Schreiber, LG; Eudy, AM; Mohammad, S, 2018) |
| "Preterm birth was defined as a birth <37 weeks gestation." | 1.48 | Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. ( Clowse, MEB; Eudy, AM; Haroun, T; James, AH; Jayasundara, M; Neil, L, 2018) |
| "Admission Systemic Lupus Erythematosus Disease Activity Index scores (30 vs." | 1.48 | Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( Cohen, EM; Costenbader, KH; D'Silva, K; Kreps, D; Son, MB, 2018) |
| "Hydroxychloroquine (HCQ) is a commonly used medicine for the treatment of systemic lupus erythematosus (SLE), and Th17 cells are closely related to the pathogenesis of SLE." | 1.48 | Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus. ( Li, M; Yang, J; Yang, X, 2018) |
| "Methods Mepacrine was added to 46 systemic lupus erythematosus patients unresponsive to treatment with the following drug combinations: hydroxychloroquine + prednisone + immunosuppressive drugs ( n = 24), hydroxychloroquine + prednisone ( n = 16), hydroxychloroquine + prednisone + retinoids ( n = 2), hydroxychloroquine alone ( n = 1), hydroxychloroquine + one immunosuppressive drug ( n = 1), hydroxychloroquine + prednisone + one immunosuppressive drug + belimumab ( n = 1) or hydroxychloroquine + prednisone + belimumab ( n = 1)." | 1.48 | Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. ( Agesta, N; Martinez-Zapico, A; Ortego-Centeno, N; Porta, S; Ríos, R; Ruiz-Irastorza, G; Ugarte, A, 2018) |
| "Hydroxychloroquine was protective of mortality from serious infections (HR 9." | 1.48 | Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. ( Ling, GR; Teh, CL; Wan, SA, 2018) |
| "However, the effect of HCQ on UC-MSCs in lupus nephritis (LN) has not been investigated." | 1.48 | Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice. ( Chen, Q; Han, X; Kuang, S; Liao, X; Luan, Y; Ma, J; Mai, S; Tian, X; Wei, Y; Wu, Y; Yang, J; Yang, Y; Zou, L, 2018) |
| "Hydroxychloroquine (HCQ) is an old antimalarial drug that has proven to be a safe and effective treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases." | 1.48 | Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood. ( Charlier, B; Conti, V; Dal Piaz, F; Filippelli, A; Izzo, V; Pingeon, M; Valentini, G, 2018) |
| "We aimed to assess the impact of ophthalmology weight-based hydroxychloroquine (HCQ) dosing guidelines on prescribing patterns." | 1.48 | Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. ( Choi, HK; Jorge, AM; Marmor, MF; Melles, RB; Zhang, Y, 2018) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| "Retinal involvement in systemic lupus erythematosus (SLE) and Sjögren syndrome (SS) may be subclinical and thus underdiagnosed." | 1.48 | Evidence for the Detection of Subclinical Retinal Involvement in Systemic Lupus Erythematosus and Sjögren Syndrome: A Potential Association with Therapies. ( Aloe, G; Canofari, C; Cesareo, M; Chimenti, MS; Conigliaro, P; Draghessi, G; Nucci, C; Perricone, R; Triggianese, P; Valeri, C, 2018) |
| " At least one side effect was reported by 19." | 1.48 | Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. ( Alessandri, C; Ceccarelli, F; Conti, F; Garufi, C; Massaro, L; Miranda, F; Morello, F; Moscarelli, E; Perricone, C; Spinelli, FR; Truglia, S; Valesini, G, 2018) |
| "Hydroxychloroquine (HCQ) is a widely prescribed medication to patients with systemic lupus erythematosus (SLE), with potential anti-inflammatory effects." | 1.48 | Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. ( Alirezaei, A; Dormanesh, B; Etemad Rezaie, A; Jahandoost, F; Khoshdel, AR; Mahmoudi, M; Monzavi, SM; Shariati-Sarabi, Z; Tavakol Afshari, J, 2018) |
| "Vitamin D deficiency was frequent in Chinese SLE patients and was associated with more active disease at baseline and over time, as well as a trend of more severe lupus flares." | 1.48 | Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysis. ( Bro, ET; Ho, LY; Jannetto, PJ; Mok, CC; Singh, RJ, 2018) |
| "The hydroxychloroquine was indicated for systemic lupus erythematosus in 73." | 1.46 | Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. ( Bahloul, E; Bahloul, Z; Garbaa, S; Jallouli, M; Marzouk, S; Masmoudi, A; Turki, H, 2017) |
| "We describe a case of MAS secondary to systemic lupus erythematosus in a young female that responded well to rituximab in lieu of etoposide." | 1.46 | Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus. ( Junga, Z; Keith, M; Stitt, R; Tracy, C, 2017) |
| "We included 124 patients with systemic lupus erythematosus or rheumatoid arthritis who were treated with HCQ." | 1.46 | Choroidal Thinning Associated With Hydroxychloroquine Retinopathy. ( Ahn, SJ; Joung, JY; Lee, BR; Ryu, SJ, 2017) |
| " The HCQ group showed a trend towards lower dosage of prednisone (OR 0." | 1.46 | Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. ( de Hair, MJH; Derksen, RHWM; Fritsch-Stork, RDE; Kroese, SJ; Lely, AT; Limper, M; van Laar, JM, 2017) |
| "Juvenile systemic lupus erythematosus (JSLE) is a complex multisystemic autoimmune disorder of unknown cause." | 1.46 | Juvenile systemic lupus erythematosus in Nigeria. ( Adelowo, OO; Akintayo, RO; Animashaun, BA; Olaosebikan, BH, 2017) |
| "Methods We identified systemic lupus erythematosus patients initiating immunosuppressive drugs or hydroxychloroquine using claims data from two US commercial health plans and Medicaid (2000-2012)." | 1.46 | Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. ( Feldman, CH; Feldman, S; Kim, SC; Liu, J; Solomon, DH, 2017) |
| "Psoriasis was diagnosed in 63 patients (49 females, 14 males) for a prevalence of 3." | 1.46 | Psoriasis in systemic lupus erythematosus: a single-center experience. ( Gladman, DD; Pakchotanon, R; Polachek, A; Su, J; Tselios, K; Urowitz, MB; Yap, KS, 2017) |
| " However, long-term use can be associated with irreversible retinal toxicity." | 1.46 | Hydroxychloroquine retinopathy: an emerging problem. ( Downes, SM; Gourier, H; Latasiewicz, M; Luqmani, R; Sharma, SM; Yusuf, IH, 2017) |
| "Hydroxychloroquine (HCQ) use was found as a protective factor for CVD." | 1.43 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. ( Alpay-Kanıtez, N; Aral, O; Artim-Esen, B; Demir, S; Erer, B; Gül, A; İnanç, M; Kamalı, S; Öcal, L; Omma, A; Pehlivan, Ö; Şahinkaya, Y, 2016) |
| "Hydroxychloroquine (HCQ) is an effective treatment for patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) and has been used for these patients in more than 70 nations." | 1.43 | Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus. ( Morita, S; Takahashi, T; Yokota, N; Yoshida, Y, 2016) |
| "Hydroxychloroquine was the most common (76%), followed by azathioprine (15%) and methotrexate (13%)." | 1.43 | Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007. ( Elfving, P; Kaipiainen-Seppänen, O; Kautiainen, H; Pohjolainen, T; Puolakka, K; Virta, LJ, 2016) |
| "Prednisone was associated with higher very low-density lipoprotein, low-density lipoprotein, HDL, and triglycerides." | 1.43 | Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy. ( Connelly, MA; Durcan, L; Magder, LS; Otvos, JD; Petri, M; Winegar, DA, 2016) |
| "The treatment of systemic lupus erythematosus (SLE) is complex, with a wide range of drugs commonly prescribed." | 1.43 | Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. ( Chang, DJ; Kan, H; Molta, C; Nagar, S; Patel, J; Wallace, DJ, 2016) |
| "To determine dosing patterns and examine predictors of filled hydroxychloroquine (HCQ) prescriptions in patients with systemic lupus erythematosus (SLE) with end-stage renal disease (ESRD)." | 1.43 | Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. ( Bethel, M; Carbone, LD; Li, S; Machua, W; Nahman, NS; Oliver, AM; Yang, FM, 2016) |
| "Vitamin D deficiency is highly prevalent in patients with SLE." | 1.43 | Severe vitamin D deficiency increases the risk for moderate to severe disease activity in Chinese patients with SLE. ( Gao, CC; Gao, GM; Li, TF; Liu, SY; Liu, ZS; Wu, ZZ; Zheng, ZH, 2016) |
| " Cases (1555 patients with SLE who developed HZ) and controls (3049 age- and sex-matched patients with SLE but without HZ) were analyzed for use of various immunosuppressive medications in the preceding 3-month period, and dose-response relationships were determined." | 1.43 | Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. ( Chen, GS; Hu, SC; Lin, CL; Lin, YC; Wang, TN; Yen, FL, 2016) |
| "Transverse myelitis is a rare complication of systemic lupus erythematosus (SLE)." | 1.42 | Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. ( Aumaitre, O; Broussolle, C; Cacoub, P; Costedoat-Chalumeau, N; Hot, A; Iwaz, J; Marignier, R; Maucort-Boulch, D; Saison, J; Sarrot-Reynauld, F; Schleinitz, N; Sève, P; Tebib, J; Vital-Durand, D, 2015) |
| "Acute toxic hepatitis was diagnosed, which rapidly returned to normal after cessation of the suspected causative medication, hydroxychloroquine, and subsequent administration of mycophenolate mofetil." | 1.42 | Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. ( Abdel Galil, SM, 2015) |
| "Thus, the pregnancy was considered a high-risk pregnancy." | 1.42 | [Systemic lupus erythematosus and a medical history of deep vein thrombosis in a 27-year-old pregnant woman]. ( Puppe, V, 2015) |
| "To examine the epidemiology of serious infections, a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE), in a nationwide cohort of SLE and lupus nephritis (LN) patients." | 1.42 | Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. ( Costenbader, KH; Feldman, CH; Franklin, JM; Hiraki, LT; Kim, SC; Marty, FM; Winkelmayer, WC, 2015) |
| "In 22 SLE patients with chronic renal insufficiency (median serum creatinine clearance 52 ml/minute [range 23-58 ml/minute]) who received 400 mg/day HCQ, the median blood HCQ concentration was significantly higher than that in the 509 patients from the PLUS study (1,338 ng/ml [range 504-2,229 ng/ml] versus 917 ng/ml [range 208-3316 ng/ml]) (P < 0." | 1.42 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. ( Ackermann, F; Amoura, Z; Asli, B; Aumaître, O; Blanchet, B; Cacoub, P; Cohen-Bittan, J; Costedoat-Chalumeau, N; Desmurs-Clavel, H; Fain, O; Francès, C; Galicier, L; Hulot, JS; Jallouli, M; Kahn, JE; Le Guern, V; Le Thi Huong, D; Leroux, G; Limal, N; Lioté, F; Mariette, X; Papo, T; Perard, L; Piette, JC; Pourrat, J; Sacré, K; Sailler, L; Sellam, J; Smail, A; Stirnemann, J; Zahr, N, 2015) |
| "The diagnosis of systemic lupus erythematosus (SLE) was established and even though transverse myelitis as a rare presentation of SLE has a poor outcome, the patient improved with cyclophosphamide, high-dose corticosteroids and hydroxychloroquine." | 1.42 | Lupus or syphilis? That is the question! ( Alves, JD; Duarte, JA; Henriques, CC; Sousa, C, 2015) |
| "Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening dermatological conditions." | 1.42 | [Systemic lupus erythematosus presenting as Stevens-Johnson syndrome]. ( Bellakhal, S; Ben Kaab, B; Derbel, F; Douggui, MH; Souissi, A; Teyeb, Z, 2015) |
| "Forty-two patients with systemic lupus erythematosus underwent ocular examination based on visual acuity evaluation, optical coherence tomography retinal thickness measurements, and multifocal electroretinography (mfERG) records at first visit." | 1.42 | Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study. ( Chatziralli, IP; Gatzioufas, Z; Kitsos, G; Koutsandrea, C; Moschos, MM; Nitoda, E, 2015) |
| "Troxis necrosis is a novel mechanism for drug-induced hepatitis, including immunomodulatory medications including a monoclonal anti-TWEAK antibody and Cellcept and Plaquenil, two widely used immunosuppression/anti-rejection medications." | 1.42 | Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy. ( Datta, A; Fleishman, W; French, SW; Karpouzas, G; Penunuri, A; Wei, CH, 2015) |
| "Juvenile systemic lupus erythematosus (JSLE) is a rare multisystem autoimmune disease with broad heterogeneity of clinical manifestations." | 1.42 | [Juvenile systemic lupus erythematosus with unusual manifestation of lupus-associated panniculitis]. ( Hashemie, H; Hoff, NP; Homey, B; Klossowski, N; Meller, S; Neubert, J; Oommen, PT; Reifenberger, J, 2015) |
| "Twenty-six out of 93 pregnancies with systemic lupus erythematosus (SLE) experienced flares during pregnancy." | 1.42 | Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study. ( Fei, Y; Hao, D; Li, Y; Liu, Y; Luo, Y; Zhang, L; Zhao, Y, 2015) |
| " There is disagreement about dosing; rheumatologists recommend weight-based dosing while some other specialists advocate height-based "ideal body weight" dosing." | 1.42 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. ( Clarke, WA; Durcan, L; Magder, LS; Petri, M, 2015) |
| "The coexistence of systemic lupus erythematosus (SLE) and multiple sclerosis (MS) in the same individual has rarely been described." | 1.40 | Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history. ( Amoiridis, G; Bertsias, G; Boumpas, DT; Fanouriakis, A; Mastorodemos, V; Pamfil, C; Papadaki, E; Plaitakis, A; Sidiropoulos, P, 2014) |
| "Here we report a case of a 22-year-old systemic lupus erythematosus (SLE) patient with three years' disease duration, stable on prednisone and hydroxychloroquine, who was found to have prolactinoma and recurrent GM after she discontinued medication on her own accord." | 1.40 | An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine. ( Shi, TY; Yang, YJ; Zhang, FC; Zhang, LN, 2014) |
| "Patients with systemic lupus erythematosus (SLE) have a higher prevalence of subclinical atherosclerosis and higher risk of cardiovascular (CV) events compared to the general population." | 1.40 | Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. ( Ammirati, E; Banfi, M; Baragetti, A; Bottoni, G; Bozzolo, EP; Catapano, AL; Cianflone, D; Contri, R; Garlaschelli, K; Grigore, L; Manfredi, AA; Monaco, C; Norata, GD; Palini, AG; Pirillo, A; Sabbadini, MG; Scotti, I; Uboldi, P, 2014) |
| "Papulonodular mucinosis (PNM) in particular is an uncommon cutaneous manifestation of LE." | 1.40 | Papulonodular mucinosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. ( Desai, S; Korta, DZ; Patel, RR; Sanchez, MR, 2014) |
| "Hydroxychloroquine-treated lupus patients showed a lower incidence of thromboembolic disease." | 1.40 | Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. ( Algieri, F; Duarte, J; Gálvez, J; Gómez-Guzmán, M; Gómez-Morales, M; Jiménez, R; López-Farré, AJ; O'Valle, F; Pérez-Vizcaino, F; Romero, M; Sabio, JM; Sánchez, M; Zarzuelo, MJ, 2014) |
| " And it is safe for pregnant women and fetuses." | 1.40 | [Prospective study of efficacy and safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus]. ( Gao, Z; Hao, D; Jin, D; Liu, J; Xu, D; Zhao, Y, 2014) |
| "To explore the hypothesis that cases of systemic lupus erythematosus (SLE) would be found more frequently in community members with high prior uranium exposure in the Fernald Community Cohort (FCC)." | 1.40 | Association of systemic lupus erythematosus with uranium exposure in a community living near a uranium-processing plant: a nested case-control study. ( Buckholz, JM; Harley, JB; James, JA; Kottyan, LC; Lu-Fritts, PY; Pinney, SM; Xie, C, 2014) |
| "Hydroxychloroquine has rarely been associated with TEN, with one case proving fatal." | 1.40 | Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. ( Cameron, MC; Dominguez, A; Word, AP, 2014) |
| "We present a 45-years-old suspected systemic lupus erythematosus (SLE) woman who had papulonodular mucinosis (PNM), without other cutaneous LE lesion." | 1.40 | Papulonodular mucinosis in a suspected systemic lupus erythematosus patient. ( Ausavarungnirun, R; Srisuttiyakorn, C, 2014) |
| "Systemic lupus erythematosus was diagnosed in a 34-year-old pregnant woman because of leukopenia, typical skin rash, clinical and biochemical signs of muscle involvement, and positive serology (antinuclear antibodies and anti-double-stranded DNA)." | 1.39 | Myopathy complicating lupus pregnancy. ( d'Amati, G; Framarino-dei-Malatesta, M; Gattamelata, A; Giordano, C; Piccioni, MG; Priori, R; Valesini, G, 2013) |
| "Given the infrequent occurrence of hydroxychloroquine toxic effects, few data are available about the presenting features and long-term follow-up of patients with hydroxychloroquine retinopathy, making it difficult to surmise the clinical course of patients after cessation of drug treatment." | 1.39 | Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. ( Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013) |
| "She also had developed anasarca two years prior to presentation." | 1.39 | Systemic lupus erythematosus and granulomatous lymphadenopathy. ( Dhakal, AK; Shah, SC; Shakya, A; Shakya, H; Shiva, RK; Shrestha, D, 2013) |
| "The progression from DLE to systemic lupus erythematosus has been reported in up to 28% of patients." | 1.39 | Pulmonary hemorrhage in a patient initially presenting with discoid lupus. ( Jiménez-Encarnación, E; Vilá, S; Vilá-Rivera, K, 2013) |
| "Hydroxychloroquine (HCQ) has been shown in retrospective studies to decrease aPL titers in laboratory studies, and to decrease thrombosis risk in patients with systemic lupus erythematosus (SLE)." | 1.39 | Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. ( Broder, A; Putterman, C, 2013) |
| "While pleuropulmonary involvement in systemic lupus erythematosus (SLE) is a common occurrence, shrinking lung syndrome (SLS) is a rare complication of SLE, particularly in children." | 1.39 | Symptoms of shrinking lung syndrome reveal systemic lupus erythematosus in a 12-year-old girl. ( Berner, R; Geiger, J; Heinzmann, A; Hufnagel, M; Meinicke, H, 2013) |
| "New hydroxychloroquine toxicity was found in 2 of 183 returning patients (1." | 1.39 | Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. ( Browning, DJ, 2013) |
| "Systemic lupus erythematosus is one of the diseases, which can be associated with thrombotic microangiopathy." | 1.39 | Auricular chondritis and thrombotic microangiopathy: an unusual combination revealing systemic lupus erythematosus. ( Anguel, N; Bellon, N; Goujard, C; Lambotte, O; Vandendries, C, 2013) |
| "Tuberculosis is known to induce and exacerbate SLE and it becomes quite difficult to diagnose tuberculosis in this setting, owing to a similar, overlapping presentation of tuberculosis and SLE." | 1.39 | Disseminated tuberculosis in a patient with antinuclear antibody-negative systemic lupus erythematosus: a rare association. ( Aggarwal, P; Dev, N; Kumar, G; Kumar, N, 2013) |
| "We also assessed joint pain determined by patient visual analog scale (VAS), malaise (VAS), patient global assessment of SLE (VAS), and constitutional and musculoskeletal symptoms according to the British Isles Lupus Assessment Group (BILAG) disease activity index." | 1.38 | Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). ( Inada, S; Kato, Y; Sugii, S; Yokogawa, N, 2012) |
| "A total of 218 individuals with CLE or systemic lupus erythematosus and lupus nonspecific skin disease seen between January 5, 2007, and July 30, 2010." | 1.38 | Impact of smoking in cutaneous lupus erythematosus. ( Chang, AY; Feng, R; Foering, KP; Okawa, J; Piette, EW; Ten Have, TR; Werth, VP, 2012) |
| " Careful screening with multiple tests can detect toxic damage before prominent loss of the outer nuclear layer." | 1.38 | Comparison of screening procedures in hydroxychloroquine toxicity. ( Marmor, MF, 2012) |
| "Chorea is frequently a presenting feature, and is strongly related to the presence of antiphospholipid antibodies." | 1.38 | [Chorea, lupus and antiphospholipid antibodies]. ( Costedoat-Chalumeau, N; Leroux, G; Piette, JC; Reiner, P; Vidailhet, M, 2012) |
| "Bullous systemic lupus erythematosus (SLE) is a kind of LE-non-specific bullous skin disease that is rarely induced by a medication." | 1.38 | Methimazole-induced bullous systemic lupus erythematosus: a case report. ( Byun, HJ; Cho, KH; Lee, EB; Seo, JY, 2012) |
| "Treatment with dapsone resulted in complete resolution of the skin lesions." | 1.37 | Erythema elevatum diutinum in systemic lupus erythematosus. ( Chan, Y; Mok, CC; Tang, WY, 2011) |
| "We report a case of acquired thrombotic thrombocytopenic purpura (TTP) in a 34-year old patient with a prior diagnosis of systemic lupus erythematosis (SLE) who was recently started on hydroxychloroquine." | 1.37 | Acquired thrombotic thrombocytopenic purpura: puzzles, curiosities and conundrums. ( Mar, N; Mendoza Ladd, A, 2011) |
| "Catatonia is a syndrome of physical and behavioral abnormalities that can result from psychiatric, neurological, or medical illness." | 1.37 | Catatonia as the presenting symptom in systemic lupus erythematosus. ( Pustilnik, S; Trutia, A, 2011) |
| "However, a few cases of minimal change glomerulopathy have been reported in association with systemic lupus erythematosus (SLE)." | 1.37 | A case of minimal change disease treated successfully with mycophenolate mofetil in a patient with systemic lupus erythematosus. ( Hong, YH; Jung, YW; Kim, HJ; Lee, CK; Oh, MJ; Yun, DY, 2011) |
| "Bone infarcts were also associated with these factors." | 1.36 | A case of SLE with bilateral osteonecrosis of femoral heads and bone infarct in distal of femur. ( Karimifar, M; Karimzadeh, H; Mottaghi, P; Salesi, M; Sayedbonakdar, Z, 2010) |
| "In addition, she had a central scotoma (RE > LE) on automated visual field analysis (Humphrey central 30 degrees )." | 1.36 | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. ( Leroy, BP; Salu, P; Uvijls, A; van den Brande, P, 2010) |
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| "Few studies have examined thrombosis in systemic lupus erythematosus (SLE), none have included Asian-Americans, and most have had small sample sizes." | 1.35 | Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. ( Cleveland, CM; Criswell, LA; Kaiser, R, 2009) |
| "Blepharitis is a rare involvement of the chronic lupus erythematosus and in case that is isolated, the diagnosis is belated and can lead to complications." | 1.35 | [Blepharitis--rare in systemic lupus erythematosus]. ( Anna-Adrien, C; Edit, FJ; Gyl, F; Irimie, M; Oanţă, A, 2008) |
| "Fatigue was quantified using a 0-10 visual analogue scale (VAS)." | 1.35 | Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. ( Aguirre, C; Egurbide, MV; Martinez-Berriotxoa, A; Olivares, N; Ruiz-Irastorza, G, 2008) |
| "Association of celiac disease with systemic lupus erythematosus is rare, even though HLA B8 and DR3 are commonly associated with these diseases." | 1.35 | Systemic lupus erythematosus, celiac disease and antiphospholipid antibody syndrome: a rare association. ( Gupta, D; Mirza, N, 2008) |
| "Hydroxychloroquine (HCQ) has a long elimination half-life and its concentration in whole blood can be measured easily." | 1.34 | Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. ( Amoura, Z; Aymard, G; Costedoat-Chalumeau, N; Hulot, JS; Lechat, P; Leroux, G; Marra, D; Piette, JC, 2007) |
| "In patients with systemic lupus erythematosus (SLE), hydroxychloroquine prevents disease flares and damage accrual and facilitates the response to mycophenolate mofetil in those with renal involvement." | 1.34 | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). ( Alarcón, GS; Bastian, HM; Bertoli, AM; Calvo-Alén, J; Fessler, BJ; McGwin, G; Reveille, JD; Vilá, LM, 2007) |
| " A young patient presenting with toxic maculopathy after 57 g of hydroxychloroquine and a daily dosage of 2 mg/kg body weight prompted us to retrospectively look at our patients examined in this respect over about 1 year." | 1.34 | [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]. ( Berndt, S; Foerster, J; Rüther, K; Schroeter, J, 2007) |
| "The first case, in a patient with systemic lupus erythematosus, was found to have megamitochondria in addition to myelin figures seen by electron microscopy." | 1.34 | New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. ( Barouch, LA; Champion, HC; Halushka, MK; Soong, TR; Wigley, FM, 2007) |
| "A 39-year-old woman with a history of systemic lupus erythematosus developed chest pain and conduction abnormalities." | 1.33 | Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. ( Amin, S; Bhatia, S; Edwards, WD; Keating, RJ; Sinak, LJ; Williams, A, 2005) |
| "Osteonecrosis is common in systemic lupus erythematosus (SLE) and often disabling." | 1.33 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. ( Alarcón, GS; Baethge, BA; Bastian, HM; Calvo-Alén, J; Cepeda, EJ; Fernández, M; Fessler, BJ; González, EB; McGwin, G; Reveille, JD; Roseman, JM; Toloza, S; Vilá, LM, 2006) |
| "Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls." | 1.33 | Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. ( Benne, CA; Bijl, M; De Vries, JJ; Holvast, A; Horst, G; Huckriede, A; Kallenberg, CG; Wilschut, J, 2006) |
| " We report a case of chronic use of HCQ associated with torsade de pointes." | 1.33 | Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. ( Chen, CY; Lin, CC; Wang, FL, 2006) |
| "Hearing loss can accompany systemic lupus erythematosus (SLE)." | 1.33 | Asymptomatic sensorineural hearing loss in patients with systemic lupus erythematosus. ( Cassano, G; Chiavarini, J; Graf, C; Heredia, C; Paira, S; Rico, L; Roverano, S, 2006) |
| "The association psoriasis and systemic lupus erythematosus (SLE) is a very uncommon association." | 1.32 | [Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems]. ( Arlet, P; Astudillo, L; Carreiro, M; Dahan, S; Ollier, S; Sailler, L, 2003) |
| "Pulmonary hemorrhage is a major life-threatening manifestation in children and adolescents with systemic lupus erythematosus, as well as in adults." | 1.32 | Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. ( Lindsley, CB; Samad, AS, 2003) |
| "Skin involvement in systemic lupus erythematosus (SLE) occurs in varied forms." | 1.32 | Lupus erythematosus tumidus in systemic lupus erythematosus: novel association and possible role of early treatment in prevention of discoid lupus erythematosus. ( Jolly, M; Laumann, AE; Shea, CR; Utset, TO, 2004) |
| "Nail changes occur in about 25% of systemic lupus erythematosus (SLE) cases." | 1.32 | Hyperkeratotic nail discoid lupus erythematosus evolving towards systemic lupus erythematosus: therapeutic difficulties. ( André, J; Bourguignon, R; de la Brassinne, M; Richert, B, 2004) |
| "Hydroxychloroquine therapy was significantly associated with lower SLICC/ACR DI." | 1.31 | Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. ( Amit-Vazina, M; Gorshtein, A; Guedj, D; Majadla, R; Molad, Y; Weinberger, A; Wysenbeek, AJ, 2002) |
| "The effect of systemic lupus erythematosus (SLE) treatment drugs on PKC (protein kinase C) activity and cell growth was studied using GI-101A breast tumor cells." | 1.31 | Effect of systemic lupus erythematosus (SLE) treatment drugs on GI-101A breast tumor cell growth. ( Fernandez, Y; Ramakrishnan, R; Rathinavelu, A, 2000) |
| "We report on a case of a 17-year-old female with systemic lupus erythematosus (SLE), with a clinical history of complex partial seizure, who developed a tonicoclonic crisis after receiving hydroxychloroquine for 2 weeks at a dosage of 200 mg/day (5 mg/kg)." | 1.31 | Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. ( Cappelli, M; Danieli, MG; Fraticelli, P; Malcangi, G; Palmieri, C, 2000) |
| "In SLE patients, with sensorineural hearing loss, echocardiography should be performed looking for evidence of aortic insufficiency, which may be steroid responsive." | 1.31 | Sensorineural hearing loss in conjunction with aortic insufficiency in systemic lupus erythematosus. ( Barland, P; Peeva, E, 2001) |
| "The serological hallmark of systemic lupus erythematosus (SLE) is the presence of antibodies against double-stranded DNA." | 1.31 | Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. ( Chen, CY; Chen, MY; Chuang, CY; Lee, GL; Liu, MF; Liu, ST; Wang, CR; Yin, GD, 2001) |
| "This report describes the case of an appropriately dosed patient who developed maculopathy <8 years after starting hydroxychloroquine (HCQ) therapy for systemic lupus erythematosus." | 1.31 | Early hydroxychloroquine macular toxicity. ( Warner, AE, 2001) |
| "Many patients with systemic lupus erythematosus (SLE) and fibromyalgia (FM) may spend less time exposed to the sun than healthy individuals and thus might have low vitamin D levels." | 1.31 | Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. ( Algra, A; Bell, DA; Bijlsma, JW; Harth, M; Huisman, AM; Jacobs, JW; Vieth, R; White, KP, 2001) |
| " We revised the antimalarials use in Rheumatology, their utility, doses, adverse events and risk factors as cumulate doses, ideal daily doses, renal function and ophthalmological reviews recommendations." | 1.31 | [Eye toxicity of antimalarial agents]. ( Cabana Vázquez, M; Graña Gil, J; Sánchez Meizoso, MO; Vázquez González, A, 2002) |
| "A woman with systemic lupus erythematosus developed severe myopathy after a septicemic episode, and her treatment before admission was hydroxychloroquine sulfate and prednisolone." | 1.30 | Hydroxychloroquine myopathy. ( Richards, AJ, 1998) |
| "Hydroxychloroquine (HCQ) is a valuable and possibly underused agent in treating mild lupus." | 1.29 | The use of hydroxychloroquine in lupus pregnancy: the British experience. ( Buchanan, NM; Hughes, GR; Khamashta, MA, 1996) |
| "Both patients were treated for systemic lupus erythematosus; one patient was treated with 400 to 800 mg of hydroxychloroquine per day (6." | 1.28 | Hydroxychloroquine retinopathy. ( Berson, EL; Gaudio, AR; Kini, MM; Sandberg, MA; Weiner, A, 1991) |
| "A case of transverse myelopathy in systemic lupus erythematosus with subacute onset and fatal course is reported." | 1.26 | [Transverse myelopathy and systemic lupus erythematosus. Report of a case and review of the literature]. ( Borges, TM; de Macedo, DD; de Mattos, JP, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 79 (7.88) | 18.7374 |
| 1990's | 61 (6.08) | 18.2507 |
| 2000's | 124 (12.36) | 29.6817 |
| 2010's | 402 (40.08) | 24.3611 |
| 2020's | 337 (33.60) | 2.80 |
| Authors | Studies |
|---|---|
| Bitoun, S | 1 |
| Nocturne, G | 1 |
| Seror, R | 1 |
| Mariette, X | 3 |
| Akca, ÜK | 1 |
| Batu, ED | 2 |
| Kısaarslan, AP | 1 |
| Poyrazoğlu, H | 1 |
| Ayaz, NA | 1 |
| Sözeri, B | 1 |
| Sağ, E | 1 |
| Atalay, E | 1 |
| Demir, S | 2 |
| Karadağ, ŞG | 1 |
| Demir, F | 1 |
| Bilginer, Y | 1 |
| Gümrük, F | 1 |
| Özen, S | 2 |
| Loghmani, A | 1 |
| Ford, B | 1 |
| Derbes, S | 1 |
| Kuroda, K | 1 |
| Itagane, M | 1 |
| Kinjo, M | 1 |
| de Sire, A | 1 |
| Tedesco Silva, LM | 1 |
| Cortes, A | 1 |
| Rossi, B | 1 |
| Boll, L | 1 |
| Waclawovsky, G | 1 |
| Eibel, B | 1 |
| Cadaval Gonçalves, S | 1 |
| Irigoyen, MC | 1 |
| Martinez, D | 1 |
| Haase, I | 2 |
| Fischer-Betz, R | 4 |
| Li, XB | 1 |
| Cao, NW | 1 |
| Chu, XJ | 1 |
| Zhou, HY | 1 |
| Wang, H | 2 |
| Yu, SJ | 1 |
| Ye, DQ | 2 |
| Li, BZ | 1 |
| Borrelli, E | 1 |
| Battista, M | 1 |
| Cascavilla, ML | 1 |
| Viganò, C | 1 |
| Borghesan, F | 1 |
| Nicolini, N | 1 |
| Clemente, L | 1 |
| Sacconi, R | 1 |
| Barresi, C | 1 |
| Marchese, A | 1 |
| Miserocchi, E | 1 |
| Modorati, G | 1 |
| Bandello, F | 1 |
| Querques, G | 1 |
| Braga, A | 1 |
| Barros, T | 1 |
| Faria, R | 1 |
| Marinho, A | 1 |
| Carvalheira, G | 1 |
| Rocha, G | 1 |
| Farinha, F | 1 |
| Neves, E | 1 |
| Vasconcelos, C | 1 |
| Braga, J | 1 |
| Lim, JW | 1 |
| Lee, JH | 1 |
| Kim, HJ | 2 |
| Huang, H | 3 |
| Mu, L | 1 |
| Zhang, Z | 5 |
| Gao, D | 2 |
| Hao, Y | 2 |
| Zhou, W | 1 |
| Yang, JX | 1 |
| Williamson, KA | 1 |
| Duarte-García, A | 2 |
| Zavala-Flores, E | 1 |
| Salcedo-Matienzo, J | 1 |
| Quiroz-Alva, A | 1 |
| Berrocal-Kasay, A | 1 |
| Lodge, FM | 1 |
| Moody, WE | 1 |
| Tosounidou, S | 2 |
| Chue, CD | 1 |
| Curtis, E | 1 |
| Neil, DAH | 1 |
| Bradlow, W | 1 |
| Sullivan, JK | 1 |
| Littlejohn, EA | 1 |
| Gernaat, SAM | 1 |
| Simard, JF | 3 |
| Wikström, AK | 1 |
| Svenungsson, E | 3 |
| Arkema, EV | 1 |
| Ayano, M | 1 |
| Kimoto, Y | 1 |
| Mitoma, H | 1 |
| Akahoshi, M | 1 |
| Ono, N | 1 |
| Arinobu, Y | 1 |
| Akashi, K | 1 |
| Horiuchi, T | 1 |
| Niiro, H | 1 |
| Gao, R | 1 |
| Deng, W | 1 |
| Meng, C | 1 |
| Cheng, K | 1 |
| Zeng, X | 3 |
| Qin, L | 1 |
| Almeida-Brasil, CC | 5 |
| Hanly, JG | 6 |
| Urowitz, M | 7 |
| Clarke, AE | 10 |
| Ruiz-Irastorza, G | 17 |
| Gordon, C | 10 |
| Ramsey-Goldman, R | 6 |
| Petri, M | 25 |
| Ginzler, EM | 5 |
| Wallace, DJ | 16 |
| Bae, SC | 7 |
| Romero-Diaz, J | 5 |
| Dooley, MA | 5 |
| Peschken, C | 5 |
| Isenberg, D | 5 |
| Rahman, A | 5 |
| Manzi, S | 7 |
| Jacobsen, S | 6 |
| Lim, S | 1 |
| van Vollenhoven, RF | 3 |
| Nived, O | 4 |
| Jönsen, A | 5 |
| Kamen, DL | 6 |
| Aranow, C | 6 |
| Sanchez-Guerrero, J | 5 |
| Gladman, DD | 16 |
| Fortin, PR | 10 |
| Alarcón, GS | 14 |
| Merrill, JT | 7 |
| Kalunian, K | 5 |
| Ramos-Casals, M | 4 |
| Steinsson, K | 4 |
| Zoma, A | 4 |
| Askanase, A | 6 |
| Khamashta, MA | 9 |
| Bruce, IN | 7 |
| Inanc, M | 7 |
| Abrahamowicz, M | 2 |
| Bernatsky, S | 11 |
| Jorge, A | 4 |
| Lu, N | 3 |
| Choi, H | 3 |
| Esdaile, JM | 5 |
| Lacaille, D | 2 |
| Avina-Zubieta, JA | 5 |
| Anuwutnavin, S | 1 |
| Chuenchitkultavorn, V | 1 |
| Nitiyarom, R | 1 |
| Rekhawasin, T | 1 |
| Kanjanauthai, S | 1 |
| Sompagdee, N | 1 |
| Balevic, SJ | 5 |
| Weiner, D | 2 |
| Clowse, MEB | 7 |
| Eudy, AM | 8 |
| Maharaj, AR | 1 |
| Hornik, CP | 4 |
| Cohen-Wolkowiez, M | 4 |
| Gonzalez, D | 3 |
| Ji, L | 2 |
| Xie, W | 1 |
| Fasano, S | 8 |
| Bermas, B | 3 |
| Costedoat-Chalumeau, N | 35 |
| Sprow, G | 2 |
| Afarideh, M | 1 |
| Werth, VP | 3 |
| Crow, MK | 1 |
| Kirou, KA | 1 |
| Barros Edington, FL | 1 |
| de Rezende, DF | 1 |
| Dos Santos, LFS | 1 |
| Garcia, RV | 1 |
| Gadelha, SR | 1 |
| Santiago, MB | 1 |
| Peh, D | 1 |
| Wan Ahmad Kammal, WSL | 1 |
| Beh, PJ | 1 |
| Yong, ACH | 1 |
| Tan, WC | 1 |
| Lim, AL | 1 |
| Thevarajah, S | 1 |
| Stanslas, J | 1 |
| How, KN | 1 |
| Ntali, S | 1 |
| Nikolopoulos, D | 3 |
| Pantazi, L | 1 |
| Emmanouilidou, E | 1 |
| Papagoras, C | 1 |
| Fanouriakis, A | 9 |
| Dimopoulou, D | 1 |
| Kallitsakis, I | 1 |
| Boki, K | 1 |
| Dania, V | 1 |
| Sidiropoulos, PI | 1 |
| Boumpas, DT | 8 |
| Bertsias, G | 8 |
| Chang, Y | 1 |
| Di, W | 1 |
| Wu, J | 3 |
| Matthys, A | 1 |
| Megdiche, I | 1 |
| Bardel, B | 1 |
| Remy, P | 2 |
| Limal, N | 6 |
| Planté-Bordeneuve, V | 1 |
| Gendre, T | 1 |
| Gao, B | 1 |
| Tan, T | 1 |
| Cao, X | 1 |
| Pan, M | 1 |
| Yang, C | 2 |
| Wang, J | 2 |
| Shuai, Z | 1 |
| Xia, Q | 1 |
| Daftarian, N | 2 |
| Lima, A | 1 |
| Marozoff, S | 1 |
| Ojo, D | 1 |
| Levasseur, SD | 1 |
| Maberley, DAL | 1 |
| Hoens, A | 1 |
| Esdaile, J | 2 |
| Dawes, M | 1 |
| Adante, B | 1 |
| Bhui, RD | 1 |
| Bhui, SB | 1 |
| Butler, M | 1 |
| Chui, L | 1 |
| Erasmus, M | 1 |
| Etminan, M | 1 |
| Godinho, D | 1 |
| Hay, E | 1 |
| Hollands, H | 1 |
| Hoonjan, M | 1 |
| Joe, A | 1 |
| Lukaris, A | 1 |
| Mammo, Z | 1 |
| Navajas, E | 1 |
| Pakzad-Vaezi, K | 1 |
| Sanmugasunderam, S | 1 |
| Shojania, K | 1 |
| Tsai, HL | 1 |
| Chang, JW | 1 |
| Lu, JH | 1 |
| Liu, CS | 1 |
| El-Dokla, AM | 1 |
| Bonilla, E | 1 |
| Ali, S | 1 |
| Perl, A | 1 |
| Bouayed, K | 1 |
| Faid, T | 1 |
| Sakhi, A | 1 |
| Boutaleb, AM | 1 |
| Drighil, A | 1 |
| Balevic, S | 1 |
| Sanders-Schmidler, G | 1 |
| Kosinski, A | 1 |
| Molad, Y | 3 |
| Nalli, C | 1 |
| Mokbel, A | 1 |
| Tincani, A | 5 |
| Bay, C | 1 |
| van Noord, M | 1 |
| Iudici, M | 4 |
| Coscia, MA | 3 |
| Messiniti, V | 2 |
| Borgia, A | 1 |
| Tirri, R | 1 |
| Ciccia, F | 3 |
| Weidman-Evans, E | 1 |
| Porter, M | 1 |
| Baert, CA | 1 |
| Nieuwland, S | 1 |
| Sokolova, T | 1 |
| Tamirou, F | 2 |
| Houssiau, F | 2 |
| Fu, XL | 1 |
| Qian, Y | 1 |
| Jin, XH | 1 |
| Yu, HR | 1 |
| Du, L | 1 |
| Wu, H | 1 |
| Chen, HL | 1 |
| Shi, YQ | 1 |
| Mancuso, S | 1 |
| Spinelli, FR | 4 |
| Agati, L | 1 |
| Ciardi, MR | 1 |
| Garufi, C | 2 |
| Natalucci, F | 1 |
| Molteni, E | 1 |
| Truglia, S | 2 |
| Riccieri, V | 1 |
| Priori, R | 3 |
| Mastroianni, CM | 1 |
| Conti, F | 5 |
| Walbi, IA | 1 |
| Albarqi, HA | 1 |
| Alghanim, NS | 1 |
| Albadi, MA | 1 |
| Al Maimouni, HM | 1 |
| Alkahtani, SA | 1 |
| Alshabi, AM | 1 |
| Alali, AS | 1 |
| Alqahtani, F | 1 |
| Al-Najjar, AH | 1 |
| Hazzazi, MA | 1 |
| Alanazi, DS | 1 |
| Sabei, AA | 1 |
| Alsaweed, OS | 1 |
| Alajra, RK | 1 |
| Alqhtani, H | 1 |
| Clemmer, JS | 1 |
| Hillegass, WB | 1 |
| Taylor, EB | 1 |
| Barton, JC | 2 |
| Bertoli, LF | 1 |
| Zhao, Y | 5 |
| Huang, C | 1 |
| You, H | 2 |
| Zhao, J | 7 |
| Wang, Q | 3 |
| Tian, X | 3 |
| Li, M | 3 |
| Wang, Y | 5 |
| Deng, X | 1 |
| Geng, Y | 1 |
| Belmont, HM | 3 |
| Haj-Ali, M | 1 |
| Chakrabarti, K | 1 |
| McCune, WJ | 3 |
| Dorji, T | 1 |
| Hegde, A | 1 |
| Asturkar, V | 1 |
| Yangzom, S | 1 |
| Bhanu, K | 1 |
| Fotis, L | 1 |
| Gioti, O | 2 |
| Patel, J | 2 |
| Vazquez, T | 1 |
| Chin, F | 1 |
| Keyes, E | 1 |
| Yan, D | 1 |
| Diaz, D | 1 |
| Grinnell, M | 1 |
| Sharma, M | 1 |
| Li, Y | 6 |
| Feng, R | 2 |
| Dan, J | 1 |
| Aringer, M | 4 |
| Hugo, C | 1 |
| Ni, J | 1 |
| Zhu, H | 1 |
| Lu, L | 3 |
| Zhao, Z | 2 |
| Jiang, J | 1 |
| You, X | 1 |
| Ma, Y | 3 |
| Yang, Z | 1 |
| Hou, Y | 1 |
| Dou, H | 1 |
| Wakiya, R | 4 |
| Ueeda, K | 3 |
| Nakashima, S | 4 |
| Shimada, H | 4 |
| Kameda, T | 4 |
| Mansour, MMF | 1 |
| Kato, M | 4 |
| Miyagi, T | 4 |
| Sugihara, K | 2 |
| Mizusaki, M | 2 |
| Mino, R | 2 |
| Kadowaki, N | 4 |
| Dobashi, H | 4 |
| Chang, JC | 2 |
| Costenbader, KH | 13 |
| Reynolds, JA | 1 |
| Gayed, M | 1 |
| Leone, F | 1 |
| Toescu, V | 1 |
| Giles, I | 1 |
| Teh, LS | 1 |
| McHugh, N | 1 |
| Akil, M | 1 |
| Edwards, CJ | 1 |
| Huo, X | 1 |
| Finkelstein, J | 1 |
| Subasi, S | 1 |
| Kucuk, KD | 1 |
| San, S | 1 |
| Cefle, A | 1 |
| Tokuc, EO | 1 |
| Balci, S | 1 |
| Yazici, A | 1 |
| Kishibe, M | 1 |
| Takeda, K | 1 |
| Honma, M | 1 |
| Makino, Y | 1 |
| Ishida-Yamamoto, A | 1 |
| Araújo, O | 1 |
| Hernández-Rodríguez, J | 1 |
| Pelegrín, L | 1 |
| Feliu, M | 1 |
| Boland, M | 1 |
| Hernández-Negrín, H | 1 |
| Adán, A | 1 |
| Espinosa, G | 1 |
| Cervera, R | 4 |
| Miyatake, N | 2 |
| Tan, Y | 1 |
| Yang, S | 1 |
| Liu, Q | 1 |
| Li, Z | 3 |
| Mu, R | 1 |
| Qiao, J | 1 |
| Cui, L | 1 |
| Garg, S | 4 |
| Chewning, B | 2 |
| Gazeley, D | 1 |
| Gomez, S | 2 |
| Kaitz, N | 1 |
| Weber, AC | 1 |
| Rosenthal, A | 1 |
| Bartels, C | 2 |
| Karaalioğlu, B | 1 |
| Yıldırım, F | 1 |
| Mutlu, MY | 1 |
| Akkuzu, G | 1 |
| Özgür, DS | 1 |
| Bes, C | 1 |
| Arbitman, L | 1 |
| Furie, R | 1 |
| Vashistha, H | 1 |
| Niu, J | 2 |
| Chen, J | 2 |
| Green, D | 1 |
| McMahon, A | 1 |
| Schanberg, LE | 5 |
| Glaser, R | 1 |
| Burckart, GJ | 1 |
| Fairley, JL | 1 |
| Nikpour, M | 3 |
| Mack, HG | 1 |
| Brosnan, M | 1 |
| Saracino, AM | 1 |
| Pellegrini, M | 2 |
| Wicks, IP | 2 |
| Hou, W | 1 |
| Jiang, Y | 5 |
| Liu, G | 1 |
| Ren, X | 1 |
| Liu, K | 1 |
| Liu, H | 2 |
| Chen, K | 1 |
| Hoque, MR | 1 |
| Xie, H | 2 |
| Mucke, J | 1 |
| Schneider, M | 4 |
| Silver, R | 1 |
| Craigo, S | 1 |
| Porter, F | 1 |
| Osmundson, SS | 1 |
| Kuller, JA | 1 |
| Norton, ME | 1 |
| Hsu, BC | 1 |
| Chen, YH | 2 |
| Lin, CH | 4 |
| Tang, KT | 1 |
| Chen, PH | 1 |
| Tung, HH | 1 |
| Huang, KP | 1 |
| Ni, YL | 1 |
| Lin, CY | 1 |
| Jorge, AM | 5 |
| Mancini, C | 1 |
| Zhou, B | 2 |
| Ho, G | 1 |
| Zhang, Y | 6 |
| Costenbader, K | 1 |
| Choi, HK | 5 |
| Shimizu, M | 2 |
| Furudate, S | 1 |
| Nagai, Y | 1 |
| Shimada, K | 2 |
| Ohshima, M | 1 |
| Setoguchi, K | 1 |
| Hashiguchi, M | 1 |
| Yokogawa, N | 6 |
| Şenkal, N | 1 |
| Kıyan, E | 1 |
| Demir, AA | 1 |
| Yalçınkaya, Y | 1 |
| Gül, A | 2 |
| Öçal, ML | 1 |
| Esen, BA | 1 |
| Sada, KE | 2 |
| Katayama, Y | 1 |
| Asano, Y | 1 |
| Hayashi, K | 1 |
| Miyawaki, Y | 2 |
| Ohashi, K | 1 |
| Katsuyama, E | 1 |
| Katsuyama, T | 1 |
| Takano-Narazaki, M | 1 |
| Matsumoto, Y | 1 |
| Yoshimi, R | 3 |
| Shimojima, Y | 2 |
| Ohno, S | 2 |
| Kajiyama, H | 2 |
| Ichinose, K | 2 |
| Sato, S | 2 |
| Fujiwara, M | 2 |
| Yajima, N | 2 |
| Omer, MH | 1 |
| Salama, H | 1 |
| Alghaythi, AM | 1 |
| Alharbi, AA | 1 |
| AlJohani, G | 1 |
| Su, L | 1 |
| Qi, Z | 1 |
| Guan, S | 1 |
| Wei, L | 1 |
| Sun, K | 1 |
| Coles, TM | 1 |
| Voils, CI | 1 |
| Anderson, DR | 1 |
| Sadun, RE | 1 |
| Rogers, JL | 1 |
| Criscione-Schreiber, LG | 2 |
| Doss, J | 1 |
| Maheswaranathan, M | 1 |
| Zheng, YQ | 1 |
| Li, HJ | 2 |
| Chen, L | 1 |
| Lin, SP | 1 |
| Yamamoto, M | 1 |
| Saito, M | 1 |
| Yamamoto, T | 2 |
| Cai, T | 1 |
| Yang, Y | 3 |
| Zhang, JA | 1 |
| Randell, R | 1 |
| Beard, C | 1 |
| Jimenez, AL | 1 |
| Valle, A | 2 |
| Mustehsan, MH | 1 |
| Wang, S | 5 |
| Law, J | 1 |
| Guerrero, MS | 1 |
| Mowrey, WB | 3 |
| Horton, DB | 1 |
| Briceno, D | 1 |
| Broder, A | 5 |
| Lenfant, T | 3 |
| Ameen Ismail, A | 1 |
| Sadek, SH | 1 |
| Hatata, RM | 1 |
| Yoshida, Y | 4 |
| Oka, N | 3 |
| Yorishima, A | 3 |
| Masuda, S | 3 |
| Ishitoku, M | 3 |
| Araki, K | 3 |
| Kohno, H | 3 |
| Watanabe, H | 3 |
| Sugimoto, T | 3 |
| Mokuda, S | 3 |
| Hirata, S | 3 |
| Petri, MA | 5 |
| Lim, SS | 6 |
| van Vollenhoven, R | 4 |
| Askanase, AD | 5 |
| Khamashta, M | 5 |
| Lukusa, L | 3 |
| Tsurane, K | 3 |
| Kaneko, K | 3 |
| Yoshida, K | 4 |
| Tanaka, R | 3 |
| Sago, H | 3 |
| Murashima, A | 4 |
| Ponfilly-Sotier, MP | 3 |
| Mahevas, T | 3 |
| Rivière, S | 3 |
| Dellal, A | 3 |
| Belfeki, N | 4 |
| Carrat, F | 3 |
| Fain, O | 8 |
| Mekinian, A | 3 |
| Zhang, N | 3 |
| Zhang, HX | 3 |
| Li, YW | 3 |
| Ye, S | 2 |
| Zhao, X | 3 |
| Liu, Y | 5 |
| Pinheiro, FO | 1 |
| Martins Carvalho, M | 1 |
| Madureira, P | 1 |
| Seabra Rato, M | 1 |
| Macedo, F | 1 |
| Costa, L | 1 |
| Jiménez-Antón, A | 1 |
| Jiménez-Gallo, D | 1 |
| Millán-Cayetano, JF | 1 |
| Navarro-Navarro, I | 1 |
| Linares-Barrios, M | 1 |
| Melles, RB | 5 |
| Marmor, MF | 6 |
| Conell, C | 1 |
| McCormick, N | 2 |
| Damirchi, M | 1 |
| Aghaie, M | 1 |
| Sedighi, S | 1 |
| Tavassoli, S | 1 |
| Roshandel, G | 1 |
| Hassani, M | 1 |
| Abdolahi, N | 1 |
| Cornet, A | 3 |
| Andersen, J | 4 |
| Tani, C | 4 |
| Mosca, M | 6 |
| Gheet, FS | 1 |
| Dawoud, HE | 1 |
| El-Shahaby, WA | 1 |
| Elrifaey, SM | 1 |
| Abdelnabi, HH | 1 |
| Caravaca-Fontán, F | 1 |
| Yandian, F | 1 |
| Fervenza, FC | 1 |
| Novelli, L | 1 |
| Barbati, C | 1 |
| Capuano, C | 1 |
| Recalchi, S | 1 |
| Ceccarelli, F | 3 |
| Vomero, M | 1 |
| Alessandri, C | 4 |
| Morrone, S | 1 |
| Zhong, X | 1 |
| Jin, YB | 1 |
| Zhang, Q | 1 |
| Liu, SL | 1 |
| He, J | 2 |
| Zubiaur, J | 1 |
| Herrero-Morant, A | 1 |
| Margarida de Castro, A | 1 |
| Pérez-Barquín, R | 1 |
| Ferraz-Amaro, I | 1 |
| Loricera, J | 1 |
| Castañeda, S | 1 |
| Blanco, R | 3 |
| Ru, L | 1 |
| Xu, J | 2 |
| Lin, Z | 1 |
| Cao, L | 1 |
| Zhang, L | 6 |
| Lam, NV | 2 |
| Brown, JA | 1 |
| Sharma, R | 2 |
| Lee, JE | 1 |
| Nam, DR | 1 |
| Sung, YK | 2 |
| Kim, YJ | 1 |
| Jung, SY | 2 |
| Bartels, CM | 2 |
| Feldman, CH | 10 |
| Zell, J | 1 |
| Barber, CEH | 1 |
| Haseley, L | 1 |
| Jatwani, S | 1 |
| Johansson, T | 1 |
| Limanni, A | 1 |
| Rodgers, W | 1 |
| Rovin, BH | 1 |
| Santiago-Casas, Y | 1 |
| Suter, LG | 1 |
| Barnado, A | 2 |
| Ude, J | 1 |
| Aguirre, A | 1 |
| Li, J | 10 |
| Schmajuk, G | 2 |
| Yazdany, J | 6 |
| Hawtin, S | 1 |
| André, C | 1 |
| Collignon-Zipfel, G | 1 |
| Appenzeller, S | 1 |
| Bannert, B | 1 |
| Baumgartner, L | 1 |
| Beck, D | 1 |
| Betschart, C | 1 |
| Boulay, T | 1 |
| Brunner, HI | 5 |
| Ceci, M | 1 |
| Deane, J | 1 |
| Feifel, R | 1 |
| Ferrero, E | 1 |
| Kyburz, D | 1 |
| Lafossas, F | 1 |
| Loetscher, P | 1 |
| Merz-Stoeckle, C | 1 |
| Michellys, P | 1 |
| Nuesslein-Hildesheim, B | 1 |
| Raulf, F | 1 |
| Rush, JS | 1 |
| Ruzzante, G | 1 |
| Stein, T | 1 |
| Zaharevitz, S | 1 |
| Wieczorek, G | 1 |
| Siegel, R | 1 |
| Gergely, P | 1 |
| Shisha, T | 1 |
| Junt, T | 1 |
| Machado-Alba, JE | 1 |
| Machado-Duque, ME | 1 |
| Gaviria-Mendoza, A | 1 |
| Duarte-Rey, C | 1 |
| González-Rangel, A | 1 |
| Hajji, M | 1 |
| Gorsane, I | 1 |
| Badrouchi, S | 1 |
| Litaiem, N | 1 |
| Rammeh, S | 1 |
| Ben Hamida, F | 1 |
| Abderrahim, E | 1 |
| Phoophiboon, V | 1 |
| Brown, P | 2 |
| Burns, KEA | 1 |
| El Hussein, MT | 1 |
| Wong, C | 1 |
| Nguyen, Y | 1 |
| Blanchet, B | 4 |
| Urowitz, MB | 10 |
| Isenberg, DA | 1 |
| Le Guern, V | 11 |
| Mackay, M | 1 |
| Kalunian, KC | 2 |
| Peschken, CA | 3 |
| Buyon, J | 1 |
| Liang, S | 1 |
| Wei, Z | 1 |
| Fang, H | 1 |
| Guan, T | 1 |
| Ferguson, S | 1 |
| Keevil, J | 1 |
| Bjerkaas Hanssen, M | 1 |
| Malm Gulati, A | 1 |
| Koksvik, H | 1 |
| Wallenius, M | 1 |
| Rao, IR | 1 |
| Kolakemar, A | 1 |
| Shenoy, SV | 1 |
| Prabhu, RA | 1 |
| Nagaraju, SP | 1 |
| Rangaswamy, D | 1 |
| Bhojaraja, MV | 1 |
| Hidekawa, C | 1 |
| Saigusa, Y | 1 |
| Tamura, J | 1 |
| Kojitani, N | 1 |
| Suzuki, N | 1 |
| Sakurai, N | 1 |
| Yoshioka, Y | 1 |
| Sugiyama-Kawahara, Y | 1 |
| Kunishita, Y | 2 |
| Kishimoto, D | 2 |
| Higashitani, K | 1 |
| Sato, Y | 1 |
| Komiya, T | 1 |
| Nagai, H | 2 |
| Hamada, N | 1 |
| Maeda, A | 1 |
| Tsuchida, N | 1 |
| Hirahara, L | 1 |
| Soejima, Y | 1 |
| Takase-Minegishi, K | 2 |
| Kirino, Y | 2 |
| Nakajima, H | 2 |
| Kalaw, FGP | 1 |
| Arnett, J | 1 |
| Baxter, SL | 1 |
| Walker, E | 1 |
| Pedersen, B | 1 |
| Borooah, S | 1 |
| Yassin, NA | 1 |
| Abdelsalam, M | 1 |
| El-Sabbagh, AM | 1 |
| Morsy, AI | 1 |
| Haleem, AA | 1 |
| El-Shenbaby, I | 1 |
| El Wakeel, GA | 1 |
| Hammad, A | 1 |
| Hamdy, N | 1 |
| Abd-El Ghafaar, DM | 1 |
| Elmarghany, EB | 1 |
| Korkor, MS | 1 |
| Eid, R | 1 |
| Lomanto Silva, R | 1 |
| Swabe, GM | 1 |
| Sattui, SE | 1 |
| Magnani, JW | 1 |
| Yousefi, M | 1 |
| Rukerd, MRZ | 1 |
| Binafar, H | 1 |
| Shoaie, S | 1 |
| Mirkamali, H | 1 |
| Pourzand, P | 1 |
| Kaveh, R | 1 |
| Zhang, F | 1 |
| Zhang, BY | 1 |
| Fan, R | 1 |
| Cheng, T | 1 |
| Hu, XR | 1 |
| Liu, YQ | 1 |
| Cen, X | 1 |
| Bu, YJ | 1 |
| Cao, JP | 1 |
| Chen, FW | 1 |
| Chen, JW | 1 |
| Gödecke, V | 1 |
| Witte, T | 1 |
| Arliny, Y | 1 |
| Yanifitri, DB | 1 |
| Utami, WA | 1 |
| Geraldine, S | 1 |
| Wen, X | 2 |
| Huang, X | 1 |
| Shu, Q | 1 |
| Wang, D | 1 |
| Geng, L | 1 |
| Jin, Z | 2 |
| Shen, W | 1 |
| Ge, W | 2 |
| Zhu, Y | 1 |
| Sun, L | 4 |
| Englert, KA | 1 |
| Dyduch, G | 1 |
| Kłosowicz, A | 1 |
| Spałkowska, M | 1 |
| Jaworek, AK | 1 |
| Migacz-Gruszka, K | 1 |
| Jarosz-Chudek, A | 1 |
| Mercuri, SR | 1 |
| Szpor, J | 1 |
| Mazzoccoli, G | 1 |
| Damiani, G | 1 |
| Wojas-Pelc, A | 1 |
| Castillo Dayer, PV | 1 |
| Lozano Rivas, N | 1 |
| Martínez Ferrín, JJ | 1 |
| Victoria Martínez, AM | 1 |
| Sánchez-Pedreño Guillen, P | 1 |
| Marras Fernández-Cid, C | 1 |
| Marder, W | 2 |
| Mukwikwi, ER | 1 |
| Pineau, CA | 2 |
| Vinet, E | 4 |
| Nashi, E | 1 |
| Kalache, F | 1 |
| Grenier, LP | 1 |
| Chang, A | 1 |
| Stolin, G | 1 |
| Fan, J | 1 |
| Larreta, BR | 1 |
| Fishbein, GA | 1 |
| Wallace, WD | 1 |
| Baas, AS | 1 |
| Cruz, D | 1 |
| Parisis, D | 1 |
| Bernier, C | 1 |
| Chasset, F | 5 |
| Arnaud, L | 4 |
| Elkhalifa, M | 1 |
| Magder, LS | 6 |
| Goldman, DW | 2 |
| Bodard, Q | 1 |
| Carre, D | 1 |
| Chenal, P | 1 |
| Zarnitsky, C | 1 |
| Midhat, M | 1 |
| Litrowski, N | 1 |
| Takamasu, E | 1 |
| Sugii, S | 2 |
| Endo, Y | 2 |
| Koga, T | 2 |
| Umeda, M | 1 |
| Furukawa, K | 1 |
| Sasaki, D | 1 |
| Yanagihara, K | 1 |
| Kawakami, A | 2 |
| Kariburyo, F | 1 |
| Xie, L | 1 |
| Sah, J | 1 |
| Li, N | 1 |
| Lofland, JH | 1 |
| Anderson, PO | 1 |
| de Moreuil, C | 1 |
| Alavi, Z | 1 |
| Pasquier, E | 1 |
| Zen, M | 2 |
| Saccon, F | 2 |
| Gatto, M | 2 |
| Montesso, G | 1 |
| Larosa, M | 1 |
| Benvenuti, F | 1 |
| Iaccarino, L | 2 |
| Doria, A | 4 |
| Fouad, SA | 1 |
| Esmat Mahmoud Ali, SM | 1 |
| Rezk Alnaggar, ARL | 1 |
| Mahfouz, S | 1 |
| Essam, M | 1 |
| El-Gendy, H | 1 |
| Babaoglu, H | 1 |
| Goldman, D | 2 |
| Manor, U | 1 |
| Dankovich, N | 1 |
| Boleslavsky, D | 1 |
| Kivity, S | 2 |
| Stienlauf, S | 1 |
| Hanneman, K | 1 |
| Alberdi, HV | 1 |
| Karur, GR | 1 |
| Tselios, K | 4 |
| Harvey, PJ | 1 |
| Akhtari, S | 1 |
| Osuntokun, T | 1 |
| Wald, RM | 1 |
| Thavendiranathan, P | 1 |
| Butany, J | 2 |
| Al-Nokhatha, SA | 1 |
| Khogali, HI | 1 |
| Al Shehhi, MA | 1 |
| Jassim, IT | 1 |
| Gao, M | 1 |
| Sheng, N | 1 |
| Yang, X | 2 |
| Rabin, JC | 1 |
| Ramirez, K | 1 |
| Mena-Vázquez, N | 1 |
| Fernández-Nebro, A | 2 |
| Pego-Reigosa, JM | 1 |
| Galindo, M | 2 |
| Melissa-Anzola, A | 1 |
| Uriarte-Isacelay, E | 1 |
| Olivé-Marqués, A | 1 |
| Aurrecoechea, E | 1 |
| Freire, M | 1 |
| Tomero, E | 1 |
| García-Villanueva, MJ | 1 |
| Stoye, C | 1 |
| Salas-Heredia, E | 1 |
| Bernal-Vidal, JA | 2 |
| Salgado, E | 1 |
| Javier Novoa, F | 1 |
| Ibáñez-Barcelo, M | 1 |
| Torrente-Segarra, V | 2 |
| Narvaez, J | 1 |
| Calvet, J | 1 |
| Moriano Morales, C | 1 |
| Ramon Vazquez-Rodriguez, T | 1 |
| Garcia de la Peña, P | 1 |
| Bohórquez, C | 1 |
| Andreu-Sánchez, JL | 1 |
| Cobo-Ibañez, T | 1 |
| Bonilla, G | 2 |
| Lozano-Rivas, N | 1 |
| Montilla, C | 1 |
| Toyos, FJ | 1 |
| De la Fuente, JLM | 1 |
| Expósito, L | 1 |
| Ruiz-Lucea, ME | 1 |
| Vals, E | 1 |
| Manero-Ruiz, J | 1 |
| Rua-Figueroa, I | 1 |
| Matsuda-Hirose, H | 1 |
| Sho, Y | 1 |
| Yamate, T | 1 |
| Nakamura, Y | 1 |
| Saito, K | 2 |
| Takeo, N | 1 |
| Nishida, H | 1 |
| Ishii, K | 1 |
| Sugiura, K | 1 |
| Hatano, Y | 1 |
| Gutta, S | 1 |
| Das, S | 2 |
| Kodiatte, TA | 1 |
| Vimala, LR | 1 |
| Esteve-Valverde, E | 1 |
| Tapiz-Reula, A | 1 |
| Ruiz, D | 1 |
| Alijotas-Reig, J | 1 |
| Hurtado, PR | 1 |
| Hurtado-Pérez, E | 1 |
| Luo, C | 1 |
| Bednarz, J | 1 |
| Hissaria, P | 1 |
| A Peh, C | 1 |
| Do, SC | 2 |
| Rizk, NM | 1 |
| Druzin, ML | 2 |
| Ayoub, I | 1 |
| Singh, P | 1 |
| Ardoin, S | 1 |
| Brodsky, S | 1 |
| Hebert, L | 1 |
| Dias-Santos, A | 1 |
| Tavares Ferreira, J | 1 |
| Pinheiro, S | 1 |
| Cunha, JP | 1 |
| Alves, M | 1 |
| Papoila, AL | 1 |
| Moraes-Fontes, MF | 1 |
| Proença, R | 1 |
| Unnithan, R | 1 |
| Hansen, KE | 1 |
| Ward, JM | 1 |
| Hess, JN | 1 |
| Davis, LS | 2 |
| Miyagawa, I | 2 |
| Nakano, K | 2 |
| Nakayamada, S | 2 |
| Iwata, S | 2 |
| Hanami, K | 2 |
| Fukuyo, S | 2 |
| Kubo, S | 2 |
| Kawabe, A | 1 |
| Miyazaki, Y | 1 |
| Inoue, Y | 2 |
| Ueno, M | 2 |
| Ohkubo, N | 1 |
| Fujita, Y | 1 |
| Tanaka, Y | 2 |
| Yeo, KJ | 1 |
| Chen, HH | 2 |
| Chen, YM | 2 |
| Chen, DY | 2 |
| Lai, CM | 1 |
| Chao, WC | 1 |
| Brites, L | 1 |
| Rodrigues, M | 1 |
| Luis, M | 1 |
| Santiago, M | 1 |
| Liu, T | 1 |
| Shi, N | 1 |
| Zhang, S | 4 |
| Silverman, GJ | 1 |
| Duan, XW | 1 |
| Niu, H | 1 |
| Lee, HJ | 1 |
| Kim, SJ | 2 |
| Fiehn, C | 1 |
| Ness, T | 1 |
| Weseloh, C | 1 |
| Specker, C | 1 |
| Hadjiski, D | 1 |
| Detert, J | 1 |
| Krüger, K | 1 |
| Guo, JY | 2 |
| Ren, ZG | 1 |
| Xuan, YY | 1 |
| Li, TF | 2 |
| Liu, XJ | 1 |
| Niu, CZ | 1 |
| Li, JY | 2 |
| Liu, SY | 3 |
| Goehner Schweizer, K | 1 |
| Maurer, B | 1 |
| Xu, C | 2 |
| Williams, J | 1 |
| Collins, JE | 2 |
| Mano, C | 1 |
| Tatsumi, T | 1 |
| Ishikawa, T | 1 |
| Sekiguchi, M | 1 |
| Iwahara, Y | 1 |
| Hiramitsu, S | 1 |
| Miyasaka, N | 1 |
| Jakhar, D | 1 |
| Kaur, I | 1 |
| Goyal, M | 2 |
| Mathian, A | 13 |
| Mahevas, M | 2 |
| Rohmer, J | 1 |
| Roumier, M | 1 |
| Cohen-Aubart, F | 1 |
| Amador-Borrero, B | 1 |
| Barrelet, A | 1 |
| Chauvet, C | 1 |
| Chazal, T | 1 |
| Delahousse, M | 1 |
| Devaux, M | 1 |
| Euvrard, R | 1 |
| Fadlallah, J | 1 |
| Florens, N | 1 |
| Haroche, J | 3 |
| Hié, M | 1 |
| Juillard, L | 1 |
| Lhote, R | 1 |
| Maillet, T | 1 |
| Richard-Colmant, G | 1 |
| Palluy, JB | 1 |
| Pha, M | 2 |
| Perard, L | 5 |
| Rivière, E | 1 |
| Sène, D | 1 |
| Sève, P | 2 |
| Morélot-Panzini, C | 1 |
| Viallard, JF | 1 |
| Virot, JS | 1 |
| Benameur, N | 1 |
| Zahr, N | 5 |
| Yssel, H | 1 |
| Godeau, B | 3 |
| Amoura, Z | 34 |
| Dion, J | 1 |
| Maisonobe, T | 1 |
| Chacón-Dulcey, V | 1 |
| López-Labady, J | 1 |
| Villarroel-Dorrego, M | 1 |
| Frías, J | 1 |
| Tirado, W | 1 |
| González, N | 2 |
| Pérez Alfonzo, R | 1 |
| Felten, R | 1 |
| Lipsker, D | 1 |
| Sibilia, J | 1 |
| Konig, MF | 3 |
| Kim, AH | 1 |
| Scheetz, MH | 1 |
| Graef, ER | 1 |
| Liew, JW | 1 |
| Simard, J | 1 |
| Machado, PM | 1 |
| Gianfrancesco, M | 2 |
| Langguth, D | 1 |
| Robinson, PC | 2 |
| Khalaf, S | 1 |
| Khan, N | 1 |
| Al-Mallah, M | 1 |
| Kassi, M | 1 |
| Shah, D | 1 |
| Bozzalla Cassione, E | 2 |
| Zanframundo, G | 2 |
| Biglia, A | 2 |
| Codullo, V | 2 |
| Montecucco, C | 2 |
| Cavagna, L | 2 |
| Romão, VC | 1 |
| Cruz-Machado, AR | 1 |
| Fonseca, JE | 1 |
| Zheng, Y | 1 |
| De Vera, M | 1 |
| Sciascia, S | 3 |
| Schreiber, K | 2 |
| Radin, M | 1 |
| Roccatello, D | 2 |
| Krämer, BK | 1 |
| Stach, K | 1 |
| Umeda, Y | 1 |
| Ito, K | 1 |
| Ansai, S | 1 |
| Hoashi, T | 1 |
| Saeki, H | 1 |
| Kanda, N | 1 |
| Sayhi, S | 1 |
| Achour, TB | 1 |
| Mezri, S | 1 |
| Hamdi, MS | 1 |
| Nour, G | 1 |
| Bilel, A | 1 |
| Abdelhafidh, NB | 1 |
| Ajili, F | 1 |
| Louzir, B | 1 |
| Mendel, A | 2 |
| Thorne, JC | 1 |
| Johnson, SR | 1 |
| Wu, CY | 1 |
| Tan, M | 1 |
| Huang, JY | 2 |
| Chiou, JY | 1 |
| Wei, JC | 3 |
| Vázquez-Otero, I | 1 |
| Medina-Cintrón, N | 1 |
| Arroyo-Ávila, M | 1 |
| González-Sepúlveda, L | 1 |
| Vilá, LM | 8 |
| Hachulla, E | 2 |
| Le Gouellec, N | 1 |
| Launay, D | 1 |
| Balquet, MH | 1 |
| Maillard, H | 1 |
| Azar, R | 1 |
| Boldron, A | 1 |
| Bataille, P | 1 |
| Lambert, M | 2 |
| Buchdahl, AL | 1 |
| Allorge, D | 1 |
| Hatron, PY | 1 |
| Sobanski, V | 1 |
| Hennart, B | 1 |
| Clerson, P | 1 |
| Morell-Dubois, S | 1 |
| Salah, S | 1 |
| Leroux, G | 15 |
| Bousquet, E | 2 |
| Francès, C | 9 |
| Morel, N | 6 |
| Chezel, J | 1 |
| Papo, T | 6 |
| Cacoub, P | 9 |
| Mouthon, L | 1 |
| Guettrot-Imbert, G | 3 |
| Cohen, P | 1 |
| Régent, A | 1 |
| Mauget-Faÿsse, M | 1 |
| Piette, JC | 28 |
| Jallouli, M | 10 |
| Favalli, EG | 1 |
| Gerosa, M | 2 |
| Murgo, A | 1 |
| Caporali, R | 2 |
| Fujieda, Y | 1 |
| Teh, B | 1 |
| Carlsson, H | 1 |
| Hjorton, K | 1 |
| Abujrais, S | 1 |
| Rönnblom, L | 2 |
| Åkerfeldt, T | 1 |
| Kultima, K | 1 |
| Carbillon, L | 1 |
| Benbara, A | 1 |
| Boujenah, J | 1 |
| Wallace, B | 1 |
| Washer, L | 1 |
| Kahlenberg, JM | 2 |
| Luo, X | 1 |
| Peng, Y | 1 |
| Barber, MRW | 1 |
| Ebrahimiadib, N | 1 |
| Riazi-Esfahani, H | 1 |
| Heidari, M | 1 |
| Mahmoudi, A | 1 |
| Wille, F | 1 |
| Birkmeier, S | 1 |
| Tiemann, K | 1 |
| Lewalter, T | 1 |
| Klingel, K | 1 |
| Rabe, C | 1 |
| Sick, P | 1 |
| Holubar, J | 1 |
| Le Quintrec, M | 1 |
| Letaief, H | 1 |
| Faillie, JL | 1 |
| Pers, YM | 2 |
| Jorgensen, C | 1 |
| González-García, A | 1 |
| López-Rodríguez, M | 1 |
| Redondo, S | 1 |
| Patier, JL | 1 |
| Masso, P | 1 |
| Tenorio, M | 1 |
| Fajardo, GS | 1 |
| Sarhane, Y | 1 |
| Lacalzada, MM | 1 |
| Manzano, L | 1 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| Fahmy Mansour, MM | 1 |
| Mihailovic, N | 1 |
| Leclaire, MD | 1 |
| Eter, N | 1 |
| Brücher, VC | 1 |
| Thémans, P | 1 |
| Dauby, N | 1 |
| Schrooyen, L | 1 |
| Lebout, F | 1 |
| Delforge, M | 1 |
| Nasreddine, R | 1 |
| Libois, A | 1 |
| Payen, MC | 1 |
| Konopnicki, D | 1 |
| Wuillaume, F | 1 |
| Lescrainier, C | 1 |
| Verlinden, V | 1 |
| Dogné, JM | 1 |
| Hamdani, J | 1 |
| Musuamba, FT | 1 |
| Guo, J | 1 |
| Ren, Z | 1 |
| Li, T | 1 |
| Liu, S | 2 |
| Yu, Z | 1 |
| Hanly, J | 1 |
| Mak, A | 2 |
| Pons-Estel, BA | 1 |
| Gendebien, Z | 1 |
| von Frenckell, C | 1 |
| Ribbens, C | 1 |
| André, B | 1 |
| Thys, M | 1 |
| Gangolf, M | 1 |
| Seidel, L | 1 |
| Malaise, MG | 1 |
| Malaise, O | 1 |
| Gruber, R | 1 |
| Kuntz, T | 1 |
| Oellig, F | 1 |
| Paschos, A | 1 |
| Tigges, C | 1 |
| Kreuter, A | 1 |
| Polanski, JF | 1 |
| Tanaka, EA | 1 |
| Barros, H | 1 |
| Chuchene, AG | 1 |
| Miguel, PTG | 1 |
| Skare, TL | 1 |
| Nuño, L | 1 |
| Novella Navarro, M | 1 |
| Franco-Gómez, K | 1 |
| Aguado, P | 1 |
| Peiteado, D | 1 |
| Monjo, I | 1 |
| Tornero, C | 1 |
| Villalba, A | 1 |
| Miranda-Carus, ME | 1 |
| De Miguel, E | 1 |
| Bogas, P | 1 |
| Castilla-Plaza, A | 1 |
| Bernad-Pineda, M | 1 |
| García-Lorenzo, E | 1 |
| Rodríguez-Araya, T | 1 |
| Balsa, A | 1 |
| Plüß, M | 1 |
| Chehab, G | 2 |
| Korsten, P | 1 |
| Hosokawa, Y | 1 |
| Oiwa, H | 1 |
| Ferreira, A | 1 |
| Oliveira-E-Silva, A | 1 |
| Bettencourt, P | 1 |
| Shukla, A | 1 |
| Gaur, P | 1 |
| Shaharir, SS | 2 |
| Maulana, SA | 1 |
| Shahril, NS | 1 |
| Mohd, R | 1 |
| Mustafar, R | 2 |
| Said, MSM | 1 |
| Rahman, RA | 1 |
| Patil, P | 1 |
| Pathak, H | 1 |
| Santhanam, S | 1 |
| Goel, A | 1 |
| Sharma, V | 1 |
| Pandey, A | 1 |
| Gupta, N | 1 |
| Jain, R | 1 |
| Akerkar, S | 1 |
| Das, P | 1 |
| Dudam, R | 1 |
| Mendiratta, N | 1 |
| Pandey, BD | 1 |
| Cb, M | 1 |
| Singh, BK | 1 |
| Kumar, S | 2 |
| Nolkha, N | 1 |
| Jain, S | 2 |
| Sharma, A | 2 |
| Misra, DP | 1 |
| Constantinides, VC | 1 |
| Deligianni, C | 1 |
| Dimitrakopoulos, A | 1 |
| Paraskevas, GP | 1 |
| Kapaki, E | 1 |
| Davis, A | 1 |
| Chang, J | 1 |
| Shapiro, S | 1 |
| Klein-Gitelman, M | 1 |
| Faerber, J | 1 |
| Katcoff, H | 1 |
| Cidav, Z | 2 |
| Mandell, DS | 2 |
| Knight, A | 1 |
| Nirk, EL | 1 |
| Reggiori, F | 1 |
| Mauthe, M | 1 |
| He, F | 1 |
| Luo, Q | 1 |
| Lei, M | 1 |
| Fan, L | 1 |
| Shao, X | 1 |
| Hu, K | 1 |
| Qin, S | 1 |
| Yu, N | 1 |
| Cao, J | 1 |
| Yang, L | 1 |
| Teh, CL | 3 |
| Cheong, YK | 1 |
| Wan Musa, WR | 1 |
| Wan Mohd Akbar, SA | 1 |
| Mat Husin, N | 1 |
| Gun, SC | 1 |
| Janardana, R | 1 |
| Haridas, V | 1 |
| Priya, V | 1 |
| Bhat, V | 1 |
| Singh, Y | 1 |
| Rao, VK | 1 |
| Jois, R | 1 |
| Srikantiah, C | 1 |
| Pinto, B | 2 |
| Shobha, V | 1 |
| Salvarani, C | 1 |
| Mancuso, P | 1 |
| Gradellini, F | 1 |
| Viani, N | 1 |
| Pandolfi, P | 1 |
| Reta, M | 1 |
| Carrozzi, G | 1 |
| Sandri, G | 1 |
| Bajocchi, G | 1 |
| Galli, E | 1 |
| Muratore, F | 1 |
| Boiardi, L | 1 |
| Pipitone, N | 1 |
| Cassone, G | 1 |
| Croci, S | 1 |
| Marata, AM | 1 |
| Costantini, M | 1 |
| Giorgi Rossi, P | 1 |
| Suszek, D | 1 |
| Górak, A | 1 |
| Majdan, M | 1 |
| Kabeerdoss, J | 1 |
| Danda, D | 1 |
| Lin, C | 1 |
| Wang, Z | 1 |
| Xia, X | 1 |
| Montero, F | 1 |
| Martínez-Barrio, J | 1 |
| Serrano-Benavente, B | 1 |
| González, T | 1 |
| Rivera, J | 1 |
| Molina Collada, J | 1 |
| Castrejón, I | 2 |
| Álvaro-Gracia, J | 1 |
| Pablos, JL | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Gonzalez-Gay, MA | 1 |
| Martinez-Lopez, D | 1 |
| Alvaro-Gracia, JM | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Demirkan, FG | 1 |
| Doğan, S | 1 |
| Kalyoncu Uçar, A | 1 |
| Sönmez, HE | 1 |
| Aktay Ayaz, N | 1 |
| Troldborg, A | 2 |
| Bay-Laurberg, T | 1 |
| Clemmensen, K | 1 |
| Deleuran, B | 1 |
| Fernandez-Ruiz, R | 1 |
| Bornkamp, N | 1 |
| Kim, MY | 3 |
| Zezon, A | 1 |
| Tseng, CE | 1 |
| Saxena, A | 3 |
| Salmon, JE | 2 |
| Lockshin, M | 1 |
| Buyon, JP | 7 |
| Izmirly, PM | 4 |
| Sakai, R | 1 |
| Honda, S | 1 |
| Tanaka, E | 1 |
| Majima, M | 1 |
| Konda, N | 1 |
| Takada, H | 1 |
| Harigai, M | 1 |
| Xie, B | 1 |
| Geng, Q | 1 |
| Lu, H | 1 |
| Luo, H | 1 |
| Hu, Y | 1 |
| Song, X | 1 |
| Sbidian, E | 1 |
| Penso, L | 1 |
| Herlemont, P | 1 |
| Botton, J | 1 |
| Baricault, B | 1 |
| Semenzato, L | 1 |
| Drouin, J | 1 |
| Weill, A | 1 |
| Dray-Spira, R | 1 |
| Zureik, M | 1 |
| Notz, Q | 1 |
| Meybohm, P | 1 |
| Kranke, P | 1 |
| Weismann, D | 1 |
| Lotz, C | 1 |
| Schmalzing, M | 1 |
| Wei, Y | 2 |
| Yang, H | 1 |
| Kadosawa, K | 1 |
| Morikawa, T | 1 |
| Konishi, Y | 1 |
| Ramirez, GA | 1 |
| Beretta, L | 1 |
| Bellocchi, C | 1 |
| Argolini, LM | 1 |
| Moroni, L | 1 |
| Della Torre, E | 1 |
| Artusi, C | 1 |
| Nicolosi, S | 1 |
| Bozzolo, EP | 2 |
| Dagna, L | 1 |
| Davis, AM | 1 |
| Klein-Gitelman, MS | 1 |
| Knight, AM | 1 |
| Chiricozzi, A | 1 |
| Garcovich, S | 1 |
| Malvaso, D | 1 |
| Giovanardi, G | 1 |
| Peris, K | 1 |
| Chandra, A | 1 |
| Saha, SK | 1 |
| Ray, AK | 1 |
| Karmakar, P | 1 |
| Allard, M | 1 |
| Ghillani-Dalbin, P | 1 |
| Galicier, L | 4 |
| Aumaître, O | 5 |
| Lioté, F | 4 |
| Smail, A | 4 |
| Desmurs-Clavel, H | 4 |
| Le Thi Huong, D | 4 |
| Asli, B | 4 |
| Kahn, JE | 4 |
| Sailler, L | 6 |
| Ackermann, F | 4 |
| Sacré, K | 5 |
| Stirnemann, J | 5 |
| Cohen-Bittan, J | 4 |
| Sellam, J | 2 |
| Goulvestre, C | 1 |
| Hulot, JS | 9 |
| Vidal, M | 1 |
| Jourde-Chiche, N | 1 |
| Zurita, MF | 1 |
| Iglesias Arreaga, A | 1 |
| Luzuriaga Chavez, AA | 1 |
| Zurita, L | 2 |
| Guleva, D | 1 |
| Dourmishev, L | 1 |
| Botev, I | 1 |
| Miteva, L | 1 |
| Lentine, KL | 1 |
| Lam, NN | 1 |
| Caliskan, Y | 1 |
| Alhamad, T | 1 |
| Xiao, H | 2 |
| Schnitzler, MA | 1 |
| Chang, SH | 1 |
| Axelrod, D | 1 |
| Segev, DL | 1 |
| McAdams-DeMarco, M | 1 |
| Kasiske, BL | 1 |
| Hess, GP | 1 |
| Brennan, DC | 1 |
| Tziolos, N | 1 |
| Carvalho, JF | 1 |
| Silva, FF | 1 |
| Shoenfeld, Y | 2 |
| Gupta, A | 1 |
| Shields, KJ | 1 |
| Wasko, MC | 2 |
| Sharma, TS | 1 |
| Wang, F | 2 |
| Pan, W | 2 |
| Liu, L | 3 |
| Wu, M | 3 |
| Hu, H | 2 |
| Ding, X | 2 |
| Wei, H | 2 |
| Zou, Y | 2 |
| Qian, X | 2 |
| Wang, M | 2 |
| Tao, J | 2 |
| Tan, J | 2 |
| Da, Z | 2 |
| Zhang, M | 2 |
| Feng, X | 2 |
| Salgado Guerrero, M | 1 |
| Londono Jimenez, A | 1 |
| Dobrowolski, C | 1 |
| Goilav, B | 1 |
| Lambers, WM | 1 |
| Westra, J | 1 |
| Bootsma, H | 1 |
| de Leeuw, K | 2 |
| Vural, E | 1 |
| Hazar, L | 1 |
| Erol, K | 1 |
| Knudsen, SS | 1 |
| Knudsen, JS | 1 |
| Christensen, J | 1 |
| Laursen, TM | 1 |
| Deleuran, BW | 1 |
| Bech, BH | 1 |
| Faraone, I | 1 |
| Labanca, F | 1 |
| Ponticelli, M | 1 |
| De Tommasi, N | 1 |
| Milella, L | 1 |
| Fayed, A | 1 |
| El Menyawi, MM | 1 |
| Ghanema, M | 1 |
| Shaker, O | 1 |
| Elgohary, R | 1 |
| Abd Rahman, R | 2 |
| Min Tun, K | 1 |
| Kamisan Atan, I | 1 |
| Mohamed Said, MS | 1 |
| Zainuddin, AA | 1 |
| Sutton, KM | 1 |
| Fernando, SL | 1 |
| AlAhmed, O | 1 |
| Way, A | 1 |
| Akoghlanian, S | 1 |
| Barbar-Smiley, F | 1 |
| Lemle, S | 1 |
| MacDonald, D | 1 |
| Frost, E | 1 |
| Wise, K | 1 |
| Lee, L | 1 |
| Ardoin, SP | 2 |
| Sivaraman, V | 1 |
| Tejada Cifuentes, F | 1 |
| Lloret Callejo, Á | 1 |
| Tirado Peláez, MJ | 1 |
| Rubio Pulido, O | 1 |
| Ruiz-Morote Aragón, M | 1 |
| Fernández Urrusuno, R | 1 |
| Muñoz Carreras, MI | 1 |
| Méndez Esteban, MI | 1 |
| Maestre Sánchez, V | 1 |
| García Bonilla, A | 1 |
| Paredero Dominguez, JM | 1 |
| Arroyo Pineda, V | 1 |
| Marco Tejón, E | 1 |
| Romero Candel, G | 1 |
| Fernández Marchante, AI | 1 |
| Marco Del Rio, J | 1 |
| Ortiz Martín, T | 1 |
| López Sánchez, P | 1 |
| Kim, MS | 1 |
| Kim, MC | 1 |
| Choi, SH | 1 |
| Chung, JW | 1 |
| Choi, ST | 1 |
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
| Çağlayan, M | 1 |
| Akyol, L | 1 |
| Balcı, MA | 1 |
| Öncül, H | 1 |
| Alakuş, MF | 1 |
| Dağ, U | 1 |
| Huang, J | 1 |
| Kow, NY | 1 |
| Lee, HY | 1 |
| Fairhurst, AM | 1 |
| Sookaromdee, P | 1 |
| Wiwanitkit, V | 1 |
| Celia, AI | 1 |
| Cerbelli, B | 1 |
| Diomedi-Camassei, F | 1 |
| Leuzzi, V | 1 |
| Scrivo, R | 1 |
| d'Amati, G | 2 |
| Bories, MC | 1 |
| Gibault, L | 1 |
| Tharaux, PL | 1 |
| Bruneval, P | 1 |
| Gupta, S | 1 |
| Nakabo, S | 1 |
| Chu, J | 1 |
| Hasni, S | 2 |
| Kaplan, MJ | 1 |
| Pothen, L | 1 |
| Yildiz, H | 1 |
| Samnick, MM | 1 |
| Yombi, JC | 1 |
| Hipolito-Fernandes, D | 1 |
| Luís, ME | 1 |
| Flores, R | 1 |
| Anjos, R | 1 |
| Lorenzo-Vizcaya, A | 1 |
| Zanetti, CB | 1 |
| Pedrosa, T | 1 |
| Kupa, LVK | 1 |
| Aikawa, NE | 1 |
| Borba, EF | 2 |
| Vendramini, MBG | 1 |
| Silva, CA | 1 |
| Pasoto, SG | 1 |
| Bonfa, E | 1 |
| Nishiyama, T | 1 |
| Kondo, Y | 1 |
| Tsuboi, H | 1 |
| Noma, H | 1 |
| Tabuchi, D | 1 |
| Sugita, T | 1 |
| Okamoto, S | 1 |
| Terasaki, T | 1 |
| Honda, F | 1 |
| Ohyama, A | 1 |
| Kurata, I | 1 |
| Yagishita, M | 1 |
| Abe, S | 1 |
| Takahashi, H | 1 |
| Osada, A | 1 |
| Hagiwara, S | 1 |
| Matsumoto, I | 1 |
| Sumida, T | 1 |
| Dubey, S | 1 |
| Pandit, A | 1 |
| Ray, BK | 1 |
| Dima, A | 1 |
| Jurcut, C | 1 |
| Ichikawa, K | 1 |
| Pryor, KP | 1 |
| de Mattos, ABN | 1 |
| Garbo Baroni, L | 1 |
| Zanotto, LL | 1 |
| Furian, MEA | 1 |
| Akabane, AL | 1 |
| Smith, GP | 1 |
| Orefice, V | 1 |
| Pirone, C | 1 |
| Galoppi, P | 1 |
| Brunelli, R | 1 |
| Perrone, G | 1 |
| Wang, WH | 1 |
| Lai, CC | 2 |
| Huang, YF | 1 |
| Li, TH | 1 |
| Tsao, YP | 1 |
| Chen, WS | 2 |
| Chang, YS | 2 |
| Hannon, CW | 1 |
| McCourt, C | 1 |
| Lima, HC | 1 |
| Chen, S | 1 |
| Bennett, C | 1 |
| Manoj, M | 1 |
| Sahoo, RR | 1 |
| Singh, A | 1 |
| Hazarika, K | 1 |
| Bafna, P | 1 |
| Kaur, A | 1 |
| Wakhlu, A | 1 |
| Pierro, L | 5 |
| Lu, J | 1 |
| Huang, Y | 2 |
| Ye, Q | 1 |
| Shang, F | 1 |
| Ming, M | 1 |
| Xu, H | 2 |
| Cornwell, MG | 1 |
| Luttrell-Williams, ES | 1 |
| Golpanian, M | 1 |
| El Bannoudi, H | 1 |
| Myndzar, K | 1 |
| Izmirly, P | 1 |
| Katz, S | 1 |
| Smilowitz, NR | 1 |
| Engel, A | 1 |
| Clancy, R | 1 |
| Ruggles, K | 1 |
| Berger, JS | 1 |
| Kabataş, N | 1 |
| Özateş, S | 1 |
| Avarisli, NA | 1 |
| Kakil, SB | 1 |
| Özişler, C | 1 |
| Osmani, Z | 1 |
| Schrama, TJ | 1 |
| Zacouris-Verweij, W | 1 |
| Frankel, S | 1 |
| Bultink, IEM | 2 |
| Hill, DD | 1 |
| Egger, PJ | 1 |
| Fu, Q | 1 |
| Duan, J | 1 |
| Ma, D | 1 |
| Guo, Q | 1 |
| Gao, J | 1 |
| Zhang, G | 1 |
| Xu, K | 1 |
| Muller, R | 2 |
| Jarrot, PA | 1 |
| Kaplanski, G | 1 |
| Martelli Júnior, H | 1 |
| Marques, NP | 1 |
| Marques, NCT | 1 |
| Gomes de Lucena, E | 1 |
| Martelli, DRB | 1 |
| Oliveira, EA | 1 |
| McVeigh, ED | 1 |
| Batool, A | 1 |
| Stromberg, A | 1 |
| Abdel-Latif, A | 1 |
| Kazzaz, NM | 1 |
| Liu, PK | 1 |
| Ryu, J | 1 |
| Yeh, LK | 1 |
| Chen, KJ | 1 |
| Tsang, SH | 1 |
| Wang, NK | 1 |
| Randell, RL | 1 |
| Singler, L | 1 |
| Cunningham, A | 1 |
| Yoshida, M | 1 |
| Minowa, K | 1 |
| Amano, H | 1 |
| Asai, Y | 1 |
| Yamaji, K | 1 |
| Tamura, N | 1 |
| Lo, CH | 1 |
| Wang, YH | 1 |
| Tsai, CF | 1 |
| Chan, KC | 1 |
| Li, LC | 1 |
| Lo, TH | 1 |
| Su, CH | 1 |
| Sallam, MA | 1 |
| Beltagi, AS | 1 |
| Abdellatif, MA | 1 |
| Awadalla, MA | 1 |
| Midorikawa, H | 1 |
| Kiniwa, Y | 1 |
| Minagawa, A | 1 |
| Osawa, K | 1 |
| Shirai, T | 1 |
| Sano, T | 1 |
| Nakamura, K | 1 |
| Ashida, A | 1 |
| Ueno, KI | 1 |
| Takeichi, T | 1 |
| Akiyama, M | 1 |
| Okuyama, R | 1 |
| Long, Y | 1 |
| Leng, X | 1 |
| Wang, G | 1 |
| Zhuo, N | 1 |
| Liao, Z | 1 |
| Qi, W | 1 |
| Tian, F | 1 |
| Wen, Z | 1 |
| Lee, J | 2 |
| Lee, YJ | 1 |
| Kim, Y | 1 |
| Kim, M | 1 |
| Chavatza, K | 1 |
| Kostopoulou, M | 2 |
| Togia, K | 1 |
| Andreoli, L | 1 |
| Boletis, J | 1 |
| Houssiau, FA | 1 |
| Jayne, D | 2 |
| Yang, P | 1 |
| Alexander, RV | 1 |
| Rey, DS | 1 |
| Conklin, J | 1 |
| Domingues, V | 1 |
| Ahmed, M | 1 |
| Qureshi, J | 1 |
| Weinstein, A | 1 |
| Chen, FY | 1 |
| Chen, SW | 1 |
| Chen, X | 1 |
| Ye, Z | 3 |
| Menet, J | 1 |
| Agrinier, N | 1 |
| Dufrost, V | 1 |
| Conart, JB | 1 |
| Wahl, D | 1 |
| Duprez, KA | 1 |
| Zuily, S | 1 |
| Jolly, M | 3 |
| Sehgal, V | 1 |
| Arora, S | 2 |
| Azizoddin, D | 1 |
| Devilliers, H | 1 |
| Inoue, M | 1 |
| Toloza, S | 2 |
| Bertoli, A | 1 |
| Blazevic, I | 1 |
| Moldovan, I | 1 |
| Torralba, KD | 1 |
| Mazzoni, D | 1 |
| Cicognani, E | 1 |
| Goker, B | 1 |
| Haznedaroglu, S | 1 |
| Bourre-Tessier, J | 1 |
| Navarra, SV | 1 |
| Clarke, A | 2 |
| Weisman, M | 1 |
| Wallace, D | 1 |
| Mok, CC | 6 |
| Sonigo, G | 1 |
| Jachiet, M | 1 |
| Bessis, D | 1 |
| Cordel, N | 1 |
| Faucon, C | 1 |
| Petit, A | 1 |
| Cordoliani, F | 1 |
| Bagot, M | 2 |
| Senet, P | 1 |
| Barbaud, A | 1 |
| Bouaziz, JD | 2 |
| Horino, T | 2 |
| Ogasawara, M | 1 |
| Kashio, T | 1 |
| Inotani, S | 1 |
| Ishihara, M | 1 |
| Ohnishi, H | 1 |
| Komori, M | 1 |
| Ichii, O | 2 |
| Terada, Y | 2 |
| Renaldi, J | 1 |
| Koumpouras, F | 1 |
| Dong, X | 2 |
| Lekpa, FK | 1 |
| Ngahane, BHM | 1 |
| Njonnou, SRS | 1 |
| Fouda, H | 1 |
| Halle, MP | 1 |
| Njankouo, YM | 1 |
| Dzudie, A | 1 |
| Choukem, SP | 1 |
| Luma, HN | 1 |
| Magendiran, B | 1 |
| Jose, A | 1 |
| Kolar Vishwanath, V | 1 |
| Bammigatti, C | 1 |
| Bahloul, E | 1 |
| Garbaa, S | 1 |
| Marzouk, S | 1 |
| Masmoudi, A | 1 |
| Turki, H | 1 |
| Bahloul, Z | 1 |
| Reimold, AM | 1 |
| Lateef, A | 2 |
| Ho, LY | 2 |
| Tse, SM | 2 |
| Chan, KL | 2 |
| Fernandez-Sanz, A | 1 |
| Bucar-Barjud, M | 1 |
| Ruiz-Serrano, J | 1 |
| Saez-Comet, L | 1 |
| Capablo-Liesa, JL | 1 |
| Vinay, K | 1 |
| Sawatkar, G | 1 |
| Dogra, S | 1 |
| Saikia, UN | 1 |
| Gallego Muñoz, C | 1 |
| Olmos Gutiérrez, L | 1 |
| Guerrero Navarro, N | 1 |
| Parra Alonso, E | 1 |
| Lisney, AR | 1 |
| Szelinski, F | 1 |
| Reiter, K | 1 |
| Burmester, GR | 1 |
| Rose, T | 1 |
| Dörner, T | 2 |
| Pantano, I | 3 |
| Valentini, G | 4 |
| Guiot, A | 2 |
| Couturier, M | 2 |
| Tebib, JG | 2 |
| Abouaf, L | 2 |
| Coury, F | 2 |
| Acevedo, M | 1 |
| Pretini, J | 1 |
| Micelli, M | 1 |
| Sequeira, G | 1 |
| Kerzberg, E | 1 |
| Mohammad, S | 1 |
| Sumitomo, N | 1 |
| Miura, M | 1 |
| Shibuya, K | 1 |
| Goto, M | 1 |
| Charlier, B | 2 |
| Pingeon, M | 2 |
| Dal Piaz, F | 2 |
| Filippelli, A | 2 |
| Izzo, V | 2 |
| Jayasundara, M | 1 |
| Haroun, T | 1 |
| Neil, L | 1 |
| James, AH | 1 |
| Hong, EH | 1 |
| Ahn, SJ | 3 |
| Lim, HW | 1 |
| Lee, BR | 3 |
| Xu, B | 1 |
| Zhou, M | 1 |
| Fu, R | 1 |
| Guo, C | 1 |
| Gaskin, F | 1 |
| Fu, SM | 1 |
| Yang, N | 1 |
| Soh, MC | 1 |
| Nelson-Piercy, C | 1 |
| Westgren, M | 1 |
| McCowan, L | 1 |
| Pasupathy, D | 1 |
| Margiotta, DP | 1 |
| Navarini, L | 2 |
| Riccardi, A | 2 |
| Afeltra, A | 2 |
| Wu, SF | 1 |
| Chang, CB | 1 |
| Hsu, JM | 1 |
| Lu, MC | 1 |
| Lai, NS | 1 |
| Li, C | 1 |
| Tung, CH | 1 |
| Junga, Z | 1 |
| Stitt, R | 1 |
| Tracy, C | 1 |
| Keith, M | 1 |
| Telek, HH | 2 |
| Yesilirmak, N | 2 |
| Sungur, G | 2 |
| Ozdemir, Y | 2 |
| Yesil, NK | 2 |
| Ornek, F | 2 |
| Babary, H | 1 |
| Liu, X | 2 |
| Ayatollahi, Y | 1 |
| Chen, XP | 1 |
| Doo, L | 1 |
| Uppaluru, LK | 1 |
| Kwak, MK | 1 |
| Kulaga, C | 1 |
| Modjinou, D | 1 |
| Olech, E | 1 |
| Yoo, JW | 1 |
| Ryu, SJ | 1 |
| Joung, JY | 1 |
| Piscianz, E | 1 |
| Cuzzoni, E | 1 |
| Tesser, A | 1 |
| Sapra, P | 1 |
| Tommasini, A | 1 |
| Tal, Y | 1 |
| Maoz Segal, R | 1 |
| Langevitz, P | 1 |
| Darnizki, Z | 1 |
| Agmon-Levin, N | 1 |
| Hsu, CY | 2 |
| Lin, YS | 2 |
| Su, YJ | 2 |
| Lin, HF | 2 |
| Lin, MS | 2 |
| Syu, YJ | 2 |
| Cheng, TT | 2 |
| Yu, SF | 1 |
| Chen, JF | 2 |
| Chen, TH | 2 |
| Lazovic, B | 1 |
| Zlatkovic-Svenda, M | 1 |
| Jasarovic, D | 1 |
| Stevanovic, D | 1 |
| An, N | 1 |
| Chen, Y | 1 |
| Wang, C | 2 |
| Wu, ZH | 1 |
| Xue, J | 1 |
| Ye, L | 1 |
| Liu, HF | 1 |
| Pan, Q | 1 |
| Pakchotanon, R | 2 |
| Su, J | 4 |
| Lee, SG | 1 |
| Park, EK | 1 |
| Park, JH | 1 |
| Kweon, SM | 1 |
| Kim, YK | 1 |
| Kim, GT | 1 |
| Kiyani, A | 1 |
| Parperis, K | 2 |
| Matsuda, T | 1 |
| Ly, NTM | 1 |
| Kambe, N | 1 |
| Nguyen, CTH | 1 |
| Ueda-Hayakawa, I | 1 |
| Son, Y | 1 |
| Okamoto, H | 1 |
| Feng, SW | 1 |
| Luo, ZY | 1 |
| He, XQ | 1 |
| Liu, JH | 1 |
| Luo, DQ | 1 |
| Filotico, R | 1 |
| Mastrandrea, V | 1 |
| Kroese, SJ | 1 |
| de Hair, MJH | 1 |
| Limper, M | 1 |
| Lely, AT | 1 |
| van Laar, JM | 1 |
| Derksen, RHWM | 1 |
| Fritsch-Stork, RDE | 1 |
| Lin, TC | 1 |
| Barbhaiya, M | 1 |
| Guan, H | 4 |
| Chen, SK | 1 |
| Mazur-Nicorici, L | 1 |
| Sadovici-Bobeica, V | 1 |
| Garabajiu, M | 1 |
| Mazur, M | 1 |
| Cohen, EM | 1 |
| D'Silva, K | 1 |
| Kreps, D | 1 |
| Son, MB | 1 |
| Collins, J | 1 |
| Subramanian, SV | 2 |
| Solomon, DH | 5 |
| Kawachi, I | 2 |
| Siega-Riz, AM | 1 |
| Engel, SM | 1 |
| Franceschini, N | 1 |
| Howard, AG | 1 |
| Omarjee, L | 1 |
| Jaquinandi, V | 1 |
| Camarzana, A | 1 |
| Rouleau, F | 1 |
| Mezdad, TH | 1 |
| Le Tourneau, T | 1 |
| Mahe, G | 1 |
| Belizna, C | 2 |
| Scalzi, LV | 1 |
| Hollenbeak, CS | 1 |
| Mascuilli, E | 1 |
| Olsen, N | 1 |
| Yang, J | 3 |
| McDougall, JA | 1 |
| Helmick, CG | 1 |
| Johnston, JM | 1 |
| Gaddy, JR | 1 |
| Ferucci, ED | 1 |
| Guillotin, V | 1 |
| Bouhet, A | 1 |
| Barnetche, T | 1 |
| Richez, C | 2 |
| Truchetet, ME | 1 |
| Seneschal, J | 2 |
| Duffau, P | 2 |
| Lazaro, E | 3 |
| Ugarte, A | 5 |
| Porta, S | 1 |
| Ríos, R | 1 |
| Martinez-Zapico, A | 1 |
| Ortego-Centeno, N | 3 |
| Agesta, N | 1 |
| Wan, SA | 1 |
| Ling, GR | 1 |
| Mai, S | 1 |
| Zou, L | 1 |
| Liao, X | 1 |
| Luan, Y | 1 |
| Han, X | 1 |
| Wu, Y | 1 |
| Kuang, S | 1 |
| Ma, J | 1 |
| Chen, Q | 1 |
| Conti, V | 1 |
| Floris, A | 1 |
| Piga, M | 2 |
| Mangoni, AA | 1 |
| Bortoluzzi, A | 2 |
| Erre, GL | 1 |
| Cauli, A | 1 |
| Plantone, D | 1 |
| Koudriavtseva, T | 1 |
| Shi, W | 1 |
| Duan, M | 1 |
| Jie, L | 1 |
| Sun, W | 1 |
| An, J | 1 |
| Woodward, JJ | 1 |
| Lai, W | 1 |
| Minie, M | 1 |
| Sun, X | 1 |
| Tanaka, L | 1 |
| Snyder, JM | 1 |
| Sasaki, T | 1 |
| Elkon, KB | 1 |
| Kim, DG | 1 |
| Yoon, CK | 1 |
| Kim, HW | 1 |
| Lee, SJ | 1 |
| Barailler, H | 1 |
| Milpied, B | 1 |
| Chauvel, A | 1 |
| Claraz, P | 1 |
| Taïeb, A | 1 |
| Darrigade, AS | 1 |
| Danza, A | 2 |
| Shippey, EA | 1 |
| Wagler, VD | 1 |
| Collamer, AN | 1 |
| Conigliaro, P | 1 |
| Triggianese, P | 1 |
| Draghessi, G | 1 |
| Canofari, C | 1 |
| Aloe, G | 1 |
| Chimenti, MS | 1 |
| Valeri, C | 1 |
| Nucci, C | 1 |
| Perricone, R | 2 |
| Cesareo, M | 1 |
| Fernandes, MRN | 1 |
| Soares, DBR | 1 |
| Thien, CI | 1 |
| Carneiro, S | 2 |
| Chen, YC | 1 |
| Zhang, W | 1 |
| Ding, F | 1 |
| Müller-Calleja, N | 1 |
| Lackner, KJ | 1 |
| Tekin, ZE | 1 |
| Yener, GO | 1 |
| Yüksel, S | 1 |
| Moscarelli, E | 1 |
| Miranda, F | 1 |
| Perricone, C | 1 |
| Massaro, L | 1 |
| Morello, F | 1 |
| Valesini, G | 2 |
| Rai, SK | 1 |
| Young, LH | 2 |
| Monzavi, SM | 1 |
| Alirezaei, A | 1 |
| Shariati-Sarabi, Z | 2 |
| Tavakol Afshari, J | 1 |
| Mahmoudi, M | 1 |
| Dormanesh, B | 1 |
| Jahandoost, F | 1 |
| Khoshdel, AR | 1 |
| Etemad Rezaie, A | 1 |
| Bro, ET | 1 |
| Singh, RJ | 1 |
| Jannetto, PJ | 2 |
| Wang, WM | 1 |
| Wang, KY | 1 |
| Wang, T | 1 |
| Jin, HZ | 1 |
| Fang, K | 1 |
| Keeling, SO | 1 |
| Bissonauth, A | 1 |
| Vandermeer, B | 1 |
| Rayess, N | 1 |
| Patel, VR | 1 |
| Dammacco, R | 1 |
| Procaccio, P | 1 |
| Racanelli, V | 1 |
| Vacca, A | 1 |
| Dammacco, F | 1 |
| Chera, HH | 1 |
| Cohen, M | 1 |
| Ishakis, R | 1 |
| Rosen, Y | 1 |
| Ozeri, DJ | 1 |
| Kishi, C | 1 |
| Motegi, SI | 1 |
| Yasuda, M | 1 |
| Ishikawa, O | 1 |
| Sperati, CJ | 1 |
| Rosenberg, AZ | 1 |
| Groot, N | 1 |
| Shaikhani, D | 1 |
| Teng, YKO | 1 |
| Bijl, M | 2 |
| Dolhain, RJEM | 1 |
| Zirkzee, E | 1 |
| Fritsch-Stork, R | 1 |
| Kamphuis, S | 1 |
| Margiotta, DPE | 1 |
| Borik, L | 1 |
| Petzelbauer, P | 1 |
| Quint, T | 1 |
| Wöhrl, S | 1 |
| Kinaciyan, T | 1 |
| Heil, PM | 1 |
| Green, TP | 1 |
| Barsalou, J | 1 |
| Berhanu, A | 1 |
| Fors-Nieves, C | 1 |
| Shah, U | 1 |
| Laskin, CA | 1 |
| Levesque, K | 1 |
| Silverman, ED | 1 |
| Kosic Knez, N | 1 |
| Šiško, K | 1 |
| Holc, I | 1 |
| Pahor, D | 1 |
| Pahor, A | 1 |
| Gracner, T | 1 |
| Dobranici, M | 1 |
| Tocitu, A | 1 |
| Delcea, C | 1 |
| Dan, GA | 1 |
| Ung, C | 1 |
| Hanaoka, H | 3 |
| Iida, H | 3 |
| Kiyokawa, T | 3 |
| Takakuwa, Y | 3 |
| Kawahata, K | 3 |
| Cai, L | 1 |
| Zhang, J | 2 |
| Zhou, C | 1 |
| Joung, J | 1 |
| Piggott, KD | 1 |
| Apte, R | 1 |
| Yates, M | 1 |
| Bowman, SJ | 1 |
| DeParis, SW | 1 |
| Joseph, SS | 1 |
| Nguyen, T | 1 |
| Reveley, C | 1 |
| Rodrigues, F | 1 |
| Bachmeyer, C | 1 |
| Ivo, R | 1 |
| Lopes, CA | 1 |
| Reis, R | 1 |
| Olsen, NJ | 3 |
| James, JA | 4 |
| Arriens, C | 1 |
| Ishimori, ML | 2 |
| Chong, BF | 1 |
| Liao, D | 1 |
| Chinchilli, VM | 1 |
| Karp, DR | 3 |
| Hannah, CE | 1 |
| Moye, MS | 1 |
| Wanat, KA | 1 |
| Liu, V | 1 |
| Emmi, G | 1 |
| Bettiol, A | 1 |
| Palterer, B | 1 |
| Silvestri, E | 1 |
| Vitiello, G | 1 |
| Parronchi, P | 1 |
| Prisco, D | 1 |
| Shankarasivam, G | 1 |
| Declerck, D | 1 |
| Diamantis, S | 1 |
| Vatcher, D | 1 |
| Dorfman, AL | 1 |
| Shen, Y | 1 |
| You, JY | 1 |
| Sun, V | 1 |
| Khan, A | 1 |
| Polomeno, RC | 1 |
| Lachapelle, P | 1 |
| Liu, LH | 1 |
| Fevrier, HB | 1 |
| Goldfien, R | 1 |
| Hemmerling, A | 1 |
| Herrinton, LJ | 1 |
| Sandhu, VK | 2 |
| Goel, N | 1 |
| Duro, T | 1 |
| Martín-Iglesias, D | 1 |
| Artaraz, J | 1 |
| Fonollosa, A | 1 |
| Arteagabeitia, A | 1 |
| Noé, G | 1 |
| Combarel, D | 1 |
| Lori, L | 1 |
| Tissot, N | 1 |
| Seycha, A | 1 |
| Funck-Brentano, C | 2 |
| Krüssel, J | 1 |
| Fehm, T | 1 |
| Germeyer, A | 1 |
| Suerdieck, MB | 1 |
| Kreuzer, V | 1 |
| Liebenthron, J | 1 |
| Alunno, A | 1 |
| Bajema, I | 1 |
| Boletis, JN | 1 |
| Govoni, M | 1 |
| Kouloumas, M | 1 |
| Kuhn, A | 1 |
| Larsen, JL | 1 |
| Lerstrøm, K | 1 |
| Moroni, G | 2 |
| Smolen, JS | 1 |
| Tesar, V | 1 |
| Wenzel, J | 1 |
| Cabral, RTS | 1 |
| Klumb, EM | 1 |
| Weisman, MH | 3 |
| Tao, CY | 1 |
| Shang, J | 1 |
| Chen, T | 1 |
| Yu, D | 1 |
| Jiang, YM | 1 |
| Liu, D | 1 |
| Cheng, GY | 2 |
| Xiao, J | 1 |
| Zhao, ZZ | 1 |
| Zone Abid, I | 1 |
| Kaibi, I | 1 |
| Turki, R | 1 |
| Gargouri, S | 1 |
| Feki, J | 1 |
| Seo, MR | 1 |
| Chae, J | 1 |
| Kim, YM | 1 |
| Cha, HS | 1 |
| Choi, SJ | 1 |
| Oh, S | 1 |
| Roh, CR | 1 |
| Proano, C | 1 |
| Kimball, GP | 1 |
| Li, GM | 1 |
| Liu, HM | 1 |
| Guan, WZ | 1 |
| Wu, BB | 1 |
| Feng, JY | 1 |
| Mansour, MF | 1 |
| Rodriguez-Smith, J | 1 |
| Geraldino-Pardilla, L | 1 |
| Perel-Winkler, A | 1 |
| Miceli, J | 1 |
| Neville, K | 1 |
| Danias, G | 1 |
| Nguyen, S | 1 |
| Dervieux, T | 1 |
| Kapoor, T | 1 |
| Giles, J | 1 |
| Hong, AS | 1 |
| Desta, M | 1 |
| Hong, JM | 1 |
| Ohning, GV | 1 |
| Pillinger, MH | 1 |
| Modjinou, DV | 1 |
| Shindo, E | 1 |
| Shikano, K | 1 |
| Kawazoe, M | 1 |
| Kusunoki, N | 1 |
| Hashimoto, Y | 1 |
| Nanki, T | 1 |
| Vithoosan, S | 1 |
| Karunarathna, T | 1 |
| Shanjeeban, P | 1 |
| Piranavan, P | 1 |
| Matthias, T | 1 |
| Gamlaksha, D | 1 |
| Liyadipita, A | 1 |
| Kulatunga, A | 1 |
| Michaud, M | 2 |
| Catros, F | 1 |
| Ancellin, S | 1 |
| Gaches, F | 2 |
| Stojan, G | 1 |
| Yang, SJ | 1 |
| Song, HM | 1 |
| Reese, T | 1 |
| Dickson, AL | 1 |
| Shuey, MM | 1 |
| Gandelman, JS | 1 |
| Barker, KA | 1 |
| Neal, JE | 1 |
| Khan, OA | 1 |
| Dupont, WD | 1 |
| Stein, CM | 2 |
| Chung, CP | 1 |
| Shadhu, K | 1 |
| Ramlagun, D | 1 |
| Ping, X | 1 |
| Messiant, V | 1 |
| Defoort-Dhellemmes, S | 1 |
| Smirnov, V | 1 |
| Ruiz-Estevez, B | 1 |
| Ruiz-Arruza, I | 2 |
| Martin-Cascon, M | 1 |
| Blanco, P | 2 |
| Carmichael, SJ | 1 |
| Day, RO | 1 |
| Tett, SE | 1 |
| Ekwom, PE | 1 |
| Schleich, MA | 1 |
| Füzéry, AK | 1 |
| Breaud, AR | 1 |
| Emezienna, N | 1 |
| Schools, S | 1 |
| Clarke, WA | 2 |
| Stelton, CR | 1 |
| Connors, DB | 1 |
| Walia, SS | 1 |
| Walia, HS | 1 |
| Gattamelata, A | 1 |
| Giordano, C | 1 |
| Piccioni, MG | 1 |
| Framarino-dei-Malatesta, M | 1 |
| Aubry-Rozier, B | 1 |
| Fabreguet, I | 1 |
| Khubchandani, SR | 1 |
| Bichle, LS | 1 |
| Akhavan, PS | 1 |
| Lou, W | 2 |
| Diav-Citrin, O | 1 |
| Blyakhman, S | 1 |
| Shechtman, S | 1 |
| Ornoy, A | 1 |
| Ulviye, Y | 1 |
| Betul, T | 1 |
| Nur, TH | 1 |
| Selda, C | 1 |
| Blasco, LM | 1 |
| Goossens, N | 1 |
| Spahr, L | 1 |
| Rubbia-Brandt, L | 1 |
| Silva, JC | 1 |
| Mariz, HA | 1 |
| Rocha, LF | 1 |
| Oliveira, PS | 1 |
| Dantas, AT | 1 |
| Duarte, AL | 1 |
| Pitta, Ida R | 1 |
| Galdino, SL | 1 |
| Pitta, MG | 1 |
| Huong, du LT | 2 |
| Moguelet, P | 1 |
| Factor, C | 1 |
| Miyara, M | 1 |
| Saadoun, D | 2 |
| De Gennes, C | 2 |
| Chapelon, C | 2 |
| Wechsler, B | 6 |
| Erten, S | 1 |
| Taskaldiran, I | 1 |
| Yakut, ZI | 1 |
| Morgan, ND | 1 |
| Patel, SV | 1 |
| Dvorkina, O | 1 |
| Tracy, CL | 1 |
| Blakey, B | 1 |
| Parker, G | 1 |
| Roebuck, J | 1 |
| Mititelu, M | 1 |
| Wong, BJ | 1 |
| Brenner, M | 1 |
| Bryar, PJ | 1 |
| Jampol, LM | 2 |
| Fawzi, AA | 2 |
| Fangtham, M | 1 |
| Kiriakidou, M | 1 |
| Cotton, D | 1 |
| Taichman, D | 1 |
| Williams, S | 1 |
| Putterman, C | 2 |
| Chafin, CB | 1 |
| Regna, NL | 1 |
| Hammond, SE | 1 |
| Reilly, CM | 1 |
| Shrestha, D | 1 |
| Dhakal, AK | 1 |
| Shiva, RK | 1 |
| Shakya, A | 1 |
| Shah, SC | 1 |
| Shakya, H | 1 |
| Pouchot, J | 1 |
| Marra, D | 3 |
| Khellaf, M | 1 |
| Chabrol, A | 1 |
| Roudot-Thoraval, F | 2 |
| Languille, L | 1 |
| Bierling, P | 2 |
| Michel, M | 1 |
| Bogaczewicz, J | 1 |
| Sobów, T | 1 |
| Bogaczewicz, A | 1 |
| Robak, E | 1 |
| Bienkowski, P | 1 |
| Sysa-Jedrzejowska, A | 2 |
| Wozniacka, A | 2 |
| Mastorodemos, V | 1 |
| Pamfil, C | 1 |
| Papadaki, E | 1 |
| Sidiropoulos, P | 1 |
| Plaitakis, A | 1 |
| Amoiridis, G | 1 |
| Fallahi, S | 1 |
| Akbarian, M | 1 |
| Dabiri, S | 1 |
| Mir, A | 1 |
| Boyd, KP | 1 |
| Meehan, SA | 1 |
| McLellan, B | 1 |
| Vilá-Rivera, K | 1 |
| Jiménez-Encarnación, E | 1 |
| Vilá, S | 1 |
| Peart, E | 1 |
| Clowse, ME | 3 |
| Zhang, LN | 1 |
| Shi, TY | 1 |
| Yang, YJ | 1 |
| Zhang, FC | 1 |
| Ben Dhaou, B | 1 |
| Aydi, Z | 1 |
| Baili, L | 1 |
| Ketari, S | 1 |
| Boussema, F | 1 |
| Rokbani, L | 1 |
| Dominguez-Gutierrez, PR | 1 |
| Ceribelli, A | 2 |
| Satoh, M | 1 |
| Sobel, ES | 1 |
| Reeves, WH | 1 |
| Chan, EK | 1 |
| Cooper, WO | 1 |
| Cheetham, TC | 1 |
| Li, DK | 1 |
| Callahan, ST | 1 |
| Morgan, TM | 1 |
| Shintani, AK | 1 |
| Chen, N | 1 |
| Griffin, MR | 1 |
| Ray, WA | 1 |
| Pokroy-Shapira, E | 1 |
| Gelernter, I | 1 |
| Zhao, L | 2 |
| Ma, H | 3 |
| Jiang, Z | 3 |
| Ma, N | 1 |
| Ammirati, E | 1 |
| Contri, R | 1 |
| Baragetti, A | 1 |
| Palini, AG | 1 |
| Cianflone, D | 1 |
| Banfi, M | 1 |
| Uboldi, P | 1 |
| Bottoni, G | 1 |
| Scotti, I | 1 |
| Pirillo, A | 1 |
| Grigore, L | 1 |
| Garlaschelli, K | 1 |
| Monaco, C | 1 |
| Catapano, AL | 1 |
| Sabbadini, MG | 1 |
| Manfredi, AA | 1 |
| Norata, GD | 1 |
| Desai, S | 1 |
| Korta, DZ | 1 |
| Patel, RR | 1 |
| Sanchez, MR | 1 |
| Gómez-Guzmán, M | 1 |
| Jiménez, R | 1 |
| Romero, M | 1 |
| Sánchez, M | 1 |
| Zarzuelo, MJ | 1 |
| Gómez-Morales, M | 1 |
| O'Valle, F | 1 |
| López-Farré, AJ | 1 |
| Algieri, F | 1 |
| Gálvez, J | 1 |
| Pérez-Vizcaino, F | 1 |
| Sabio, JM | 2 |
| Duarte, J | 1 |
| Meng, J | 1 |
| Lu, Y | 1 |
| Hao, D | 2 |
| Xu, D | 1 |
| Liu, J | 3 |
| Jin, D | 1 |
| Gao, Z | 1 |
| Dunogué, B | 2 |
| Nika, M | 1 |
| Blachley, TS | 1 |
| Edwards, P | 1 |
| Lee, PP | 1 |
| Stein, JD | 1 |
| Al Hussaini, M | 1 |
| Hammouda, EI | 1 |
| Hammouda, AE | 1 |
| Feng, L | 1 |
| Graves, GS | 1 |
| Adam, MK | 1 |
| Stepien, KE | 2 |
| Han, DP | 2 |
| Biermann, MH | 1 |
| Veissi, S | 1 |
| Maueröder, C | 1 |
| Chaurio, R | 1 |
| Berens, C | 1 |
| Herrmann, M | 1 |
| Munoz, LE | 1 |
| Lu-Fritts, PY | 1 |
| Kottyan, LC | 1 |
| Xie, C | 1 |
| Buckholz, JM | 1 |
| Pinney, SM | 1 |
| Harley, JB | 3 |
| Saison, J | 1 |
| Maucort-Boulch, D | 1 |
| Iwaz, J | 1 |
| Marignier, R | 1 |
| Vital-Durand, D | 1 |
| Hot, A | 1 |
| Tebib, J | 1 |
| Schleinitz, N | 1 |
| Sarrot-Reynauld, F | 1 |
| Broussolle, C | 1 |
| Houssen, ME | 1 |
| El-Mahdy, RH | 1 |
| Shahin, DA | 1 |
| Chiang, E | 1 |
| Sarantopoulos, A | 1 |
| Gkougkourelas, I | 1 |
| Boura, P | 1 |
| Pérez-Sánchez, N | 1 |
| Esponda-Juárez, K | 1 |
| Cimarra Álvarez, M | 1 |
| Aleo Luján, E | 1 |
| Toledano Martínez, E | 1 |
| Fernandez-Rivas, MM | 1 |
| Gafor, AH | 1 |
| Said, MS | 1 |
| Kong, NC | 1 |
| Joo, YB | 1 |
| Shim, JS | 1 |
| Kim, JH | 1 |
| Lee, EK | 1 |
| Lee, HS | 1 |
| Koh, JH | 1 |
| Ko, HS | 1 |
| Kwok, SK | 2 |
| Ju, JH | 2 |
| Park, SH | 4 |
| Jones, DW | 1 |
| Wright, D | 1 |
| Jankowski, TA | 1 |
| Cameron, MC | 1 |
| Word, AP | 1 |
| Dominguez, A | 1 |
| Hammami, S | 1 |
| Bdioui, F | 1 |
| Ouaz, A | 1 |
| Loghmari, H | 1 |
| Mahjoub, S | 1 |
| Saffar, H | 1 |
| Abdel Galil, SM | 1 |
| Asensio-Sánchez, VM | 1 |
| Cukras, C | 1 |
| Huynh, N | 1 |
| Vitale, S | 1 |
| Wong, WT | 1 |
| Ferris, FL | 1 |
| Sieving, PA | 1 |
| Ausavarungnirun, R | 1 |
| Srisuttiyakorn, C | 1 |
| Lan, TH | 1 |
| Chang, SN | 1 |
| Wang, JS | 1 |
| Hung, WT | 1 |
| Lan, JL | 1 |
| Brézin, AP | 1 |
| Puppe, V | 1 |
| Changcharoen, B | 1 |
| Bolger, DT | 1 |
| Cortés-Hernández, J | 1 |
| Egri, N | 1 |
| Vilardell-Tarrés, M | 1 |
| Ordi-Ros, J | 1 |
| Hiraki, LT | 1 |
| Winkelmayer, WC | 1 |
| Marty, FM | 1 |
| Franklin, JM | 1 |
| Kim, SC | 3 |
| Gonzalez-Rivera, T | 1 |
| Cairoli, E | 2 |
| Danese, N | 2 |
| Teliz, M | 1 |
| Bruzzone, MJ | 1 |
| Ferreira, J | 1 |
| Rebella, M | 2 |
| Cayota, A | 1 |
| Bhavsar, KV | 1 |
| Mukkamala, LK | 1 |
| Freund, KB | 1 |
| Prior-Español, Á | 1 |
| Martínez-Morillo, M | 1 |
| Riveros-Frutos, A | 1 |
| Olivé, A | 2 |
| Croyle, L | 1 |
| Morand, EF | 3 |
| Tedeschi, SK | 2 |
| Massarotti, E | 2 |
| Fine, A | 2 |
| Bermas, BL | 2 |
| Sebastiani, GD | 1 |
| Prevete, I | 1 |
| Iuliano, A | 1 |
| Bettio, S | 1 |
| Coladonato, L | 1 |
| Fineschi, I | 1 |
| Mathieu, A | 1 |
| Debellemanière, G | 1 |
| Flores, M | 1 |
| Tumahai, P | 1 |
| Meillat, M | 1 |
| Bidaut Garnier, M | 1 |
| Delbosc, B | 1 |
| Saleh, M | 1 |
| Pourrat, J | 4 |
| Zeller, L | 2 |
| Barski, L | 1 |
| Shleyfer, E | 1 |
| Netz, U | 1 |
| Stavi, V | 1 |
| Abu-Shakra, M | 2 |
| Barbosa, C | 1 |
| Duarte, JA | 1 |
| Henriques, CC | 1 |
| Sousa, C | 1 |
| Alves, JD | 1 |
| Leroux, M | 1 |
| Desveaux, C | 1 |
| Parcevaux, M | 1 |
| Julliac, B | 1 |
| Gouyon, JB | 1 |
| Dallay, D | 1 |
| Pellegrin, JL | 1 |
| Boukerrou, M | 1 |
| Bellakhal, S | 1 |
| Ben Kaab, B | 1 |
| Teyeb, Z | 1 |
| Souissi, A | 1 |
| Derbel, F | 1 |
| Douggui, MH | 1 |
| Moschos, MM | 2 |
| Nitoda, E | 1 |
| Chatziralli, IP | 1 |
| Gatzioufas, Z | 1 |
| Koutsandrea, C | 1 |
| Kitsos, G | 1 |
| Hagberg, N | 1 |
| Wang, JM | 1 |
| Huang, WC | 1 |
| Wen, CY | 1 |
| Lee, CH | 1 |
| Yang, CY | 1 |
| Wu, MF | 1 |
| Levy, M | 2 |
| Bourrat, E | 1 |
| Baudouin, V | 1 |
| Guillem, C | 1 |
| Peuchmaur, M | 1 |
| Deschênes, G | 1 |
| Fila, M | 1 |
| Kiykim, A | 1 |
| Ogulur, I | 1 |
| Baris, S | 1 |
| Salzer, E | 1 |
| Karakoc-Aydiner, E | 1 |
| Ozen, AO | 1 |
| Garncarz, W | 1 |
| Hirschmugl, T | 1 |
| Krolo, A | 1 |
| Yucelten, AD | 1 |
| Boztug, K | 1 |
| Barlan, IB | 1 |
| Rainsford, KD | 1 |
| Parke, AL | 3 |
| Clifford-Rashotte, M | 1 |
| Kean, WF | 1 |
| Zou, YF | 1 |
| Xu, JH | 1 |
| Pan, FM | 1 |
| Tao, JH | 1 |
| Xu, SQ | 1 |
| Cai, J | 1 |
| Lian, L | 1 |
| Chen, PL | 1 |
| Wang, DG | 1 |
| Liu, SX | 1 |
| Liang, CM | 1 |
| Ye, QL | 1 |
| Tian, G | 1 |
| Gu, YY | 1 |
| Pan, HF | 1 |
| Su, H | 1 |
| Wei, CH | 1 |
| Penunuri, A | 1 |
| Karpouzas, G | 1 |
| Fleishman, W | 1 |
| Datta, A | 1 |
| French, SW | 1 |
| Lee, JY | 2 |
| Vinayagamoorthy, N | 1 |
| Han, K | 1 |
| Park, KS | 1 |
| Jung, SH | 1 |
| Park, SW | 1 |
| Chung, YJ | 1 |
| Hashemie, H | 1 |
| Klossowski, N | 1 |
| Oommen, PT | 1 |
| Neubert, J | 1 |
| Homey, B | 1 |
| Hoff, NP | 1 |
| Reifenberger, J | 1 |
| Meller, S | 1 |
| Artim-Esen, B | 1 |
| Şahinkaya, Y | 1 |
| Pehlivan, Ö | 1 |
| Alpay-Kanıtez, N | 1 |
| Omma, A | 1 |
| Erer, B | 1 |
| Kamalı, S | 1 |
| Aral, O | 1 |
| Öcal, L | 1 |
| Luo, Y | 1 |
| Fei, Y | 1 |
| Kansal, A | 1 |
| Tripathi, D | 1 |
| Rai, MK | 1 |
| Agarwal, V | 1 |
| Branch, DW | 1 |
| Levy, RA | 2 |
| Middeldorp, S | 1 |
| Pavord, S | 1 |
| Hunt, BJ | 2 |
| Durcan, L | 4 |
| Talavera-Garcia, E | 1 |
| Lliso, G | 1 |
| Cuadrado, MJ | 1 |
| Virdis, A | 1 |
| Duranti, E | 1 |
| Vagnani, S | 1 |
| Carli, L | 1 |
| Kühl, AA | 1 |
| Solini, A | 1 |
| Baldini, C | 1 |
| Talarico, R | 1 |
| Bombardieri, S | 1 |
| Taddei, S | 1 |
| Parikh, VS | 1 |
| Modi, YS | 1 |
| Au, A | 1 |
| Ehlers, JP | 1 |
| Srivastava, SK | 1 |
| Schachat, AP | 1 |
| Singh, RP | 1 |
| Tsang-A-Sjoe, MW | 1 |
| Bultink, IE | 1 |
| Elera-Fitzcarrald, C | 1 |
| Alfaro-Lozano, JL | 1 |
| Pastor-Asurza, CA | 1 |
| Morita, S | 1 |
| Takahashi, T | 1 |
| Yokota, N | 1 |
| Desai, RJ | 1 |
| Huybrechts, KF | 1 |
| Bateman, BT | 1 |
| Hernandez-Diaz, S | 1 |
| Mogun, H | 1 |
| Gopalakrishnan, C | 1 |
| Patorno, E | 1 |
| Cruz, AJ | 1 |
| Castro, A | 1 |
| Galán-Puchades, MT | 1 |
| Clancy, RM | 1 |
| Markham, AJ | 1 |
| Neamtu, DV | 1 |
| Eller, AW | 1 |
| Cohen, SY | 1 |
| Penn, HJ | 1 |
| Langman, LJ | 1 |
| Basaran, O | 1 |
| Aydın, F | 1 |
| Celikel, BA | 1 |
| Uncu, N | 1 |
| Cakar, N | 1 |
| Elfving, P | 1 |
| Puolakka, K | 1 |
| Kautiainen, H | 1 |
| Virta, LJ | 1 |
| Pohjolainen, T | 1 |
| Kaipiainen-Seppänen, O | 1 |
| Winegar, DA | 1 |
| Connelly, MA | 1 |
| Otvos, JD | 1 |
| Shimomatsu, T | 1 |
| Kanazawa, N | 2 |
| Mikita, N | 1 |
| Nakatani, Y | 1 |
| Inaba, Y | 1 |
| Ikeda, T | 2 |
| Kondo, T | 1 |
| Furukawa, F | 2 |
| Varan, O | 1 |
| Kucuk, H | 1 |
| Tufan, A | 1 |
| Boutin, DL | 1 |
| Noviani, M | 1 |
| Wasserman, S | 1 |
| Coulombe, J | 1 |
| Boccara, O | 1 |
| Kan, H | 1 |
| Nagar, S | 1 |
| Molta, C | 1 |
| Chang, DJ | 2 |
| Bethel, M | 1 |
| Yang, FM | 1 |
| Li, S | 1 |
| Nahman, NS | 1 |
| Oliver, AM | 1 |
| Machua, W | 1 |
| Carbone, LD | 1 |
| Gao, CC | 1 |
| Wu, ZZ | 1 |
| Gao, GM | 2 |
| Liu, ZS | 2 |
| Zheng, ZH | 2 |
| Hu, SC | 1 |
| Yen, FL | 1 |
| Wang, TN | 1 |
| Lin, YC | 1 |
| Lin, CL | 1 |
| Chen, GS | 1 |
| Khokhar, N | 1 |
| Pawlak-Buś, K | 1 |
| Gaca-Wysocka, M | 1 |
| Grzybowski, A | 1 |
| Leszczyński, P | 1 |
| Iselin, KC | 1 |
| Marti, P | 1 |
| Pless, M | 1 |
| Chatre, C | 1 |
| Filippi, N | 1 |
| Roubille, F | 1 |
| Stannard, JN | 1 |
| Sabato, LA | 1 |
| Mendes, LA | 1 |
| Cox, ZL | 1 |
| Yeon Lee, J | 1 |
| Ki Kwok, S | 1 |
| Hyeon Ju, J | 1 |
| Su Park, K | 1 |
| Ferreira, CS | 1 |
| Beato, J | 1 |
| Falcão, MS | 1 |
| Brandão, E | 1 |
| Falcão-Reis, F | 1 |
| Carneiro, ÂM | 1 |
| Shulman, S | 1 |
| Wollman, J | 1 |
| Brikman, S | 1 |
| Padova, H | 1 |
| Elkayam, O | 2 |
| Paran, D | 4 |
| Harvey, P | 1 |
| Mak, S | 1 |
| Chantal, M | 1 |
| Moorthy, LN | 1 |
| Baldino, ME | 1 |
| Kurra, V | 1 |
| Puwar, D | 1 |
| Llanos, A | 1 |
| Peterson, MG | 1 |
| Hassett, AL | 1 |
| Lehman, TJ | 1 |
| Lam, NC | 1 |
| Ghetu, MV | 1 |
| Bieniek, ML | 1 |
| Kibune, N | 1 |
| Shimomura, Y | 1 |
| Hasegawa, A | 1 |
| Saeki, T | 1 |
| Umemori, Y | 1 |
| Abe, R | 1 |
| van den Hoogen, LL | 1 |
| Fritsch-Stork, RD | 1 |
| Versnel, MA | 1 |
| Derksen, RH | 1 |
| van Roon, JA | 1 |
| Radstake, TR | 1 |
| Deligny, C | 1 |
| Chatelet, JN | 1 |
| Auffret, M | 1 |
| Combret, S | 1 |
| Bondon-Guitton, E | 1 |
| Gautier, S | 1 |
| Adelowo, OO | 1 |
| Olaosebikan, BH | 1 |
| Animashaun, BA | 1 |
| Akintayo, RO | 1 |
| Staveri, C | 1 |
| Karokis, D | 1 |
| Liossis, SC | 1 |
| Feldman, S | 1 |
| Corzo, P | 1 |
| Salman-Monte, TC | 1 |
| Polino, L | 1 |
| Mojal, S | 1 |
| Carbonell-Abelló, J | 1 |
| Ponticelli, C | 1 |
| Apostolopoulos, D | 1 |
| Harris, JG | 1 |
| Maletta, KI | 1 |
| Kuhn, EM | 1 |
| Olson, JC | 1 |
| Huang, L | 1 |
| Kuang, Y | 1 |
| Wei, D | 1 |
| Li, W | 1 |
| Yin, Q | 1 |
| Pang, J | 1 |
| Abou Assalie, N | 1 |
| Durcan, R | 1 |
| Aberle, T | 1 |
| Bourn, RL | 1 |
| Munroe, ME | 1 |
| Chen, H | 1 |
| Roberts, VC | 1 |
| Guthridge, JM | 1 |
| Bean, K | 1 |
| Robertson, JM | 1 |
| Sivils, KL | 1 |
| Rasmussen, A | 1 |
| Liles, M | 1 |
| DeKoninck, P | 1 |
| Murthi, P | 1 |
| Wallace, EM | 1 |
| González, NS | 1 |
| Lorenzo, N | 1 |
| Parodis, Y | 1 |
| Ortiz, MBA | 1 |
| Kechida, M | 1 |
| Perez, JCR | 1 |
| Yap, KS | 1 |
| Polachek, A | 1 |
| Latasiewicz, M | 1 |
| Gourier, H | 1 |
| Yusuf, IH | 1 |
| Luqmani, R | 1 |
| Sharma, SM | 1 |
| Downes, SM | 1 |
| Yuan, Y | 1 |
| Jing, W | 1 |
| Mathias, SD | 1 |
| Berry, P | 1 |
| Pascoe, K | 1 |
| de Vries, J | 1 |
| Colwell, HH | 1 |
| Jafri, K | 1 |
| Zahed, H | 1 |
| Wysham, KD | 1 |
| Patterson, S | 1 |
| Nolan, AL | 1 |
| Bucknor, MD | 1 |
| Chaganti, RK | 1 |
| Srinivasa, A | 1 |
| Youssef, MM | 1 |
| El-Fayoumi, D | 1 |
| Sidky, MK | 1 |
| Hegazy, AI | 1 |
| Marzouk, H | 1 |
| Eltanamly, RM | 1 |
| Golder, V | 1 |
| Hoi, A | 1 |
| Hu, C | 1 |
| Wan, JP | 1 |
| Wen, C | 1 |
| Koneru, S | 2 |
| Kocharla, L | 1 |
| Higgins, GC | 2 |
| Ware, A | 2 |
| Passo, MH | 2 |
| Farhey, YD | 1 |
| Mongey, AB | 2 |
| Graham, TB | 2 |
| Houk, JL | 2 |
| Collins, GB | 1 |
| McAllister, MS | 1 |
| Fleury, O | 1 |
| Droitcourt, C | 1 |
| Polard, E | 1 |
| Chevrant-Breton, J | 1 |
| Puri, PK | 1 |
| Lountzis, NI | 1 |
| Tyler, W | 1 |
| Ferringer, T | 1 |
| Kaiser, R | 1 |
| Cleveland, CM | 1 |
| Criswell, LA | 3 |
| Masatlioğlu, SP | 1 |
| Göktay, F | 1 |
| Mansur, AT | 1 |
| Akkaya, AD | 1 |
| Güneş, P | 1 |
| Gyl, F | 1 |
| Anna-Adrien, C | 1 |
| Oanţă, A | 1 |
| Irimie, M | 1 |
| Edit, FJ | 1 |
| Stevens, MA | 1 |
| Yeaney, GA | 1 |
| Lacomis, D | 1 |
| Tektonidou, MG | 1 |
| Laskari, K | 1 |
| Panagiotakos, DB | 1 |
| Moutsopoulos, HM | 1 |
| Hersh, AO | 1 |
| von Scheven, E | 1 |
| Panopalis, P | 1 |
| Trupin, L | 2 |
| Julian, L | 1 |
| Katz, P | 1 |
| Yelin, E | 2 |
| Chiffoleau, A | 1 |
| Guillet, A | 1 |
| Zanlonghi, X | 1 |
| Jolliet, P | 1 |
| Namazi, MR | 1 |
| Manohar, VA | 1 |
| Moder, KG | 1 |
| Edwards, WD | 2 |
| Klarich, K | 1 |
| Kroshinsky, D | 1 |
| Stone, JH | 1 |
| Bloch, DB | 1 |
| Sepehr, A | 1 |
| Turgut, B | 1 |
| Turkcuoglu, P | 1 |
| Serdar Koca, S | 1 |
| Aydemir, O | 1 |
| Salesi, M | 1 |
| Karimifar, M | 1 |
| Mottaghi, P | 1 |
| Sayedbonakdar, Z | 1 |
| Karimzadeh, H | 1 |
| Cavazzana, I | 1 |
| Sala, R | 1 |
| Bazzani, C | 1 |
| Zane, C | 1 |
| Cattaneo, R | 1 |
| Calzavara-Pinton, PG | 1 |
| Franceschini, F | 1 |
| Xicoy, B | 1 |
| Jové, J | 1 |
| Ribera, JM | 1 |
| Feliu, E | 1 |
| Tan, KB | 1 |
| Lau, TC | 1 |
| Bag, AK | 1 |
| Curé, JK | 1 |
| Sullivan, JC | 1 |
| Roberson, GH | 1 |
| Jang, SJ | 1 |
| Wu, YC | 1 |
| Chuang, WY | 1 |
| Chung, CM | 1 |
| Luo, SF | 1 |
| Chu, PH | 1 |
| Schell, J | 1 |
| Godara, P | 1 |
| Rha, J | 1 |
| Carroll, J | 1 |
| Jung, H | 1 |
| Bobba, R | 1 |
| Ablin, JN | 1 |
| Boguslavski, V | 1 |
| Aloush, V | 1 |
| Levartovski, D | 1 |
| Caspi, D | 1 |
| George, J | 1 |
| Kettaneh, A | 1 |
| Wong, JS | 1 |
| Ngeh, NK | 1 |
| Loh, WL | 1 |
| Pons-Estel, GJ | 1 |
| González, LA | 1 |
| Reveille, JD | 7 |
| McGwin, G | 7 |
| Salu, P | 1 |
| Uvijls, A | 1 |
| van den Brande, P | 1 |
| Leroy, BP | 1 |
| Halabi-Tawil, M | 1 |
| Liou, LB | 1 |
| Chao, WJ | 1 |
| Penn, SK | 1 |
| Kao, AH | 1 |
| Schott, LL | 1 |
| Elliott, JR | 1 |
| Toledo, FG | 1 |
| Kuller, L | 1 |
| Llanos, C | 2 |
| Le, PU | 1 |
| Guerra, MM | 1 |
| Wolfe, F | 1 |
| Lee, CK | 3 |
| Lee, TH | 1 |
| Lee, SH | 1 |
| Chung, IK | 1 |
| Kim, HS | 1 |
| Chan, Y | 1 |
| Tang, WY | 1 |
| Bader-Meunier, B | 1 |
| Kobak, S | 1 |
| Deveci, H | 1 |
| Rekedal, LR | 1 |
| Garg, R | 1 |
| Bhatia, R | 1 |
| Gleeson, T | 1 |
| Lu, B | 1 |
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Galarza-Maldonado, C | 1 |
| Kourilovitch, MR | 1 |
| Molineros, JE | 1 |
| Cardiel, MH | 1 |
| Soroka, NF | 1 |
| Yagur, VY | 1 |
| Doukh, N | 1 |
| Donado, CD | 1 |
| Díez, EM | 1 |
| Mar, N | 1 |
| Mendoza Ladd, A | 1 |
| Szymezak, J | 1 |
| Ankri, A | 1 |
| Fischer, AM | 1 |
| Darnige, L | 1 |
| Michalski, JP | 1 |
| Kodner, C | 1 |
| Haddad, F | 1 |
| Anouti, S | 1 |
| Maalouly, G | 1 |
| Koussa, S | 1 |
| Tanga, L | 1 |
| Centofanti, M | 1 |
| Oddone, F | 1 |
| Parravano, M | 1 |
| Parisi, V | 1 |
| Ziccardi, L | 1 |
| Kroegler, B | 1 |
| Manni, G | 1 |
| Yildirim-Toruner, C | 1 |
| Diamond, B | 1 |
| Pusongchai, T | 1 |
| Jungthirapanich, J | 1 |
| Khositseth, S | 1 |
| Lim, SC | 1 |
| Tang, SP | 1 |
| Efthimiou, P | 1 |
| Kukar, M | 1 |
| Hersh, A | 1 |
| Zenone, T | 1 |
| Knefati, Y | 1 |
| Efe, C | 1 |
| Purnak, T | 1 |
| Ozaslan, E | 1 |
| Ozbalkan, Z | 1 |
| Karaaslan, Y | 1 |
| Altiparmak, E | 1 |
| Muratori, P | 1 |
| Wahlin, S | 1 |
| Wang, W | 1 |
| Yu, JN | 1 |
| Tao, XJ | 1 |
| Muthukrishnan, P | 1 |
| Roukoz, H | 1 |
| Grafton, G | 1 |
| Jessurun, J | 1 |
| Colvin-Adams, M | 1 |
| Abarientos, C | 1 |
| Sperber, K | 1 |
| Shapiro, DL | 1 |
| Aronow, WS | 1 |
| Chao, CP | 1 |
| Ash, JY | 1 |
| Rizvi, R | 1 |
| Hojjati, M | 1 |
| Newton-Cheh, C | 1 |
| Lin, AE | 1 |
| Baggish, AL | 1 |
| Williams, VL | 1 |
| Cohen, PR | 1 |
| Londhey, VA | 1 |
| Buche, AS | 1 |
| Kini, SH | 1 |
| Rajadhyaksha, GC | 1 |
| Dall'era, M | 1 |
| Chakravarty, EF | 1 |
| Pustilnik, S | 1 |
| Trutia, A | 1 |
| Madhok, R | 1 |
| Wu, O | 1 |
| Esposito, F | 1 |
| Galfetti, M | 1 |
| Lava, SA | 1 |
| Balestra, B | 1 |
| Bianchetti, MG | 1 |
| Ravindran, V | 1 |
| Kato, Y | 1 |
| Inada, S | 1 |
| Lorcy, S | 1 |
| Hacia, J | 1 |
| Roche, C | 1 |
| de Biasi, C | 1 |
| Lightburne, E | 1 |
| Morand, JJ | 1 |
| Ting, TV | 1 |
| Kudalkar, D | 1 |
| Nelson, S | 1 |
| Cortina, S | 1 |
| Pendl, J | 1 |
| Budhani, S | 1 |
| Neville, J | 1 |
| Taylor, J | 1 |
| Huggins, J | 1 |
| Drotar, D | 1 |
| Piette, EW | 1 |
| Foering, KP | 1 |
| Chang, AY | 1 |
| Okawa, J | 1 |
| Ten Have, TR | 1 |
| Lerang, K | 1 |
| Gilboe, IM | 1 |
| Gran, JT | 1 |
| Eymard, B | 1 |
| Benveniste, O | 1 |
| Hong, YH | 2 |
| Yun, DY | 2 |
| Jung, YW | 2 |
| Oh, MJ | 1 |
| Elqatni, M | 1 |
| Mekouar, F | 1 |
| Sekkach, Y | 1 |
| Elomri, N | 1 |
| Fatihi, J | 1 |
| Amezyane, T | 1 |
| Abouzahir, A | 1 |
| Ghafir, D | 1 |
| Goykhman, P | 1 |
| Mehta, PK | 1 |
| Minissian, M | 1 |
| Thomson, LE | 1 |
| Berman, DS | 1 |
| Shufelt, CL | 1 |
| Bairey Merz, CN | 1 |
| Ma, L | 1 |
| Lin, B | 1 |
| Wu, DH | 1 |
| Wang, GC | 1 |
| Willis, R | 1 |
| Seif, AM | 1 |
| Martinez-Martinez, LA | 1 |
| González, EB | 3 |
| Dang, N | 1 |
| Papalardo, E | 1 |
| Pierangeli, SS | 1 |
| Reiner, P | 1 |
| Vidailhet, M | 1 |
| Kojuri, J | 1 |
| Nazarinia, MA | 1 |
| Ghahartars, M | 1 |
| Mahmoody, Y | 1 |
| Rezaian, Gr | 1 |
| Liaghat, L | 1 |
| Keith, MP | 1 |
| Pitchford, C | 1 |
| Bernstein, WB | 1 |
| Yu, SL | 1 |
| Chan, PK | 1 |
| Wong, CK | 1 |
| Szeto, CC | 1 |
| Ho, SC | 1 |
| So, K | 1 |
| Yu, MM | 1 |
| Yim, SF | 1 |
| Cheung, TH | 1 |
| Wong, MC | 1 |
| Cheung, JL | 1 |
| Yeung, AC | 1 |
| Li, EK | 2 |
| Tam, LS | 2 |
| Pisoni, CN | 1 |
| Friedman, D | 1 |
| Garra, V | 1 |
| Shahane, A | 1 |
| Khasnis, A | 1 |
| Gota, C | 1 |
| Kishimoto, M | 1 |
| Deshpande, GA | 1 |
| Okada, M | 1 |
| McCune, JM | 1 |
| Seo, JY | 1 |
| Byun, HJ | 1 |
| Cho, KH | 1 |
| Lee, EB | 1 |
| Tang, C | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Hong, JY | 1 |
| Hsiao, KH | 1 |
| Chou, CT | 1 |
| Abbasi, S | 1 |
| Tarter, L | 1 |
| Farzaneh-Far, R | 1 |
| Farzaneh-Far, A | 1 |
| Zhang, X | 1 |
| Liu, GZ | 1 |
| Zeng, XF | 1 |
| Sumpter, MD | 1 |
| Tatro, LS | 1 |
| Stoecker, WV | 1 |
| Rader, RK | 1 |
| Azimian, M | 1 |
| Gultekin, SH | 1 |
| Hata, JL | 1 |
| Atkinson, JB | 1 |
| Ely, KA | 1 |
| Fuchs, HA | 1 |
| Mobley, BC | 1 |
| Meinicke, H | 1 |
| Heinzmann, A | 1 |
| Geiger, J | 1 |
| Berner, R | 1 |
| Hufnagel, M | 1 |
| Boutin, du LT | 1 |
| Tanguy, ML | 1 |
| Lechat, P | 7 |
| Musset, L | 2 |
| Lim, LS | 1 |
| Feldman, BM | 1 |
| Browning, DJ | 1 |
| Bellon, N | 1 |
| Anguel, N | 1 |
| Vandendries, C | 1 |
| Goujard, C | 1 |
| Lambotte, O | 1 |
| Kumar, N | 1 |
| Aggarwal, P | 1 |
| Dev, N | 1 |
| Kumar, G | 1 |
| Luc, S | 1 |
| Greenblatt, DJ | 1 |
| Kalish, R | 1 |
| McAlindon, TE | 1 |
| Gorshtein, A | 1 |
| Wysenbeek, AJ | 1 |
| Guedj, D | 1 |
| Majadla, R | 1 |
| Weinberger, A | 1 |
| Amit-Vazina, M | 1 |
| Toubi, E | 4 |
| Kessel, A | 3 |
| Rosner, I | 3 |
| Rozenbaum, M | 3 |
| Lorber, M | 1 |
| Sabo, E | 1 |
| Golan, TD | 2 |
| Astudillo, L | 1 |
| Carreiro, M | 1 |
| Dahan, S | 1 |
| Ollier, S | 1 |
| Arlet, P | 2 |
| Mavrikakis, I | 1 |
| Sfikakis, PP | 3 |
| Mavrikakis, E | 1 |
| Rougas, K | 2 |
| Nikolaou, A | 1 |
| Kostopoulos, C | 1 |
| Mavrikakis, M | 3 |
| Harten, P | 1 |
| Pineau, C | 1 |
| Joseph, L | 2 |
| Tutrone, WD | 1 |
| Spann, CT | 1 |
| Scheinfeld, N | 2 |
| Deleo, VA | 1 |
| Samad, AS | 1 |
| Lindsley, CB | 1 |
| CORNBLEET, T | 1 |
| LEWIS, HM | 1 |
| FRUMESS, GM | 1 |
| MULLINS, JF | 1 |
| WATTS, FL | 1 |
| WILSON, CJ | 1 |
| BENNETT, JH | 2 |
| REES, RB | 2 |
| TYE, MJ | 2 |
| ANSELL, HB | 2 |
| WOLF, M | 1 |
| APPEL, B | 2 |
| SCHIFF, B | 1 |
| GOODE, P | 1 |
| WHITE, H | 1 |
| FRAGA, S | 1 |
| GALLA, F | 1 |
| LOFFERER, O | 1 |
| PLASUN, R | 1 |
| BRODTHAGEN, H | 1 |
| SYLVEST, B | 1 |
| FREDRIKSSON, T | 1 |
| LODIN, A | 1 |
| ROSENGREN, S | 1 |
| TUFFANELLI, D | 1 |
| ABRAHAM, RK | 1 |
| DUBOIS, EI | 1 |
| CAHN, MM | 1 |
| LEVY, EJ | 1 |
| SHAFFER, B | 1 |
| RUGGIERO, HA | 1 |
| BORC, K | 1 |
| YAFFEE, HS | 1 |
| RUTLEDGE, WU | 1 |
| GREENWALD, ES | 1 |
| BERESDEVIN, M | 1 |
| BETTLEY, FR | 1 |
| LOUYOT, P | 1 |
| GAUCHER, A | 1 |
| JEANBLANC, J | 1 |
| MONTET, Y | 1 |
| VANCAUWENBERGE, H | 1 |
| FRANCHIMONT, P | 1 |
| LAMBERT, PH | 1 |
| LAPIERE, CM | 1 |
| LEFEBVRE, P | 1 |
| LISIN, N | 1 |
| SALMON, J | 1 |
| BARTHOLOMEW, LE | 2 |
| MCDUFFIE, FC | 1 |
| KABIR, DI | 2 |
| LORINCZ, AL | 1 |
| JANSEN, GT | 1 |
| DILLAHA, CJ | 1 |
| HONEYCUTT, WM | 1 |
| KRAAK, JH | 2 |
| VAN KETEL, W | 2 |
| PRAKKEN, JR | 2 |
| VAN ZWET, W | 2 |
| Shahnaz, S | 1 |
| Choksi, MT | 1 |
| Tan, IJ | 1 |
| Duhaut, P | 1 |
| Huong, DL | 2 |
| Sebbough, D | 1 |
| Vauthier, D | 1 |
| Denjoy, I | 1 |
| Lupoglazoff, JM | 1 |
| Laumann, AE | 1 |
| Shea, CR | 1 |
| Utset, TO | 1 |
| Nord, JE | 1 |
| Shah, PK | 1 |
| Rinaldi, RZ | 1 |
| Moschos, MN | 1 |
| Apostolopoulos, M | 1 |
| Mallias, JA | 1 |
| Bouros, C | 1 |
| Theodossiadis, GP | 1 |
| Ghaussy, NO | 1 |
| Sibbitt, W | 1 |
| Bankhurst, AD | 1 |
| Qualls, CR | 1 |
| Ingster-Moati, I | 1 |
| Crochet, M | 1 |
| Manchon, E | 1 |
| Anquetil, D | 1 |
| Lestrade, C | 1 |
| Jacob, A | 1 |
| Le Brun, D | 1 |
| Albuisson, E | 1 |
| Maturi, RK | 1 |
| Yu, M | 1 |
| Weleber, RG | 1 |
| Pluenneke, AC | 1 |
| Blomquist, PH | 1 |
| Richert, B | 1 |
| André, J | 1 |
| Bourguignon, R | 1 |
| de la Brassinne, M | 1 |
| Lardet, D | 1 |
| Martin, S | 1 |
| Truchetet, F | 1 |
| Cuny, JF | 1 |
| Virion, JM | 1 |
| Schmutz, JL | 1 |
| Yebra-Bango, M | 1 |
| Tutor-Ureta, P | 1 |
| Jiménez-Alonso, J | 2 |
| Carrillo-Alascio, PL | 1 |
| Jiménez-Jáimez, J | 1 |
| Jiménez-Jáimez, E | 1 |
| Hidalgo-Tenorio, C | 1 |
| Guzmán-Ubeda, M | 1 |
| Jáimez, L | 2 |
| Cáliz, R | 1 |
| García-Sánchez, A | 1 |
| Gallego, M | 1 |
| Caminal, L | 1 |
| Callejas-Rubio, JL | 2 |
| Font, J | 1 |
| Boddaert, J | 1 |
| Huong, DLT | 1 |
| Godeau, P | 1 |
| Dancey, P | 1 |
| Constantin, E | 1 |
| Duffy, CM | 1 |
| Scuccimarri, R | 1 |
| Chen, HC | 1 |
| Lai, JH | 1 |
| Huang, GS | 1 |
| Gao, HW | 1 |
| Chen, CH | 1 |
| Kuo, SY | 1 |
| Chang, DM | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Turkmen, M | 1 |
| Soylu, A | 1 |
| Demir, K | 1 |
| Kasap, B | 1 |
| Sarioglu, S | 1 |
| Kavukcu, S | 1 |
| Fessler, BJ | 4 |
| Roseman, J | 2 |
| Bastian, HM | 4 |
| Friedman, AW | 1 |
| Baethge, BA | 3 |
| Vilá, L | 1 |
| Ho, KT | 1 |
| Ahn, CW | 1 |
| Tan, FK | 1 |
| Calvo-Alén, J | 4 |
| Keating, RJ | 1 |
| Bhatia, S | 1 |
| Amin, S | 1 |
| Williams, A | 1 |
| Sinak, LJ | 1 |
| Fernández, M | 2 |
| Roseman, JM | 1 |
| Cepeda, EJ | 1 |
| Lai, TY | 2 |
| Chan, WM | 2 |
| Li, H | 1 |
| Lai, RY | 1 |
| Lam, DS | 2 |
| Sunkureddi, PR | 1 |
| Washington, R | 1 |
| Salazar, A | 1 |
| Douglass, P | 1 |
| Holvast, A | 1 |
| Huckriede, A | 1 |
| Wilschut, J | 1 |
| Horst, G | 1 |
| De Vries, JJ | 1 |
| Benne, CA | 1 |
| Kallenberg, CG | 1 |
| Al-Raqum, HA | 1 |
| Uppal, SS | 1 |
| Al-Mutairy, M | 1 |
| Kumari, R | 1 |
| Ben Ghorbel, I | 1 |
| Sioud Dhrif, A | 1 |
| Chelaifa, K | 1 |
| Miled, M | 1 |
| Houman, MH | 1 |
| Ko, CH | 1 |
| Ng, J | 1 |
| Hurst, M | 1 |
| Wiggli, S | 1 |
| Lüthy, J | 1 |
| Tyndall, A | 1 |
| Vogt, T | 1 |
| Chen, CY | 2 |
| Wang, FL | 1 |
| Lin, CC | 1 |
| Reynaert, S | 1 |
| Setterfield, J | 1 |
| Black, MM | 1 |
| Salamon, M | 1 |
| Lesiak, A | 1 |
| McCauliffe, DP | 1 |
| de Winter, S | 1 |
| van Buchem, MA | 1 |
| Vermeer, MH | 1 |
| Ngai, JW | 1 |
| Lafyatis, R | 1 |
| York, M | 1 |
| Marshak-Rothstein, A | 1 |
| Hammoud, HA | 1 |
| Aymard, G | 2 |
| Ghillani, P | 1 |
| Roverano, S | 1 |
| Cassano, G | 1 |
| Paira, S | 1 |
| Chiavarini, J | 1 |
| Graf, C | 1 |
| Rico, L | 1 |
| Heredia, C | 1 |
| Sallmann, S | 1 |
| Fiebig, B | 1 |
| Hedrich, CM | 1 |
| Heubner, G | 1 |
| Gahr, M | 1 |
| Magder, L | 2 |
| Witter, F | 1 |
| Bertoli, AM | 2 |
| Lyons, JS | 1 |
| Severns, ML | 1 |
| Gopal, S | 1 |
| Pile, JC | 1 |
| Brotman, DJ | 1 |
| Barete, S | 1 |
| Le Pelletier, F | 1 |
| Rios-Fernández, R | 1 |
| Tomás-Jiménez, C | 1 |
| Rodriguez-Padilla, JA | 1 |
| Hedges, TR | 1 |
| Monson, B | 1 |
| Srinivasan, V | 1 |
| Wojtkowski, M | 1 |
| Reichel, E | 1 |
| Duker, JS | 1 |
| Schuman, JS | 1 |
| Fujimoto, JG | 1 |
| Kwon, CM | 1 |
| Kim, HD | 1 |
| Cho, HS | 1 |
| Choi, JH | 1 |
| Rüther, K | 1 |
| Foerster, J | 1 |
| Berndt, S | 1 |
| Schroeter, J | 1 |
| Kim-Howard, XR | 1 |
| Bruner, BF | 1 |
| Jonsson, MK | 1 |
| McClain, MT | 1 |
| Arbuckle, MR | 1 |
| Walker, C | 1 |
| Dennis, GJ | 1 |
| Shishov, M | 1 |
| Farhey, Y | 1 |
| Sandborg, C | 1 |
| Tanay, A | 1 |
| Leibovitz, E | 1 |
| Frayman, A | 1 |
| Zimlichman, R | 1 |
| Shargorodsky, M | 1 |
| Gavish, D | 1 |
| Puissant, B | 1 |
| Méliani, P | 1 |
| Castex, JO | 1 |
| Saivin, S | 1 |
| Adoue, D | 1 |
| Fournie, B | 1 |
| Montastruc, JL | 1 |
| Lapeyre-Mestre, M | 1 |
| Blancher, A | 1 |
| Ermann, J | 1 |
| Soong, TR | 1 |
| Barouch, LA | 1 |
| Champion, HC | 1 |
| Wigley, FM | 1 |
| Halushka, MK | 1 |
| Stahl, NI | 1 |
| Egurbide, MV | 1 |
| Olivares, N | 1 |
| Martinez-Berriotxoa, A | 1 |
| Aguirre, C | 1 |
| Ural, UM | 1 |
| Kiliç, A | 1 |
| Güngör, T | 1 |
| Ozdal, B | 1 |
| Mollamahmutoğlu, L | 1 |
| Flach, AJ | 1 |
| Gupta, D | 1 |
| Mirza, N | 1 |
| Shearer, RV | 1 |
| Dubois, EL | 2 |
| Hart, WM | 1 |
| Burde, RM | 1 |
| Johnston, GP | 1 |
| Drews, RC | 1 |
| Fowler, JF | 1 |
| Callen, JP | 2 |
| Lanham, JG | 1 |
| Hughes, GR | 5 |
| Kremer, JM | 1 |
| Rynes, RI | 1 |
| Rodichok, LD | 1 |
| Pelton, EW | 1 |
| Block, EA | 1 |
| Tassinari, RB | 1 |
| Silver, RJ | 1 |
| Olansky, AJ | 1 |
| Frenkel, M | 1 |
| Nashel, DJ | 1 |
| Ulmer, CC | 1 |
| Habib, GS | 1 |
| Stimmer, MM | 1 |
| Quismorio, FP | 2 |
| Ilowite, NT | 1 |
| Copperman, N | 1 |
| Leicht, T | 1 |
| Kwong, T | 1 |
| Jacobson, MS | 1 |
| Neumann, R | 1 |
| Foster, CS | 1 |
| Walsh, DS | 1 |
| Farley, MF | 1 |
| Beard, JS | 1 |
| Sau, P | 1 |
| Tesar, J | 1 |
| James, WD | 1 |
| Kutz, DC | 1 |
| Bridges, AJ | 1 |
| Williams, HJ | 1 |
| Egger, MJ | 1 |
| Singer, JZ | 1 |
| Willkens, RF | 1 |
| Clegg, DO | 1 |
| Skosey, JL | 1 |
| Brooks, RH | 1 |
| Steen, VD | 1 |
| Aylward, JM | 1 |
| Spalton, DJ | 1 |
| Verdon Roe, GM | 1 |
| Baird, JS | 1 |
| Mazzuca, SA | 1 |
| Yung, R | 1 |
| Brandt, KD | 1 |
| Yee, RD | 1 |
| Katz, BP | 1 |
| Lakatta, C | 1 |
| Linker-Israeli, M | 2 |
| Hyun, S | 1 |
| Klinenberg, JR | 1 |
| Stecher, V | 1 |
| Fagundus, DM | 1 |
| Leroy, EC | 1 |
| Schaller, JG | 1 |
| Metzger, AL | 2 |
| Stecher, VJ | 2 |
| Hodis, HN | 1 |
| Wickham, E | 1 |
| Blankenhorn, DH | 1 |
| Klaiman, MD | 1 |
| Miller, SD | 1 |
| Ochonisky, S | 1 |
| Intrator, L | 1 |
| Wechsler, J | 1 |
| Revuz, J | 1 |
| Senécal, JL | 2 |
| Chartier, S | 1 |
| Rothfield, N | 3 |
| Lima, F | 2 |
| Alves, J | 1 |
| Simpson, J | 1 |
| Buchanan, NM | 3 |
| Chute, JP | 1 |
| Hoffmeister, K | 1 |
| Cotelingam, J | 1 |
| Davis, TA | 1 |
| Frame, JN | 1 |
| Jamieson, T | 1 |
| Papazoglou, S | 1 |
| Vaiopoulos, G | 1 |
| Kerslake, S | 1 |
| Rothfield, NF | 2 |
| Podrebarac, TA | 1 |
| Jovaisas, A | 1 |
| Karsh, J | 1 |
| Parke, A | 1 |
| West, B | 1 |
| Tubéry, M | 1 |
| Brousset, P | 1 |
| Anzieu, B | 1 |
| Dubarry, B | 1 |
| Massip, P | 1 |
| Duffaut, M | 1 |
| Harris, ED | 1 |
| Meng, XW | 1 |
| Feller, JM | 1 |
| Ziegler, JB | 1 |
| Pittman, SM | 1 |
| Ireland, CM | 1 |
| Shipley, M | 1 |
| Silman, A | 1 |
| Ochsendorf, FR | 1 |
| Runne, U | 1 |
| Tsakonas, E | 1 |
| Choquette, D | 1 |
| Cividino, A | 1 |
| Danoff, D | 1 |
| Osterland, CK | 1 |
| Yeadon, C | 1 |
| Smith, CD | 1 |
| Tercedor, J | 1 |
| García-Lora, E | 1 |
| Singer, NG | 1 |
| Richards, AJ | 1 |
| Galindo-Rodriguez, G | 1 |
| Newman, S | 1 |
| Suarez-Almazor, ME | 1 |
| Russell, AS | 1 |
| Rahman, P | 1 |
| Yuen, K | 1 |
| Hallett, D | 1 |
| Panaritis, T | 1 |
| Gans, M | 1 |
| Lecocq, P | 1 |
| Wyderkiewicz, E | 1 |
| Mikolajczak, P | 1 |
| Guerbeau, G | 1 |
| Shteyngarts, AR | 1 |
| Warner, MR | 1 |
| Camisa, C | 1 |
| Trapani, S | 1 |
| Ermini, M | 1 |
| Falcini, F | 1 |
| Geffray, L | 1 |
| Cévallos, R | 1 |
| Tribout, B | 1 |
| Veyssier, P | 1 |
| Holme, SA | 1 |
| Holmes, SC | 1 |
| Jordan, P | 1 |
| Brookes, JG | 1 |
| Nikolic, G | 1 |
| Le Couteur, DG | 1 |
| Lam, CW | 1 |
| Tomlinson, B | 1 |
| Fernandez, Y | 1 |
| Ramakrishnan, R | 1 |
| Rathinavelu, A | 1 |
| Granel, B | 1 |
| Serratrice, J | 1 |
| Swiader, L | 1 |
| Gambarelli, F | 1 |
| Daniel, L | 1 |
| Fossat, C | 1 |
| Hesse-Bonérandi, S | 1 |
| Pache, X | 1 |
| Disdier, P | 1 |
| Weiller, PJ | 1 |
| Malcangi, G | 1 |
| Fraticelli, P | 1 |
| Palmieri, C | 1 |
| Cappelli, M | 1 |
| Danieli, MG | 1 |
| Lakshminarayanan, S | 1 |
| Walsh, S | 1 |
| Mohanraj, M | 1 |
| Comín-Colet, J | 1 |
| Sánchez-Corral, MA | 1 |
| Alegre-Sancho, JJ | 1 |
| Valverde, J | 1 |
| López-Gómez, D | 1 |
| Sabaté, X | 1 |
| Juan-Mas, A | 1 |
| Esplugas, E | 1 |
| Peeva, E | 1 |
| Barland, P | 1 |
| Boyd, AS | 1 |
| King, LE | 1 |
| Frohman, LP | 1 |
| Frieman, BJ | 1 |
| Wolansky, L | 1 |
| Vilela, VS | 1 |
| Cataldo, MJ | 1 |
| Ramos, RC | 1 |
| Duarte, JL | 1 |
| Tura, BR | 1 |
| Albuquerque, EM | 1 |
| Jesús, NR | 1 |
| Liu, ST | 1 |
| Wang, CR | 1 |
| Yin, GD | 1 |
| Liu, MF | 1 |
| Lee, GL | 1 |
| Chen, MY | 1 |
| Chuang, CY | 1 |
| Warner, AE | 1 |
| Godfrey, TR | 1 |
| Ryan, PF | 1 |
| Buratti, S | 1 |
| Szer, IS | 1 |
| Spencer, CH | 1 |
| Bartosh, S | 1 |
| Reiff, A | 1 |
| Barthel, HR | 1 |
| Huisman, AM | 1 |
| White, KP | 1 |
| Algra, A | 1 |
| Harth, M | 1 |
| Vieth, R | 1 |
| Jacobs, JW | 1 |
| Bijlsma, JW | 1 |
| Bell, DA | 1 |
| Arnal, C | 1 |
| Léone, J | 1 |
| Taillan, B | 1 |
| Schaeffer, A | 1 |
| Manzouri, B | 1 |
| Egan, CA | 1 |
| Hykin, PG | 1 |
| Graña Gil, J | 1 |
| Cabana Vázquez, M | 1 |
| Vázquez González, A | 1 |
| Sánchez Meizoso, MO | 1 |
| Brinkley, JR | 1 |
| Ryan, SJ | 1 |
| de Macedo, DD | 1 |
| de Mattos, JP | 1 |
| Borges, TM | 1 |
| Sontheimer, RD | 1 |
| Thomas, JR | 1 |
| Gilliam, JN | 1 |
| Ladanyi, E | 1 |
| Nagy, E | 2 |
| Baler, GR | 1 |
| Gyarmati, L | 1 |
| Stampf, G | 1 |
| Morzsányi, E | 1 |
| Soós, G | 1 |
| Ablonczy, E | 1 |
| Conte, JJ | 1 |
| Mignon-Conte, MA | 1 |
| Fournie, GJ | 1 |
| Blanche, P | 1 |
| Sicard, D | 1 |
| Reardon, EV | 1 |
| Clough, JD | 1 |
| McCloud, PI | 1 |
| Littlejohn, GO | 1 |
| Howard, D | 1 |
| Repke, J | 1 |
| Disla, E | 1 |
| Brar, H | 1 |
| Taranta, A | 1 |
| Weiner, A | 1 |
| Sandberg, MA | 1 |
| Gaudio, AR | 1 |
| Kini, MM | 1 |
| Berson, EL | 1 |
| Lockshin, MD | 1 |
| Buskila, D | 1 |
| Koren, G | 1 |
| McGalliard, J | 1 |
| Bell, AL | 1 |
| Turnbull, BA | 1 |
| Kern, PA | 1 |
| Iskander, MK | 1 |
| Khan, M | 1 |
| Becker, NJ | 1 |
| Crockett, RS | 1 |
| Valenzeno, DP | 1 |
| Abdou, NI | 1 |
| Muirden, KD | 1 |
| Omdal, R | 1 |
| Dickstein, K | 1 |
| von Brandis, C | 1 |
| Miescher, PA | 1 |
| Johnson, MW | 1 |
| Vine, AK | 1 |
| Cullen, AP | 1 |
| Chou, BR | 1 |
| Ratliff, NB | 1 |
| Estes, ML | 1 |
| Myles, JL | 1 |
| Shirey, EK | 1 |
| McMahon, JT | 1 |
| Clark, SK | 1 |
| Laugier, P | 1 |
| Orusco, M | 1 |
| Chatelanat, F | 1 |
| Humair, L | 1 |
| Posternak, F | 1 |
| Lloyd, DD | 1 |
| Balfe, JW | 1 |
| Barkin, M | 1 |
| Gelfand, EW | 1 |
| Henkind, P | 2 |
| Gold, DH | 1 |
| Mantel, W | 1 |
| Holtz, G | 1 |
| Jones, BR | 1 |
| Voop, HV | 1 |
| Rekant, SI | 1 |
| Becker, LE | 1 |
| Snyder, GG | 1 |
| McCarthy, RE | 1 |
| Toomey, JM | 1 |
| Hauptmann, G | 1 |
| Grosshans, E | 1 |
| Heid, E | 1 |
| Mayer, S | 1 |
| Basset, A | 1 |
| Laaksonen, AL | 2 |
| Koskiahde, V | 2 |
| Juva, K | 2 |
| Wenger, ME | 1 |
| Bole, GG | 1 |
| Wierzchowiecki, M | 1 |
| Nylander, U | 1 |
| Burnham, TK | 2 |
| Neblett, TR | 1 |
| Fine, G | 2 |
| Lester, RS | 1 |
| Murray, K | 1 |
| Sassaman, FW | 1 |
| Cassidy, JT | 1 |
| Alpern, M | 1 |
| Maaseidvaag, F | 1 |
| Verbov, JL | 1 |
| Borrie, PF | 1 |
| Carr, RE | 1 |
| Siegel, IM | 1 |
| Malkinson, FD | 1 |
| Chiari, JJ | 1 |
| Freyberg, RH | 1 |
| Ahuja, GK | 1 |
| Schumacher, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial[NCT04161339] | Phase 4 | 50 participants (Anticipated) | Interventional | 2019-07-01 | Recruiting | ||
| Individual Patient Exposure and Response in Pediatric Lupus[NCT04358302] | 26 participants (Actual) | Interventional | 2020-09-28 | Completed | |||
| A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2020-04-17 | Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias) | ||
| Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe[NCT04397237] | 3,100 participants (Actual) | Observational | 2020-06-10 | Active, not recruiting | |||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cut[NCT01597050] | Phase 2 | 54 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS[NCT03161483] | Phase 2 | 289 participants (Actual) | Interventional | 2017-08-31 | Completed | ||
| A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems[NCT00111306] | Phase 3 | 510 participants | Interventional | 2005-06-30 | Terminated | ||
| A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE)[NCT00071487] | Phase 2 | 449 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Subcutaneous Doses of Efavaleukin Alfa in Subjects With Systemic Lupus Erythem[NCT03451422] | Phase 1 | 35 participants (Actual) | Interventional | 2018-04-10 | Completed | ||
| A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus[NCT01162681] | Phase 2 | 547 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lup[NCT00299819] | Phase 1 | 45 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of TAB08 in Patients With Systemic Lupus Erythematosus, Not Adequately Controlled With Current Concomitant Therapy[NCT02711813] | Phase 2 | 60 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Administrative reasons) | ||
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus[NCT03252587] | Phase 2 | 363 participants (Actual) | Interventional | 2017-09-21 | Completed | ||
| Potential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLE[NCT02932137] | 30 participants (Actual) | Interventional | 2016-05-05 | Completed | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Chinese Subjects With Active Systemic Lupus Erythematosus[NCT04060888] | Phase 3 | 0 participants (Actual) | Interventional | 2020-07-14 | Withdrawn (stopped due to Pre-planned IA (global study) showed lack of efficacy in this indication. No new safety signals observed, findings consistent with known profile.) | ||
| Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations[NCT01112215] | Phase 4 | 240 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus[NCT02437890] | Phase 2 | 312 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids[NCT02953821] | Phase 4 | 172 participants (Actual) | Interventional | 2016-12-16 | Completed | ||
| Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study)[NCT02270957] | Phase 2 | 66 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Phase1/2, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Pharmacokinetics of One 12 Week Treatment Cycle of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects With Moderate to Severe Di[NCT01449071] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus[NCT01283139] | Phase 2 | 834 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosu[NCT02265744] | Phase 2 | 730 participants (Actual) | Interventional | 2014-11-13 | Completed | ||
| A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007[NCT00660881] | Phase 2 | 210 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Using the Cholinergic Anit-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain[NCT02822989] | 18 participants (Anticipated) | Interventional | 2017-11-01 | Enrolling by invitation | |||
| A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus[NCT02665364] | Phase 2 | 185 participants (Actual) | Interventional | 2015-09-23 | Terminated (stopped due to Reorganization proceedings of the sponsor) | ||
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)[NCT01205438] | Phase 3 | 1,124 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy[NCT04058028] | Phase 2 | 244 participants (Actual) | Interventional | 2020-02-19 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis[NCT02514967] | Phase 3 | 3 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Study halted prematurely and will not resume. Subjects were seen until February 2017) | ||
| A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)[NCT03312907] | Phase 3 | 292 participants (Actual) | Interventional | 2018-03-01 | Completed | ||
| A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)[NCT02660944] | Phase 2 | 64 participants (Actual) | Interventional | 2016-01-03 | Completed | ||
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE[NCT02975336] | Phase 2 | 469 participants (Actual) | Interventional | 2017-01-04 | Terminated (stopped due to Study is completed; primary analysis completed.) | ||
| Efficacy and Safety of Twice-daily Application of Delgocitinib Cream 20 mg/g for 6 Weeks in Subjects With Active Discoid Lupus Erythematosus.[NCT03958955] | Phase 2 | 27 participants (Actual) | Interventional | 2019-07-09 | Terminated (stopped due to Terminated due to recruitment challenges.) | ||
| A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)[NCT01484496] | Phase 3 | 839 participants (Actual) | Interventional | 2011-11-16 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus[NCT03616964] | Phase 3 | 778 participants (Actual) | Interventional | 2018-08-02 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis[NCT02074020] | Phase 3 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn | ||
| A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus[NCT02446912] | Phase 3 | 460 participants (Actual) | Interventional | 2015-06-09 | Completed | ||
| Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine (NAC) (SNAC)[NCT00775476] | Phase 2 | 290 participants (Anticipated) | Interventional | 2022-03-31 | Recruiting | ||
| A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus[NCT02446899] | Phase 3 | 373 participants (Actual) | Interventional | 2015-07-09 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)[NCT02708095] | Phase 2 | 314 participants (Actual) | Interventional | 2016-03-24 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus[NCT03517722] | Phase 3 | 516 participants (Actual) | Interventional | 2018-04-16 | Terminated (stopped due to Study terminated early as a result of the outcome of the pre-planned Interim Analysis) | ||
| A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus[NCT03978520] | Phase 2 | 341 participants (Actual) | Interventional | 2019-07-25 | Completed | ||
| A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With o[NCT02847598] | Phase 2 | 264 participants (Actual) | Interventional | 2016-10-20 | Completed | ||
| A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease[NCT00624351] | Phase 2 | 227 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.[NCT00383214] | Phase 3 | 54 participants (Actual) | Interventional | 2005-05-31 | Terminated | ||
| A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus[NCT02554019] | Phase 2 | 36 participants (Actual) | Interventional | 2015-09-28 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus[NCT02349061] | Phase 2 | 102 participants (Actual) | Interventional | 2015-10-15 | Completed | ||
| A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus[NCT01649765] | Phase 2 | 93 participants (Actual) | Interventional | 2012-09-07 | Active, not recruiting | ||
| A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus[NCT02185040] | Phase 2 | 42 participants (Actual) | Interventional | 2014-09-16 | Completed | ||
| A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease[NCT01753401] | Phase 4 | 38 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia[NCT01345253] | Phase 3 | 709 participants (Actual) | Interventional | 2011-05-23 | Completed | ||
| A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active L[NCT01551069] | Phase 3 | 103 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Dipyridamole Assessment for Flare Reduction in SLE[NCT01781611] | 18 participants (Actual) | Interventional | 2013-02-28 | Terminated (stopped due to Slow recruitment) | |||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus[NCT03616912] | Phase 3 | 830 participants (Actual) | Interventional | 2018-08-02 | Terminated (stopped due to Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.) | ||
| A Phase II Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus[NCT02465580] | Phase 2 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)[NCT03845517] | Phase 2 | 350 participants (Actual) | Interventional | 2019-04-18 | Completed | ||
| A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus[NCT01438489] | Phase 2 | 626 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Can Individualized Diet and Lifestyle Modifications Derived From Digital Therapeutics and Health Coaching Improve Symptoms of Systemic Lupus Erythematosus[NCT03426384] | 50 participants (Actual) | Interventional | 2018-02-12 | Completed | |||
| Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study[NCT04341441] | Phase 3 | 624 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.) | ||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| Improvement of Medication Adherence in Adolescents With SLE Using Web-based Education With and Without a Social Media Intervention[NCT03218033] | 37 participants (Actual) | Interventional | 2014-05-01 | Completed | |||
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493] | Phase 2 | 10 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Study of Anti-Malarials in Incomplete Lupus Erythematosus[NCT03030118] | Phase 2 | 187 participants (Actual) | Interventional | 2017-12-28 | Active, not recruiting | ||
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Screening Biomarkers for Severe Lupus Based on Multi-omics Studies[NCT05539001] | 152 participants (Anticipated) | Observational [Patient Registry] | 2023-02-01 | Recruiting | |||
| Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus[NCT02444728] | Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Because of insufficient enrollement) | ||
| Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa[NCT03275870] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2017-09-28 | Completed | ||
| Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743] | 72 participants (Actual) | Interventional | 2018-04-17 | Completed | |||
| Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires[NCT05567198] | 100 participants (Anticipated) | Observational | 2023-03-03 | Recruiting | |||
| Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF[NCT04702256] | Phase 3 | 196 participants (Anticipated) | Interventional | 2021-12-09 | Recruiting | ||
| Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia Among 40 Patients[NCT01549184] | 40 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia[NCT03229746] | Phase 4 | 40 participants (Actual) | Interventional | 2017-08-01 | Completed | ||
| Fernald Community Cohort - 18 Year Observational Study With Bio Banked Blood and Urine Samples[NCT02295085] | 9,782 participants (Actual) | Observational | 1990-09-30 | Active, not recruiting | |||
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231] | 100 participants (Anticipated) | Interventional | 2021-04-26 | Recruiting | |||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269] | Phase 4 | 384 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis[NCT05247554] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| ACtivity Trackers to ImproVe Blood Pressure: a Pilot Study[NCT03325426] | 63 participants (Actual) | Interventional | 2017-06-01 | Completed | |||
| The Impact of a Smartphone App on the Quality of Pediatric Colonoscopy Preparations[NCT04590105] | 42 participants (Actual) | Interventional | 2014-11-15 | Completed | |||
| Effectiveness and Cost-effectiveness of a Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With Systemic Lupus Erythematosus[NCT03537638] | 237 participants (Actual) | Interventional | 2018-04-16 | Completed | |||
| QT Dispersion in Patients With Systemic Lupus Erythematosus: the Impact of Disease Activity[NCT01031797] | 124 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| Home Monitoring of Fetal Heart Rhythm in Pregnancies of Anti-Ro/SSA Positive Women for the Treatment of Congenital Heart Block (FETAL HOPE)[NCT05958446] | 200 participants (Anticipated) | Observational | 2022-04-14 | Recruiting | |||
| Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus[NCT02455089] | 143 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study[NCT00413361] | Phase 4 | 543 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Impact of Immunosuppression in Patients With Inflammatory Bowel Disease on Responsiveness to Influenza Vaccine[NCT00542776] | 146 participants (Actual) | Observational | 2007-10-31 | Completed | |||
| [NCT00005436] | 0 participants | Observational | 1991-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial
| Intervention | participants (Number) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 1 |
Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Control | 2 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
Percentage of patients who achieved at least a 50% decrease from baseline in the total combined Erythema and Scaling score of all treated lesions at Week 4. A decrease is an improvement in measurement of erythema and scaling of the lesions. (NCT01597050)
Timeframe: Up to Week 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Drug: R932333 | 22.2 |
| Placebo | 27.8 |
"The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means not at all, and 4 means very much. The total FACIT-Fatigue score ranges from 0 to 52. Note: Data presented is Adjusted mean data." (NCT03161483)
Timeframe: Week 24
| Intervention | scores on a scale (Mean) |
|---|---|
| PBO QD | 3.8 |
| 0.15 mg QD | 2.7 |
| 0.30 mg QD | 3.1 |
| 0.45 mg QD | 5.2 |
The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease. (NCT03161483)
Timeframe: Week 24
| Intervention | scores on a scale (Mean) |
|---|---|
| PBO QD | -0.803 |
| 0.15 mg QD | -0.805 |
| 0.30 mg QD | -0.819 |
| 0.45 mg QD | -0.883 |
"Joint tenderness and swelling will be noted as present or absent, with no quantitation of severity using a 28- joint count. Note: Data presented is Adjusted mean data." (NCT03161483)
Timeframe: Week 24
| Intervention | swollen joints (Mean) |
|---|---|
| PBO QD | -6.7 |
| 0.15 mg QD | -6.0 |
| 0.30 mg QD | -6.0 |
| 0.45 mg QD | -6.6 |
"Joint tenderness and swelling will be noted as present or absent, with no quantitation of severity using a 28- joint count. Note: Data presented is Adjusted mean data." (NCT03161483)
Timeframe: Week 24
| Intervention | tender joints (Mean) |
|---|---|
| PBO QD | -7.9 |
| 0.15 mg QD | -6.8 |
| 0.30 mg QD | -6.7 |
| 0.45 mg QD | -7.6 |
The primary objective is to evaluate the clinical efficacy of three doses of CC-220 (0.45 mg once per day [QD], 0.3 mg QD or 0.15 mg QD) compared to placebo, for the treatment of active systemic lupus erythematosus (SLE) using the SLE Responder Index at Week 24 Composite endpoint SRI(4), defined by the following criteria: - Reduction from Baseline of ≥ 4 points in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score and - No new one or more British Isles Lupus Assessment Group (BILAG) A or new (excludes A to B) 2 or more BILAG B items compared to Baseline using BILAG 2004 Index and - No worsening from Baseline defined by an increase of < 0.30 points from Baseline on a Physician's Global Assessment (PGA) visual analog scale (VAS) from 0-3 (NCT03161483)
Timeframe: Week 24
| Intervention | Number of participants (Number) |
|---|---|
| PBO QD | 29 |
| 0.15 mg QD | 20 |
| 0.30 mg QD | 33 |
| 0.45 mg QD | 44 |
The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and non-scarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together. (NCT03161483)
Timeframe: Week 24
| Intervention | Number of participants (Number) |
|---|---|
| PBO QD | 8 |
| 0.15 mg QD | 8 |
| 0.30 mg QD | 8 |
| 0.45 mg QD | 13 |
The BILAG 2004 is a composite index that is based on the Classic BILAG index. It is a clinical measure of lupus disease activity. This tool assesses the changing severity of clinical manifestations of SLE using an ordinal scale scoring system that contain 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological). Activity in each organ system is scored as: A=most active disease; B=intermediate activity; C=mild, stable disease; D=previous involvement, currently inactive; E=no previous activity. (NCT03161483)
Timeframe: Week 24
| Intervention | Number of participants (Number) |
|---|---|
| PBO QD | 65 |
| 0.15 mg QD | 38 |
| 0.30 mg QD | 59 |
| 0.45 mg QD | 70 |
The SLEDAI 2K score measures disease activity through assessment of 24 lupus manifestations using a weighted score of 1 to 8 points. A manifestation is recorded if it is present over the previous 30 days regardless of severity or whether it has improved or worsened. A SLEDAI 2K score of 3 to 4 points is representative of active disease and a decrease of 1 to 2 points is considered clinically meaningful. (NCT03161483)
Timeframe: Week 24
| Intervention | Number of participants (Number) |
|---|---|
| PBO QD | 30 |
| 0.15 mg QD | 20 |
| 0.30 mg QD | 35 |
| 0.45 mg QD | 45 |
Percent change from Baseline in oral corticosteroid (OCS) dose in subjects with prednisone or equivalent ≥ 10 mg/day at Baseline Note: Data presented is Adjusted mean data. (NCT03161483)
Timeframe: Week 24
| Intervention | percent change from baseline (Mean) |
|---|---|
| PBO QD | -7.9 |
| 0.15 mg QD | -5.1 |
| 0.30 mg QD | -3.8 |
| 0.45 mg QD | -1.4 |
The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease. (NCT03161483)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| PBO QD | 78.3 |
| 0.15 mg QD | 90.5 |
| 0.30 mg QD | 73.2 |
| 0.45 mg QD | 85.2 |
Standardized total oral corticosteroid (OCS) dose. (NCT03161483)
Timeframe: Through Week 24
| Intervention | mg (Mean) |
|---|---|
| PBO QD | 1139.7 |
| 0.15 mg QD | 1101.9 |
| 0.30 mg QD | 1071.8 |
| 0.45 mg QD | 1105.5 |
Number of participants who experienced a TEAE during the course of the study (NCT03161483)
Timeframe: from first dose to 28 days post-last dose through Week 24 (placebo-controlled phase), approximately 28 weeks total
| Intervention | Number of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE | Any Drug-related TEAE | Any Serious TEAE | Any Severe TEAE | Any TEAE Leading to Drug Interruption | Any TEAE Leading to Drug Withdrawal | Any TEAE Leading to Death | |
| 0.15 mg QD | 31 | 14 | 3 | 3 | 10 | 2 | 0 |
| 0.30 mg QD | 64 | 36 | 4 | 4 | 14 | 11 | 0 |
| 0.45 mg QD | 63 | 32 | 6 | 1 | 23 | 4 | 0 |
| PBO QD | 54 | 24 | 7 | 5 | 15 | 6 | 1 |
- The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to ≤ 7.5 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24 - The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to < 10 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24 (NCT03161483)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 24, <= 7.5 mg/day | Week 24, < 10 mg/day | |
| 0.15 mg QD | 0.0 | 0.0 |
| 0.30 mg QD | 3.3 | 3.3 |
| 0.45 mg QD | 0.0 | 0.0 |
| PBO QD | 3.2 | 6.5 |
The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score. (NCT00071487)
Timeframe: Baseline and every 4 to 8 weeks through Week 52
| Intervention | ratio score*days (Mean) |
|---|---|
| Placebo Plus SOC | 315.4 |
| Belimumab 1 mg/kg Plus SOC | 310.6 |
| Belimumab 4 mg/kg Plus SOC | 300.4 |
| Belimumab 10 mg/kg Plus SOC | 302.7 |
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score. (NCT00071487)
Timeframe: Baseline and every 4 to 8 weeks through Week 52
| Intervention | ratio score*days (Mean) |
|---|---|
| Placebo Plus SOC | 317.3 |
| Belimumab 1 mg/kg Plus SOC | 288.7 |
| Belimumab 4 mg/kg Plus SOC | 320.3 |
| Belimumab 10 mg/kg Plus SOC | 286.9 |
The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0. (NCT00071487)
Timeframe: Baseline, 52 weeks
| Intervention | percent change (Mean) |
|---|---|
| Placebo Plus SOC | -19.1 |
| Belimumab 1 mg/kg Plus SOC | -20.8 |
| Belimumab 4 mg/kg Plus SOC | -26.5 |
| Belimumab 10 mg/kg Plus SOC | -22.0 |
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare. (NCT00071487)
Timeframe: Baseline, 24 weeks
| Intervention | percent change (Mean) |
|---|---|
| Placebo Plus SOC | -17.2 |
| Belimumab 1 mg/kg Plus SOC | -23.3 |
| Belimumab 4 mg/kg Plus SOC | -11.3 |
| Belimumab 10 mg/kg Plus SOC | -23.7 |
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare (NCT00071487)
Timeframe: Baseline, 52 weeks
| Intervention | percent change (Mean) |
|---|---|
| Placebo Plus SOC | -20.6 |
| Belimumab 1 mg/kg Plus SOC | -29.7 |
| Belimumab 4 mg/kg Plus SOC | -23.9 |
| Belimumab 10 mg/kg Plus SOC | -27.9 |
Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline. (NCT00071487)
Timeframe: Baseline, weeks 40 to 52
| Intervention | percentatge of particpants (Number) |
|---|---|
| Placebo Plus SOC | 27.1 |
| Belimumab 1 mg/kg Plus SOC | 20.0 |
| Belimumab 4 mg/kg Plus SOC | 31.4 |
| Belimumab 10 mg/kg Plus SOC | 44.7 |
"The SLE Flare Index categorized SLE flare as mild or moderate or severe based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT00071487)
Timeframe: 0 to 52 weeks
| Intervention | days (Median) |
|---|---|
| Placebo Plus SOC | 83 |
| Belimumab 1 mg/kg Plus SOC | 68 |
| Belimumab 4 mg/kg Plus SOC | 61 |
| Belimumab 10 mg/kg Plus SOC | 70 |
SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit. (NCT00071487)
Timeframe: 0 to 52 weeks
| Intervention | days (Median) |
|---|---|
| Placebo Plus SOC | 78 |
| Belimumab 1 mg/kg Plus SOC | 63 |
| Belimumab 4 mg/kg Plus SOC | 84 |
| Belimumab 10 mg/kg Plus SOC | 62 |
Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362). (NCT00071487)
Timeframe: Up to 84 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Percent of patients with at least 1 AE | Percent of patients with at least 1 SAE | Percent of patients with an AE resulting in death | |
| Belimumab 1 mg/kg Plus SOC | 97.4 | 18.4 | 0.9 |
| Belimumab 10 mg/kg Plus SOC | 97.3 | 16.2 | 0.9 |
| Belimumab 4 mg/kg Plus SOC | 96.4 | 13.5 | 0 |
| Open-Label Extension Period: All Active | 96.2 | 9.6 | 0 |
| Placebo Plus SOC | 97.3 | 19.5 | 0 |
A TEAE was defined as any adverse event (AE) starting on or after the first dose of investigational product through to the safety follow-up visit. Any clinically significant changes in physical examinations, vital signs, and clinical laboratory test results were recorded as AEs. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 7 |
| AMG 592 Cohort 1 | 5 |
| AMG 592 Cohort 2 | 5 |
| AMG 592 Cohort 3 | 7 |
| AMG 592 Cohort 4 | 3 |
| AMG 592 Cohort 5 | 4 |
(NCT03451422)
Timeframe: Day 1 (pre-dose) and 6 to 72 hours post-dose, and Days 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Days 92, 99, 113 and 127
| Intervention | hour*ng/mL (Mean) | |
|---|---|---|
| First dose (Day 1) | Last dose (Day 85) | |
| AMG 592 Cohort 1 | 538 | 773 |
| AMG 592 Cohort 2 | 915 | 1120 |
| AMG 592 Cohort 3 | 1560 | 542 |
| AMG 592 Cohort 4 | 1960 | 3260 |
| AMG 592 Cohort 5 | 3770 | 3010 |
(NCT03451422)
Timeframe: Day 1 (pre-dose) and 6 to 72 hours post-dose, and Days 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Days 92, 99, 113 and 127
| Intervention | ng/mL (Mean) | |
|---|---|---|
| First dose (Day 1) | Last dose (Day 85) | |
| AMG 592 Cohort 1 | 7.92 | 9.24 |
| AMG 592 Cohort 2 | 13.0 | 18.9 |
| AMG 592 Cohort 3 | 25.7 | 10.0 |
| AMG 592 Cohort 4 | 30.7 | 56.5 |
| AMG 592 Cohort 5 | 44.3 | 51.6 |
Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 binding antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)
| Intervention | Participants (Count of Participants) |
|---|---|
| Binding anti-AMG 592 antibody | |
| Placebo | 0 |
Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 binding antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Binding anti-AMG 592 antibody | Binding anti-IL-2 antibody | |
| AMG 592 Cohort 2 | 3 | 2 |
| AMG 592 Cohort 3 | 6 | 0 |
| AMG 592 Cohort 4 | 2 | 1 |
| AMG 592 Cohort 5 | 4 | 0 |
| AMG 592 Cohort 1 | 3 | 1 |
Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 neutralizing antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)
| Intervention | Participants (Count of Participants) |
|---|---|
| Neutralizing anti-AMG 592 antibody | |
| Placebo | 0 |
Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 neutralizing antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Neutralizing anti-AMG 592 antibody | Neutralizing anti-IL-2 antibody | |
| AMG 592 Cohort 1 | 0 | 0 |
| AMG 592 Cohort 2 | 2 | 0 |
| AMG 592 Cohort 3 | 1 | 0 |
| AMG 592 Cohort 4 | 0 | 0 |
| AMG 592 Cohort 5 | 2 | 0 |
(NCT03451422)
Timeframe: Day 1 (pre-dose) and 6 to 72 hours post-dose, and Days 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Days 92, 99, 113 and 127
| Intervention | hours (Median) | |
|---|---|---|
| First dose (Day 1) | Last dose (Day 85) | |
| AMG 592 Cohort 1 | 24.0 | 25.2 |
| AMG 592 Cohort 2 | 47.6 | 26.2 |
| AMG 592 Cohort 3 | 24.1 | 18.0 |
| AMG 592 Cohort 4 | 24.6 | 24.1 |
| AMG 592 Cohort 5 | 17.8 | 16.7 |
"BICLA responder is defined as a patient whose disease course fulfills all of the following:~Improvement in all organ systems with activity graded as BILAG-2004 A (severe disease activity) or B (moderate disease activity) at baseline~No new organ system with activity graded as BILAG A; no more than 1 new organ system with activity graded as BILAG B~No increase from baseline in Systemic Lupus Erythematosus SLEDAI-2K score (≤ 0 points for change from baseline score)~No increase ≥ 10% in the Physician's Global Assessment of Disease Activity on a 3-point visual analog scale from no disease activity to severe disease activity~No discontinuation of investigational product or use of restricted medications beyond the protocol allowed threshold before assessment" (NCT03252587)
Timeframe: At week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 23 |
| BMS-986165 3 mg | 43 |
| BMS-986165 6 mg | 33 |
| BMS-986165 12 mg | 32 |
"LLDAS is defined as follows:~SLEDAI-2K ≤ 4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity measured as maintaining a D (no disease activity but suggests the system had previously been affected) or E (no current or previous disease activity) score in BILAG Gastrointestinal Body System~No new lupus disease activity compared with the previous assessment measured as no new or worsening individual BILAG parameters~Physician's Global Assessment of Disease Activity ≤ 1 on a 3-point visual analog scale from no disease activity to severe disease activity~A current prednisolone (or equivalent) dose ≤ 7.5 mg daily~Well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents" (NCT03252587)
Timeframe: At Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 12 |
| BMS-986165 3 mg | 33 |
| BMS-986165 6 mg | 22 |
| BMS-986165 12 mg | 23 |
"SRI(4) responder is defined as a patient whose disease course fulfills all of the following:~A 4-point or greater reduction from baseline in SLEDAI-2K score~No new British Isles Lupus Assessment Group (BILAG) A (severe disease activity) and not more than 1 new BILAG B (moderate disease activity) organ domain grade~No worsening from baseline in the Physician's Global Assessment of Disease Activity Scale by more than 0.3 points on a 3-point visual analog scale from no disease activity to severe disease activity" (NCT03252587)
Timeframe: At week 32
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 31 |
| BMS-986165 3 mg | 53 |
| BMS-986165 6 mg | 46 |
| BMS-986165 12 mg | 40 |
"SRI(4) responder is defined as a patient whose disease course fulfills all of the following:~A 4-point or greater reduction from baseline in SLEDAI-2K score~No new British Isles Lupus Assessment Group (BILAG) A (severe disease activity) or not more than 1 new BILAG B (moderate disease activity) organ domain grade~No worsening from baseline in the Physician's Global Assessment of Disease Activity Scale by more than 0.3 points on a 3-point visual analog scale from no disease activity to severe disease activity" (NCT03252587)
Timeframe: At week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 31 |
| BMS-986165 3 mg | 52 |
| BMS-986165 6 mg | 44 |
| BMS-986165 12 mg | 42 |
Number of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score ≥ 10 at baseline who achieve a CLASI response, defined as a decrease of ≥ 50% from baseline CLASI activity score (ranges from 0-70, where a higher score is associated with high disease activity). CLASI assesses by body surface area; points are given for presence of erythema, scale, hypertrophy, mucous membrane lesions, recent hair loss, and physician-observed alopecia (NCT03252587)
Timeframe: At week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 4 |
| BMS-986165 3 mg | 16 |
| BMS-986165 6 mg | 14 |
| BMS-986165 12 mg | 18 |
Percent change from baseline in anti-double-stranded DNA (dsDNA) levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 52
| Intervention | Percent Change from Baseline (Mean) |
|---|---|
| Placebo | 276.26 |
| BMS-986165 3 mg | 16.51 |
| BMS-986165 6 mg | -31.79 |
| BMS-986165 12 mg | -19.32 |
Percent change from baseline in anti-double-stranded DNA (dsDNA) levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 32
| Intervention | Percent Change from Baseline (Mean) |
|---|---|
| Placebo | 21.36 |
| BMS-986165 3 mg | -15.24 |
| BMS-986165 6 mg | -11.31 |
| BMS-986165 12 mg | -24.17 |
Maximum observed plasma concentration (Cmax) for the following treatments: BMS-986165 and its active metabolite BMT-153261. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. (NCT03252587)
Timeframe: Pre-dose, 0.5, 2, 4, and 6 hours post dose on week 12
| Intervention | NG/ML (Geometric Mean) | |
|---|---|---|
| BMS-986165 | Metabolite BMT-153261 | |
| BMS-986165 12 mg | 96.249 | 11.748 |
| BMS-986165 3 mg | 38.033 | 6.358 |
| BMS-986165 6 mg | 76.400 | 12.133 |
Time of maximum observed plasma concentration (Tmax) for the following treatments: BMS-986165 and its active metabolite BMT-153261. (NCT03252587)
Timeframe: Pre-dose, 0.5, 2, 4, 6, and 10 hours post dose on week 12
| Intervention | Hours (Median) | |
|---|---|---|
| BMS-986165 | Metabolite BMT-153261 | |
| BMS-986165 12 mg | 2.0000 | 3.7330 |
| BMS-986165 3 mg | 2.0000 | 4.0000 |
| BMS-986165 6 mg | 2.0000 | 4.0000 |
Trough observed plasma concentration (Ctrough) for the following treatments: BMS-986165 and its active metabolite BMT-153261. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. (NCT03252587)
Timeframe: Pre-dose, 0.5, 2, 4, and 6 hours post dose on week 2, 4, 8, 12, 24, 32, and 48
| Intervention | NG/ML (Geometric Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMS-986165 week 2 | BMS-986165 week 4 | BMS-986165 week 8 | BMS-986165 week 12 | BMS-986165 week 24 | BMS-986165 week 32 | BMS-986165 week 48 | Metabolite BMT-153261 week 2 | Metabolite BMT-153261 week 4 | Metabolite BMT-153261 week 8 | Metabolite BMT-153261 week 12 | Metabolite BMT-153261 week 24 | Metabolite BMT-153261 week 32 | Metabolite BMT-153261 week 48 | |
| BMS-986165 12 mg | 30.8135 | 20.1182 | 26.7961 | 22.1237 | 21.8720 | 24.5060 | 15.9576 | 8.7920 | 7.2703 | 8.1451 | 7.4071 | 6.6608 | 6.8734 | 5.8602 |
| BMS-986165 3 mg | 14.3737 | 14.6095 | 13.0328 | 10.7517 | 10.2546 | 8.5293 | 6.8493 | 4.2667 | 5.0886 | 4.1293 | 3.7325 | 3.3669 | 2.9759 | 2.8708 |
| BMS-986165 6 mg | 29.2909 | 22.9170 | 12.9587 | 28.7751 | 13.9273 | 15.5285 | 21.7890 | 8.4841 | 7.7803 | 5.2290 | 9.3281 | 5.2229 | 5.2925 | 6.8838 |
"Change from baseline in the following 40-joint count: phalangeal joints of the hand, second through fifth metacarpophalangeal joints of the hand, and individual metatarsophalangeal joints of the feet, Bilateral first metacarpophalangeal joints and shoulders. Each of 40 joints count is evaluated based upon the presence or absence of:~Tender joint count (0 to 40)~Swollen joint count (0 to 40)~Tender and swollen joint count (0 to 40) A larger joint count indicates more severe disease." (NCT03252587)
Timeframe: Baseline and week 48
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Tender | Swollen | Tender + Swollen | |
| BMS-986165 12 mg | -12.3 | -9.9 | -9.7 |
| BMS-986165 3 mg | -12.2 | -8.5 | -8.2 |
| BMS-986165 6 mg | -11.7 | -8.8 | -8.5 |
| Placebo | -11.2 | -8.3 | -8.2 |
Number of participants with abnormalities in electrocardiograms (ECGs) assessed by QTcF, PR interval, and QRS interval (NCT03252587)
Timeframe: From baseline to up to week 48
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: QTcF 450 to < 480 | Baseline: QTcF 480 to < 500 | Baseline: QTcF >= 500 | Baseline: PR Interval >= 200 | Baseline: QRS Interval >=200 | Week 4: QTcF 450 to < 480 | Week 4: QTcF 480 to < 500 | Week4: QTcF >= 500 | Week 4: PR Interval >= 200 | Week 4: QRS Interval: >= 200 | Week 8: QTcF 450 to < 480 | Week 8: QTcF 480 to < 500 | Week 8: QTcF >=500 | Week 8: PR Interval >= 200 | Week 8 QRS Interval >=200 | Week 12: QTcF 450 to < 480 | Week 12: QTcF 480 to < 500 | Week 12: QTcF >= 500 | Week 12: PR Interval >= 200 | Week 12: QRS Interval >=200 | Week 32: QTcF 450 to < 480 | Week 32: QTcF 480 to < 500 | Week 32: QTcF >=500 | Week 32: PR Interval >= 200 | Week 32: QRS Interval >= 200 | Week 48: QTcF: 450 to < 480 | Week 48: QTcF 480 to < 500 | Week 48: QTcF >=500 | Week 48: PR Interval: >= 200 | Week 48: QRS Interval: >= 200 | |
| BMS-986165 12 mg | 5 | 0 | 0 | 6 | 0 | 6 | 0 | 1 | 5 | 0 | 1 | 2 | 0 | 6 | 0 | 8 | 0 | 1 | 4 | 0 | 5 | 0 | 0 | 5 | 0 | 5 | 0 | 0 | 3 | 0 |
| BMS-986165 3 mg | 3 | 1 | 0 | 4 | 0 | 6 | 2 | 0 | 7 | 0 | 5 | 0 | 0 | 6 | 0 | 4 | 0 | 0 | 8 | 0 | 5 | 0 | 0 | 7 | 0 | 2 | 0 | 0 | 7 | 0 |
| BMS-986165 6 mg | 6 | 0 | 1 | 6 | 0 | 5 | 1 | 0 | 4 | 0 | 6 | 1 | 0 | 5 | 0 | 6 | 0 | 0 | 4 | 0 | 2 | 2 | 0 | 5 | 0 | 8 | 0 | 0 | 6 | 0 |
| Placebo | 9 | 1 | 0 | 5 | 0 | 5 | 0 | 0 | 7 | 0 | 7 | 0 | 0 | 5 | 0 | 3 | 0 | 0 | 6 | 0 | 5 | 0 | 0 | 5 | 0 | 7 | 0 | 0 | 4 | 0 |
Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure (NCT03252587)
Timeframe: From first dose to 30 days post last dose (Up to 52 weeks)
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2: Heart Rate: Value > 100 and change from baseline > 30 | Week 2: Heart Rate: Value < 55 and change from baseline < -15 | Week 2: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 2: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 2: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 2: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 4: Heart Rate: Value > 100 and change from baseline > 30 | Week 4: Heart Rate: Value < 55 and change from baseline < -15 | Week 4: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 4: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 4: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 4: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 8: Heart Rate: Value > 100 and change from baseline > 30 | Week 8: Heart Rate: Value < 55 and change from baseline < -15 | Week 8: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 8: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 8: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 8: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 12: Heart Rate: Value > 100 and change from baseline > 30 | Week 12: Heart Rate: Value < 55 and change from baseline < -15 | Week 12: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 12: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 12: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 12: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 16: Heart Rate: Value > 100 and change from baseline > 30 | Week 16: Heart Rate: Value < 55 and change from baseline < -15 | Week 16: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 16: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 16: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 16: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 20: Heart Rate: Value > 100 and change from baseline > 30 | Week 20: Heart Rate: Value < 55 and change from baseline < -15 | Week 20: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 20: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 20: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 20: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 24: Heart Rate: Value > 100 and change from baseline > 30 | Week 24: Heart Rate: Value < 55 and change from baseline < -15 | Week 24: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 24: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 24: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 24: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 28: Heart Rate: Value > 100 and change from baseline > 30 | Week 28: Heart Rate: Value < 55 and change from baseline < -15 | Week 28: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 28: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 28: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 28: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 32: Heart Rate: Value > 100 and change from baseline > 30 | Week 32: Heart Rate: Value < 55 and change from baseline < -15 | Week 32: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 32: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 32: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 32: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 36: Heart Rate: Value > 100 and change from baseline > 30 | Week 36: Heart Rate: Value < 55 and change from baseline < -15 | Week 36: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 36: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 36: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 36: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 40: Heart Rate: Value > 100 and change from baseline > 30 | Week 40: Heart Rate: Value < 55 and change from baseline < -15 | Week 40: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 40: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 40: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 40: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 44: Heart Rate: Value > 100 and change from baseline > 30 | Week 44: Heart Rate: Value < 55 and change from baseline < -15 | Week 44: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 44: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 44: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 44: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 48: Heart Rate: Value > 100 and change from baseline > 30 | Week 48: Heart Rate: Value < 55 and change from baseline < -15 | Week 48: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 48: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 48: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 48: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | Week 52: Heart Rate: Value > 100 and change from baseline > 30 | Week 52: Heart Rate: Value < 55 and change from baseline < -15 | Week 52: Systolic Blood Pressure: Value > 140 and change from baseline > 20 | Week 52: Systolic Blood Pressure: Value < 90 and change from baseline < -20 | Week 52: Diastolic Blood Pressure: Value > 90 and change from baseline > 10 | Week 52: Diastolic Blood Pressure: Value < 55 and change from baseline < -10 | |
| BMS-986165 12 mg | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| BMS-986165 3 mg | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 0 | 4 | 1 | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| BMS-986165 6 mg | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with any grade adverse events (AEs) and any grade serious adverse events (SAEs). An adverse event (AE) including SAEs is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in participants that do not necessarily have causal relationship with treatment (NCT03252587)
Timeframe: From first dose to 30 days post last dose (Up to 52 weeks)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| BMS-986165 12 mg | 75 | 7 |
| BMS-986165 3 mg | 85 | 7 |
| BMS-986165 6 mg | 81 | 8 |
| Placebo | 79 | 11 |
"Global systemic lupus erythematosus (SLE) clinical response in participants based on interferon-regulated gene (IRG) status (high versus low IRG signature). IRG-high vs. IRG-low was determined using a 5-interferon (IFN) gene set during the sample collected at screening period. SRI(4) responder is defined as a patient whose disease course fulfills all of the following:~A 4-point or greater reduction from baseline in SLEDAI-2K score~No new British Isles Lupus Assessment Group (BILAG) A (severe disease activity) or not more than 1 new BILAG B (moderate disease activity) organ domain grade~No worsening from baseline in the Physician's Global Assessment of Disease Activity Scale by more than 0.3 points on a 3-point visual analog scale from no disease activity to severe disease activity" (NCT03252587)
Timeframe: At week 32
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| IFN Low | IFN High | |
| BMS-986165 12 mg | 5 | 35 |
| BMS-986165 3 mg | 7 | 46 |
| BMS-986165 6 mg | 11 | 35 |
| Placebo | 10 | 21 |
"Number of participants with laboratory abnormalities in specific liver tests based on US conventional units. The potential drug-induced liver injury is defined by the presence of all of the following:~Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) elevation > 3× Upper Limit of Normal (ULN)~Total bilirubin > 2× ULN, without initial findings of cholestasis (elevated serum alkaline phosphatase)~No other immediately apparent possible causes of AST or AST elevation and hyperbilirubinemia, including, but not limited to, viral hepatitis, preexisting chronic or acute liver disease, or the administration of other drug(s) known to be hepatotoxic" (NCT03252587)
Timeframe: From first dose to 30 days post last dose (Up to 52 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ALT or AST > 3XULN | ALT or AST > 5XULN | Total Bilirubin > 2XULN | ALT or AST > 3XULN and Total Bilirubin > 2XULN on the same day | |
| BMS-986165 12 mg | 2 | 1 | 0 | 0 |
| BMS-986165 3 mg | 5 | 1 | 0 | 0 |
| BMS-986165 6 mg | 3 | 1 | 0 | 0 |
| Placebo | 2 | 2 | 0 | 0 |
Percent change from baseline in complement proteins C3 and C4 levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 32
| Intervention | Percent Change from Baseline (Mean) | |
|---|---|---|
| C3 | C4 | |
| BMS-986165 12 mg | 10.84 | 25.13 |
| BMS-986165 3 mg | 5.78 | 12.32 |
| BMS-986165 6 mg | 12.42 | 16.71 |
| Placebo | -0.58 | -3.27 |
Percent change from baseline in complement proteins C3 and C4 levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 52
| Intervention | Percent Change from Baseline (Mean) | |
|---|---|---|
| C3 | C4 | |
| BMS-986165 12 mg | 14.74 | 20.43 |
| BMS-986165 3 mg | 5.33 | 3.57 |
| BMS-986165 6 mg | 7.60 | 24.96 |
| Placebo | 3.57 | 84.52 |
Percent change from baseline in interferon-regulated gene (IRG) expression levels. IRG-high vs. IRG-low was determined using a 5-interferon (IFN) gene set during the sample collected at screening period. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 44
| Intervention | Percent Change from Baseline (Mean) | |
|---|---|---|
| IFN High | IFN Low | |
| BMS-986165 12 mg | -47.5561 | -41.7645 |
| BMS-986165 3 mg | -39.7478 | -18.0641 |
| BMS-986165 6 mg | -55.5691 | -36.4510 |
| Placebo | -0.8130 | 4.7381 |
Percent change from baseline in interferon-regulated gene (IRG) expression levels. IRG-high vs. IRG-low was determined using a 5-interferon (IFN) gene set during the sample collected at screening period. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 32
| Intervention | Percent Change from Baseline (Mean) | |
|---|---|---|
| IFN High | IFN Low | |
| BMS-986165 12 mg | -61.0515 | -42.9701 |
| BMS-986165 3 mg | -40.7944 | -27.4897 |
| BMS-986165 6 mg | -54.6988 | -42.8107 |
| Placebo | -4.3993 | -2.6555 |
"The primary endpoint was evaluated by determining if there was a dose-response relationship between the mBICLA response rate at Week 24 and the dose administered, using the Multiple Comparison Procedure - Modelling (MCP-Mod) methodology. The existence of several candidate parametric models was assumed and multiple comparison techniques were used to choose the model(s) most likely to represent the true underlying dose-response curve. The selected model could further be used to guide the choice of adequate doses.~mBICLA responders were defined as subjects who met all of the following criteria:~BILAG-2004 normal improvement: all A scores at Baseline improved to B, C or D, and all B scores improved to C or D.~No worsening in disease activity: no new BILAG-2004 A scores and ≤ 1 new increase to B.~No worsening of total mSLEDAI-2K score from Baseline.~No significant deterioration (< 10% worsening from Baseline) in PGA.~No treatment failure (including the premature" (NCT02437890)
Timeframe: At Week 24 visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 29 |
| ALX-0061 75 mg q4w | 28 |
| ALX-0061 150 mg q4w | 24 |
| ALX-0061 150 mg q2w | 24 |
| ALX-0061 225 mg q2w | 23 |
(NCT02437890)
Timeframe: From first administration of ALX-0061 up to and including follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 32 |
| ALX-0061 75 mg q4w | 16 |
| ALX-0061 150 mg q4w | 18 |
| ALX-0061 150 mg q2w | 31 |
| ALX-0061 225 mg q2w | 38 |
(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48
| Intervention | unit(s) (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 103.0 | 56.7 | 68.4 |
| ALX-0061 150 mg q4w | 98.9 | 73.6 | 73.5 |
| ALX-0061 225 mg q2w | 82.4 | 41.1 | 41.9 |
| ALX-0061 75 mg q4w | 109.6 | 107.0 | 113.1 |
| Placebo | 101.1 | 95.8 | 102.2 |
(NCT02437890)
Timeframe: at Baseline, Week 24, and Week 48
| Intervention | IU/mL (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 68.92 | 14.98 | 9.13 |
| ALX-0061 150 mg q4w | 52.88 | 46.99 | 74.21 |
| ALX-0061 225 mg q2w | 73.34 | 23.25 | 15.53 |
| ALX-0061 75 mg q4w | 145.87 | 68.27 | 59.48 |
| Placebo | 132.90 | 81.36 | 81.80 |
(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48
| Intervention | nmol/L (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 66.32 | 3.83 | 4.41 |
| ALX-0061 150 mg q4w | 38.89 | 26.08 | 23.20 |
| ALX-0061 225 mg q2w | 32.23 | 3.20 | 4.02 |
| ALX-0061 75 mg q4w | 49.05 | 47.22 | 37.65 |
| Placebo | 43.58 | 59.43 | 30.70 |
(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 105.8 | 75.3 | 83.2 |
| ALX-0061 150 mg q4w | 101.9 | 82.0 | 79.0 |
| ALX-0061 225 mg q2w | 98.6 | 71.8 | 72.3 |
| ALX-0061 75 mg q4w | 100.2 | 95.7 | 93.2 |
| Placebo | 102.3 | 101.7 | 95.8 |
(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 18.7 | 8.7 | 9.8 |
| ALX-0061 150 mg q4w | 15.9 | 10.6 | 10.5 |
| ALX-0061 225 mg q2w | 16.3 | 7.9 | 8.1 |
| ALX-0061 75 mg q4w | 17.8 | 17.4 | 17.3 |
| Placebo | 17.3 | 17.5 | 16.3 |
(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48
| Intervention | g/L (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 3.2 | 1.9 | 1.9 |
| ALX-0061 150 mg q4w | 3.2 | 2.3 | 2.3 |
| ALX-0061 225 mg q2w | 3.1 | 1.9 | 1.9 |
| ALX-0061 75 mg q4w | 3.2 | 3.3 | 3.3 |
| Placebo | 3.2 | 3.3 | 3.3 |
(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 42.14 | 668.57 | 650.73 |
| ALX-0061 150 mg q4w | 38.10 | 603.51 | 610.86 |
| ALX-0061 225 mg q2w | 36.92 | 634.49 | 659.79 |
| ALX-0061 75 mg q4w | 37.63 | 198.26 | 224.66 |
| Placebo | 42.22 | 39.70 | 39.41 |
(NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | µg/mL (Geometric Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 18.1 | 17.9 |
| ALX-0061 150 mg q4w | 2.05 | 2.17 |
| ALX-0061 225 mg q2w | 30.7 | 36.1 |
| ALX-0061 75 mg 4qw | 0.118 | 0.155 |
"The British Isles Lupus Assessment Group 2004 (BILAG-2004) is a comprehensive composite clinical index that has been developed based on the principle of a physician's intention to treat using a nominal consensus approach. In the index, the nine systems (not organs) considered are: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, renal, ophthalmic and hematological. Disease activity in each of the nine systems is categorized into five levels: grades A (= severe disease activity requiring systemic high dose oral corticosteroids, i.v. pulse corticosteroids, etc.) to E (= system never involved).~BILAG total score is derived by assigning the following value to each grade and summing the sores over all organ systems:~A = 12, B = 8, C = 1, D/E = 0. The total score ranges from 0-108, with 108 representing high disease activity in all 9 systems requiring high doses of corticosteroids, starting/increasing immunosuppressive drugs, etc." (NCT02437890)
Timeframe: At Baseline, Week 24 and Week 48
| Intervention | score (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 17.4 | 7.2 | 6.0 |
| ALX-0061 150 mg q4w | 15.2 | 7.0 | 5.2 |
| ALX-0061 225 mg q2w | 17.3 | 7.4 | 6.2 |
| ALX-0061 75 mg q4w | 17.9 | 5.7 | 4.0 |
| Placebo | 17.4 | 6.8 | 6.0 |
Twenty-eight joints are assessed for swollenness (a score of 1 for a joint denotes a presence of swollenness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are swollen). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SJC28 Score and geographic region as covariates. A negative change denotes an improvement. (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | score (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -4.8 | -5.1 |
| ALX-0061 150 mg q4w | -4.9 | -4.7 |
| ALX-0061 225 mg q2w | -4.5 | -4.5 |
| ALX-0061 75 mg q4w | -5.0 | -5.4 |
| Placebo | -4.8 | -5.0 |
Twenty-eight joints are assessed for tenderness (a score of 1 for a joint denotes a presence of tenderness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are tender). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline TJC28 Score and geographic region as covariates. A negative change denotes and improvement. (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | score (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -5.8 | -6.6 |
| ALX-0061 150 mg q4w | -6.4 | -6.4 |
| ALX-0061 225 mg q2w | -5.5 | -6.5 |
| ALX-0061 75 mg q4w | -6.8 | -7.4 |
| Placebo | -6.8 | -6.6 |
"CLASI Damage is scored based on dyspigmentation and scarring. Evaluation of dyspigmentation and scarring is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (dyspigmentation: 0=absent, 1=present; scarring: 0=absent, 1=scarring, 2=severely atrophic scarring or panniculitis). Subjects are also asked whether dyspigmentation due to SLE lesions usually remains visible for >12 months, which is considered permanent and results in doubling of the dyspigmentation score. Scarring alopecia is scored as follows: 0=absent, 3=1 quadrant, 4=2 quadrants, 5=3 quadrants, 6=affects the whole skull. Total score ranges from 0-56, with higher scores indicating more damaged skin.~Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Damage Score and geographic region as covariates. Negative change = improvement." (NCT02437890)
Timeframe: At Week 12, Week 24 and Week 48
| Intervention | score (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -0.3 | 0.3 | 0.4 |
| ALX-0061 150 mg q4w | -0.1 | -0.4 | -0.3 |
| ALX-0061 225 mg q2w | -0.4 | -0.1 | -0.7 |
| ALX-0061 75 mg q4w | 0.1 | -0.4 | -0.1 |
| Placebo | 0.1 | 0.4 | 0.0 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline eGFR and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | mL/min/1.73m2 (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -0.90 | -1.47 |
| ALX-0061 150 mg q4w | -1.72 | 4.66 |
| ALX-0061 225 mg q2w | -8.91 | -8.08 |
| ALX-0061 75 mg q4w | 4.83 | 2.47 |
| Placebo | -1.63 | -6.00 |
"CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (erythema: 0=absent, 1=pink, 2=red, 3=dark red; scale: 0=absent, 1=scale, 2=verrucous/hypertrophic). Mucous membrane involvement and acute hair loss are scored based on the presence (=1) or absence (=0).~Nonscarring alopecia is scored as 0=absent, 1=diffuse/non-inflammatory, 2=focal or patchy in 1 quadrant, 3=focal or patchy in >1 quadrant. The total score ranges from 0-70, with higher scores indicating more severe skin disease.~Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Activity Score and geographic region as covariates. Negative change = improvement" (NCT02437890)
Timeframe: At Week 12, Week 24 and Week 48
| Intervention | score (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -1.6 | -1.3 | -2.1 |
| ALX-0061 150 mg q4w | -1.4 | -1.6 | -2.5 |
| ALX-0061 225 mg q2w | -1.3 | -1.8 | -3.0 |
| ALX-0061 75 mg q4w | -1.9 | -2.1 | -3.0 |
| Placebo | -2.4 | -1.1 | -1.3 |
"The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | score (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 0.45 | -1.07 |
| ALX-0061 150 mg q4w | -0.56 | -0.07 |
| ALX-0061 225 mg q2w | -1.18 | -2.02 |
| ALX-0061 75 mg q4w | -0.99 | -0.58 |
| Placebo | 0.08 | 1.50 |
The Systemic Lupus Erythematosus Disease Activity Index 2000 is a 1-page weighted score for 24 items (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, etc). The manifestations felt to be most commonly contributing to disease activity are included and scored based on the presence (= 1 multiplied by weight) or absence (= 0) within 30 days prior to the evaluation. The total score ranges from 0-105 (= sum of individual scores), with 105 being higher disease activity. mSLEDAI-2K derives from the standard index by omitting low complement. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline mSLEDAI-2K Score and geographic region as covariates. A negative change from baseline reflects an improvement. (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | score (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -4.3 | -4.9 |
| ALX-0061 150 mg q4w | -3.8 | -4.3 |
| ALX-0061 225 mg q2w | -3.6 | -4.9 |
| ALX-0061 75 mg q4w | -4.6 | -5.2 |
| Placebo | -4.0 | -4.5 |
"The subject makes a mark between 0 (very good) and 100 mm (very bad) on the VAS to indicate how the subject is doing, while considering all the ways SLE affects him/her.~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline Patient's Global Assessment and geographic region as covariates.~A negative change from baseline reflects an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -20.1 | -27.2 |
| ALX-0061 150 mg q4w | -14.9 | -22.1 |
| ALX-0061 225 mg q2w | -16.0 | -25.9 |
| ALX-0061 75 mg q4w | -13.5 | -21.5 |
| Placebo | -12.4 | -15.1 |
"The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | score (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 4.67 | 8.62 |
| ALX-0061 150 mg q4w | 6.77 | 8.67 |
| ALX-0061 225 mg q2w | 5.01 | 8.85 |
| ALX-0061 75 mg q4w | 4.56 | 6.97 |
| Placebo | 4.71 | 3.73 |
"The physician makes a mark between 0 (no disease) and 100 mm (severe disease) on the visual analogue scale (VAS) to indicate disease activity (independent of the subject's self-assessment).~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline PGA score and geographic region as covariates.~A negative change from baseline reflects an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -23.5 | -30.1 |
| ALX-0061 150 mg q4w | -26.2 | -30.2 |
| ALX-0061 225 mg q2w | -22.7 | -30.5 |
| ALX-0061 75 mg q4w | -28.4 | -32.9 |
| Placebo | -25.2 | -28.3 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline proteinuria and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | g/mol (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -3.02 | -0.49 |
| ALX-0061 150 mg q4w | 1.03 | -1.62 |
| ALX-0061 225 mg q2w | 0.16 | -1.21 |
| ALX-0061 75 mg q4w | 1.77 | 3.83 |
| Placebo | 6.17 | 4.89 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline serum creatinine and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | umol/L (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -3.98 | -4.04 |
| ALX-0061 150 mg q4w | -1.50 | -6.26 |
| ALX-0061 225 mg q2w | -0.86 | -1.24 |
| ALX-0061 75 mg q4w | -3.29 | -1.87 |
| Placebo | -1.25 | 1.19 |
(NCT02437890)
Timeframe: From Baseline to Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Baseline to Week 24 | Baseline to Week 48 | |
| ALX-0061 150 mg q2w | 7 | 9 |
| ALX-0061 150 mg q4w | 6 | 10 |
| ALX-0061 225 mg q2w | 6 | 9 |
| ALX-0061 75 mg q4w | 6 | 6 |
| Placebo | 8 | 8 |
(NCT02437890)
Timeframe: From Baseline to Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Baseline to Week 24 | Baseline to Week 48 | |
| ALX-0061 150 mg q2w | 2 | 4 |
| ALX-0061 150 mg q4w | 2 | 4 |
| ALX-0061 225 mg q2w | 1 | 2 |
| ALX-0061 75 mg q4w | 0 | 0 |
| Placebo | 1 | 4 |
Number and percentage of subjects who discontinued Prednisone (or equivalent) by Week 48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare (NCT02437890)
Timeframe: Up to and including Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BILAG-2004-defined Flare | mSFI-defined Flare | |
| ALX-0061 150 mg q2w | 1 | 1 |
| ALX-0061 150 mg q4w | 1 | 2 |
| ALX-0061 225 mg q2w | 0 | 0 |
| ALX-0061 75 mg q4w | 0 | 0 |
| Placebo | 0 | 0 |
Number and percentage of subjects whose prednisone equivalent dose was >7.5 mg/day at baseline and reduced to ≤7.5 mg/day during Weeks 40-48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare after the first prednisone equivalent dose decrease. (NCT02437890)
Timeframe: Between Week 40 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BILAG-2004-defined Flare | mSFI-defined Flare | |
| ALX-0061 150 mg q2w | 1 | 1 |
| ALX-0061 150 mg q4w | 5 | 4 |
| ALX-0061 225 mg q2w | 3 | 4 |
| ALX-0061 75 mg q4w | 2 | 2 |
| Placebo | 3 | 3 |
Enhanced improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D and no worsening between consecutive visits from baseline up to the considered visit Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 6 | 6 |
| ALX-0061 150 mg q4w | 11 | 7 |
| ALX-0061 225 mg q2w | 13 | 7 |
| ALX-0061 75 mg q4w | 16 | 10 |
| Placebo | 7 | 5 |
"Normal Improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D.~Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint" (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 25 | 22 |
| ALX-0061 150 mg q4w | 28 | 29 |
| ALX-0061 225 mg q2w | 24 | 25 |
| ALX-0061 75 mg q4w | 29 | 34 |
| Placebo | 31 | 34 |
"An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D.~Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint" (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 21 | 18 |
| ALX-0061 150 mg q4w | 18 | 18 |
| ALX-0061 225 mg q2w | 25 | 22 |
| ALX-0061 75 mg q4w | 24 | 27 |
| Placebo | 25 | 26 |
"An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D.~Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint" (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 36 | 33 |
| ALX-0061 150 mg q4w | 36 | 35 |
| ALX-0061 225 mg q2w | 33 | 31 |
| ALX-0061 75 mg q4w | 39 | 38 |
| Placebo | 41 | 40 |
Number and percentage of mBICLA responders at Week 24 and Week 48 (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 24 | 19 |
| ALX-0061 150 mg q4w | 22 | 22 |
| ALX-0061 225 mg q2w | 22 | 22 |
| ALX-0061 75 mg q4w | 28 | 32 |
| Placebo | 28 | 28 |
"The composite index mSRI-4 enables quantification of decrease and increase in disease activity in a broad spectrum of manifestations thereby offering a comprehensive assessment of SLE disease status. mSRI combines advantages from 3 validated measurement tools. The mSRI-4 criteria for response are:~modified SLE disease activity index 2000 (mSLEDAI-2K): ≥ 4 point reduction (covers global disease improvement),~British Isles Lupus Assessment Group 2004 (BILAG-2004): no new A domain score and no more than 1 new increase to B (covers organ-specific disease improvement),~Physician's Global Assessment (PGA) (is used as validity and safety net for items that were not addressed by the other two indices): < 10% increase from Baseline (no worsening) When all 3 criteria are met, the subject is a mSRI-4 responder at that time point.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 33 | 26 |
| ALX-0061 150 mg q4w | 30 | 29 |
| ALX-0061 225 mg q2w | 29 | 33 |
| ALX-0061 75 mg q4w | 39 | 36 |
| Placebo | 37 | 34 |
"The mSRI-5 criteria for response are:~mSLEDAI-2K: ≥ 5 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 5 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 20 | 16 |
| ALX-0061 150 mg q4w | 19 | 18 |
| ALX-0061 225 mg q2w | 16 | 22 |
| ALX-0061 75 mg q4w | 24 | 28 |
| Placebo | 17 | 20 |
"The mSRI-6 criteria for response are:~mSLEDAI-2K: ≥ 6 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 6 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation" (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 19 | 16 |
| ALX-0061 150 mg q4w | 19 | 16 |
| ALX-0061 225 mg q2w | 15 | 22 |
| ALX-0061 75 mg q4w | 23 | 28 |
| Placebo | 16 | 20 |
"The mSRI-7 criteria for response are:~mSLEDAI-2K: ≥ 7 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 7 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 12 | 8 |
| ALX-0061 150 mg q4w | 8 | 7 |
| ALX-0061 225 mg q2w | 7 | 9 |
| ALX-0061 75 mg q4w | 8 | 14 |
| Placebo | 9 | 12 |
"The mSRI-8 criteria for response are:~mSLEDAI-2K: ≥ 8 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 8 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 10 | 7 |
| ALX-0061 150 mg q4w | 8 | 7 |
| ALX-0061 225 mg q2w | 7 | 8 |
| ALX-0061 75 mg q4w | 7 | 14 |
| Placebo | 9 | 11 |
(NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 16 | 16 |
| ALX-0061 150 mg q4w | 19 | 23 |
| ALX-0061 225 mg q2w | 16 | 19 |
| ALX-0061 75 mg q4w | 24 | 27 |
| Placebo | 15 | 20 |
Defined as non-protocol allowed increase in steroid dose, start i.v. or i.m. steroids, or start or increase of immunosuppressant (NCT02437890)
Timeframe: From Baseline to Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Baseline to Week 24 | Baseline to Week 48 | |
| ALX-0061 150 mg q2w | 2 | 6 |
| ALX-0061 150 mg q4w | 4 | 9 |
| ALX-0061 225 mg q2w | 3 | 6 |
| ALX-0061 75 mg q4w | 0 | 1 |
| Placebo | 2 | 5 |
Efficacy Laboratory Parameters (Urinalysis) - Active Urine Sediment Number of subjects who were urine sediment negative at Baseline, but positive at Week 24 and Week 48, respectively. (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | 0 | 0 |
| ALX-0061 150 mg q4w | 0 | 0 |
| ALX-0061 225 mg q2w | 0 | 0 |
| ALX-0061 75 mg q4w | 0 | 0 |
| Placebo | 1 | 0 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline prednisone equivalent total daily dose and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48
| Intervention | percentage (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| ALX-0061 150 mg q2w | -1.40 | -2.32 |
| ALX-0061 150 mg q4w | 0.25 | -1.03 |
| ALX-0061 225 mg q2w | -3.46 | -1.73 |
| ALX-0061 75 mg q4w | -0.80 | -3.22 |
| Placebo | 3.87 | 6.93 |
Among some adults, having a period of SLE symptoms-called flares-may happen every so often, sometimes even years apart, and go away at other times-called remission. The SFI categorizes SLE flares as mild, moderate or severe. (NCT02953821)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Gel | 3 |
| Acthar Gel | 0 |
"BILAG records disease activity occurring over the past 4 weeks, and is used to determine whether different course of treatment is required. The BILAG-2004 index covers 97 signs/symptoms across 9 organ systems. Each question is answered as 0-not present, 1-improving, 2-same, 3-worse, or 4-new.~The BILAG-2004 index categorizes disease activity in each organ system into five different levels from A to E. Grade A represents very active disease, Grade B represents moderate disease activity, Grade C indicates mild stable disease, and grade D implies no disease activity, but suggests the organ system had previously been affected. Grade E indicates no current or previous disease activity. A score is applied to each grade of each organ system using coding scheme of A=12, B=8, C=1, and D/E=0 and is summarized as a total score ranging 0-108. Higher scores indicate more severe disease activity." (NCT02953821)
Timeframe: Baseline, Week 16, Week 24
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 16 | Week 24 | |
| Acthar Gel | 18.0 | 7.7 | 6.9 |
| Placebo Gel | 18.2 | 9.7 | 8.0 |
The CLASI total activity score reflects ongoing inflammation that can be treated, with points given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Mild, moderate, and severe disease correspond with CLASI activity score ranges of 0 to 9, 10 to 20, and 21 to 70, respectively. Higher scores indicate more disease activity, lower scores indicate improvement. (NCT02953821)
Timeframe: at Baseline and Weeks 4, 8, and 16
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | |
| Acthar Gel | 7.9 | 5.6 | 5.0 | 4.0 | 3.4 |
| Placebo Gel | 7.1 | 5.8 | 5.0 | 4.5 | 3.8 |
The 28 Joint Count includes assessment of swelling and tenderness in the shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and knees. The investigator counts how many of the 28 joints are swollen or tender at the given week. (NCT02953821)
Timeframe: at Baseline and at Weeks 4, 8, 12 and 16
| Intervention | Joints (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | |
| Acthar Gel | 8.2 | 4.2 | 2.9 | 2.3 | 1.9 |
| Placebo Gel | 7.2 | 4.9 | 3.8 | 2.9 | 2.8 |
The SLEDAI-2K is a modified version of a composite score based on the presence or absence of clinical signs, clinical symptoms, and immunologic laboratory results taken within 10 days of the evaluations. Each of the descriptors has a weighted score and the total score of SLEDAI-2K is the sum of all 24 descriptor scores. The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity. Decrease from baseline indicates improvement. (NCT02953821)
Timeframe: Week 16, Week 24
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 16 | Week 24 | |
| Acthar Gel | 41 | 44 |
| Placebo Gel | 40 | 46 |
(NCT02953821)
Timeframe: Week 20, Week 24
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 20 | Week 24 | |
| Acthar Gel | 3 | 4 |
| Placebo Gel | 5 | 6 |
PGA is a 100 mm visual analogue scale where higher scores indicate more severe disease activity. Lower scores indicate improvement. (NCT02953821)
Timeframe: Baseline, Week 16, Week 24
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 16 | Week 24 | |
| Acthar Gel | 60.6 | 30.2 | 25.5 |
| Placebo Gel | 58.8 | 33.2 | 26.9 |
The SLEDAI is a discontinuous scoring system that weights disease activity not by severity of individual symptoms but by the weighting of organs. This makes it less robust for comparing one group of patients to another, but it is quite useful to gave numbers of patients with improvement, since to lower the score a rigorous improvement must be documented (NCT02270957)
Timeframe: Comparison of Baseline to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Abatacept | 9 |
| Placebo | 8 |
"The British Isles Lupus Assessment Group Index is a scoring system for progress of disease activity over the prior month with a scoring system that rates each organ system as A or severe, B or moderate, C or mild vs no activity in the past month. To meet the BICLA endpoint requires all baseline severe features (BILAG A) improving to moderate (BILAG B), mild or resolved, and all baseline BILAG B features improving to mild or resolved without increase in any other feature on either the BILAG or a different measure called the SLEDAI (SLE Disease Activity Index). Furthermore there must be no increase in Physician's Global Assessment or any rescue medications after the month 2 visit. Only those meeting all of these criteria meet the primary endpoint." (NCT02270957)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Abatacept | 8 |
| Placebo | 8 |
Comparing the endpoint date at six months to Baseline, there must be a 4 point decreased in SLEDAI score (SLEDAI is defined as the SLE Disease Activity Index). The SLEDAI is a discontinuous scale in which each type of sign or symptom of active SLE is assigned a fixed number of points. Although the scale includes possible signs or symptoms adding up to more than 100 points it is rare for any (even very severe) patient to ever have a total score > 20. To meet the SLE Responder Index endpoint, There must also be no worsening of BILAG (British Isles Lupus Assessment Group Index (described in the primary endpoint section) and no worsening of PGA (a visual analogue scale reflecting physicians global assessment) by more than 10% of the scale. To meet this endpoint there must also be no new or increased medication initiated after Baseline other than the steroid rescues up to Month 2. (NCT02270957)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Abatacept | 9 |
| Placebo | 8 |
The 12-lead ECG data were summarized and evaluated. Number of participants with clinically significant abnormal ECG findings as assessed by cardiologist were recorded and reported as TEAEs. (NCT01283139)
Timeframe: Day 1 up to Week 56
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Sifalimumab 200 Milligram (mg) | 0 |
| Sifalimumab 600 mg | 1 |
| Sifalimumab 1,200 mg | 0 |
SRI (4) responder is defined as: 1) a reduction in baseline SLEDAI-2K disease activity score of >=4 points (with increased DNA binding item of SLEDAI-2K score based on the ANA Multi-Lyte® ANA-II Plus Test System); 2) no worsening in Physician Global Assessment (MDGA) (worsening is defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale) and 3) no worsening in BILAG-2004 (worsening is defined as at least 1 new 'A' score or 2 new 'B' scores on the BILAG-2004 compared with baseline). (NCT01283139)
Timeframe: Day 365
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 42.0 |
| Sifalimumab 200 Milligram (mg) | 57.5 |
| Sifalimumab 600 mg | 50.0 |
| Sifalimumab 1,200 mg | 57.5 |
SRI (4) responder is defined as: 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) disease activity score of greater than or equal to (>=) 4 points (with increased deoxyribonucleic acid [DNA] binding item of SLEDAI-2K score based on the ANA Multi-Lyte® ANA-II Plus Test System); 2) no worsening in Physician Global Assessment (MDGA) (worsening is defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale) and 3) no worsening in British Isles Lupus Assessment Group (BILAG-2004) (worsening is defined as at least 1 new 'A' score or 2 new 'B' scores on the BILAG-2004 compared with baseline). (NCT01283139)
Timeframe: Day 365
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.4 |
| Sifalimumab 200 Milligram (mg) | 58.3 |
| Sifalimumab 600 mg | 56.5 |
| Sifalimumab 1,200 mg | 59.8 |
Laboratory investigations included hematology, serum chemistries and urinalysis parameters. Participants with clinically significant abnormalities in these laboratory investigations recorded as TEAEs were reported. (NCT01283139)
Timeframe: Day 1 up to Week 61
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anaemia | White blood cell count increased | Neutrophil count increased | Iron deficiency anaemia | Haemoglobin decreased | Lymphocyte count decreased | White blood cell count decreased | Autoimmune haemolytic anaemia | Eosinophilia | Haematocrit increased | Haemoglobin increased | Leukopenia | Lymphopenia | Neutropenia | Neutrophil count decreased | Platelet count increased | Red blood cell count decreased | Thrombocytopenia | Platelet count decreased | Monocyte count increased | Hypokalaemia | Alanine aminotransferase increased | Gamma-glutamyltransferase increased | Hypertriglyceridaemia | Dyslipidaemia | Hepatic enzyme increased | Aspartate aminotransferase increased | Blood creatine phosphokinase increased | Blood creatinine increased | Blood glucose increased | Hyperglycaemia | Transaminases increased | Blood potassium decreased | Low density lipoprotein increased | Blood albumin decreased | Blood alkaline phosphatase decreased | Blood calcium increased | Blood cholesterol increased | Blood homocysteine increased | Liver function test abnormal | Hyperlipidaemia | Hypoalbuminaemia | Hypoglycaemia | Blood bilirubin increased | Hypocalcaemia | Blood triglycerides increased | Hyperbilirubinaemia | Hypertransaminasaemia | |
| Placebo | 1 | 3 | 3 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 2 | 1 | 4 | 5 | 5 | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 0 |
| Sifalimumab 1,200 mg | 2 | 3 | 2 | 2 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 5 | 3 | 4 | 3 | 2 | 0 | 2 | 0 | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Sifalimumab 200 Milligram (mg) | 4 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sifalimumab 600 mg | 4 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 1 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
Vital sign assessments included blood pressure, pulse rate, temperature, weight and respiratory rate. Vital signs abnormalities recorded as TEAEs were reported. (NCT01283139)
Timeframe: Day 1 up to Week 61
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pyrexia | Hypertension | Weight increased | Blood pressure increased | Chills | Hypertensive crisis | Orthostatic hypotension | Weight decreased | Hypotension | |
| Placebo | 3 | 7 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Sifalimumab 1,200 mg | 7 | 4 | 2 | 0 | 1 | 1 | 1 | 1 | 0 |
| Sifalimumab 200 Milligram (mg) | 2 | 4 | 1 | 2 | 2 | 0 | 0 | 0 | 0 |
| Sifalimumab 600 mg | 6 | 5 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of investigational product, for the period extending until the end of participant participation in the study. (NCT01283139)
Timeframe: Day 1 up to Week 74
| Intervention | participants (Number) | |
|---|---|---|
| TEAE | TESAE | |
| Placebo | 94 | 19 |
| Sifalimumab 1,200 mg | 93 | 21 |
| Sifalimumab 200 Milligram (mg) | 97 | 16 |
| Sifalimumab 600 mg | 97 | 22 |
Percentage of participants on >=10 mg/day oral corticosteroids (OCS) at baseline who were able to taper it to <=7.5 mg/day by Day 365 were recorded. (NCT01283139)
Timeframe: Day 365
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Reduce OCS to <=7.5 mg/day: Yes | Reduce OCS to <=7.5 mg/day: No | |
| Placebo | 6.5 | 93.5 |
| Sifalimumab 1,200 mg | 6.2 | 93.8 |
| Sifalimumab 200 Milligram (mg) | 8.2 | 91.8 |
| Sifalimumab 600 mg | 9.4 | 90.6 |
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). (NCT01283139)
Timeframe: Day 365
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Achieved > 3-point improvement: Yes | Achieved > 3-point improvement: No | |
| Placebo | 30.5 | 69.5 |
| Sifalimumab 1,200 mg | 35.6 | 64.4 |
| Sifalimumab 200 Milligram (mg) | 38.1 | 61.9 |
| Sifalimumab 600 mg | 42.2 | 57.8 |
The CLASI consists of two scores, the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. Damage is scored in terms of dyspigmentation and scarring, including scarring alopecia. The percentage of participants with a CLASI activity score >=10 at baseline who achieved a clinically significant (>=4-point) reduction at Day 365 were reported. (NCT01283139)
Timeframe: Day 365
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Achieved >=4-point reduction: Yes | Achieved >=4-point reduction: No | |
| Placebo | 48.6 | 51.4 |
| Sifalimumab 1,200 mg | 73.1 | 26.9 |
| Sifalimumab 200 Milligram (mg) | 72.7 | 27.3 |
| Sifalimumab 600 mg | 57.6 | 42.4 |
Mean Change from Baseline Over Time; Measured by Disease Activity Score 28: A single score on a continuous scale (0-9.4). The level of RA disease activity can be interpreted as low (DAS28 <=3.2),moderate (3.2 < DAS28 <=5.1), or as high disease activity (DAS28 > 5.1) (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169
| Intervention | Scores on a scale (Mean) |
|---|---|
| Experimental: 12.5mg SC BMS-931699 Weekly | -4.63 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | -4.63 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | -4.75 |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | -4.42 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | -3.84 |
Pharmacokinetics of BMS-931699 derived from serum concentration versus time data; Ctrough = Trough level serum concentration of BMS-931699 at time point specified Pharmacokinetic Population: defined as all subjects who receive any study medication and have any available concentration-time data. (NCT02265744)
Timeframe: Day 169
| Intervention | ng/mL (Mean) |
|---|---|
| Experimental: 12.5mg SC BMS-931699 Weekly | 2040 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 640.8 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 207.1 |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 62.2 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 0 |
"The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) is a measure of systemic lupus erythematosus (SLE) response. BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline." (NCT02265744)
Timeframe: At Day 169
| Intervention | Percentage of participants (Number) |
|---|---|
| Experimental: 12.5mg SC BMS-931699 Weekly | 59.4 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 63.2 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 57.4 |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 58.6 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 59.2 |
Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage. (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Percentage of participants (Number) |
|---|---|
| Experimental: 12.5mg SC BMS-931699 Weekly | 39.3 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 46.9 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 34.5 |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 36.1 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 42.4 |
"BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline; No changes in concomitant medications according to the following criteria: No increase of or addition of a new immunosuppressant agent (azathioprine,mycophenolic acid/mycophenolate mofetil, methotrexate, anti-malarial, leflunomide) over baseline levels; No increase in corticosteroid dose above baseline level outside of those allowed per protocol." (NCT02265744)
Timeframe: At Day 85
| Intervention | Percentage of participants (Number) |
|---|---|
| Experimental: 12.5mg SC BMS-931699 Weekly | 69.6 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 64.7 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 57.4 |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 57.1 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 54.9 |
RESPIRATION RATE (RESP) (PER MIN) RESP > 16 OR RESP CHANGE FROM BASELINE > 10 (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Percentage of participants (Number) |
|---|---|
| Experimental: 12.5mg SC BMS-931699 Weekly | 82.4 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 85.5 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 75.0 |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 70.0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 81.7 |
TEMPERATURE (TEMP) (C) TEMP > 38.3 OR TEMP CHANGE FROM BASELINE > 1.6 (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Percentage of participants (Number) |
|---|---|
| Experimental: 12.5mg SC BMS-931699 Weekly | 0 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 1.5 |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 1.4 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 1.4 |
Overall British Isles Lupus Assessment Group-2004 score, BILAG Scores: A=Severe disease activity, B=Moderate disease activity, C=Mild disease, D=Inactive disease but previously affected, E=System never involved.The categories are converted to a numeric score (A=9, B=3, C=1, D=0, E=0) and treated as a continuous variable. Higher score= more severe disease activity. (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169
| Intervention | Score (Mean) | |
|---|---|---|
| BILAG-2004 Score Day 85 | BILAG-2004 Score Day 169 | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | -8.66 | -9.73 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | -8.83 | -10.46 |
| Experimental: 12.5mg SC BMS-931699 Weekly | -10.31 | -11.50 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | -7.07 | -8.98 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | -7.94 | -9.78 |
Physician Global Assessment of Arthritis was measured by asking the physician to assess the participant's current arthritis disease activity by placing a vertical line on a 0 to 100 millimeter (mm) visual analog scale (VAS), where 0 mm = very good and 100 mm = very bad. (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169
| Intervention | Score (Mean) | |
|---|---|---|
| MDGA score Day 85 | MDGA score Day 169 | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | -20.55 | -26.71 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | -23.87 | -26.87 |
| Experimental: 12.5mg SC BMS-931699 Weekly | -28.77 | -29.30 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | -21.00 | -28.68 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | -23.83 | -25.28 |
Systemic Lupus Erythematosus Disease Activity Index, SLEDAI; Version 2000, also known as SLEDAI-2K. The SLEDAI-2K score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169
| Intervention | Score (Mean) | |
|---|---|---|
| SLEDAI-2K Score Day 85 | SLEDAI-2K Score Day 169 | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | -4.02 | -4.82 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | -3.24 | -4.17 |
| Experimental: 12.5mg SC BMS-931699 Weekly | -3.61 | -4.88 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | -3.17 | -3.98 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | -3.29 | -4.15 |
Percent of participants requiring use of corticosteroids and mmunosuppressants use over time (NCT02265744)
Timeframe: Up to one day prior to the first dose of long-term extension period or up to 42 days post last short-term dose date, which ever is earlier
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Corticosteroids: Oral | Corticosteroids: Oral inhalation | Immunosuppressant | Immunosuppressant Azathioprine | Immunosuppressant Methotrexate | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 84.3 | 0 | 51.4 | 28.6 | 24.3 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 82.4 | 0 | 63.2 | 29.4 | 35.3 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 89.9 | 0 | 46.4 | 23.2 | 26.1 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 86.8 | 1.5 | 38.2 | 14.7 | 25.0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 94.4 | 0 | 59.2 | 33.8 | 26.8 |
Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage. (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Day 85 | Day 169 | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | -1.82 | -2.94 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | -3.20 | -3.78 |
| Experimental: 12.5mg SC BMS-931699 Weekly | -2.31 | -3.17 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | -1.69 | -2.47 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | -3.11 | -3.57 |
IMMUNE ACTIVATION MARKERS:C-REACTIVE PROTEIN (CRP) CRP MG/L H > 1.5×ULN; CRP, HIGH SENSITIVITY MG/L H > 1.5×ULN; (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |
|---|---|---|
| C-Reactive Protein (CRP) Low | C-Reactive Protein (CRP) High | |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | NA | 18 |
| Experimental: 12.5mg SC BMS-931699 Weekly | NA | 19 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | NA | 22 |
IMMUNE ACTIVATION MARKERS:C-REACTIVE PROTEIN (CRP) CRP MG/L H > 1.5×ULN; CRP, HIGH SENSITIVITY MG/L H > 1.5×ULN; (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| C-Reactive Protein (CRP) Low | C-Reactive Protein (CRP) High | CRP, High Sensitivity Low | CRP, High Senstivity High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | NA | 18 | NA | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | NA | 22 | NA | 1 |
GLUCOSE TESTS:GLUCOSE, FASTING SERUM MMOL/L H > 1.3×ULN IF PRE-RX IS MISSING OR > 1.3×ULN IF PRE-RX <= ULN OR > 2×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN GLUCOSE, FASTING SERUM MMOL/L L < 0.8×LLN IF PRE-RX IS MISSING OR < 0.8×LLN IF PRE-RX >= LLN OR < 0.8×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; PROTEIN TESTS:ALBUMIN G/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN PROTEIN, TOTAL G/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN PROTEIN, TOTAL G/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Glucose, Fasting serum, Low | Glucose, Fasting Serum, High | Albumin, Low | Albumin, High | Protein, Total, Low | Protein, Total, High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 4 | 0 | 2 | 0 | 1 | 1 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 3 | 3 | 2 | 0 | 0 | 0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 1 | 3 | 1 | 0 | 0 | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 0 | 0 | 2 | 0 | 1 | 1 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 5 | 4 | 1 | 0 | 0 | 0 |
OTHER CHEMISTRY TESTING LIPID TESTS: CHOLESTEROL, TOTAL (TC) MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN TRIGLYCERIDES, FASTING MMOL/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN PANCREATIC TESTS: AMYLASE, TOTAL U/L H > 1.5×ULN; LIPASE, TOTAL (TURBIDIMETRIC ASSAY) U/L H > 1.5×ULN; LIPASE, TOTAL (COLORIMETRIC ASSAY) U/L H > 1.5×ULN; ENDOCRINE TESTS:CORTISOL, AM NMOL/L L < 138 THYROID STIMULATING HORMONE (TSH) TSH MU/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cholesterol, Total (TC) Low | Cholesterol, Total (TC) High | Triglycerides, Fasting Low | Triglycerides, Fasting High | Amylase, Total Low | Amylase, Total High | Lipase, Total (Colorimetric Assay) Low | Lipase, Total (Colorimetric Assay) High | Lipase, Total (Turbidimetric Assay) Low | Lipase, Total (Turbidimetric Assay) High | Thyroid Stimulating Hormone, Low | Thyroid Stimulating Hormone, High | |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | NA | 12 | NA | 12 | NA | 0 | NA | 1 | NA | 1 | NA | 0 |
OTHER CHEMISTRY TESTING LIPID TESTS: CHOLESTEROL, TOTAL (TC) MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN TRIGLYCERIDES, FASTING MMOL/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN PANCREATIC TESTS: AMYLASE, TOTAL U/L H > 1.5×ULN; LIPASE, TOTAL (TURBIDIMETRIC ASSAY) U/L H > 1.5×ULN; LIPASE, TOTAL (COLORIMETRIC ASSAY) U/L H > 1.5×ULN; ENDOCRINE TESTS:CORTISOL, AM NMOL/L L < 138 THYROID STIMULATING HORMONE (TSH) TSH MU/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Cholesterol, Total (TC) Low | Cholesterol, Total (TC) High | Triglycerides, Fasting Low | Triglycerides, Fasting High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | NA | 10 | NA | 10 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | NA | 4 | NA | 13 |
| Experimental: 12.5mg SC BMS-931699 Weekly | NA | 5 | NA | 12 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | NA | 8 | NA | 8 |
OTHER CHEMISTRY TESTING CARDIAC TESTS: CREATINE KINASE (CK) CK U/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN; TROPONIN-I, CARDIAC SPECIFIC UG/L H > ULN; METABOLITE TESTS:URIC ACID URIC MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; CHEM TEST, MULTI INDICATIONS : LACTATE DEHYDROGENASE (LD) LD U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |
|---|---|---|
| Creatine Kinase Low | Creatine Kinase High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | NA | 3 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | NA | 5 |
| Experimental: 12.5mg SC BMS-931699 Weekly | NA | 5 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | NA | 1 |
OTHER CHEMISTRY TESTING CARDIAC TESTS: CREATINE KINASE (CK) CK U/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN; TROPONIN-I, CARDIAC SPECIFIC UG/L H > ULN; METABOLITE TESTS:URIC ACID URIC MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; CHEM TEST, MULTI INDICATIONS : LACTATE DEHYDROGENASE (LD) LD U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Creatine Kinase Low | Creatine Kinase High | TROPONIN-I, CARDIAC SPECIFIC Low | TROPONIN-I, CARDIAC SPECIFIC High | Uric Acid, Low | Uric Acid, High | Lactate dehydrogenase (LD) low | Lactate dehydrogenase (LD) high | |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | NA | 3 | NA | 0 | NA | 0 | NA | 0 |
QUALITATIVE URINE CHEMISTRY: BLOOD, URINE N/A H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 1 OR >= 2×PRE-RX IF PRE-RX >= 1 GLUCOSE, URINE N/A H >= 1 IF PRE-RX IS MISSING OR >= 1 IF PRE-RX < 1 OR >= 2×PRE-RX IF PRE-RX >= 1 PROTEIN, URINE UNKNOWN H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 1 OR >= 2×PRE-RX IF PRE-RX >= 1 URINALYSIS II URINE WBC + RBC ; RBC, URINE HPF H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 2 OR >= 4 IF PRE-RX >= 2 WBC, URINE HPF H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 2 OR >= 4 IF PRE-RX >= 2 (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Blood, Urine, Low | Blood, Urine, High | Glucose, Urine, Low | Glucose, Urine, High | Protein, Urine, Low | Protein, Urine, High | RBC, Urine, Low | RBC, Urine, High | WBC, Urine, Low | WBC, Urine, High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | NA | 21 | NA | 0 | NA | 7 | NA | 17 | NA | 31 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | NA | 21 | NA | 2 | NA | 7 | NA | 19 | NA | 29 |
| Experimental: 12.5mg SC BMS-931699 Weekly | NA | 18 | NA | 2 | NA | 7 | NA | 18 | NA | 28 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | NA | 20 | NA | 0 | NA | 13 | NA | 13 | NA | 31 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | NA | 20 | NA | 1 | NA | 10 | NA | 18 | NA | 25 |
CALCIUM, TOTAL MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; CALCIUM, TOTAL MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; CHLORIDE, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; CHLORIDE, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Calcium, Total, Low | Calcium, Total, High | Chloride, Serum, Low | Chloride, Serum, High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 0 | 0 | 0 | 0 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 0 | 0 | 0 | 0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 0 | 0 | 0 | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 1 | 0 | 0 | 0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 0 | 0 | 0 | 0 |
BICARBONATE MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; BICARBONATE MMOL/L L < 0.8×LLN IF PRE-RX IS MISSING OR < 0.8×LLN IF PRE-RX >= LLN OR < 0.8×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; POTASSIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; POTASSIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; MAGNESIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN MAGNESIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |
|---|---|---|
| Potassium, Serum, Low | Potassium, Serum, High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 1 | 1 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 0 | 0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 1 | 0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 1 | 0 |
BICARBONATE MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; BICARBONATE MMOL/L L < 0.8×LLN IF PRE-RX IS MISSING OR < 0.8×LLN IF PRE-RX >= LLN OR < 0.8×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; POTASSIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; POTASSIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; MAGNESIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN MAGNESIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Bicarbonate, Low | Bicarbonate, High | Magnesium, Serum, Low | Magnesium, Serum, High | Potassium, Serum, Low | Potassium, Serum, High | |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 0 | 0 | 0 | 0 | 1 | 1 |
SODIUM, SERUM MMOL/L H > 1.05×ULN IF PRE-RX IS MISSING OR > 1.05×ULN IF PRE-RX <= ULN OR > 1.05×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN SODIUM, SERUM MMOL/L L < 0.95×LLN IF PRE-RX IS MISSING OR < 0.95×LLN IF PRE-RX >= LLN OR < 0.95×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN PHOSPHORUS, INORGANIC PHOS MMOL/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN PHOSPHORUS, INORGANIC PHOS MMOL/L L < 0.85×LLN IF PRE-RX IS MISSING OR < 0.85×LLN IF PRE-RX >=LLN OR < 0.85×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Sodium, Serum Low | Sodium, Serum High | Phosphorus, Inorganic, Low | Phosphorus, Inorganic, High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 0 | 0 | 1 | 1 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 0 | 0 | 2 | 0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 0 | 0 | 0 | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 0 | 0 | 4 | 0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 0 | 0 | 0 | 0 |
Although there are no identified risks for BMS-931699, BMS has developed a list of events of special interest for the BMS-931699 program based on the known biologic class effects, the mechanism of action of BMS-931699, overall potential consequences of mmunosuppression, and preliminary data from unblinded clinical trials. Event categories of special interest for this study may include, but are not limited to: Infections, Autoimmunity, Malignancies, Injection-related reactions (NCT02265744)
Timeframe: On or after the first dose date of short-term study medication and up to 42 days post last short-term dose date or up to the day prior to the first dose of long-term extension period, whichever is earlier
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Serious Adverse Events | Related SAEs | Related Adverse Events | AEs of Malignancies | AEs of Infections and Infestations | AEs Leading to Discontinuation | Adverse Events of Autoimmunity | Most Common Adverse Events | Adverse Events of Local Injection Reactions | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 8 | 0 | 19 | 0 | 39 | 9 | 0 | 59 | 3 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 5 | 3 | 30 | 0 | 41 | 5 | 0 | 56 | 8 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 5 | 3 | 33 | 0 | 38 | 8 | 4 | 59 | 10 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 9 | 5 | 29 | 0 | 35 | 9 | 0 | 60 | 10 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 6 | 1 | 19 | 0 | 30 | 3 | 1 | 62 | 4 |
LIVER FUNCTION TESTS:ALKALINE PHOSPHATASE (ALP) ALP U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; BILIRUBIN, DIRECT UMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN G-GLUTAMYL TRANSFERASE (GGT) GGT U/L H > 1.15×ULN IF PRE-RX IS MISSING OR > 1.15×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN BILIRUBIN, TOTAL UMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine Aminotransferase Low | Alanine Aminotransferase High | Alkaline Phosphatase Low | Alkaline Phosphatase High | Aspartate Aminotransferase Low | Aspartate Aminotransferase High | Bilirubin, Direct Low | Bilirubin Direct, High | Bilirubin Total, Low | Bilirubin Total, High | G-Glutamyl Transferase, Low | G-Glutamyl Transferase, High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | NA | 9 | NA | 5 | NA | 8 | NA | 1 | NA | 1 | NA | 15 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | NA | 17 | NA | 3 | NA | 13 | NA | 13 | NA | 0 | NA | 14 |
| Experimental: 12.5mg SC BMS-931699 Weekly | NA | 12 | NA | 2 | NA | 10 | NA | 0 | NA | 0 | NA | 18 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | NA | 6 | NA | 2 | NA | 11 | NA | 0 | NA | 0 | NA | 16 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | NA | 8 | NA | 8 | NA | 10 | NA | 0 | NA | 1 | NA | 13 |
HEMATOLOGY I: ERYTHROCYTE/PLATELET ATTRIBUTES HEMOGLOBIN G/L L < 0.85×PRE-RX; HEMATOCRIT VOL L < 0.85×PRE-RX; PLATELET COUNT X10*9 C/L H > 1.5×ULN (ULN = Upper Limit of Normal) IF PRE-RX IS MISSING OR > 1.5×ULN PLATELET COUNT X10*9 C/L L < 0.85×LLN (LLN = Lower Limit of Normal) IF PRE-RX IS MISSING OR < 0.85×LLN IF PRE-RX >= LLN OR < 0.85×PRE-RX IF PRE-RX < LLN; ERYTHROCYTES RBC X10*12 C/L L < 0.85×PRE-RX HEMATOLOGY II QUANTITATIVE WBC : LEUKOCYTES X10*9 C/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF LLN <= PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; LEUKOCYTES WBC X10*9 C/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF LLN <= PRE-RX <= ULN OR < 0.85×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Erythrocytes Low | Erythrocytes High | Hematocrit Low | Hematocrit High | Hemoglobin Low | Hemoglobin High | Platelet count low | Platelet count high | Quantitative WBC: Leukocytes low | Quantitative WBC: Leukocytes high | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 3 | NA | 5 | NA | 4 | NA | 1 | 1 | 16 | 3 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 4 | NA | 10 | NA | 4 | NA | 1 | 0 | 18 | 1 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 4 | NA | 6 | NA | 4 | NA | 1 | 0 | 12 | 1 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 6 | NA | 5 | NA | 5 | NA | 1 | 0 | 12 | 0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 5 | NA | 8 | NA | 5 | NA | 2 | 0 | 16 | 1 |
WBC DIFFERENTIAL COUNT: BASOPHILS (ABSOLUTE) X10*9 C/L H > 0.4; BLASTS (ABSOLUTE) X10*9 C/L H > 0; EOSINOPHILS (ABSOLUTE) EOSA X10*9 C/L H > 0.75; LYMPHOCYTES (ABSOLUTE) X10*9 C/L H > 7.5; LYMPHOCYTES (ABSOLUTE) X10*9 C/L L < 0.75; MONOCYTES (ABSOLUTE) X10*9 C/L H > 2; NEUTROPHILS (ABSOLUTE) X10*9 C/L L < 1.5 IF PRE-RX IS MISSING OR < 1.5 IF PRE-RX >= 1.5 OR < 0.85×PRE-RX IF PRE-RX < 1.5; COAGULATION activated Partial thromboplastin time (APTT) SEC H > 1.5×ULN; INTL NORMALIZED RATIO (INR) INR FRACTION H > 1.5×ULN PROTHROMBIN TIME (PT) PT SEC H > 1.5×ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Basophils (Absolute) Low | Basophils (Absolute) High | Eosinophils (Absolute) Low | Eosinophils (Absolute) High | Lymphocytes (Absolute) Low | Lymphocytes (Absolute) High | Monocytes (Absolute) High | Monocytes (Absolute) Low | Neutrophils (Absolute) Low | Neutrophils (Absolute) High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | NA | 0 | NA | 2 | 25 | 0 | NA | 0 | 7 | NA |
| Experimental: 12.5mg SC BMS-931699 Weekly | NA | 0 | NA | 3 | 21 | 0 | NA | 0 | 10 | NA |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | NA | 0 | NA | 0 | 24 | 0 | NA | 0 | 5 | NA |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | NA | 0 | NA | 1 | 25 | 0 | NA | 0 | 4 | NA |
WBC DIFFERENTIAL COUNT: BASOPHILS (ABSOLUTE) X10*9 C/L H > 0.4; BLASTS (ABSOLUTE) X10*9 C/L H > 0; EOSINOPHILS (ABSOLUTE) EOSA X10*9 C/L H > 0.75; LYMPHOCYTES (ABSOLUTE) X10*9 C/L H > 7.5; LYMPHOCYTES (ABSOLUTE) X10*9 C/L L < 0.75; MONOCYTES (ABSOLUTE) X10*9 C/L H > 2; NEUTROPHILS (ABSOLUTE) X10*9 C/L L < 1.5 IF PRE-RX IS MISSING OR < 1.5 IF PRE-RX >= 1.5 OR < 0.85×PRE-RX IF PRE-RX < 1.5; COAGULATION activated Partial thromboplastin time (APTT) SEC H > 1.5×ULN; INTL NORMALIZED RATIO (INR) INR FRACTION H > 1.5×ULN PROTHROMBIN TIME (PT) PT SEC H > 1.5×ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils (Absolute) Low | Basophils (Absolute) High | Blasts (Absolute) Low | Blasts (Absolute) High | Eosinophils (Absolute) Low | Eosinophils (Absolute) High | Lymphocytes (Absolute) Low | Lymphocytes (Absolute) High | Monocytes (Absolute) High | Monocytes (Absolute) Low | Neutrophils (Absolute) Low | Neutrophils (Absolute) High | |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | NA | 0 | NA | 0 | NA | 0 | 29 | 0 | NA | 0 | 8 | NA |
KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN CREATININE UMOL/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.33×PRE-RX IF PRE-RX > ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L < 0.8×PRE-RX; UREA UREA MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Blood Urea Nitrogen, Low | Blood Urea Nitrogen, High | Creatinine, Low | Creatinine, High | |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | NA | 10 | NA | 1 |
KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN CREATININE UMOL/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.33×PRE-RX IF PRE-RX > ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L < 0.8×PRE-RX; UREA UREA MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Blood Urea Nitrogen, Low | Blood Urea Nitrogen, High | Creatinine, Low | Creatinine, High | Urea, Low | Urea, High | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | NA | 14 | NA | 2 | NA | 0 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | NA | 11 | NA | 0 | NA | 0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | NA | 9 | NA | 2 | NA | 0 |
KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN CREATININE UMOL/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.33×PRE-RX IF PRE-RX > ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L < 0.8×PRE-RX; UREA UREA MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood Urea Nitrogen, Low | Blood Urea Nitrogen, High | Creatinine, Low | Creatinine, High | GLOMERULAR FILTRATION RATE, CALC. Low | GLOMERULAR FILTRATION RATE, CALC. High | Urea, Low | Urea, High | |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | NA | 3 | NA | 0 | 0 | NA | NA | 0 |
QTc (corrected QT) Fridericia, PR Interval, QRS Interval and Change from baseline in QTCF (NCT02265744)
Timeframe: Up to 42 days post last dose of short-term double-blind study medication or up to the day prior to the start of long-term extension period, whichever is earlier.
| Intervention | Participants (Count of Participants) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| QTC Fredericia (msec) <= 450 | QTC Fredericia (msec) 450< To <= 480 | QTC Fredericia (msec) 480 < to <= 500 | QTC Fredericia (msec) > 500 | PR Interval (msec) <= 200 | PR Interval (msec) > 200 | QRS Interval (msec) <= 120 | QRS Interval (msec) > 120 | Change from baseline in QTCF (msec) <= 30 | Change from baseline in QTCF (msec) 30 To <= 60 | Change from baseline in QTCF (msec) > 60 | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 56 | 11 | 0 | 3 | 66 | 4 | 67 | 3 | 55 | 2 | 3 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 58 | 8 | 1 | 1 | 68 | 0 | 67 | 1 | 59 | 7 | 2 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 56 | 12 | 0 | 1 | 69 | 0 | 68 | 1 | 66 | 2 | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 58 | 5 | 2 | 3 | 64 | 4 | 66 | 2 | 54 | 7 | 3 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 65 | 5 | 1 | 0 | 68 | 3 | 70 | 1 | 62 | 5 | 0 |
"SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.~An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).~An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)" (NCT02265744)
Timeframe: At Day 169
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| SRI (4) | SRI (5) | SRI (6) | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 44.3 | 31.4 | 31.4 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 48.5 | 29.4 | 26.5 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 55.1 | 37.7 | 37.7 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 39.7 | 27.9 | 27.9 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 49.3 | 33.8 | 33.8 |
"SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.~An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).~An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)" (NCT02265744)
Timeframe: At Day 85
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| SRI (4) | SRI (5) | SRI (6) | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 47.1 | 31.4 | 31.4 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 48.5 | 32.4 | 30.9 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 49.3 | 29.0 | 29.0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 41.2 | 25.0 | 25.0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 43.7 | 28.2 | 26.8 |
Immunogenicity defined as positive for anti-drug antibodies post-baseline measurement if baseline missing or negative. If baseline is positive, then immunogenicity is defined as a positive post-baseline measurement with titer value 4 times greater than baseline. (A) all subjects with a laboratory reported positive antibody responses to BMS-931699 during the short-term double-blind treatment period are included. Overall: At least one positive sample relative to baseline during short-term double-blind and follow-up period. (NCT02265744)
Timeframe: Day 169
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| % with Neutralizing activity | % with Neutralizing activity (Baseline) | % with Neutralizing activity (Overall) | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 34.1 | 0 | 34.1 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 41.2 | 5.9 | 35.3 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 23.1 | 0 | 23.1 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 64.7 | 0 | 64.7 |
SYSTOLIC BLOOD PRESSURE (SYSBP) (MMHG); SYSBP > 140 AND CHANGE FROM BASELINE > 20 OR SYSBP < 90 AND CHANGE FROM BASELINE < -20; DIASTOLIC BLOOD PRESSURE (DIABP) > 90 AND CHANGE FROM BASELINE > 10 OR DIABP < 55 AND CHANGE FROM BASELINE < -10; (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| SYSTOLIC BLOOD PRESSURE (MMHG) SITTING | SYSTOLIC BLOOD PRESSURE (MMHG) STANDING | SYSTOLIC BLOOD PRESSURE (MMHG) SUPINE | DIASTOLIC BLOOD PRESSURE (MM HG) SITTING | DIASTOLIC BLOOD PRESSURE (MM HG) STANDING | DIASTOLIC BLOOD PRESSURE (MM HG) SUPINE | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 10.0 | 11.4 | 0 | 17.1 | 21.4 | 0 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 11.6 | 14.5 | 0 | 26.1 | 18.8 | 0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 17.6 | 14.7 | 0 | 17.6 | 27.9 | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 10.3 | 8.8 | 1 | 11.8 | 25.0 | 0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 15.5 | 20.0 | 0 | 9.9 | 20.0 | 0 |
HEART RATE (HR) Beats per min (BPM): HR > 100 AND CHANGE FROM BASELINE > 30 OR HR < 55 AND CHANGE FROM BASELINE < -15 (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| HEART RATE (BPM) SITTING | HEART RATE (BPM) STANDING | HEART RATE (BPM) SUPINE | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 2.9 | 7.1 | 0 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 2.9 | 4.3 | 0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 5.9 | 5.9 | 0 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 2.9 | 7.4 | 0 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 5.6 | 5.7 | 0 |
Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169 (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | g/L (Mean) | |||||
|---|---|---|---|---|---|---|
| C3, Baseline | C3, Day 85 | C3, Day 169 | C4, Baseline | C4, Day 85 | C4, Day 169 | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 1.028 | 1.083 | 1.077 | 0.202 | 0.215 | 0.207 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 1.029 | 1.014 | 1.010 | 0.185 | 0.195 | 0.185 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 1.068 | 1.037 | 1.045 | 0.201 | 0.206 | 0.212 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 0.990 | 1.030 | 1.027 | 0.177 | 0.190 | 0.187 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 0.991 | 0.986 | 0.992 | 0.183 | 0.179 | 0.184 |
Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169. No anti-dsDNA data was available for this report (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Percentage (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline Negative Day 85 Negative | Baseline Negative Day 85 Positive | Baseline Positive Day 85 Negative | Baseline Positive Day 85 Positive | Baseline Negative Day 169 Negative | Baseline Negative Day 169 Positive | Baseline Positive Day 169 Negative | Baseline Positive Day 169 Positive | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 50.0 | 50.0 | 2.0 | 98.0 | 57.1 | 42.9 | 4.3 | 95.7 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 57.1 | 42.9 | 3.4 | 96.6 | 33.3 | 66.7 | 2.0 | 98.0 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 62.5 | 37.5 | 11.3 | 88.7 | 71.4 | 28.6 | 9.3 | 90.7 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 100.0 | 0 | 1.8 | 98.2 | 100.0 | 0 | 5.8 | 94.2 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 60.0 | 40.0 | 0 | 100.0 | 40.0 | 60.0 | 1.8 | 98.2 |
Percent CD4+ Receptor Occupancy and percent CD8+ Receptor Occupancy (NCT02265744)
Timeframe: At Day 85 and Day 169
| Intervention | Percentage (Mean) | |||||
|---|---|---|---|---|---|---|
| %CD4+ RO Baseline | %CD4+ RO Day 85 | %CD4+ RO Day 169 | %CD8+ RO Baseline | %CD8+ RO Day 85 | %CD8+ RO Day 169 | |
| Experimental: 1.25mg SCBMS-931699 Every Other Week | 0 | 37.155 | 44.115 | 0 | 32.516 | 40.989 |
| Experimental: 12.5mg SC BMS-931699 Every Other Week | 0 | 83.244 | 77.210 | 0 | 81.730 | 74.726 |
| Experimental: 12.5mg SC BMS-931699 Weekly | 0 | 95.722 | 92.390 | 0 | 95.831 | 92.043 |
| Experimental: 5mg SC Injection BMS-931699 Every Other Week | 0 | 70.520 | 74.286 | 0 | 68.960 | 69.850 |
| Placebo Comparator: 0mg SC Weekly BMS-931699 | 0 | 0.350 | 0.334 | 0 | 0.160 | 0.235 |
"British Isles Lupus Assessment Group (BILAG)-2004 index, it categorizes disease activity into 5 different levels from A to E, with Grade A representing very active disease and Grade E indicating no current or previous disease activity. Scoring was based on a total of 101 items, grouped into 9 organ/systems and the summation of the numerical values for the nine-system scores was given by the following formula: Numerical global score = A*12 + B*8 + C*1, where A, B and C represent the number of Grades A, B and C respectively at each assessment. Grades D and E are considered as 0 (Chee-Seng Yee et al, 2010). The minimum score is 0 with no predefined maximum. The higher scores mean a worse outcome.~The BILAG global score change from baseline to Last Available Value (LVA) week 24 and week 36 were presented analyzed." (NCT02665364)
Timeframe: Last Available Value (LVA) between week 24 and week 36
| Intervention | scores on a scale (Mean) |
|---|---|
| IFN-K | -11.43 |
| Placebo | -10.76 |
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) was specifically developed to assess the cutaneous manifestations of SLE. It measures both disease activity and permanent damage (e.g. dyspigmentation and scarring) over the entire body surface. CLASI total activity score ranges from 0 to 70, with higher scores indicating more severe skin disease. (NCT02665364)
Timeframe: Baseline and Week 36
| Intervention | scores on a scale (Mean) |
|---|---|
| IFN-K | -3.22 |
| Placebo | -2.85 |
mean daily dose of corticosteroid (CS) (prednisone equivalent) (NCT02665364)
Timeframe: At W36
| Intervention | mg/day (Mean) |
|---|---|
| IFN-K | 5.42 |
| Placebo | 7.06 |
"British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responder was defined as a subject who had the following criteria at week 36:~All BILAG A scores at baseline improve to B/C/D and all BILAG B scores improve to C/D at W36, and~No BILAG worsening in other body systems: no new BILAG A or ≥ 2 new BILAG B scores at W36, and~No worsening in SLEDAI-2K total score at W36 compared with baseline, and~No deterioration in Physician Global Assessment (PGA) (< 10% worsening) on Visual Analog Scale (VAS) 100 mm at W36 compared with baseline, and~No addition or increased dose level of anti-malarial drugs or immunosuppressive drugs or CS* between W24 and W36 (*≤5 mg prednisolone or equivalent /day at W24 and no increase until W36)." (NCT02665364)
Timeframe: At Week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 35 |
| Placebo | 29 |
Subjects who had the following criteria defined as : SRI-4 plus CS ≤5mg/day -excluding IFN-K subjects without positive anti-IFN-alpha neutralizing antibodies (NCT02665364)
Timeframe: At week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 40 |
| Placebo | 30 |
participant who had the following criteria defined as : SRI-4 plus CS ≤7.5mg/day -excluding IFN-K Patients without positive anti-IFN-alpha neutralizing antibodies (NCT02665364)
Timeframe: At week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 43 |
| Placebo | 33 |
"SRI-4 plus CS ≤ 5mg/day responder was defined as a participant who had the following criteria at Week 36:~reduction ≥4 points in SELENA-SLEDAI at week 36 compared with baseline, and~no new BILAG A at week 36, and~no more than 1 new BILAG B at week 36, and~no deterioration in PGA (<10% worsening) on 100-mm VAS compared with baseline plus corticosteroids (CS) ≤5mg equivalent prednisolone per day at week 36" (NCT02665364)
Timeframe: At Week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 43 |
| Placebo | 30 |
"SRI (4) plus CS ≤ 7.5 mg/day responder was defined as a participant who had the following criteria at week 36:~reduction ≥4 points in SELENA-SLEDAI at week 36 compared with baseline, and~no new BILAG A at week 36, and~no more than 1 new BILAG B at week 36, and~no deterioration in PGA (<10% worsening) on 100-mm VAS compared with baseline plus CS ≤7.5mg equivalent prednisolone per day at week 36" (NCT02665364)
Timeframe: At Week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 46 |
| Placebo | 33 |
"Lupus low disease activity state (LLDAS) was conceptually defined as 'a state which, if sustained, is associated with a low likelihood of adverse outcome, considering disease activity and medication safety'. Subsequently defined using consensus methodology, LLDAS is attained if all the following items are met:~SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity~No new features of lupus disease activity compared with the previous assessment~SELENA-SLEDAI physician global assessment (PGA, scale 0-3) ≤1~Current prednisolone (or equivalent) dose ≤7.5 mg daily~Well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs" (NCT02665364)
Timeframe: At Week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 45 |
| Placebo | 25 |
"SLE Responder Index (SRI); SRI-4 responder was defined as a subject who had the following criteria at week 36:~reduction ≥4 points in SELENA-SLEDAI at week 36 compared with baseline, and~no new BILAG A at week 36, and~no more than 1 new BILAG B at week 36, and~no deterioration in PGA (<10% worsening) on 100-mm VAS compared with baseline" (NCT02665364)
Timeframe: W36 (9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 57 |
| Placebo | 54 |
Individual serum antibody neutralizing capacity against recombinant IFN-alpha2b was measured by reporter gene assay using Interferon Sensitive Response Element (ISRE) reporter. (NCT02665364)
Timeframe: At week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 72 |
| Placebo | 0 |
Number of participants who reported any treatment-related adverse events until month 9 (NCT02665364)
Timeframe: 9 months
| Intervention | Participants (Count of Participants) |
|---|---|
| IFN-K | 75 |
| Placebo | 71 |
The biological endpoint aimed at evaluating the neutralization of the IFN gene signature following treatment with IFN-K compared to placebo, as measured by the % change from baseline of the expression of IFN-induced genes. (NCT02665364)
Timeframe: Baseline and Last Available Value (LVA) between week 24 and week 36
| Intervention | percent change (Mean) |
|---|---|
| IFN-K | -31.04 |
| Placebo | -0.44 |
Safety of Estrogens in Systemic Lupus Erythematosus National Assessment (SELENA)-SLEDAI, is a slightly modified version of the SLEDAI. This is a weighted index in which signs and symptoms, laboratory tests, and Physician's Global Assessment (PGA) for each of nine organ systems are given a weighted score and summed up if present at the time of the visit or in the preceding 10 days. The maximum theoretical score for the SELENA SLEDAI is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease. (NCT02665364)
Timeframe: Baseline and Week 36
| Intervention | SELENA SLEDAI Score (Mean) |
|---|---|
| IFN-K | -5.48 |
| Placebo | -5.54 |
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus (SLICC/ACR-DI) captures permanent changes which have occurred in patients with SLE, regardless of causality. The questionnaire contains 41 items covering 12 different organ systems. The score of items ranges from 1 to 3 and the total score from 0 to 47. By definition score 0 corresponds to diagnostics and damage over time can only be stable or increase, theoretically to a maximum of 47 points. (NCT02665364)
Timeframe: Baseline and Week 36
| Intervention | scores on a scale (Mean) |
|---|---|
| IFN-K | -0.09 |
| Placebo | -0.17 |
A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine). (NCT01205438)
Timeframe: Baseline, 52 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| LY2127399 Every 2 Weeks | -0.7 |
| LY2127399 Every 4 Weeks | -0.5 |
| Placebo | -0.5 |
PGA is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening defined as increase of ≤ 0.30 points from Baseline. (NCT01205438)
Timeframe: Baseline, 52 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| LY2127399 Every 2 Weeks | -21.2 |
| LY2127399 Every 4 Weeks | -19.2 |
| Placebo | -15.1 |
Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. (NCT01205438)
Timeframe: Baseline, 52 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| LY2127399 Every 2 Weeks | -5.1 |
| LY2127399 Every 4 Weeks | -4.8 |
| Placebo | -3.7 |
Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE. (NCT01205438)
Timeframe: Baseline, 52 weeks
| Intervention | International Units (IU) (Mean) |
|---|---|
| LY2127399 Every 2 Weeks | -27.7 |
| LY2127399 Every 4 Weeks | -26.4 |
| Placebo | -7.0 |
The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare. (NCT01205438)
Timeframe: Baseline through 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| LY2127399 Every 2 Weeks | 134 |
| LY2127399 Every 4 Weeks | 144 |
| Placebo | 160 |
A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit. (NCT01205438)
Timeframe: 52 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| LY2127399 Every 2 Weeks | 21.2 |
| LY2127399 Every 4 Weeks | 14.7 |
| Placebo | 11.5 |
"Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of < 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)~SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data." (NCT01205438)
Timeframe: 52 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| LY2127399 Every 2 Weeks | 38.7 |
| LY2127399 Every 4 Weeks | 34.8 |
| Placebo | 27.7 |
"Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of < 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.~SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data." (NCT01205438)
Timeframe: 52 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| LY2127399 Every 2 Weeks | 38.5 |
| LY2127399 Every 4 Weeks | 34.8 |
| Placebo | 27.7 |
An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit. (NCT01205438)
Timeframe: 52 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| LY2127399 Every 2 Weeks | 4.7 |
| LY2127399 Every 4 Weeks | 6.2 |
| Placebo | 5.9 |
Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100.No worsening defined as increase of ≤ 0.30 points from Baseline. (NCT01205438)
Timeframe: 52 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| LY2127399 Every 2 Weeks | 32.8 |
| LY2127399 Every 4 Weeks | 37.8 |
| Placebo | 42.8 |
SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. (NCT01205438)
Timeframe: Baseline, 52 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 52 Weeks | |
| LY2127399 Every 2 Weeks | 10.3 | -4.9 |
| LY2127399 Every 4 Weeks | 10.4 | -4.7 |
| Placebo | 9.8 | -3.6 |
The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL. (NCT01205438)
Timeframe: Baseline, 52 weeks
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Health | Emotional Health | Body Image | Pain | Planning | Fatigue | Intimate Relationships | Burden to Others | |
| LY2127399 Every 2 Weeks | 69.0 | 72.7 | 73.6 | 68.5 | 71.0 | 65.5 | 68.4 | 62.6 |
| LY2127399 Every 4 Weeks | 66.2 | 72.3 | 72.8 | 67.5 | 70.7 | 62.4 | 66.1 | 63.7 |
| Placebo | 70.7 | 74.0 | 73.1 | 71.4 | 73.2 | 69.3 | 72.4 | 69.2 |
Clinical remission was defined as clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. The duration of clinical remission (PI assessed) was the longest period between 2 visits that the participant was a clinical remission responder at all visits and was calculated as the first visit of clinical remission minus last visit of clinical remission plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Up to Week 104
| Intervention | Days (Median) |
|---|---|
| Belimumab + Placebo | 31.0 |
| Belimumab + Rituximab | 73.0 |
| Belimumab + Standard Therapy | 176.0 |
Duration of disease control was defined as SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day. The duration of disease control (PI assessed) was the longest period between 2 visits that the participant was a disease control responder at all visits and calculated as the first visit of disease control minus last visit of disease control plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity (NCT03312907)
Timeframe: Up to Week 104
| Intervention | Days (Median) |
|---|---|
| Belimumab + Placebo | 49.5 |
| Belimumab + Rituximab | 116.0 |
| Belimumab + Standard Therapy | 116.0 |
Percentage of participants with a state of CLR (PI assessed) at Week 104 was defined as percentage of participants with a clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores) achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day, sustained for at least 24 weeks(from Week 80 to Week 104). Sustained CLR is longest period a participant maintains CLR without a break, calculated as last consecutive CLR date minus first consecutive CLR date plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: From Week 80 to Week 104
| Intervention | Percentage of participants (Number) |
|---|---|
| Belimumab + Placebo | 2.8 |
| Belimumab + Rituximab | 2.1 |
| Belimumab + Standard Therapy | 4.3 |
Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-double stranded deoxyribonucleic [dsDNA] and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day at Week 64. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Week 64
| Intervention | Percentage of participants (Number) |
|---|---|
| Belimumab + Placebo | 5.6 |
| Belimumab + Rituximab | 6.3 |
| Belimumab + Standard Therapy | 10.6 |
Percentage of participants with a state of CR (Principal Investigator [PI] assessed) was defined as percentage of participants with a SLEDAI-2K=0 achieved without immunosuppressants and with corticosteroids at prednisone equivalent dose of 0 mg/day,sustained for at least 24 weeks. Sustained CR was longest period a participant maintains CR without break calculated as last consecutive CR date minus first consecutive CR date plus 1. SLEDAI-2K consisted of 24 individual items within each 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at time of visit or in preceding 10 days. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms),higher scores indicates increased disease activity. Percentage of participants with a state of CR sustained for at least 24 weeks at any visit during Week 52 to Week 104 were reported. (NCT03312907)
Timeframe: Week 52 to Week 104
| Intervention | Percentage of participants (Number) |
|---|---|
| Belimumab + Placebo | 2.8 |
| Belimumab + Rituximab | 0 |
| Belimumab + Standard Therapy | 6.4 |
Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day at Week 104. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Week 104
| Intervention | Percentage of participants (Number) |
|---|---|
| Belimumab + Placebo | 6.9 |
| Belimumab + Rituximab | 11.1 |
| Belimumab + Standard Therapy | 21.3 |
Percentage of participants with a state of disease control (Independent blinded assessor [IBA]) was defined as the percentage of participants with a Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K)score less than or equal to(<=)2 achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day at Week 52. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in previous 10 days,consisting 24 individual items in which signs and symptoms, laboratory tests and physician's assessment for each item within each of 9 organ systems were given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of visit or in preceding 10 days. The SLEDAI-2K score was sum of all 24 individual items from the SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Week 52
| Intervention | Percentage of participants (Number) |
|---|---|
| Belimumab + Placebo | 16.7 |
| Belimumab + Rituximab | 19.4 |
| Belimumab + Standard Therapy | 25.5 |
Clinical remission sustained for at least 24 weeks and maintained through Week 104 was defined as clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. Time to CLR (PI assessed) was defined as first visit of sustained CLR until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained CLR was longest period a participant maintained clinical remission without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Up to Week 104
| Intervention | Days (Median) |
|---|---|
| Belimumab + Placebo | NA |
| Belimumab + Rituximab | NA |
| Belimumab + Standard Therapy | NA |
Disease control sustained for at least 24 weeks and maintained through Week 104 was defined as SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day. Time to disease control (PI assessed) was defined as the first visit of sustained disease control until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained disease control was longest period a participant maintained disease control without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K , ranges from 0 (no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity. (NCT03312907)
Timeframe: Up to Week 104
| Intervention | Days (Median) |
|---|---|
| Belimumab + Placebo | NA |
| Belimumab + Rituximab | NA |
| Belimumab + Standard Therapy | NA |
Time to first SLE flare was the number of days from treatment start date until the participant met an event. Time to first flare was defined as event date minus treatment start date plus 1. Time to first flare was measured by modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare. (NCT03312907)
Timeframe: Up to Week 104
| Intervention | Days (Median) |
|---|---|
| Belimumab + Placebo | 168.0 |
| Belimumab + Rituximab | 170.0 |
| Belimumab + Standard Therapy | 168.0 |
Time to first severe SLE flare was the number of days from treatment start date until the participant met an event. Time to first severe flare was defined as event date minus treatment start date plus 1. Time to first severe flare was measured by Modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare. Analysis of first severe flare was performed on the modified SLE Flare index that excludes severe flares that were triggered only by an increase is SLEDAI-2K score to greater than 12. (NCT03312907)
Timeframe: Up to Week 104
| Intervention | Days (Median) |
|---|---|
| Belimumab + Placebo | 372.0 |
| Belimumab + Rituximab | 379.0 |
| Belimumab + Standard Therapy | 730.0 |
The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The higher score for the questions, the greater the fatigue. The total score was the sum of the responses from all questions (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104
| Intervention | Scores on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 8; n=66, 132, 44 | Week 12; n=66, 133, 44 | Week 26; n=61, 115, 40 | Week 40; n=63, 122, 43 | Week 52; n=64, 120, 41 | Week 64;n=62, 117, 36 | Week 72; n=59, 107, 33 | Week 104; n=55, 111, 36 | |
| Belimumab + Placebo | 4.2 | 4.7 | 3.1 | 6.0 | 6.5 | 4.9 | 5.6 | 5.7 |
| Belimumab + Rituximab | 4.6 | 4.0 | 5.4 | 5.2 | 6.1 | 6.2 | 5.2 | 7.1 |
| Belimumab + Standard Therapy | 4.8 | 3.8 | 4.1 | 5.2 | 5.1 | 4.6 | 2.9 | 3.1 |
LupusQoL is a SLE-specific health related qualify of life (HRQOL) instrument with 34 questions across 8 domains:Physical health(8 items),Pain(3 items),Planning(3 items),Intimate relationship(2 items),Burden to others(3 items),Emotional health(6 items),Body image(5 items),Fatigue(4 items). Questions were related to participants experience in prior 4 weeks.A 5-point Likert response format was used, ranging from 0(all of the time) to 4(never) for each question. Individual domain scores were reported which were calculated by taking sum of responses to all items within each domain. Individual domain scores range:Physical health(0-32),Pain(0-12),Planning(0-12),Intimate relationship(0-8),Burden to others(0-12),Emotional health(0-24),Body image(0-20),Fatigue(0-16). Higher score indicates better HRQOL. Baseline value was latest pre-dose assessment with a non-missing value including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104
| Intervention | Scores on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical health; Week 8; n=66, 132, 44 | Physical health; Week 12; n=66, 133, 44 | Physical health; Week 26; n=61, 115, 40 | Physical health; Week 40; n=63, 122, 43 | Physical health; Week 52; n=64, 120, 41 | Physical health; Week 64; n=62, 117, 36 | Physical health; Week 72; n=59, 107, 33 | Physical health; Week 104; n=55, 111, 36 | Pain; Week 8; n=66, 132, 44 | Pain; Week 12; n=66, 133, 44 | Pain; Week 26; n=61, 115, 40 | Pain; Week 40; n=63, 122, 43 | Pain; Week 52; n=64, 120, 41 | Pain; Week 64; n=62, 117, 36 | Pain; Week 72; n=59, 107, 33 | Pain; Week 104; n=55, 111, 36 | Planning; Week 8; n=66, 132, 44 | Planning; Week 12; n=66, 133, 44 | Planning; Week 26; n=61, 115, 40 | Planning; Week 40; n=63, 122, 43 | Planning; Week 52; n=64, 120, 41 | Planning; Week 64; n=62, 117, 36 | Planning; Week 72; n=59, 107, 33 | Planning; Week 104; n=55, 111, 36 | Intimate relationship; Week 8; n=51, 110, 36 | Intimate relationship; Week 12; n=52, 106, 36 | Intimate relationship; Week 26; n=48, 86, 30 | Intimate relationship; Week 40; n=50, 94, 30 | Intimate relationship; Week 52; n=51, 91, 30 | Intimate relationship; Week 64; n=47, 90, 25 | Intimate relationship; Week 72; n=42, 83, 21 | Intimate relationship; Week 104; n=40, 85,27 | Burden to others; Week 8; n=66, 132, 44 | Burden to others; Week 12; n=66, 133, 44 | Burden to others; Week 26; n=61, 115, 40 | Burden to others; Week 40; n=63, 122, 43 | Burden to others; Week 52; n=64, 120, 41 | Burden to others; Week 64; n=62, 117, 36 | Burden to others; Week 72; n=59, 107, 33 | Burden to others; Week 104; n=55, 111, 36 | Emotional health; Week 8; n=66, 132, 44 | Emotional health; Week 12; n=66, 133, 44 | Emotional health; Week 26; n=61,115, 40 | Emotional health; Week 40; n=63, 122, 43 | Emotional health; Week 52; n=64, 120, 41 | Emotional health; Week 64; n=62, 117, 36 | Emotional health; Week 72; n=59, 107, 33 | Emotional health; Week 104; n=55, 111, 36 | Body image; Week 8; n=60, 114, 37 | Body image; Week 12; n=58, 118, 39 | Body image; Week 26; n=56, 96, 33 | Body image; Week 40; n=54, 103, 35 | Body image; Week 52; n=55, 101, 33 | Body image; Week 64; n=52, 98, 27 | Body image; Week 72; n=44, 93, 25 | Body image; Week 104; n=48, 94, 28 | Fatigue; Week 8; n=66,132, 44 | Fatigue; Week 12; n=66, 133, 44 | Fatigue; Week 26; n=61, 115, 40 | Fatigue; Week 40; n=63, 122, 43 | Fatigue; Week 52; n=64, 120, 41 | Fatigue; Week 64; n=62, 117, 36 | Fatigue; Week 72; n=59, 107, 33 | Fatigue; Week 104; n=55, 111, 36 | |
| Belimumab + Placebo | 3.0 | 3.5 | 3.3 | 8.5 | 8.1 | 5.8 | 7.0 | 6.2 | 5.8 | 7.5 | 7.0 | 12.3 | 13.9 | 10.2 | 13.1 | 13.8 | 3.4 | 4.5 | 3.4 | 11.6 | 11.6 | 7.8 | 9.2 | 12.1 | -1.2 | -2.6 | -1.3 | 4.3 | 4.7 | -4.5 | 0.0 | -0.3 | 7.3 | 11.4 | 8.7 | 13.9 | 16.5 | 14.4 | 17.1 | 18.9 | 5.2 | 8.1 | 7.7 | 9.7 | 10.2 | 8.1 | 8.8 | 6.8 | 5.7 | 1.9 | 5.8 | 8.9 | 7.9 | 6.0 | 7.8 | 4.4 | 9.8 | 8.2 | 8.6 | 11.9 | 14.2 | 10.5 | 12.1 | 9.4 |
| Belimumab + Rituximab | 6.0 | 5.8 | 10.5 | 9.5 | 10.0 | 10.2 | 9.1 | 10.6 | 11.4 | 13.0 | 17.2 | 18.0 | 17.6 | 17.4 | 17.0 | 19.0 | 8.0 | 7.6 | 9.9 | 12.2 | 12.6 | 14.5 | 11.4 | 14.2 | 5.2 | 4.6 | 8.9 | 7.7 | 6.6 | 11.0 | 8.6 | 11.2 | 6.8 | 8.4 | 10.5 | 12.6 | 14.9 | 17.0 | 14.4 | 15.0 | 6.4 | 4.5 | 6.7 | 6.7 | 7.8 | 9.3 | 6.2 | 9.3 | 8.9 | 10.1 | 9.0 | 8.2 | 9.1 | 11.3 | 8.7 | 11.4 | 9.2 | 7.0 | 11.4 | 10.3 | 12.0 | 14.0 | 13.1 | 14.3 |
| Belimumab + Standard Therapy | 6.3 | 6.4 | 11.6 | 8.2 | 11.6 | 9.5 | 8.5 | 7.2 | 10.4 | 6.1 | 13.1 | 12.6 | 15.7 | 13.2 | 11.9 | 12.5 | 10.0 | 7.8 | 12.1 | 10.7 | 14.0 | 7.2 | 6.6 | 8.8 | 7.6 | 7.6 | 14.2 | 15.8 | 15.8 | 12.5 | 5.4 | 4.6 | 10.6 | 6.4 | 7.5 | 12.0 | 15.0 | 12.3 | 11.1 | 12.7 | 11.6 | 9.1 | 10.1 | 9.4 | 11.4 | 8.1 | 6.6 | 10.5 | 5.7 | 5.9 | 5.7 | 5.1 | 10.3 | 7.7 | 2.5 | 3.5 | 8.5 | 10.4 | 11.9 | 11.3 | 16.6 | 10.8 | 11.6 | 9.7 |
The Patient's Global Assessment (PtGA) of Disease Activity is a single-item, participant reported scale developed for the assessment of the participant's overall rating of their disease activity due to SLE. The scale measures disease activity ranging from 0 (Very Well) to 10 (Very Poor) and the higher score indicates severe disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104
| Intervention | Scores on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 8; n=66, 132, 44 | Week 12; n=66, 133, 44 | Week 26; n=61, 115, 40 | Week 40; n=63, 123, 43 | Week 52; n=64, 120, 41 | Week 64; n=62, 117, 36 | Week 72; n=59, 107, 33 | Week 104; n=55, 111, 36 | |
| Belimumab + Placebo | -0.96 | -0.69 | -0.95 | -1.77 | -1.74 | -1.41 | -1.46 | -1.61 |
| Belimumab + Rituximab | -1.06 | -1.07 | -1.50 | -1.60 | -1.82 | -1.96 | -1.81 | -2.00 |
| Belimumab + Standard Therapy | -0.91 | -1.57 | -1.57 | -1.67 | -1.84 | -1.96 | -1.43 | -1.98 |
The Physician's Global Assessment (PGA) was a physician-reported visual analogue scale that provides an overall measure of the participant's current disease activity. Physician's Global Assessment was collected on a 10 centimeter (cm) visual analogue scale (VAS) by placing a mark on the scale between 0 (no disease activity) to 10 (maximum disease activity). The PGA score was then rescaled for reporting by multiplying the collected score by 3 divided by 10. Hence, the PGA score ranges from 0 to 3 with higher scores indicating greater disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
| Intervention | Scores on a scale (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4; n=72, 142, 45 | Week 8; n=66, 135, 44 | Week 12; n=66, 137, 44 | Week 16; n=68, 132, 44 | Week 20; n=66, 130, 44 | Week 24; n=62, 130, 43 | Week 26; n=62, 120, 40 | Week 28; n=63, 127, 43 | Week 32; n=62, 124, 43 | Week 36; n=64, 126, 43 | Week 40; n=63, 126, 43 | Week 44; n=63, 124, 43 | Week 48; n=59, 121, 40 | Week 52; n=64, 122, 41 | Week 60; n=61, 120, 37 | Week 64; n=62, 120, 36 | Week 72; n=58, 110, 33 | Week 80; n=57, 112, 37 | Week 88; n=59, 109, 36 | Week 96; n=54, 109, 35 | Week 104; n=55, 114, 36 | |
| Belimumab + Placebo | -0.285 | -0.535 | -0.592 | -0.619 | -0.697 | -0.770 | -0.786 | -0.781 | -0.851 | -0.916 | -0.893 | -0.800 | -0.885 | -0.947 | -0.836 | -0.876 | -0.928 | -0.949 | -1.060 | -1.016 | -1.052 |
| Belimumab + Rituximab | -0.247 | -0.520 | -0.660 | -0.717 | -0.787 | -0.766 | -0.811 | -0.817 | -0.864 | -0.927 | -0.925 | -0.905 | -0.928 | -0.938 | -0.848 | -0.943 | -0.944 | -0.954 | -0.993 | -0.994 | -1.074 |
| Belimumab + Standard Therapy | -0.303 | -0.585 | -0.654 | -0.759 | -0.786 | -0.965 | -0.929 | -0.980 | -1.005 | -0.917 | -0.993 | -0.970 | -0.956 | -1.004 | -1.206 | -1.095 | -1.047 | -1.138 | -1.140 | -1.214 | -1.085 |
The SLEDAI-2K consisted of 24 individual items within 9 organ systems. Each item was given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in the preceding 10 days. Weighted scores for central nervous system (CNS) (7 items) was 8; for vascular (1 item) was 8; for Musculoskeletal (2 items) was 4; for Renal (4 items) was 4; for Mucocutaneous (3 items) was 2; for Cardiovascular and Respiratory (2 items) was 2; for Immunologic (2 items) was 2;for Constitutional (1 item) was 1 and for Hematologic (2 items) was 1. SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
| Intervention | Scores on a scale (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4; n=69, 137, 43 | Week 8; n=63, 132, 43 | Week 12; n=63, 131, 43 | Week 16; n=65, 129, 43 | Week 20; n=63, 127, 44 | Week 24; n=61, 128, 43 | Week 26; n=61, 118, 40 | Week 28; n=62, 125, 43 | Week 32; n=61, 125, 43 | Week 36; n=61, 125, 43 | Week 40; n=62, 125, 43 | Week 44; n=62, 122, 43 | Week 48; n=59, 122, 40 | Week 52; n=62, 119, 39 | Week 60; n=57, 114, 37 | Week 64; n=60, 117, 36 | Week 72; n=49, 103, 30 | Week 80; n=46, 102, 36 | Week 88; n=49, 101, 34 | Week 96; n=49, 100, 34 | Week 104; n=50, 104, 34 | |
| Belimumab + Placebo | -1.4 | -3.2 | -2.8 | -3.4 | -3.8 | -4.0 | -4.1 | -3.7 | -4.7 | -5.0 | -4.6 | -4.7 | -4.5 | -5.3 | -5.0 | -5.1 | -5.2 | -5.4 | -5.3 | -5.6 | -5.1 |
| Belimumab + Rituximab | -0.8 | -2.9 | -3.6 | -4.4 | -5.0 | -5.0 | -5.4 | -5.1 | -5.7 | -5.6 | -5.8 | -6.1 | -6.2 | -6.1 | -5.8 | -6.2 | -6.6 | -6.5 | -6.5 | -7.0 | -7.2 |
| Belimumab + Standard Therapy | -1.3 | -2.9 | -2.9 | -4.1 | -3.8 | -5.0 | -5.0 | -5.2 | -5.3 | -5.0 | -5.0 | -5.2 | -5.3 | -5.6 | -6.0 | -5.5 | -5.3 | -6.0 | -6.1 | -6.1 | -6.3 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AESIs were Malignant Neoplasms, Post-Injection Systemic Reactions (PISR), All Infections of Special Interest (Opportunistic Infections (OI), Herpes Zoster (HZ), Tuberculosis (TB), and Sepsis), Depression (including mood disorders and anxiety)/suicide/self-injury and Deaths. Data for number of participants with AESIs has been summarized. (NCT03312907)
Timeframe: Up to Week 104
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Malignant Neoplasms | PISR | All Infections of Special Interest | Depression/suicide/self-injury | Deaths | |
| Belimumab + Placebo | 1 | 7 | 5 | 9 | 1 |
| Belimumab + Rituximab | 1 | 19 | 12 | 16 | 2 |
| Belimumab + Standard Therapy | 1 | 4 | 5 | 5 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situations as per medical or scientific judgment. Data for number of participants with SAE and non-SAE (>=5 %) has been summarized. (NCT03312907)
Timeframe: Up to Week 111 (including 8 weeks of safety follow-up)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| SAE | non-SAE | |
| Belimumab + Placebo | 10 | 48 |
| Belimumab + Rituximab | 32 | 109 |
| Belimumab + Standard Therapy | 15 | 53 |
Lupus low disease activity state (LLDAS) was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety. The LLDAS response criteria were: (1) SLEDAI-2K <=4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity; (2) no new features of lupus disease activity compared with the previous assessment; (3) PGA (scale 0-3), <=1; (4) current prednisolone (or equivalent) dose <=7.5 mg daily; and (5) well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. Percentage of participants that met the LLDAS response criteria were reported. (NCT03312907)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96 and 104
| Intervention | Percentage of participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 26 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Week 60 | Week 64 | Week 72 | Week 80 | Week 88 | Week 96 | Week 104 | |
| Belimumab + Placebo | 0 | 9.7 | 8.3 | 11.1 | 11.1 | 12.5 | 22.2 | 20.8 | 29.2 | 30.6 | 22.2 | 30.6 | 26.4 | 27.8 | 26.4 | 20.8 | 22.2 | 18.1 | 23.6 | 20.8 | 20.8 |
| Belimumab + Rituximab | 2.1 | 1.4 | 9.7 | 16.7 | 25.7 | 22.2 | 25.7 | 25.0 | 31.9 | 34.0 | 33.3 | 37.5 | 37.5 | 34.0 | 23.6 | 30.6 | 31.3 | 26.4 | 24.3 | 30.6 | 32.6 |
| Belimumab + Standard Therapy | 2.1 | 10.6 | 6.4 | 19.1 | 19.1 | 36.2 | 34.0 | 34.0 | 36.2 | 29.8 | 38.3 | 31.9 | 31.9 | 29.8 | 36.2 | 31.9 | 31.9 | 34.0 | 29.8 | 36.2 | 38.3 |
Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity (NCT03312907)
Timeframe: Weeks 64, 80 and 104
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Week 64 | Week 80 | Week 104 | |
| Belimumab + Placebo | 5.6 | 4.2 | 1.4 |
| Belimumab + Rituximab | 6.3 | 4.2 | 4.2 |
| Belimumab + Standard Therapy | 10.6 | 12.8 | 6.4 |
Percentage of participants with a state of clinical remission was defined as the percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants (which was allowed in Belimumab+ Standard therapy arm only) and with corticosteroids at a prednisone equivalent dose of 0 mg/day using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. Percentage of participants with a state of clinical remission using the PI assessment of SLEDAI-2K were summarized. (NCT03312907)
Timeframe: Weeks 60, 64, 72, 80, 88, 96 and 104
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 60 | Week 64 | Week 72 | Week 80 | Week 88 | Week 96 | Week 104 | |
| Belimumab + Placebo | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 | 4.2 | 2.8 |
| Belimumab + Rituximab | 3.5 | 5.6 | 3.5 | 4.2 | 2.1 | 4.2 | 3.5 |
| Belimumab + Standard Therapy | 10.6 | 10.6 | 14.9 | 14.9 | 14.9 | 12.8 | 6.4 |
Percentage of participants with a state of complete remission (PI assessed) was defined as the percentage of participants with a SLEDAI-2K score =0, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in the previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within for each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Weeks 60, 64, 72, 80, 88, 96 and 104
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 60 | Week 64 | Week 72 | Week 80 | Week 88 | Week 96 | Week 104 | |
| Belimumab + Placebo | 5.6 | 5.6 | 4.2 | 2.8 | 2.8 | 1.4 | 1.4 |
| Belimumab + Rituximab | 0.7 | 0.7 | 0.7 | 1.4 | 0 | 0.7 | 0.7 |
| Belimumab + Standard Therapy | 6.4 | 6.4 | 6.4 | 8.5 | 4.3 | 6.4 | 4.3 |
Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Weeks 12, 26, 40, 52, 64, 80 and 104
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 12 | Week 26 | Week 40 | Week 52 | Week 64 | Week 80 | Week 104 | |
| Belimumab + Placebo | 8.3 | 16.7 | 13.9 | 16.7 | 11.1 | 6.9 | 6.9 |
| Belimumab + Rituximab | 12.5 | 21.5 | 20.8 | 19.4 | 18.1 | 13.2 | 11.1 |
| Belimumab + Standard Therapy | 21.3 | 25.5 | 23.4 | 25.5 | 25.5 | 27.7 | 21.3 |
Percentage of participants with a state of disease control was defined as the percentage of participants with a SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day, using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0 (no symptoms) to 105 (presence of all defined symptoms), higher scores representing increased disease activity. Percentage of participants with a state of disease control using the PI assessment of SLEDAI-2K were summarized. (NCT03312907)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
| Intervention | Percentage of participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 26 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Week 60 | Week 64 | Week 72 | Week 80 | Week 88 | Week 96 | Week 104 | |
| Belimumab + Placebo | 2.8 | 13.9 | 11.1 | 15.3 | 13.9 | 18.1 | 15.3 | 11.1 | 15.3 | 19.4 | 16.7 | 18.1 | 18.1 | 19.4 | 18.1 | 11.1 | 9.7 | 8.3 | 11.1 | 8.3 | 8.3 |
| Belimumab + Rituximab | 3.5 | 9.0 | 12.5 | 22.2 | 24.3 | 25.0 | 25.7 | 25.7 | 28.5 | 27.8 | 24.3 | 26.4 | 26.4 | 20.1 | 20.8 | 18.1 | 12.5 | 13.2 | 9.7 | 12.5 | 11.8 |
| Belimumab + Standard Therapy | 8.5 | 21.3 | 19.1 | 29.8 | 31.9 | 34.0 | 25.5 | 36.2 | 31.9 | 27.7 | 23.4 | 27.7 | 27.7 | 27.7 | 23.4 | 27.7 | 23.4 | 31.9 | 21.3 | 31.9 | 23.4 |
The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions, the greater the fatigue. The total score was the sum of the responses (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. A participant was considered to had an improvement exceeding the minimal clinically important difference if they had >=4 points improvement in their FACIT-Fatigue Scale score from Baseline. Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the MCID (>=4 points) were summarized. (NCT03312907)
Timeframe: Weeks 8, 12, 26, 40, 52, 64, 72 and 104
| Intervention | Percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 8; n=66, 132, 44 | Week 12; n=66, 133, 44 | Week 26; n=61, 115, 40 | Week 40; n=63, 122, 43 | Week 52; n=64, 120, 41 | Week 64; n=62, 117, 36 | Week 72; n=59, 107, 33 | Week 104; n=55, 111, 36 | |
| Belimumab + Placebo | 47.0 | 56.1 | 47.5 | 54.0 | 60.9 | 51.6 | 57.6 | 56.4 |
| Belimumab + Rituximab | 51.5 | 50.4 | 56.5 | 54.1 | 58.3 | 59.8 | 57.0 | 62.2 |
| Belimumab + Standard Therapy | 59.1 | 52.3 | 45.0 | 53.5 | 56.1 | 52.8 | 42.4 | 44.4 |
SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. An improvement was defined as a decrease(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data for following organ systems was reported: CNS total, Vascular total, Musculoskeletal total, Renal total, Mucocutaneous total, Cardiovascular (Cardio) and Respiratory (Resp) total, Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNS Total; Week 4; n= 2,3,2 | CNS Total; Week 8; n= 2,3,2 | CNS Total; Week 12; n= 2,3,2 | CNS Total; Week 16; n= 2,3,2 | CNS Total; Week 20; n= 2,3,2 | CNS Total; Week 24; n= 2,3,2 | CNS Total; Week 26; n= 2,3,2 | CNS Total; Week 28; n= 2,3,2 | CNS Total; Week 32; n= 2,3,2 | CNS Total; Week 36; n= 2,3,2 | CNS Total; Week 40; n= 2,3,2 | CNS Total; Week 44; n= 2,3,2 | CNS Total; Week 48; n= 2,3,2 | CNS Total; Week 52; n= 2,3,2 | CNS Total; Week 60; n= 2,3,2 | CNS Total; Week 64; n= 2,3,2 | CNS Total; Week 72; n= 2,3,2 | CNS Total; Week 80; n= 2,3,2 | CNS Total; Week 88; n= 2,3,2 | CNS Total; Week 96; n= 2,3,2 | CNS Total; Week 104; n=2,3,2 | Musculoskeletal Total; Week 4; n= 57, 110, 34 | Musculoskeletal Total; Week 8; n=57,110, 34 | Musculoskeletal Total; Week 12; n= 57,110,34 | Musculoskeletal Total; Week 16; n= 57,110,34 | Musculoskeletal Total; Week 20; n= 57,110,34 | Musculoskeletal Total; Week 24; n= 57,110,34 | Musculoskeletal Total;; Week 26; n=57,110,34 | Musculoskeletal Total; Week 28; n= 57,110,34 | Musculoskeletal Total; Week 32; n= 57,110,34 | Musculoskeletal Total; Week 36; n= 57,110,34 | Musculoskeletal Total; Week 40; n= 57,110,34 | Musculoskeletal Total; Week 44; n= 57,110,34 | Musculoskeletal Total; Week 48; n= 57,110,34 | Musculoskeletal Total; Week 52; n= 57,110,34 | Musculoskeletal Total; Week 60; n= 57,110,34 | Musculoskeletal Total; Week 64; n= 57,110,34 | Musculoskeletal Total; Week 72; n= 57,110,34 | Musculoskeletal Total; Week 80; n= 57,110,34 | Musculoskeletal Total; Week 88; n= 57,110,34 | Musculoskeletal Total; Week 96; n= 57,110,34 | Musculoskeletal Total; Week 104; n= 57,110,34 | Renal Total; Week 4; n= 14,23,8 | Renal Total; Week 8; n= 14, 23, 8 | Renal Total; Week 12; n= 14, 23, 8 | Renal Total; Week 16; n= 14, 23, 8 | Renal Total; Week 20; n= 14, 23, 8 | Renal Total; Week 24; n= 14, 23, 8 | Renal Total; Week 26; n= 14, 23, 8 | Renal Total; Week 28; n= 14, 23, 8 | Renal Total; Week 32; n= 14, 23, 8 | Renal Total; Week 36; n= 14, 23, 8 | Renal Total; Week 40; n=14, 23, 8 | Renal Total; Week 44; n= 14, 23, 8 | Renal Total; Week 48; n=14, 23, 8 | Renal Total; Week 52; n= 14, 23, 8 | Renal Total; Week 60; n= 14, 23, 8 | Renal Total; Week 64; n= 14, 23, 8 | Renal Total; Week 72; n= 14, 23, 8 | Renal Total; Week 80; n= 14, 23, 8 | Renal Total; Week 88; n= 14, 23, 8 | Renal Total; Week 96; n= 14, 23, 8 | Renal Total; Week 104; n= 14, 23, 8 | Mucocutaneous Total; Week 4; n= 59, 126,43 | Mucocutaneous Total; Week 8; n= 59,126,43 | Mucocutaneous Total; Week 12; n= 59, 126, 43 | Mucocutaneous Total; Week 16; n= 59, 126, 43 | Mucocutaneous Total; Week 20; n= 59, 126, 43 | Mucocutaneous Total; Week 24; n= 59, 126, 43 | Mucocutaneous Total; Week 26; n=59, 126, 43 | Mucocutaneous Total; Week 28; n= 59, 126, 43 | Mucocutaneous Total; Week 32; n= 59, 126, 43 | Mucocutaneous Total; Week 36; n= 59, 126, 43 | Mucocutaneous Total; Week 40; n= 59, 126, 43 | Mucocutaneous Total; Week 44; n= 59, 126, 43 | Mucocutaneous Total; Week 48; n= 59, 126, 43 | Mucocutaneous Total; Week 52; n=59, 126, 43 | Mucocutaneous Total; Week 60; n=59, 126, 43 | Mucocutaneous Total; Week 64; n=59, 126, 43 | Mucocutaneous Total; Week 72; n=59, 126, 43 | Mucocutaneous Total; Week 80; n= 59, 126, 43 | Mucocutaneous Total; Week 88; n= 59, 126, 43 | Mucocutaneous Total; Week 96; n= 59, 126, 43 | Mucocutaneous Total; Week 104; n= 59, 126, 43 | Immunologic Total; Week 4; n=48, 104, 34 | Immunologic Total; Week 8; n= 48, 104, 34 | Immunologic Total; Week 12; n= 48, 104, 34 | Immunologic Total; Week 16; n= 48, 104, 34 | Immunologic Total; Week 20; n= 48, 104, 34 | Immunologic Total; Week 24; n= 48, 104, 34 | Immunologic Total; Week 26; n= 48, 104, 34 | Immunologic Total; Week 28; n= 48, 104, 34 | Immunologic Total; Week 32; n= 48, 104, 34 | Immunologic Total; Week 36; n= 48, 104, 34 | Immunologic Total; Week 40; n= 48, 104, 34 | Immunologic Total; Week 44; n= 48, 104, 34 | Immunologic Total; Week 48; n= 48, 104, 34 | Immunologic Total; Week 52; n= 48, 104, 34 | Immunologic Total; Week 60; n= 48, 104, 34 | Immunologic Total; Week 64; n= 48, 104, 34 | Immunologic Total; Week 72; n=48, 104, 34 | Immunologic Total; Week 80; n=48, 104, 34 | Immunologic Total; Week 88; n=48, 104, 34 | Immunologic Total; Week 96; n=48, 104, 34 | Immunologic Total; Week 104; n=48, 104, 34 | Hematologic Total; Week 4; n= 8, 19, 3 | Hematologic Total; Week 8; n= 8, 19, 3 | Hematologic Total; Week 12; n= 8, 19, 3 | Hematologic Total; Week 16; n= 8, 19, 3 | Hematologic Total; Week 20; n= 8, 19, 3 | Hematologic Total; Week 24; n= 8, 19, 3 | Hematologic Total; Week 26; n= 8, 19, 3 | Hematologic Total; Week 28; n= 8, 19, 3 | Hematologic Total; Week 32; n= 8, 19, 3 | Hematologic Total; Week 36; n= 8, 19, 3 | Hematologic Total; Week 40; n= 8, 19, 3 | Hematologic Total; Week 44; n= 8, 19, 3 | Hematologic Total; Week 48; n= 8, 19, 3 | Hematologic Total; Week 52; n= 8, 19, 3 | Hematologic Total; Week 60; n= 8, 19, 3 | Hematologic Total; Week 64; n= 8, 19, 3 | Hematologic Total; Week 72; n= 8, 19, 3 | Hematologic Total; Week 80; n= 8, 19, 3 | Hematologic Total; Week 88; n= 8, 19, 3 | Hematologic Total; Week 96; n= 8, 19, 3 | Hematologic Total; Week 104; n= 8, 19, 3 | |
| Belimumab + Standard Therapy | 0 | 0 | 50.0 | 0 | 0 | 100 | 0 | 100 | 100 | 50.0 | 100 | 100 | 50.0 | 100 | 100 | 100 | 50.0 | 50.0 | 100 | 100 | 100 | 23.5 | 50.0 | 47.1 | 67.6 | 64.7 | 70.6 | 73.5 | 76.5 | 76.5 | 76.5 | 73.5 | 76.5 | 73.5 | 73.5 | 67.6 | 67.6 | 58.8 | 76.5 | 67.6 | 70.6 | 67.6 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 25.0 | 37.5 | 25.0 | 50.0 | 25.0 | 12.5 | 50.0 | 25.0 | 25.0 | 12.5 | 12.5 | 50.0 | 25.0 | 37.5 | 50.0 | 32.6 | 51.2 | 55.8 | 67.4 | 69.8 | 69.8 | 65.1 | 69.8 | 74.4 | 69.8 | 67.4 | 69.8 | 69.8 | 69.8 | 67.4 | 62.8 | 58.1 | 62.8 | 67.4 | 62.7 | 60.5 | 17.6 | 17.6 | 17.6 | 11.8 | 23.5 | 20.6 | 11.8 | 20.6 | 23.5 | 17.6 | 23.5 | 38.2 | 29.4 | 26.5 | 20.6 | 26.5 | 17.6 | 23.5 | 14.7 | 20.6 | 20.6 | 0 | 66.7 | 33.3 | 66.7 | 100 | 100 | 100 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 33.3 | 33.3 | 33.3 | 0 | 33.3 | 33.3 | 33.3 | 33.3 |
SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. An improvement was defined as a decrease(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data for following organ systems was reported: CNS total, Vascular total, Musculoskeletal total, Renal total, Mucocutaneous total, Cardiovascular (Cardio) and Respiratory (Resp) total, Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNS Total; Week 4; n= 2,3,2 | CNS Total; Week 8; n= 2,3,2 | CNS Total; Week 12; n= 2,3,2 | CNS Total; Week 16; n= 2,3,2 | CNS Total; Week 20; n= 2,3,2 | CNS Total; Week 24; n= 2,3,2 | CNS Total; Week 26; n= 2,3,2 | CNS Total; Week 28; n= 2,3,2 | CNS Total; Week 32; n= 2,3,2 | CNS Total; Week 36; n= 2,3,2 | CNS Total; Week 40; n= 2,3,2 | CNS Total; Week 44; n= 2,3,2 | CNS Total; Week 48; n= 2,3,2 | CNS Total; Week 52; n= 2,3,2 | CNS Total; Week 60; n= 2,3,2 | CNS Total; Week 64; n= 2,3,2 | CNS Total; Week 72; n= 2,3,2 | CNS Total; Week 80; n= 2,3,2 | CNS Total; Week 88; n= 2,3,2 | CNS Total; Week 96; n= 2,3,2 | CNS Total; Week 104; n=2,3,2 | Vascular Total; Week 4; n= 6,11,0 | Vascular Total; Week 8; n= 6,11,0 | Vascular Total; Week 12; n= 6,11,0 | Vascular Total; Week 16; n= 6,11,0 | Vascular Total; Week 20; n=6,11,0 | Vascular Total; Week 24; n= 6,11,0 | Vascular Total; Week 26; n= 6, 11, 0 | Vascular Total; Week 28; n= 6, 11,0 | Vascular Total; Week 32; n= 6,11, 0 | Vascular Total; Week 36; n= 6, 11,0 | Vascular Total; Week 40; n= 6, 11,0 | Vascular Total; Week 44; n= 6, 11, 0 | Vascular Total; Week 48; n= 6, 11, 0 | Vascular Total; Week 52; n= 6, 11, 0 | Vascular Total; Week 60; n= 6, 11, 0 | Vascular Total; Week 64; n= 6, 11, 0 | Vascular Total; Week 72; n= 6, 11, 0 | Vascular Total; Week 80; n= 6, 11, 0 | Vascular Total; Week 88; n= 6, 11, 0 | Vascular Total; Week 96; n= 6, 11, 0 | Vascular Total; Week 104; n= 6, 11, 0 | Musculoskeletal Total; Week 4; n= 57, 110, 34 | Musculoskeletal Total; Week 8; n=57,110, 34 | Musculoskeletal Total; Week 12; n= 57,110,34 | Musculoskeletal Total; Week 16; n= 57,110,34 | Musculoskeletal Total; Week 20; n= 57,110,34 | Musculoskeletal Total; Week 24; n= 57,110,34 | Musculoskeletal Total;; Week 26; n=57,110,34 | Musculoskeletal Total; Week 28; n= 57,110,34 | Musculoskeletal Total; Week 32; n= 57,110,34 | Musculoskeletal Total; Week 36; n= 57,110,34 | Musculoskeletal Total; Week 40; n= 57,110,34 | Musculoskeletal Total; Week 44; n= 57,110,34 | Musculoskeletal Total; Week 48; n= 57,110,34 | Musculoskeletal Total; Week 52; n= 57,110,34 | Musculoskeletal Total; Week 60; n= 57,110,34 | Musculoskeletal Total; Week 64; n= 57,110,34 | Musculoskeletal Total; Week 72; n= 57,110,34 | Musculoskeletal Total; Week 80; n= 57,110,34 | Musculoskeletal Total; Week 88; n= 57,110,34 | Musculoskeletal Total; Week 96; n= 57,110,34 | Musculoskeletal Total; Week 104; n= 57,110,34 | Renal Total; Week 4; n= 14,23,8 | Renal Total; Week 8; n= 14, 23, 8 | Renal Total; Week 12; n= 14, 23, 8 | Renal Total; Week 16; n= 14, 23, 8 | Renal Total; Week 20; n= 14, 23, 8 | Renal Total; Week 24; n= 14, 23, 8 | Renal Total; Week 26; n= 14, 23, 8 | Renal Total; Week 28; n= 14, 23, 8 | Renal Total; Week 32; n= 14, 23, 8 | Renal Total; Week 36; n= 14, 23, 8 | Renal Total; Week 40; n=14, 23, 8 | Renal Total; Week 44; n= 14, 23, 8 | Renal Total; Week 48; n=14, 23, 8 | Renal Total; Week 52; n= 14, 23, 8 | Renal Total; Week 60; n= 14, 23, 8 | Renal Total; Week 64; n= 14, 23, 8 | Renal Total; Week 72; n= 14, 23, 8 | Renal Total; Week 80; n= 14, 23, 8 | Renal Total; Week 88; n= 14, 23, 8 | Renal Total; Week 96; n= 14, 23, 8 | Renal Total; Week 104; n= 14, 23, 8 | Mucocutaneous Total; Week 4; n= 59, 126,43 | Mucocutaneous Total; Week 8; n= 59,126,43 | Mucocutaneous Total; Week 12; n= 59, 126, 43 | Mucocutaneous Total; Week 16; n= 59, 126, 43 | Mucocutaneous Total; Week 20; n= 59, 126, 43 | Mucocutaneous Total; Week 24; n= 59, 126, 43 | Mucocutaneous Total; Week 26; n=59, 126, 43 | Mucocutaneous Total; Week 28; n= 59, 126, 43 | Mucocutaneous Total; Week 32; n= 59, 126, 43 | Mucocutaneous Total; Week 36; n= 59, 126, 43 | Mucocutaneous Total; Week 40; n= 59, 126, 43 | Mucocutaneous Total; Week 44; n= 59, 126, 43 | Mucocutaneous Total; Week 48; n= 59, 126, 43 | Mucocutaneous Total; Week 52; n=59, 126, 43 | Mucocutaneous Total; Week 60; n=59, 126, 43 | Mucocutaneous Total; Week 64; n=59, 126, 43 | Mucocutaneous Total; Week 72; n=59, 126, 43 | Mucocutaneous Total; Week 80; n= 59, 126, 43 | Mucocutaneous Total; Week 88; n= 59, 126, 43 | Mucocutaneous Total; Week 96; n= 59, 126, 43 | Mucocutaneous Total; Week 104; n= 59, 126, 43 | Cardio and Resp Total; Week 4; n= 3, 7, 0 | Cardio and Resp Total; Week 8; n= 3, 7, 0 | Cardio and Resp Total; Week 12; n= 3, 7, 0 | Cardio and Resp Total; Week 16; n= 3, 7, 0 | Cardio and Resp Total; Week 20; n= 3,7, 0 | Cardio and Resp Total; Week 24; n= 3, 7, 0 | Cardio and Resp Total; Week 26; n=3, 7, 0 | Cardio and Resp Total; Week 28; n= 3,7, 0 | Cardio and Resp Total; Week 32; n= 3, 7, 0 | Cardio and Resp Total; Week 36; n= 3, 7, 0 | Cardio and Resp Total; Week 40; n=3,7, 0 | Cardio and Resp Total; Week 44; n= 3,7, 0 | Cardio and Resp Total; Week 48; n= 3, 7, 0 | Cardio and Resp Total; Week 52; n= 3, 7, 0 | Cardio and Resp Total; Week 60; n= 3,7,0 | Cardio and Resp Total; Week 64; n=3,7,0 | Cardio and Resp Total; Week 72; n= 3,7,0 | Cardio and Resp Total; Week 80; n=3,7,0 | Cardio and Resp Total; Week 88; n= 3,7,0 | Cardio and Resp Total; Week 96; n= 3,7,0 | Cardio and Resp Total; Week 104; n= 3,7,0 | Immunologic Total; Week 4; n=48, 104, 34 | Immunologic Total; Week 8; n= 48, 104, 34 | Immunologic Total; Week 12; n= 48, 104, 34 | Immunologic Total; Week 16; n= 48, 104, 34 | Immunologic Total; Week 20; n= 48, 104, 34 | Immunologic Total; Week 24; n= 48, 104, 34 | Immunologic Total; Week 26; n= 48, 104, 34 | Immunologic Total; Week 28; n= 48, 104, 34 | Immunologic Total; Week 32; n= 48, 104, 34 | Immunologic Total; Week 36; n= 48, 104, 34 | Immunologic Total; Week 40; n= 48, 104, 34 | Immunologic Total; Week 44; n= 48, 104, 34 | Immunologic Total; Week 48; n= 48, 104, 34 | Immunologic Total; Week 52; n= 48, 104, 34 | Immunologic Total; Week 60; n= 48, 104, 34 | Immunologic Total; Week 64; n= 48, 104, 34 | Immunologic Total; Week 72; n=48, 104, 34 | Immunologic Total; Week 80; n=48, 104, 34 | Immunologic Total; Week 88; n=48, 104, 34 | Immunologic Total; Week 96; n=48, 104, 34 | Immunologic Total; Week 104; n=48, 104, 34 | Hematologic Total; Week 4; n= 8, 19, 3 | Hematologic Total; Week 8; n= 8, 19, 3 | Hematologic Total; Week 12; n= 8, 19, 3 | Hematologic Total; Week 16; n= 8, 19, 3 | Hematologic Total; Week 20; n= 8, 19, 3 | Hematologic Total; Week 24; n= 8, 19, 3 | Hematologic Total; Week 26; n= 8, 19, 3 | Hematologic Total; Week 28; n= 8, 19, 3 | Hematologic Total; Week 32; n= 8, 19, 3 | Hematologic Total; Week 36; n= 8, 19, 3 | Hematologic Total; Week 40; n= 8, 19, 3 | Hematologic Total; Week 44; n= 8, 19, 3 | Hematologic Total; Week 48; n= 8, 19, 3 | Hematologic Total; Week 52; n= 8, 19, 3 | Hematologic Total; Week 60; n= 8, 19, 3 | Hematologic Total; Week 64; n= 8, 19, 3 | Hematologic Total; Week 72; n= 8, 19, 3 | Hematologic Total; Week 80; n= 8, 19, 3 | Hematologic Total; Week 88; n= 8, 19, 3 | Hematologic Total; Week 96; n= 8, 19, 3 | Hematologic Total; Week 104; n= 8, 19, 3 | |
| Belimumab + Placebo | 0 | 50.0 | 50.0 | 50.0 | 100 | 100 | 50.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 50.0 | 33.3 | 50.0 | 50.0 | 50.0 | 50.0 | 50.0 | 33.3 | 50.0 | 50.0 | 33.3 | 33.3 | 33.3 | 66.7 | 50.0 | 50.0 | 33.3 | 50.0 | 50.0 | 50.0 | 33.3 | 22.8 | 40.4 | 36.8 | 42.1 | 47.4 | 42.1 | 43.9 | 49.1 | 54.4 | 61.4 | 54.4 | 50.9 | 57.9 | 59.6 | 54.4 | 56.1 | 47.4 | 47.4 | 57.9 | 50.9 | 47.4 | 21.4 | 50.0 | 28.6 | 35.7 | 57.1 | 35.7 | 28.6 | 21.4 | 35.7 | 42.9 | 42.9 | 50.0 | 42.9 | 64.3 | 50.0 | 50.0 | 50.0 | 42.9 | 50.0 | 35.7 | 35.7 | 30.5 | 54.2 | 55.9 | 57.6 | 50.8 | 59.3 | 59.3 | 62.7 | 62.7 | 66.1 | 62.7 | 61.0 | 50.8 | 64.4 | 55.9 | 64.4 | 57.6 | 62.7 | 59.3 | 52.5 | 61.0 | 0 | 0 | 0 | 0 | 33.3 | 66.7 | 0 | 0 | 33.3 | 66.7 | 33.3 | 66.7 | 33.3 | 66.7 | 100 | 100 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 12.5 | 16.7 | 22.9 | 20.8 | 20.8 | 22.9 | 18.8 | 18.8 | 25.0 | 20.8 | 14.6 | 25.0 | 20.8 | 20.8 | 25.0 | 20.8 | 29.2 | 22.9 | 31.3 | 20.8 | 27.1 | 50.0 | 62.5 | 62.5 | 75.0 | 87.5 | 62.5 | 75.0 | 62.5 | 62.5 | 87.5 | 62.5 | 87.5 | 37.5 | 75.0 | 50.0 | 62.5 | 62.5 | 50.0 | 37.5 | 50.0 | 50.0 |
| Belimumab + Rituximab | 33.3 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 66.7 | 33.3 | 33.3 | 33.3 | 33.3 | 33.3 | 9.1 | 36.4 | 54.5 | 54.5 | 72.7 | 72.7 | 63.6 | 72.7 | 72.7 | 63.6 | 72.7 | 72.7 | 63.6 | 63.6 | 63.6 | 90.9 | 81.8 | 72.7 | 45.5 | 63.6 | 72.7 | 13.6 | 40.0 | 44.5 | 56.4 | 58.2 | 54.5 | 46.4 | 53.6 | 63.6 | 61.8 | 58.2 | 60.0 | 60.9 | 59.1 | 54.5 | 55.5 | 58.2 | 58.2 | 59.1 | 60.9 | 64.5 | 30.4 | 43.5 | 52.2 | 52.2 | 60.9 | 60.9 | 65.2 | 56.5 | 65.2 | 65.2 | 69.6 | 69.6 | 69.6 | 69.6 | 65.2 | 69.6 | 65.2 | 65.2 | 73.9 | 78.3 | 69.6 | 28.6 | 45.2 | 57.1 | 58.7 | 62.7 | 61.9 | 60.3 | 62.7 | 65.1 | 65.9 | 66.7 | 61.1 | 66.7 | 64.3 | 65.1 | 65.9 | 60.3 | 61.9 | 62.7 | 62.7 | 69.0 | 42.9 | 71.4 | 71.4 | 85.7 | 71.4 | 100 | 85.7 | 85.7 | 100 | 85.7 | 71.4 | 57.1 | 85.7 | 85.7 | 71.4 | 85.7 | 71.4 | 85.7 | 71.4 | 71.4 | 71.4 | 10.6 | 17.3 | 24.0 | 30.8 | 36.5 | 34.6 | 39.4 | 34.6 | 40.4 | 41.3 | 44.2 | 39.4 | 41.3 | 37.5 | 45.2 | 43.3 | 36.5 | 31.7 | 29.8 | 33.7 | 40.4 | 42.1 | 63.2 | 52.6 | 63.2 | 57.9 | 52.6 | 36.8 | 57.9 | 57.9 | 63.2 | 52.6 | 57.9 | 63.2 | 52.6 | 57.9 | 68.4 | 47.4 | 52.6 | 57.9 | 52.6 | 63.2 |
SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. A worsening was defined as an increase(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Percentage of participants with SLEDAI-2K organ worsening for following organ systems were reported;CNS total,Vascular total,Musculoskeletal total,Renal total,Mucocutaneous total,Cardio and Resp total,Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNS Total; Week 4; n= 69, 136, 43 | CNS Total; Week 8; n= 64,132, 42 | CNS Total; Week 12; n= 65, 134, 42 | CNS Total; Week 16; n= 65, 130, 42 | CNS Total; Week 20; n= 63, 128, 42 | CNS Total; Week 24; n= 61, 127, 41 | CNS Total; Week 26; n=61, 116, 38 | CNS Total; Week 28; n=62, 124, 41 | CNS Total; Week 32; n= 61, 124, 41 | CNS Total; Week 36; n=61, 124, 41 | CNS Total; Week 40; n=61, 123, 41 | CNS Total; Week 44; n= 61, 121, 41 | CNS Total; Week 48; n= 58, 120,39 | CNS Total; Week 52; n= 62, 120, 38 | CNS Total; Week 60; n=59, 117, 35 | CNS Total; Week 64; n=60, 117, 34 | CNS Total; Week 72; n= 56, 109, 31 | CNS Total; Week 80; n=55, 111, 35 | CNS Total; Week 88; n= 57, 107, 34 | CNS Total; Week 96; n=52, 107, 33 | CNS Total; Week 104; n= 53, 112, 34 | Vascular Total;Week 4; n= 65, 128, 45 | Vascular Total;Week 8; n= 61, 124, 44 | Vascular Total; Week 12; n= 62, 126, 44 | Vascular Total; Week 16; n=62, 122, 44 | Vascular Total; Week 20; n=60, 120, 44 | Vascular Total; Week 24; n= 59, 119, 43 | Vascular Total; Week 26; n=58, 109, 40 | Vascular Total;Week 28; n= 61, 116, 43 | Vascular Total;Week 32; n=59, 116, 43 | Vascular Total;Week 36; n= 59, 116, 43 | Vascular Total;Week 40; n=59, 115, 43 | Vascular Total;Week 44; n= 59, 113, 43 | Vascular Total;Week 48; n= 57, 112, 40 | Vascular Total;Week 52; n=60, 112, 40 | Vascular Total;Week 60; n= 58, 109, 37 | Vascular Total;Week 64; n=59, 109, 36 | Vascular Total;Week 72; n=55, 101, 33 | Vascular Total;Week 80; n= 54, 104, 37 | Vascular Total;Week 88; n=56, 102, 36 | Vascular Total;Week 96; n=51, 101, 35 | Vascular Total;Week 104; n=53, 105, 36 | Musculoskeletal Total; Week 4; n=15, 33, 12 | Musculoskeletal Total; Week 8; n= 15, 33, 12 | Musculoskeletal Total; Week 12; n= 15, 33, 12 | Musculoskeletal Total; Week 16; n= 15, 32, 12 | Musculoskeletal Total; Week 20; n= 15, 32, 12 | Musculoskeletal Total; Week 24; n= 15, 31, 11 | Musculoskeletal Total; Week 26; n= 15, 31, 11 | Musculoskeletal Total; Week 28; n= 14, 31, 11 | Musculoskeletal Total; Week 32; n= 15, 30, 11 | Musculoskeletal Total; Week 36; n= 14, 30, 11 | Musculoskeletal Total; Week 40; n=15, 30, 11 | Musculoskeletal Total; Week 44; n=15, 29, 11 | Musculoskeletal Total; Week 48; n= 14, 30, 10 | Musculoskeletal Total; Week 52; n= 15, 30, 11 | Musculoskeletal Total; Week 60; n= 14, 28, 11 | Musculoskeletal Total; Week 64; n=14, 29, 10 | Musculoskeletal Total; Week 72; n= 14, 27, 10 | Musculoskeletal Total; Week 80; n= 13, 26, 9 | Musculoskeletal Total; Week 88; n= 13, 25, 9 | Musculoskeletal Total; Week 96; n= 12, 26, 9 | Musculoskeletal Total; Week 104; n= 13, 27, 9 | Renal Total; Week 4; n= 57, 117, 36 | Renal Total; Week 8; n=51, 110, 36 | Renal Total; Week 12; n=53, 115, 35 | Renal Total; Week 16; n=53, 112, 35 | Renal Total; Week 20; n= 49, 108, 36 | Renal Total; Week 24; n= 49, 111, 35 | Renal Total; Week 26; n= 49, 99, 33 | Renal Total; Week 28; n= 50, 106, 36 | Renal Total; Week 32; n= 50,107, 36 | Renal Total; Week 36; n= 50, 107, 36 | Renal Total; Week 40; n= 47, 106, 34 | Renal Total; Week 44; n= 49, 103, 35 | Renal Total; Week 48; n= 47, 101, 32 | Renal Total; Week 52; n= 49, 103, 32 | Renal Total; Week 60; n=47, 96, 30 | Renal Total; Week 64; n= 50, 99, 29 | Renal Total; Week 72; n= 40, 89, 26 | Renal Total; Week 80; n= 41, 90, 29 | Renal Total; Week 88; n= 44, 85, 29 | Renal Total; Week 96; n= 43, 85, 29 | Renal Total; Week 104; n= 44, 90, 30 | Mucocutaneous Total; Week 4; n= 13, 18, 4 | Mucocutaneous Total; Week 8; n= 12, 18, 4 | Mucocutaneous Total; Week 12; n= 12, 18, 4 | Mucocutaneous Total; Week 16; n= 12, 18, 4 | Mucocutaneous Total; Week 20; n= 12, 18, 4 | Mucocutaneous Total; Week 24; n= 11, 17, 4 | Mucocutaneous Total; Week 26; n= 10, 17, 4 | Mucocutaneous Total; Week 28; n= 10, 17, 4 | Mucocutaneous Total; Week 32; n= 10, 17, 4 | Mucocutaneous Total; Week 36; n= 10, 17, 4 | Mucocutaneous Total; Week 40; n= 10, 17, 4 | Mucocutaneous Total; Week 44; n= 10, 17, 4 | Mucocutaneous Total; Week 48; n=10, 16, 3 | Mucocutaneous Total; Week 52; n= 10, 17, 4 | Mucocutaneous Total; Week 60; n= 9, 17, 4 | Mucocutaneous Total; Week 64; n= 10, 16, 4 | Mucocutaneous Total; Week 72; n=10, 16, 4 | Mucocutaneous Total; Week 80; n= 9, 17, 4 | Mucocutaneous Total; Week 88; n= 9, 16, 4 | Mucocutaneous Total; Week 96; n= 9, 15, 4 | Mucocutaneous Total; Week 104; n= 9, 17, 4 | Cardio and Resp Total; Week 4; n= 68, 132, 45 | Cardio and Resp Total; Week 8; n= 63, 128, 44 | Cardio and Resp Total; Week 12; n= 64, 130, 44 | Cardio and Resp Total; Week 16; n= 64, 126, 44 | Cardio and Resp Total; Week 20; n= 63, 124, 44 | Cardio and Resp Total; Week 24; n= 60, 123, 43 | Cardio and Resp Total; Week 26; n=59, 112, 40 | Cardio and Resp Total; Week 28; n= 61, 120, 43 | Cardio and Resp Total; Week 32; n= 60, 120, 43 | Cardio and Resp Total; Week 36; n= 60, 120, 43 | Cardio and Resp Total; Week 40; n=60, 119, 43 | Cardio and Resp Total; Week 44; n= 60, 117, 43 | Cardio and Resp Total; Week 48; n= 57, 116, 40 | Cardio and Resp Total; Week 52; n=61, 116, 40 | Cardio and Resp Total; Week 60; n= 58, 114, 37 | Cardio and Resp Total; Week 64; n= 59, 114, 36 | Cardio and Resp Total; Week 72; n= 55, 106, 33 | Cardio and Resp Total; Week 80; n= 54, 107, 37 | Cardio and Resp Total; Week 88; n= 56, 104, 36 | Cardio and Resp Total; Week 96; n=51, 104, 35 | Cardio and Resp Total; Week 104; n= 52, 109, 36 | Immunologic Total; Week 4; n=23, 37, 13 | Immunologic Total; Week 8; n=20, 37, 12 | Immunologic Total; Week 12; n=21, 37,12 | Immunologic Total; Week 16; n= 21, 35, 12 | Immunologic Total; Week 20; n= 19, 35, 12 | Immunologic Total; Week 24; n= 18, 35, 12 | Immunologic Total; Week 26; n= 18, 30, 12 | Immunologic Total; Week 28; n= 19, 35, 12 | Immunologic Total; Week 32; n= 19, 33, 12 | Immunologic Total; Week 36; n= 19, 34, 12 | Immunologic Total; Week 40; n= 19, 33, 12 | Immunologic Total; Week 44; n= 18, 33, 12 | Immunologic Total; Week 48; n= 18, 33, 11 | Immunologic Total; Week 52; n= 19, 32, 12 | Immunologic Total; Week 60; n= 18, 32, 10 | Immunologic Total; Week 64; n= 19, 33, 10 | Immunologic Total; Week 72; n= 17, 28, 9 | Immunologic Total; Week 80; n= 18, 29, 11 | Immunologic Total; Week 88; n= 19, 29, 11 | Immunologic Total; Week 96; n= 16, 30, 11 | Immunologic Total; Week 104; n= 17, 28, 12 | Hematologic Total; Week 4; n= 59, 115, 40 | Hematologic Total; Week 8; n= 52, 109, 38 | Hematologic Total; Week 12; n= 55, 110, 38 | Hematologic Total; Week 16; n=54, 107, 34 | Hematologic Total; Week 20; n= 54, 108, 40 | Hematologic Total; Week 24; n= 53, 111, 37 | Hematologic Total; Week 26; n= 53, 101, 37 | Hematologic Total; Week 28; n= 52, 106, 39 | Hematologic Total; Week 32; n=52, 110, 38 | Hematologic Total; Week 36; n= 53, 109, 40 | Hematologic Total; Week 40; n= 51, 108, 37 | Hematologic Total; Week 44; n=53, 107, 38 | Hematologic Total; Week 48; n=51, 105, 35 | Hematologic Total; Week 52; n= 53, 103, 37 | Hematologic Total; Week 60; n=53, 101, 35 | Hematologic Total; Week 64; n=54, 98, 32 | Hematologic Total; Week 72; n= 47,96, 29 | Hematologic Total; Week 80; n= 45, 94, 35 | Hematologic Total; Week 88; n= 46, 88, 32 | Hematologic Total; Week 96; n= 45, 90, 32 | Hematologic Total; Week 104; n= 46, 94, 32 | |
| Belimumab + Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.7 | 13.3 | 6.7 | 6.7 | 0 | 0 | 0 | 0 | 7.1 | 0 | 0 | 7.1 | 6.7 | 0 | 0 | 0 | 0 | 15.4 | 0 | 0 | 5.3 | 2.0 | 1.9 | 7.5 | 8.2 | 10.2 | 6.1 | 10.0 | 6.0 | 8.0 | 6.4 | 6.1 | 10.6 | 8.2 | 6.4 | 2.0 | 5.0 | 14.6 | 13.6 | 4.7 | 6.8 | 15.4 | 8.3 | 8.3 | 0 | 25.0 | 18.2 | 20.0 | 0 | 10.0 | 0 | 20.0 | 10.0 | 0 | 0 | 11.1 | 0 | 20 | 0 | 0 | 11.1 | 11.1 | 2.9 | 0 | 0 | 3.1 | 1.6 | 0 | 0 | 3.3 | 1.7 | 1.7 | 0 | 1.7 | 0 | 0 | 0 | 0 | 0 | 1.9 | 1.8 | 0 | 0 | 17.4 | 20.0 | 23.8 | 9.5 | 15.8 | 5.6 | 5.6 | 15.8 | 10.5 | 15.8 | 21.1 | 22.2 | 22.2 | 21.1 | 16.7 | 21.1 | 23.5 | 5.6 | 10.5 | 12.5 | 11.8 | 5.1 | 3.8 | 1.8 | 1.9 | 5.6 | 3.8 | 9.4 | 7.7 | 0 | 5.7 | 0 | 7.5 | 5.9 | 3.8 | 9.4 | 11.1 | 10.6 | 0 | 10.9 | 4.4 | 4.3 |
| Belimumab + Rituximab | 0 | 0 | 0 | 0.8 | 0 | 0.8 | 0.9 | 0 | 0.8 | 1.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.9 | 2.4 | 1.6 | 1.6 | 0.8 | 0 | 0.9 | 1.7 | 2.6 | 1.7 | 1.7 | 0 | 0 | 0.9 | 0 | 1.8 | 0 | 1.0 | 0 | 0 | 0 | 12.1 | 6.1 | 6.1 | 3.1 | 6.3 | 6.5 | 3.2 | 3.2 | 6.7 | 3.3 | 3.3 | 6.9 | 3.3 | 6.7 | 0 | 3.4 | 11.1 | 0 | 4.0 | 3.8 | 0 | 6.0 | 3.6 | 3.5 | 4.5 | 3.7 | 3.6 | 0 | 1.9 | 2.8 | 2.8 | 4.7 | 1.0 | 5.9 | 3.9 | 4.2 | 2.0 | 4.5 | 3.3 | 1.2 | 1.2 | 2.2 | 5.6 | 11.1 | 16.7 | 5.6 | 5.6 | 5.9 | 11.8 | 11.8 | 5.9 | 5.9 | 11.8 | 0 | 6.3 | 5.9 | 11.8 | 6.3 | 6.3 | 0 | 6.3 | 0 | 5.9 | 0.8 | 0.8 | 0.8 | 0 | 0.8 | 0 | 0 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.9 | 0 | 0 | 0 | 1.0 | 0 | 0 | 10.8 | 8.1 | 11.4 | 11.4 | 5.7 | 6.7 | 8.6 | 12.1 | 8.8 | 6.1 | 0 | 3.0 | 3.1 | 6.3 | 6.1 | 7.1 | 6.9 | 6.9 | 13.3 | 17.9 | 3.5 | 5.5 | 4.5 | 2.8 | 5.6 | 2.7 | 5.0 | 3.8 | 4.5 | 6.4 | 10.2 | 6.5 | 4.8 | 3.9 | 5.0 | 5.1 | 5.2 | 4.3 | 9.1 | 4.4 | 6.4 |
| Belimumab + Standard Therapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 | 10.0 | 9.1 | 9.1 | 10.0 | 10.0 | 11.1 | 0 | 0 | 0 | 11.1 | 5.6 | 8.6 | 2.9 | 8.3 | 2.9 | 0 | 2.8 | 2.8 | 5.6 | 0 | 2.9 | 6.3 | 3.1 | 0 | 0 | 0 | 6.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.0 | 0 | 25.0 | 25.0 | 25.0 | 25.0 | 25.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.7 | 0 | 16.7 | 0 | 0 | 0 | 8.3 | 16.7 | 8.3 | 16.7 | 8.3 | 0 | 27.3 | 8.3 | 0 | 20.0 | 11.1 | 18.2 | 18.2 | 18.2 | 16.7 | 5.0 | 0 | 10.5 | 2.9 | 5.0 | 2.7 | 10.8 | 5.1 | 7.9 | 2.5 | 5.4 | 5.3 | 0 | 2.7 | 5.7 | 6.3 | 3.4 | 5.7 | 3.1 | 3.1 | 6.3 |
The SLICC-ACR Damage Index measures irreversible (not related to active inflammation) changes occurring since the diagnosis of SLE ascertained by clinical assessment and present for at least 6 months. The questionnaire contains 39 items covering 12 different organ systems which were scored on a numerical scale between 0 (no damage) to 7 (increasing disease damage). Individual ranges for organ systems were; ocular: 0-2, neuropsychiatric: 0-6, renal: 0-3, pulmonary: 0-5, cardiovascular:0-6, peripheral vascular: 0-5, gastrointestinal:0-5, musculoskeletal: 0-6, skin: 0-3, endocrine (diabetes): 0-1, gonadal:0-1 and malignancies: 0-2. The SLICC-ACR score was calculated by taking sum of the individual scores for 12 organ systems which ranges from 0 (no damage) to 45 (increasing disease damage) where higher score indicates increasing disease damage severity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. (NCT03312907)
Timeframe: Baseline (Day 1), Week 52 and Week 104
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 52 | Week 104 | |
| Belimumab + Placebo | 1.4 | 5.6 |
| Belimumab + Rituximab | 2.1 | 5.6 |
| Belimumab + Standard Therapy | 2.1 | 6.4 |
"Mean change from baseline (from baseline to Day 85; or baseline to Day 169) in CLASI activity scores (Last Observation Carried Forward [LOCF] post censoring values).~The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations." (NCT02660944)
Timeframe: Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Day 85 | Day 169 | |
| Placebo | -6.5 | -5.7 |
| RSLV-132 | -6.2 | -6.2 |
Percentage of participants achieving a 50% improvement in CLASI activity score at Day 85 and Day 169 (LOCF post censoring due to use of exclusionary medications) (NCT02660944)
Timeframe: Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 85 | Day 169 All Participants | Day 169 Participants with Severe CLASI >/=21 | Day 169 Participants with Severe SLEDAI >/=9 | |
| Placebo | 2 | 5 | 3 | 1 |
| RSLV-132 | 11 | 14 | 7 | 4 |
Percentage of participants with a BICLA response on Day 169. This is a composite responder index incorporating the BILAG-2004, SLEDAI-2K and PGA responses. The BILAG-2004 index, an organ-based transitional activity instrument, provides disease activity scorings across nine organ systems (constitutional, mucocutaneous, neuropsychiatry, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological) on an ordinal scale (A to E) based on the physician's intention-to-treat premise. Grade A represents the most active and Grade E the least active disease. The PGA is measured on a 0 to 100 mm scale with score 0 to be No Disease Activity and score 100 to be the most Severe Disease Activity. (NCT02660944)
Timeframe: Baseline and Day 169
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Day 169 All Participants | Day 169 Participants with Severe CLASI >/=21 | Day 169 Participants with Severe SLEDAI >/=9 | |
| Placebo | 4 | 1 | 1 |
| RSLV-132 | 10 | 5 | 4 |
Percentage of participants with an Systemic Lupus Erythematous Responder Index (SRI) 4 response on Day 169. This is a composite responder index incorporating the British Isles Lupus Assessment Group (BILAG) 2004, SLEDAI-2K and Physician Global Assessment (PGA) responses. The BILAG-2004 index, an organ-based transitional activity instrument, provides disease activity scorings across nine organ systems (constitutional, mucocutaneous, neuropsychiatry, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological) on an ordinal scale (A to E) based on the physician's intention-to-treat premise. Grade A represents the most active and Grade E the least active disease. The Physician's Global Assessment is measured on a 0 to 100 mm scale with score 0 to be No Disease Activity and score 100 to be the most Severe Disease Activity. (NCT02660944)
Timeframe: Baseline and Day 169
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Day 169 All participants | Day 169 Participants with Severe CLASI >/=21 | Day 169 Participants with Severe SLEDAI >/=9 | |
| Placebo | 7 | 1 | 4 |
| RSLV-132 | 11 | 7 | 8 |
A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG 2004 assessment. (NCT02975336)
Timeframe: Baseline up to Week 52
| Intervention | Annualized flare rate ratio (Number) |
|---|---|
| DBPC Period: Placebo | 0.15 |
| DBPC Period: M2951 25 mg QD | 0.23 |
| DBPC Period: M2951 75 mg QD | 0.13 |
| DBPC Period: M2951 50 mg BID | 0.19 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 24
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | 2 |
| DBPC Period: M2951 25 mg QD | 5 |
| DBPC Period: M2951 75 mg QD | 3 |
| DBPC Period: M2951 50 mg BID | -7 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 4
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | -5 |
| DBPC Period: M2951 25 mg QD | 65 |
| DBPC Period: M2951 75 mg QD | 87 |
| DBPC Period: M2951 50 mg BID | 67 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 52
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | -14 |
| DBPC Period: M2951 25 mg QD | -19 |
| DBPC Period: M2951 75 mg QD | -14 |
| DBPC Period: M2951 50 mg BID | -52 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 56
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | 7 |
| DBPC Period: M2951 25 mg QD | -70 |
| DBPC Period: M2951 75 mg QD | -75 |
| DBPC Period: M2951 50 mg BID | -48 |
Cumulative Prednisone-equivalent Corticosteroid (CS) Dose was calculated at Week 52. (NCT02975336)
Timeframe: Week 52
| Intervention | Milligrams (Mean) |
|---|---|
| DBPC Period: Placebo | 2267.66 |
| DBPC Period: M2951 25 mg QD | 2209.46 |
| DBPC Period: M2951 75 mg QD | 2137.70 |
| DBPC Period: M2951 50 mg BID | 2205.56 |
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 24
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | 161 |
| DBPC Period: M2951 25 mg QD | 184 |
| DBPC Period: M2951 75 mg QD | 204 |
| DBPC Period: M2951 50 mg BID | 151 |
Mean total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 4
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | 150 |
| DBPC Period: M2951 25 mg QD | 236 |
| DBPC Period: M2951 75 mg QD | 296 |
| DBPC Period: M2951 50 mg BID | 229 |
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 52
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | 169 |
| DBPC Period: M2951 25 mg QD | 167 |
| DBPC Period: M2951 75 mg QD | 180 |
| DBPC Period: M2951 50 mg BID | 119 |
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 56
| Intervention | Cells per microliter (Mean) |
|---|---|
| DBPC Period: Placebo | 164 |
| DBPC Period: M2951 25 mg QD | 129 |
| DBPC Period: M2951 75 mg QD | 156 |
| DBPC Period: M2951 50 mg BID | 104 |
SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from very well(0)-very poor(100). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 21 |
| DBPC Period: M2951 25 mg QD | 25 |
| DBPC Period: M2951 75 mg QD | 22 |
| DBPC Period: M2951 50 mg BID | 25 |
SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 43 |
| DBPC Period: M2951 25 mg QD | 45 |
| DBPC Period: M2951 75 mg QD | 43 |
| DBPC Period: M2951 50 mg BID | 41 |
SRI-6 response was defined as >= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 18 |
| DBPC Period: M2951 25 mg QD | 19 |
| DBPC Period: M2951 75 mg QD | 23 |
| DBPC Period: M2951 50 mg BID | 15 |
A participant has a flare-free status if no flare has been reported during the 52-week treatment period. Participants who discontinued treatment prior to Week 52, without having a flare are counted as not being flare free at Week 52. A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. (NCT02975336)
Timeframe: up to Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 41 |
| DBPC Period: M2951 25 mg QD | 35 |
| DBPC Period: M2951 75 mg QD | 37 |
| DBPC Period: M2951 50 mg BID | 33 |
BILAG A or 2B flare is defined as at least one BILAG A grade or two BILAG B grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment period. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to systemic lupus erythematosus (SLE), divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. (NCT02975336)
Timeframe: Baseline and Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 19 |
| DBPC Period: M2951 25 mg QD | 23 |
| DBPC Period: M2951 75 mg QD | 20 |
| DBPC Period: M2951 50 mg BID | 21 |
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported. (NCT02975336)
Timeframe: Baseline up to Week 56
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 0 |
| DBPC Period: M2951 25 mg QD | 0 |
| DBPC Period: M2951 75 mg QD | 0 |
| DBPC Period: M2951 50 mg BID | 0 |
12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported. (NCT02975336)
Timeframe: Baseline up to Week 56
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 0 |
| DBPC Period: M2951 25 mg QD | 0 |
| DBPC Period: M2951 75 mg QD | 0 |
| DBPC Period: M2951 50 mg BID | 0 |
Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. (NCT02975336)
Timeframe: Baseline up to Week 56
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 0 |
| DBPC Period: M2951 25 mg QD | 0 |
| DBPC Period: M2951 75 mg QD | 0 |
| DBPC Period: M2951 50 mg BID | 0 |
Low disease activity is defined as SLEDAI-2K score <=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Clinical SLEDAI-2K score is equal to the SLEDAI-2K score from electronic case report form (eCRF) excluding the components 'Increased Deoxyribonucleic acid (DNA) Binding' and 'Low Complement'. (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 42 |
| DBPC Period: M2951 25 mg QD | 50 |
| DBPC Period: M2951 75 mg QD | 52 |
| DBPC Period: M2951 50 mg BID | 41 |
Low disease activity is defined as SLEDAI-2K score <=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 26 |
| DBPC Period: M2951 25 mg QD | 32 |
| DBPC Period: M2951 75 mg QD | 39 |
| DBPC Period: M2951 50 mg BID | 28 |
Lupus low disease activity state will be measured as: SLEDAI-2K <= 4; No activity in any major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever); No new features of disease activity compared with the previous assessment; Prednisone-equivalent <= 7.5 milligram per day; Unchanged background immunosuppressive therapy. (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 29 |
| DBPC Period: M2951 25 mg QD | 32 |
| DBPC Period: M2951 75 mg QD | 35 |
| DBPC Period: M2951 50 mg BID | 29 |
BICLA response defined as participants meeting following criteria: [1] At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry (example: all A (severe disease) scores falling to B (moderate), C (mild), or D (no activity) and all B scores falling to C or D; [2] No new BILAG A or more than one new BILAG B scores; [3] No worsening of total SLEDAI-2K score from baseline; [4] No significant deterioration (=<10%) in physician's global assessment and [5] No treatment failure (initiation of non-protocol treatment). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 30 |
| DBPC Period: M2951 25 mg QD | 29 |
| DBPC Period: M2951 75 mg QD | 33 |
| DBPC Period: M2951 50 mg BID | 24 |
SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE) divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 52 |
| DBPC Period: M2951 25 mg QD | 64 |
| DBPC Period: M2951 75 mg QD | 60 |
| DBPC Period: M2951 50 mg BID | 55 |
SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 28 |
| DBPC Period: M2951 25 mg QD | 38 |
| DBPC Period: M2951 75 mg QD | 29 |
| DBPC Period: M2951 50 mg BID | 34 |
SRI-6 response was defined as >= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 22 |
| DBPC Period: M2951 25 mg QD | 27 |
| DBPC Period: M2951 75 mg QD | 30 |
| DBPC Period: M2951 50 mg BID | 24 |
SRI-6 response was defined as >= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| DBPC Period: Placebo | 17 |
| DBPC Period: M2951 25 mg QD | 25 |
| DBPC Period: M2951 75 mg QD | 23 |
| DBPC Period: M2951 50 mg BID | 23 |
BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. A Moderate to Severe (BILAG A or 2B) flare is defined as at least one BILAG A (severe disease activity) grade or two BILAG B (moderate disease activity) grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment. It was measured using Kaplan-Meier (KM) estimates. (NCT02975336)
Timeframe: Baseline up to Week 56
| Intervention | Days (Median) |
|---|---|
| DBPC Period: Placebo | NA |
| DBPC Period: M2951 25 mg QD | NA |
| DBPC Period: M2951 75 mg QD | NA |
| DBPC Period: M2951 50 mg BID | NA |
BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. Time to first severe flare, where a severe flare is defined as at least one BILAG A (Severe disease activity) score in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52-Week Treatment. It was measured using Kaplan-Meier (KM) estimates. (NCT02975336)
Timeframe: Baseline up to Week 56
| Intervention | Days (Median) |
|---|---|
| DBPC Period: Placebo | NA |
| DBPC Period: M2951 25 mg QD | NA |
| DBPC Period: M2951 75 mg QD | NA |
| DBPC Period: M2951 50 mg BID | NA |
BILAG 2004 disease activity Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
| Intervention | Units on a Scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| DBPC Period: M2951 25 mg QD | -4 | -5 | -7 | -7 | -7 | -7 | -8 | -8 | -8 | -8 | -9 | -8 | -9 |
| DBPC Period: M2951 50 mg BID | -4 | -6 | -6 | -6 | -6 | -6 | -7 | -7 | -7 | -7 | -7 | -7 | -7 |
| DBPC Period: M2951 75 mg QD | -3 | -6 | -6 | -6 | -7 | -8 | -8 | -8 | -8 | -9 | -9 | -9 | -9 |
| DBPC Period: Placebo | -4 | -6 | -7 | -7 | -7 | -8 | -8 | -9 | -8 | -9 | -9 | -8 | -8 |
CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70). (NCT02975336)
Timeframe: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
| Intervention | Units on a Scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| DBPC Period: M2951 25 mg QD | -1 | -1 | -1 | -2 | -2 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -4 |
| DBPC Period: M2951 50 mg BID | 0 | -1 | -1 | -2 | -2 | -2 | -2 | -2 | -3 | -3 | -3 | -3 | -3 | -3 |
| DBPC Period: M2951 75 mg QD | 0 | -1 | -1 | -2 | -2 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
| DBPC Period: Placebo | -1 | -1 | -2 | -2 | -2 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (perfect health). A higher score indicates better health and positive changes from baseline indicate improvement of health. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
| Intervention | Units on a Scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | Week 32 | Week 40 | Week 52 | |
| DBPC Period: M2951 25 mg QD | 0.045 | 0.064 | 0.070 | 0.072 | 0.067 | 0.067 | 0.061 | 0.078 |
| DBPC Period: M2951 50 mg BID | 0.038 | 0.061 | 0.065 | 0.056 | 0.055 | 0.071 | 0.084 | 0.096 |
| DBPC Period: M2951 75 mg QD | 0.036 | 0.046 | 0.055 | 0.067 | 0.086 | 0.075 | 0.090 | 0.102 |
| DBPC Period: Placebo | 0.036 | 0.034 | 0.061 | 0.083 | 0.080 | 0.083 | 0.093 | 0.096 |
The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
| Intervention | Millimeter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | Week 32 | Week 40 | Week 52 | |
| DBPC Period: M2951 25 mg QD | 2 | 6 | 6 | 5 | 5 | 4 | 6 | 8 |
| DBPC Period: M2951 50 mg BID | 4 | 6 | 4 | 4 | 4 | 7 | 8 | 10 |
| DBPC Period: M2951 75 mg QD | 4 | 4 | 5 | 6 | 9 | 7 | 10 | 10 |
| DBPC Period: Placebo | 3 | 3 | 5 | 7 | 7 | 8 | 8 | 8 |
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | Week 32 | Week 40 | Week 52 | |
| DBPC Period: M2951 25 mg QD | 2 | 3 | 4 | 3 | 4 | 4 | 3 | 4 |
| DBPC Period: M2951 50 mg BID | 3 | 5 | 4 | 3 | 3 | 4 | 4 | 5 |
| DBPC Period: M2951 75 mg QD | 4 | 3 | 3 | 4 | 5 | 5 | 6 | 5 |
| DBPC Period: Placebo | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 4 |
The Lupus QoL assessment is a 34 item questionnaire across 8 domains that is designed to find out how systemic lupus erythematosus (SLE) affects a participant's life. Domains include physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4=never, 3=occasionally, 2= a good bit of the time, 1=most of the time, and 0=worst of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better health related QoL. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Health Week 4 | Physical Health Week 8 | Physical Health Week 12 | Physical Health Week 16 | Physical Health Week 24 | Physical Health Week 32 | Physical Health Week 40 | Physical Health Week 52 | Pain Week 4 | Pain Week 8 | Pain Week 12 | Pain Week 16 | Pain Week 24 | Pain Week 32 | Pain Week 40 | Pain Week 52 | Planning Week 4 | Planning Week 8 | Planning Week 12 | Planning Week 16 | Planning Week 24 | Planning Week 32 | Planning Week 40 | Planning Week 52 | Intimate Relationship Week 4 | Intimate Relationship Week 8 | Intimate Relationship Week 12 | Intimate Relationship Week 16 | Intimate Relationship Week 24 | Intimate Relationship Week 32 | Intimate Relationship Week 40 | Intimate Relationship Week 52 | Burden to Others Week 4 | Burden to Others Week 8 | Burden to Others Week 12 | Burden to Others Week 16 | Burden to Others Week 24 | Burden to Others Week 32 | Burden to Others Week 40 | Burden to Others Week 52 | Emotional Health Week 4 | Emotional Health Week 8 | Emotional Health Week 12 | Emotional Health Week 16 | Emotional Health Week 24 | Emotional Health Week 32 | Emotional Health Week 40 | Emotional Health Week 52 | Body Image Week 4 | Body Image Week 8 | Body Image Week 12 | Body Image Week 16 | Body Image Week 24 | Body Image Week 32 | Body Image Week 40 | Body Image Week 52 | Fatigue Week 4 | Fatigue Week 8 | Fatigue Week 12 | Fatigue Week 16 | Fatigue Week 24 | Fatigue Week 32 | Fatigue Week 40 | Fatigue Week 52 | |
| DBPC Period: M2951 25 mg QD | 4.7 | 6.3 | 6.7 | 6.1 | 7.2 | 6.7 | 8.2 | 9.0 | 6.7 | 9.9 | 8.8 | 8.3 | 9.3 | 9.2 | 10.9 | 12.9 | 4.9 | 8.4 | 5.8 | 5.3 | 8.1 | 7.6 | 7.8 | 7.0 | 1.6 | 4.2 | 4.7 | 1.6 | 2.1 | 1.3 | 6.6 | 4.4 | 5.2 | 9.3 | 6.7 | 8.1 | 9.0 | 6.8 | 12.4 | 10.7 | 4.7 | 7.0 | 7.6 | 7.5 | 5.6 | 4.3 | 8.3 | 6.4 | 8.4 | 7.5 | 7.1 | 7.6 | 10.2 | 8.1 | 8.2 | 9.8 | 4.3 | 7.1 | 5.8 | 6.6 | 4.8 | 3.7 | 6.1 | 4.5 |
| DBPC Period: M2951 50 mg BID | 3.5 | 4.6 | 5.7 | 6.2 | 6.1 | 7.0 | 7.1 | 7.9 | 5.7 | 6.7 | 5.5 | 6.9 | 6.2 | 8.7 | 9.6 | 9.6 | 4.6 | 3.9 | 5.1 | 6.3 | 5.6 | 6.9 | 8.0 | 10.5 | 3.2 | 3.7 | 6.4 | 4.2 | 5.3 | 1.4 | 7.8 | 8.9 | 2.2 | 8.0 | 7.3 | 7.4 | 5.8 | 8.4 | 12.1 | 10.5 | 1.8 | 5.3 | 4.7 | 6.2 | 4.3 | 6.0 | 6.7 | 7.6 | 4.0 | 6.5 | 6.6 | 5.7 | 6.7 | 5.8 | 9.0 | 7.8 | 3.9 | 4.5 | 5.0 | 4.1 | 3.6 | 4.1 | 5.3 | 6.7 |
| DBPC Period: M2951 75 mg QD | 4.0 | 3.8 | 5.6 | 7.4 | 8.4 | 9.4 | 9.6 | 11.6 | 9.0 | 7.3 | 9.8 | 10.5 | 13.0 | 12.8 | 15.3 | 14.9 | 5.4 | 5.8 | 6.8 | 6.5 | 11.5 | 9.9 | 11.6 | 9.9 | 4.7 | 9.7 | 2.3 | 3.8 | 6.7 | 6.5 | 6.4 | 8.4 | 6.8 | 5.7 | 7.4 | 6.7 | 11.8 | 9.6 | 12.4 | 13.0 | 4.2 | 2.3 | 4.9 | 7.4 | 8.9 | 9.0 | 7.6 | 8.2 | 2.5 | -1.3 | 2.3 | -0.4 | 5.8 | 3.3 | 4.6 | 5.1 | 6.2 | 4.9 | 7.3 | 7.1 | 9.0 | 8.5 | 11.0 | 11.2 |
| DBPC Period: Placebo | 1.9 | 2.8 | 4.8 | 6.6 | 6.9 | 5.7 | 7.6 | 7.1 | 3.6 | 4.8 | 7.5 | 9.4 | 9.4 | 6.7 | 11.0 | 10.2 | 4.8 | 5.5 | 7.8 | 8.3 | 7.9 | 6.5 | 9.0 | 9.9 | 3.4 | 8.2 | 5.5 | 8.8 | 6.4 | 2.5 | 12.0 | 7.4 | 5.8 | 5.6 | 8.6 | 11.8 | 10.3 | 10.6 | 16.1 | 15.3 | 6.4 | 4.5 | 6.3 | 8.3 | 7.1 | 6.3 | 8.4 | 8.5 | 3.1 | 5.7 | 6.5 | 6.7 | 6.7 | 5.1 | 7.7 | 6.6 | 4.4 | 5.0 | 6.7 | 7.7 | 7.5 | 7.0 | 11.3 | 8.9 |
The Physician's Global Assessment of Disease Activity was recorded using the 100 millimeter horizontal Visual Analog Scale (VAS). Physician rated participant's disease activity on a scale ranged from 0-100 millimeter (mm), where 0 indicated no disease activity and 100 represented maximum disease activity. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
| Intervention | Millimeter (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| DBPC Period: M2951 25 mg QD | -8 | -14 | -18 | -20 | -21 | -24 | -26 | -26 | -26 | -27 | -28 | -29 | -31 |
| DBPC Period: M2951 50 mg BID | -9 | -14 | -18 | -19 | -20 | -21 | -24 | -26 | -26 | -25 | -26 | -28 | -27 |
| DBPC Period: M2951 75 mg QD | -9 | -13 | -19 | -21 | -24 | -25 | -26 | -26 | -29 | -30 | -30 | -32 | -33 |
| DBPC Period: Placebo | -8 | -13 | -18 | -21 | -23 | -24 | -26 | -26 | -26 | -27 | -28 | -29 | -29 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 12
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | -0.62 | -0.02 | -0.20 |
| DBPC Period: M2951 50 mg BID | -0.93 | -0.03 | -0.20 |
| DBPC Period: M2951 75 mg QD | -0.72 | 0.06 | -0.18 |
| DBPC Period: Placebo | -0.36 | 0.00 | -0.01 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 2
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | -0.06 | -0.04 | -0.05 |
| DBPC Period: M2951 50 mg BID | -0.40 | -0.03 | -0.07 |
| DBPC Period: M2951 75 mg QD | -0.15 | -0.01 | -0.04 |
| DBPC Period: Placebo | -0.51 | -0.11 | 0.00 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 24
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 0.11 | 0.14 | -0.23 |
| DBPC Period: M2951 50 mg BID | -0.57 | 0.04 | -0.25 |
| DBPC Period: M2951 75 mg QD | -0.46 | 0.19 | -0.23 |
| DBPC Period: Placebo | -0.21 | 0.06 | -0.01 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 36
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 0.02 | 0.22 | -0.25 |
| DBPC Period: M2951 50 mg BID | -0.69 | 0.08 | -0.28 |
| DBPC Period: M2951 75 mg QD | -0.43 | 0.24 | -0.25 |
| DBPC Period: Placebo | -0.15 | -0.02 | -0.04 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 4
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | -0.16 | -0.04 | -0.09 |
| DBPC Period: M2951 50 mg BID | -0.45 | -0.03 | -0.08 |
| DBPC Period: M2951 75 mg QD | -0.24 | 0.03 | -0.07 |
| DBPC Period: Placebo | -0.26 | -0.01 | 0.01 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 52
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 0.29 | 0.32 | -0.25 |
| DBPC Period: M2951 50 mg BID | -0.31 | 0.18 | -0.33 |
| DBPC Period: M2951 75 mg QD | 0.35 | 0.39 | -0.21 |
| DBPC Period: Placebo | 0.41 | 0.19 | -0.02 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 56
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 1.06 | 0.48 | -0.15 |
| DBPC Period: M2951 50 mg BID | -0.40 | 0.26 | -0.21 |
| DBPC Period: M2951 75 mg QD | 0.74 | 0.35 | -0.11 |
| DBPC Period: Placebo | 0.74 | 0.23 | 0.01 |
The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0 - 100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning). (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40 and 52
| Intervention | Units on a Scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Component Summary Score at Week 4 | Physical Component Summary Score at Week 8 | Physical Component Summary Score at Week 12 | Physical Component Summary Score at Week 16 | Physical Component Summary Score at Week 24 | Physical Component Summary Score at Week 32 | Physical Component Summary Score at Week 40 | Physical Component Summary Score at Week 52 | Mental Component Summary Score at Week 4 | Mental Component Summary Score at Week 8 | Mental Component Summary Score at Week 12 | Mental Component Summary Score at Week 16 | Mental Component Summary Score at Week 24 | Mental Component Summary Score at Week 32 | Mental Component Summary Score at Week 40 | Mental Component Summary Score at Week 52 | |
| DBPC Period: M2951 25 mg QD | 2.5 | 3.5 | 3.7 | 4.0 | 4.6 | 3.8 | 4.6 | 5.4 | 1.7 | 2.2 | 3.1 | 2.5 | 2.4 | 1.8 | 1.5 | 1.7 |
| DBPC Period: M2951 50 mg BID | 2.2 | 2.2 | 3.0 | 3.4 | 2.8 | 3.8 | 4.1 | 4.8 | 2.4 | 3.6 | 2.9 | 2.9 | 2.7 | 4.3 | 4.0 | 4.6 |
| DBPC Period: M2951 75 mg QD | 3.5 | 3.0 | 4.2 | 4.4 | 5.4 | 5.4 | 5.7 | 6.5 | 1.9 | 1.6 | 0.8 | 2.8 | 3.4 | 2.8 | 3.2 | 3.9 |
| DBPC Period: Placebo | 1.2 | 1.8 | 2.4 | 3.3 | 3.4 | 3.5 | 4.2 | 3.7 | 3.9 | 2.5 | 3.1 | 3.6 | 2.9 | 3.5 | 4.5 | 3.8 |
SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
| Intervention | Units on a Scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| DBPC Period: M2951 25 mg QD | -1 | -2 | -3 | -3 | -4 | -4 | -4 | -4 | -5 | -5 | -5 | -5 | -5 |
| DBPC Period: M2951 50 mg BID | -1 | -2 | -3 | -3 | -4 | -3 | -4 | -4 | -4 | -4 | -4 | -5 | -5 |
| DBPC Period: M2951 75 mg QD | 0 | -2 | -3 | -3 | -4 | -4 | -4 | -4 | -5 | -5 | -5 | -5 | -5 |
| DBPC Period: Placebo | -1 | -2 | -3 | -4 | -4 | -4 | -4 | -4 | -4 | -5 | -4 | -4 | -5 |
Change From Baseline in Prednisone-equivalent CS Daily Dose at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported. (NCT02975336)
Timeframe: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
| Intervention | Milligram (mg) (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Week 14 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| DBPC Period: M2951 25 mg QD | 0.00 | -0.07 | -0.45 | -0.64 | -1.24 | -2.04 | -1.85 | -2.70 | -2.70 | -2.82 | -2.64 | -2.97 | -3.13 | -3.31 | -3.21 | -3.21 | -3.22 | -2.94 |
| DBPC Period: M2951 50 mg BID | 0.00 | -0.13 | -0.15 | -0.70 | -1.02 | -2.50 | -1.97 | -2.76 | -2.40 | -2.53 | -2.34 | -2.46 | -2.44 | -2.37 | -2.67 | -2.56 | -2.62 | -2.63 |
| DBPC Period: M2951 75 mg QD | 0.00 | 0.00 | -0.04 | -0.59 | -1.09 | -1.56 | -1.73 | -1.87 | -2.47 | -2.64 | -2.61 | -3.07 | -3.18 | -3.18 | -3.24 | -3.27 | -3.37 | -3.09 |
| DBPC Period: Placebo | 0.21 | 0.10 | 0.01 | -1.07 | -0.57 | -1.43 | -1.26 | -2.00 | -1.67 | -1.94 | -1.99 | -2.23 | -2.45 | -2.42 | -2.08 | -2.42 | -2.38 | -1.70 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 12. (NCT02975336)
Timeframe: Week 12
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG: | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 12.92 | 2.73 | 1.05 |
| DBPC Period: M2951 50 mg BID | 12.38 | 2.68 | 1.02 |
| DBPC Period: M2951 75 mg QD | 13.64 | 2.88 | 0.95 |
| DBPC Period: Placebo | 14.91 | 2.72 | 1.11 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 2. (NCT02975336)
Timeframe: Week 2
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 13.75 | 2.75 | 1.22 |
| DBPC Period: M2951 50 mg BID | 12.81 | 2.66 | 1.18 |
| DBPC Period: M2951 75 mg QD | 14.37 | 2.78 | 1.09 |
| DBPC Period: Placebo | 14.56 | 2.62 | 1.12 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 24. (NCT02975336)
Timeframe: Week 24
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 13.75 | 2.89 | 1.01 |
| DBPC Period: M2951 50 mg BID | 12.86 | 2.78 | 0.98 |
| DBPC Period: M2951 75 mg QD | 13.79 | 2.98 | 0.89 |
| DBPC Period: Placebo | 15.01 | 2.79 | 1.07 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 36. (NCT02975336)
Timeframe: Week 36
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 13.54 | 2.89 | 1.01 |
| DBPC Period: M2951 50 mg BID | 12.65 | 2.86 | 0.95 |
| DBPC Period: M2951 75 mg QD | 13.67 | 3.01 | 0.85 |
| DBPC Period: Placebo | 14.81 | 2.72 | 1.06 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 4. (NCT02975336)
Timeframe: Week 4
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 13.60 | 2.73 | 1.18 |
| DBPC Period: M2951 50 mg BID | 12.73 | 2.64 | 1.16 |
| DBPC Period: M2951 75 mg QD | 14.21 | 2.82 | 1.06 |
| DBPC Period: Placebo | 14.92 | 2.71 | 1.12 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 52 (NCT02975336)
Timeframe: Week 52
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 13.90 | 2.95 | 0.94 |
| DBPC Period: M2951 50 mg BID | 13.01 | 2.95 | 0.96 |
| DBPC Period: M2951 75 mg QD | 14.32 | 3.17 | 0.82 |
| DBPC Period: Placebo | 15.21 | 2.82 | 1.08 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 56 (NCT02975336)
Timeframe: Week 56
| Intervention | gram per liter (g/L) (Mean) | ||
|---|---|---|---|
| IgG | IgA | IgM | |
| DBPC Period: M2951 25 mg QD | 14.25 | 3.01 | 1.01 |
| DBPC Period: M2951 50 mg BID | 13.12 | 3.03 | 1.31 |
| DBPC Period: M2951 75 mg QD | 14.25 | 2.89 | 0.95 |
| DBPC Period: Placebo | 14.82 | 2.95 | 1.11 |
Number of Participants With Reduction From Baseline in Prednisone-equivalent Corticosteroid (CS) Daily Dose by > 0 to 25%, >25% to 50%, >50% to 100% or an Increase at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported. (NCT02975336)
Timeframe: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reduction of dose by >0-25% Week 1 | Reduction of dose by >0-25% Week 2 | Reduction of dose by >0-25% Week 4 | Reduction of dose by >0-25% Week 6 | Reduction of dose by >0-25% Week 8 | Reduction of dose by >0-25% Week 10 | Reduction of dose by >0-25% Week 12 | Reduction of dose by >0-25% Week 14 | Reduction of dose by >0-25% Week 16 | Reduction of dose by >0-25% Week 20 | Reduction of dose by >0-25% Week 24 | Reduction of dose by >0-25% Week 28 | Reduction of dose by >0-25% Week 32 | Reduction of dose by >0-25% Week 36 | Reduction of dose by >0-25% Week 40 | Reduction of dose by >0-25% Week 44 | Reduction of dose by >0-25% Week 48 | Reduction of dose by >0-25% Week 52 | Reduction of dose by >25- 50% Week 1 | Reduction of dose by >25- 50% Week 2 | Reduction of dose by >25- 50% Week 4 | Reduction of dose by >25- 50% Week 6 | Reduction of dose by >25- 50% Week 8 | Reduction of dose by >25- 50% Week 10 | Reduction of dose by >25- 50% Week 12 | Reduction of dose by >25- 50% Week 14 | Reduction of dose by >25- 50% Week 16 | Reduction of dose by >25- 50% Week 20 | Reduction of dose by >25- 50% Week 24 | Reduction of dose by >25- 50% Week 28 | Reduction of dose by >25- 50% Week 32 | Reduction of dose by >25- 50% Week 36 | Reduction of dose by >25- 50% Week 40 | Reduction of dose by >25- 50% Week 44 | Reduction of dose by >25- 50% Week 48 | Reduction of dose by >25- 50% Week 52 | Reduction of dose by >50-100% Week 1 | Reduction of dose by >50-100% Week 2 | Reduction of dose by >50-100% Week 4 | Reduction of dose by >50-100% Week 6 | Reduction of dose by >50-100% Week 8 | Reduction of dose by >50-100% Week 10 | Reduction of dose by >50-100% Week 12 | Reduction of dose by >50-100% Week 14 | Reduction of dose by >50-100% Week 16 | Reduction of dose by >50-100% Week 20 | Reduction of dose by >50-100% Week 24 | Reduction of dose by >50-100% Week 28 | Reduction of dose by >50-100% Week 32 | Reduction of dose by >50-100% Week 36 | Reduction of dose by >50-100% Week 40 | Reduction of dose by >50-100% Week 44 | Reduction of dose by >50-100% Week 48 | Reduction of dose by >50-100% Week 52 | Increased from Baseline Week 1 | Increased from Baseline Week 2 | Increased from Baseline Week 4 | Increased from Baseline Week 6 | Increased from Baseline Week 8 | Increased from Baseline Week 10 | Increased from Baseline Week 12 | Increased from Baseline Week 14 | Increased from Baseline Week 16 | Increased from Baseline Week 20 | Increased from Baseline Week 24 | Increased from Baseline Week 28 | Increased from Baseline Week 32 | Increased from Baseline Week 36 | Increased from Baseline Week 40 | Increased from Baseline Week 44 | Increased from Baseline Week 48 | Increased from Baseline Week 52 | |
| DBPC Period: M2951 25 mg QD | 0 | 2 | 5 | 4 | 6 | 3 | 11 | 2 | 10 | 10 | 10 | 8 | 7 | 5 | 5 | 5 | 5 | 5 | 0 | 0 | 2 | 1 | 9 | 6 | 9 | 6 | 12 | 11 | 9 | 12 | 11 | 13 | 15 | 15 | 14 | 12 | 0 | 0 | 1 | 1 | 3 | 3 | 6 | 6 | 13 | 13 | 14 | 14 | 16 | 17 | 15 | 15 | 15 | 17 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBPC Period: M2951 50 mg BID | 0 | 0 | 1 | 4 | 6 | 5 | 6 | 5 | 6 | 5 | 5 | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 0 | 0 | 0 | 0 | 5 | 10 | 15 | 8 | 16 | 14 | 13 | 16 | 16 | 15 | 16 | 16 | 17 | 17 | 0 | 1 | 1 | 1 | 3 | 4 | 6 | 7 | 9 | 11 | 11 | 11 | 12 | 11 | 11 | 10 | 10 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| DBPC Period: M2951 75 mg QD | 0 | 0 | 2 | 3 | 5 | 4 | 8 | 4 | 5 | 5 | 5 | 5 | 4 | 4 | 3 | 3 | 4 | 4 | 0 | 0 | 1 | 2 | 6 | 4 | 10 | 2 | 9 | 8 | 8 | 9 | 8 | 6 | 6 | 6 | 6 | 7 | 0 | 0 | 0 | 0 | 4 | 3 | 6 | 7 | 13 | 14 | 13 | 15 | 16 | 18 | 18 | 18 | 19 | 19 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBPC Period: Placebo | 0 | 1 | 1 | 3 | 6 | 0 | 5 | 2 | 5 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 4 | 5 | 7 | 14 | 7 | 16 | 13 | 12 | 14 | 15 | 15 | 15 | 15 | 15 | 16 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 5 | 5 | 7 | 7 | 9 | 11 | 10 | 10 | 10 | 9 | 9 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 56 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported. (NCT02975336)
Timeframe: Baseline up to Week 56
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any TEAEs | Any serious TEAE | |
| DBPC Period: M2951 25 mg QD | 103 | 13 |
| DBPC Period: M2951 50 mg BID | 99 | 9 |
| DBPC Period: M2951 75 mg QD | 100 | 11 |
| DBPC Period: Placebo | 96 | 10 |
Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported. (NCT02975336)
Timeframe: Baseline up to Week 56
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| DBPC Period: M2951 25 mg QD | 80 | 77 | 29 | 1 | 1 |
| DBPC Period: M2951 50 mg BID | 76 | 78 | 21 | 2 | 0 |
| DBPC Period: M2951 75 mg QD | 79 | 72 | 24 | 0 | 1 |
| DBPC Period: Placebo | 76 | 63 | 24 | 1 | 0 |
The PGIC is a self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall quality of life (QoL) related to the participants painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of any improvement (that is PGIC scale score 1, 2 or 3), no change (that is PGIC scale score 4) and any worsening (that is PGIC scale score 5, 6 or 7) are reported. (NCT02975336)
Timeframe: Week 4, 8, 12, 16, 24, 32, 40, and 52
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 472538922 | Week 472538923 | Week 472538925 | Week 472538924 | Week 872538923 | Week 872538924 | Week 872538922 | Week 872538925 | Week 1272538922 | Week 1272538923 | Week 1272538924 | Week 1272538925 | Week 1672538922 | Week 1672538923 | Week 1672538925 | Week 1672538924 | Week 2472538922 | Week 2472538923 | Week 2472538924 | Week 2472538925 | Week 3272538922 | Week 3272538923 | Week 3272538925 | Week 3272538924 | Week 4072538922 | Week 4072538923 | Week 4072538925 | Week 4072538924 | Week 5272538922 | Week 5272538923 | Week 5272538924 | Week 5272538925 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Missing | Any Improvement | No Change | Any Worsening | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 78 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 34 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 80 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 85 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 75 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 78 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 82 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 81 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 77 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 75 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 81 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 87 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 79 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 67 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 77 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 73 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 70 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 70 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 80 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 72 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 66 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 64 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 76 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 50 mg BID | 64 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: Placebo | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 25 mg QD | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DBPC Period: M2951 75 mg QD | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The erythema score is lesion-specific and based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic. (NCT03958955)
Timeframe: Week 6
| Intervention | scores on a scale (Median) |
|---|---|
| Delgocitinib Cream 20 mg/g | 1.5 |
| Delgocitinib Cream Vehicle | 1.5 |
Number of AEs from baseline to Week 6 (NCT03958955)
Timeframe: Week 0 to Week 6
| Intervention | AEs (Number) |
|---|---|
| All Subjects | 8 |
The number of lesion-specific, treatment-related AEs per target lesion will be compared for active and vehicle treatment. Lesion-specific AEs are defined as lesional/perilesional AEs (i.e. AE location within the treatment area and/or ≤2 cm from the border of a target lesion). (NCT03958955)
Timeframe: Week 0 to Week 6
| Intervention | AEs (Number) |
|---|---|
| Delgocitinib Cream 20 mg/g | 2 |
| Delgocitinib Cream Vehicle | 0 |
The erythema score is lesion-specific and based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic. (NCT03958955)
Timeframe: Week 0 to Week 6
| Intervention | lesions (Number) |
|---|---|
| Delgocitinib Cream 20 mg/g | 5 |
| Delgocitinib Cream Vehicle | 5 |
The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions. (NCT03958955)
Timeframe: Week 0 to Week 6
| Intervention | lesions (Number) |
|---|---|
| Delgocitinib Cream 20 mg/g | 3 |
| Delgocitinib Cream Vehicle | 6 |
Number of subjects with AEs from baseline to Week 6 (NCT03958955)
Timeframe: Week 0 to Week 6
| Intervention | Participants (Count of Participants) |
|---|---|
| All Subjects | 8 |
The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions. (NCT03958955)
Timeframe: Week 6
| Intervention | lesions (Number) |
|---|---|
| Delgocitinib Cream 20 mg/g | 3 |
| Delgocitinib Cream Vehicle | 6 |
The skin disease activity scores are based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The total skin disease activity score is defined as the sum of the scores for 3 clinical signs (erythema, scaling/hyperkeratosis, oedema/infiltration) for each target lesion. For the total score and the individual clinical signs, higher scores indicate more severe symptoms. Erythema is scored on a 4-point scale ranging from 0 (absent) to 3 (dark red, purple/violaceous/crusted/haemorrhagic). Hyperkeratosis/scaling is scored on a 3-point scale from 0 (absent) to 2 (verrucous hyperkeratosis). Oedema/infiltration is scored on a 3-point scale from 0 (absent) to 2 (palpable and visible). The total skin disease activity score can therefore range from 0 to 7. (NCT03958955)
Timeframe: Week 6
| Intervention | scores on a scale (Median) |
|---|---|
| Delgocitinib Cream 20 mg/g | 2.5 |
| Delgocitinib Cream Vehicle | 2.5 |
SRI response is defined as >=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of <0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (<=9 vs. >=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other). (NCT01484496)
Timeframe: Week 52
| Intervention | Percentage of par. (Number) |
|---|---|
| Placebo SC | 48.4 |
| Belimumab 200 mg SC | 61.4 |
For the analysis of steroid use, all steroid dosages were converted to a prednisone equivalent in mg. The average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, SC, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as having a prednisone reduction by >=25% from Baseline to <=7.5 mg/day during Weeks 40 through 52. At Baseline, the average daily prednisone dose was the sum of all prednisone doses over 7 consecutive days up to, but not including Day 0, divided by 7. For this analysis, the average prednisone dose was the total prednisone dose during weeks 40 through 52 divided by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline prednisone dose, Baseline SELENA SLEDAI score, (<=9 vs >=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other). (NCT01484496)
Timeframe: Baseline (Day 0, prior to dosing), Weeks 40 through Week 52
| Intervention | Percentage of par. (Number) |
|---|---|
| Placebo SC | 11.9 |
| Belimumab 200 mg SC | 18.2 |
Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SELENA SLEDAI SLE flare index that excludes severe flares that were triggered only by an increase in SELENA SLEDAI score to >12 (since this may only represent a modest increase in disease activity). Only post-baseline severe flares were considered. (NCT01484496)
Timeframe: Baseline (Day 0, prior to dosing) to Week 52
| Intervention | Days (Median) |
|---|---|
| Placebo SC | 118 |
| Belimumab 200 mg SC | 171 |
FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.26 |
| 2 mg Baricitinib | 6.90 |
| 4 mg Baricitinib | 6.96 |
The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52
| Intervention | swollen joint count (Least Squares Mean) |
|---|---|
| Placebo | -4.79 |
| 2 mg Baricitinib | -5.10 |
| 4 mg Baricitinib | -5.31 |
The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52
| Intervention | tender joint count (Least Squares Mean) |
|---|---|
| Placebo | -6.92 |
| 2 mg Baricitinib | -7.40 |
| 4 mg Baricitinib | -7.83 |
Participants assessed the worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.37 |
| 2 mg Baricitinib | -1.45 |
| 4 mg Baricitinib | -1.44 |
"The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K <=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where no activity is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the new feature is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), <=1; (4) current prednisolone (or equivalent) dose <=7.5 mg daily." (NCT03616964)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 23.2 |
| 2 mg Baricitinib | 24.0 |
| 4 mg Baricitinib | 25.4 |
"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616964)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.6 |
| 4 mg Baricitinib | 47.1 |
"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616964)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.6 |
| 2 mg Baricitinib | 46.3 |
For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by >=25% from Baseline to <=7.5 mg/day during Weeks 40 through 52. (NCT03616964)
Timeframe: Baseline, Week 40 through Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 31.7 |
| 2 mg Baricitinib | 29.8 |
| 4 mg Baricitinib | 34.3 |
The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations. (NCT03616964)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 66.1 |
| 2 mg Baricitinib | 56.9 |
| 4 mg Baricitinib | 58.0 |
AUCtau,ss reported for participants who received multiple doses of mg baricitinib was derived by a population pharmacokinetics approach. (NCT03616964)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
| Intervention | nanogram*hour/milliliter (ng*h/mL) (Geometric Mean) |
|---|---|
| 2 mg Baricitinib | 257 |
| 4 mg Baricitinib | 505 |
PK: Maximum Concentration of Baricitinib at steady-state (Cmax,ss) was derived by a population pharmacokinetics approach. (NCT03616964)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
| Intervention | nanograms per milliliter (ng/mL) (Geometric Mean) |
|---|---|
| 2 mg Baricitinib | 27.0 |
| 4 mg Baricitinib | 54.1 |
Time to first severe flare analyzed using a Cox proportional hazards model with treatment group, baseline disease activity [Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) <10; SLEDAI-2K ≥10], baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time. (NCT03616964)
Timeframe: Baseline to Week 52
| Intervention | weeks (Median) |
|---|---|
| Placebo | NA |
| 2 mg Baricitinib | NA |
| 4 mg Baricitinib | NA |
A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment. (NCT02446912)
Timeframe: Baseline to Week 52
| Intervention | Annualized flare rate ratio (Number) |
|---|---|
| Anifrolumab 150 mg | 0.62 |
| Anifrolumab 300 mg | 0.60 |
| Placebo | 0.72 |
PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms. (NCT02446912)
Timeframe: Baseline to Week 52
| Intervention | Score on a Scale (Mean) |
|---|---|
| Anifrolumab 150 mg | -2.1 |
| Anifrolumab 300 mg | -2.7 |
| Placebo | -1.7 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs. (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 80 |
| Anifrolumab 300 mg | 161 |
| Placebo | 145 |
"An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death).~AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 11 |
| Anifrolumab 300 mg | 23 |
| Placebo | 18 |
"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 35 |
| Anifrolumab 300 mg | 65 |
| Placebo | 74 |
"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 45 |
| Anifrolumab 300 mg | 84 |
| Placebo | 79 |
"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold." (NCT02446912)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 34 |
| Anifrolumab 300 mg | 74 |
| Placebo | 75 |
"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 40 |
| Anifrolumab 300 mg | 83 |
| Placebo | 79 |
"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 30 |
| Anifrolumab 300 mg | 53 |
| Placebo | 59 |
"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 40 |
| Anifrolumab 300 mg | 71 |
| Placebo | 63 |
"Maintained OCS reduction was defined by meeting all the following criteria:~Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 17 |
| Anifrolumab 300 mg | 42 |
| Placebo | 33 |
"Maintained OCS reduction was defined by meeting all of the following criteria:~Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 24 |
| Anifrolumab 300 mg | 50 |
| Placebo | 33 |
"A BICLA responder was achieved if all of the following criteria was met:~All criteria related to SRI(4) (please see primary endpoint) plus:~Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 27 |
| Anifrolumab 300 mg | 67 |
| Placebo | 49 |
"A BICLA responder was achieved if all of the following criteria was met:~All criteria related to SRI(4) (please see primary endpoint) plus:~Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 35 |
| Anifrolumab 300 mg | 83 |
| Placebo | 54 |
"50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria:~Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment." (NCT02446912)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 15 |
| Anifrolumab 300 mg | 24 |
| Placebo | 14 |
"50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all the following criteria:~Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 16 |
| Anifrolumab 300 mg | 25 |
| Placebo | 14 |
ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant. (NCT02446912)
Timeframe: Baseline to Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 0 |
| Anifrolumab 300 mg | 0 |
| Placebo | 0 |
Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 44 |
| Anifrolumab 300 mg | 71 |
| Placebo | 87 |
"Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported.~Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 3 |
| Anifrolumab 300 mg | 2 |
| Placebo | 2 |
"Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.~Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 14 |
| Anifrolumab 300 mg | 36 |
| Placebo | 46 |
"The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories.~Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 150 mg | 38 |
| Anifrolumab 300 mg | 58 |
| Placebo | 67 |
"The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered yes at any time during the treatment period (Baseline to Week 52) to one of the 10 categories:~Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide" (NCT02446912)
Timeframe: Baseline to Week 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Suicidal ideation | Suicidal behaviour | |
| Anifrolumab 150 mg | 1 | 0 |
| Anifrolumab 300 mg | 2 | 0 |
| Placebo | 2 | 1 |
A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment. (NCT02446899)
Timeframe: Baseline to Week 52
| Intervention | Annualized flare rate ratio (Number) |
|---|---|
| Anifrolumab 300 mg | 0.43 |
| Placebo | 0.64 |
"Maintained OCS reduction was defined by meeting all of the following criteria:~Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40~Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Week 40; Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 45 |
| Placebo | 25 |
"Composite endpoint BICLA was defined by meeting all of the following criteria:~Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B~No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of >0 points in SLEDAI-2K~No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS)~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 86 |
| Placebo | 57 |
"Defined by meeting all of the following criteria:~Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B~No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline to >0 points in SLEDAI-2K~No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS)~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 72 |
| Placebo | 46 |
"50% reduction in the number of swollen and tender joints compared to baseline was defined by meeting all of the following criteria:~Achieve ≥50% reduction from baseline in the number of swollen and tender joints, separately~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 30 |
| Placebo | 34 |
"50% reduction in CLASI activity score compared to baseline was defined by meeting all of the following criteria:~Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 24 |
| Placebo | 10 |
"Clinical laboratory tests were analyzed in a central clinical laboratory and included hematology, serum chemistry and urinalysis tests.~Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 72 |
| Placebo | 87 |
"Vital sign measurements included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.~Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 45 |
| Placebo | 45 |
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs. (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 162 |
| Placebo | 154 |
"An AESI is an adverse event (AE) of scientific and medical concern specific to understanding biologics. An AESI may be serious or non-serious. AESI are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, tuberculosis (TB) (including latent TB), influenza, vasculitis (non-systemic lupus erythematosus [SLE]), and major adverse cardiovascular events (MACE) (including stroke, myocardial infarction [MI], or cardiovascular death).~AESIs were collected throughout the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Anifrolumab 300 mg | 29 |
| Placebo | 20 |
"The Patient's Global Assessment of Disease Activity is a single-item, patient reported scale developed for the assessment of the patient's overall rating of their disease activity due to SLE. The scale measures disease activity through a 5 point Likert scale ranging from 0 (No disease activity) to 4 (Severe disease activity) at its worst over the past 7 days. LS mean was determined by MMRM model with baseline of response, region, baseline disease activity (SLEDAI-2K <10, >=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment*time (type III sum of squares)." (NCT02708095)
Timeframe: Baseline, Week 24
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.67 |
| 2 mg Baricitinib | -0.83 |
| 4 mg Baricitinib | -1.00 |
SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, region, baseline disease activity (SLEDAI-2K <10, >=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment*time (type III sum of squares). (NCT02708095)
Timeframe: Baseline, Week 24
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -3.82 |
| 2 mg Baricitinib | -4.07 |
| 4 mg Baricitinib | -4.39 |
Participants were defined as responder as follows using SLEDAI-2K definitions of arthritis and rash. If only arthritis is present at baseline, then arthritis must be absent at Week 24 to meet the primary endpoint. If only rash is present at baseline, then rash must be absent at Week 24 to meet the primary endpoint. If both arthritis and rash are present at baseline, then the primary endpoint is met if either arthritis, or rash, or both arthritis and rash are absent at Week 24. (NCT02708095)
Timeframe: Week 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 53.3 |
| 2 mg Baricitinib | 58.1 |
| 4 mg Baricitinib | 67.3 |
SRI-4 response is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores; and 3) no worsening (defined as an increase of ≥0.3 points [10 mm] from baseline) in Physician's Global Assessment of Disease Activity. The SRI-4 is a composite index used to assess disease activity in SLE. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). (NCT02708095)
Timeframe: Week 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 47.6 |
| 2 mg Baricitinib | 51.4 |
| 4 mg Baricitinib | 64.4 |
Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. AUC takes all time points post dose into account and one value is reported. (NCT02708095)
Timeframe: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose
| Intervention | nanogram*hour per milliliter (ng*h/mL) (Geometric Mean) |
|---|---|
| 2 mg Baricitinib | 265 |
| 4 mg Baricitinib | 569 |
Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. Cmax takes all time points post dose into account and one value is reported. (NCT02708095)
Timeframe: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose
| Intervention | nanogram per milliliter (ng/mL) (Geometric Mean) |
|---|---|
| 2 mg Baricitinib | 29.0 |
| 4 mg Baricitinib | 59.2 |
SRI-4 response:>=4-point reduction in SLEDAI-2K total score, no British Isles Lupus Assessment Group (BILAG) A (severe disease) and no more than 1 new BILAG B (moderate disease) domain score and no worsening (<10 % increase)from baseline in Physician's Global Assessment(PGA).SLEDAI measures disease activity in 9 organ systems,higher scores=more severe disease activity.Each organ system measured as either absent/present within last 30 days and weighted score across systems was utilized to calculate total SLEDAI score(range:0=no symptoms to 105=presence of all defined symptoms). Improvement is defined as reduction in SLEDAI score (BILAG) Index: assessing clinical signs, symptoms,or laboratory parameters related to SLE,divided into 9 domains. Each domain can range from A=new domain activity, B=worse domain activity, C=same domain activity, D=improving domain activity to E=absence of domain activity. PGA assesses disease activity on visual analogue scale from very well(0)-very poor(10). (NCT03517722)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo to Ustekinumab | 56.0 |
| Ustekinumab | 43.9 |
Reduction of glucocorticoid dose was defined as a reduction in average daily oral glucocorticoid dose by at least 50% (relative to the baseline dose) or reduction of average daily oral glucocorticoid dose by at least 25% (relative to the baseline dose) so that the average daily dose was reduced to less than or equal to (<=) 7.5 milligram (mg) (prednisone or equivalent). Sustained reduction of glucocorticoid dose was defined as achieving an average daily oral glucocorticoid dose reduction between Weeks 24 and 40, and sustaining that reduction through Week 52, in those participants who, at baseline, were receiving oral glucocorticoids. (NCT03517722)
Timeframe: Up to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo to Ustekinumab | 29.3 |
| Ustekinumab | 44.3 |
Percentage of participants with reduction in glucocorticoid dose by Week 40, its sustenance through Week 52, and SRI 4 composite response at Week 52 were reported. Reduction of glucocorticoid dose was defined as reduction in average daily oral glucocorticoid dose by at least 50% (relative to baseline dose) or reduction of average daily oral glucocorticoid dose by at least 25% (relative to baseline dose) so that average daily dose is reduced to <=7.5 mg (prednisone or equivalent). Sustained reduction of glucocorticoid dose was defined as achieving an average daily oral glucocorticoid dose reduction between Weeks 24 and 40, and sustaining that reduction through Week 52, in those participants who,at baseline,were receiving oral glucocorticoids. SRI-4 was defined as composite of at least 4-point improvement in SLEDAI-2K score of 0=no symptoms to 105=presence of all defined symptoms with higher scores representing increased disease activity),no worsening in BILAG and no worsening in PGA. (NCT03517722)
Timeframe: Up to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo to Ustekinumab | 23.9 |
| Ustekinumab | 30.0 |
The percentage of participants who achieved at least 50% improvement from baseline in number of joints with pain and signs of inflammation at Week 52 for participants with at least 4 joints with pain and signs of inflammation at baseline were reported. (NCT03517722)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo to Ustekinumab | 66.3 |
| Ustekinumab | 64.7 |
SRI-4 response:>=4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no BILAG A (severe disease) and no more than 1 new BILAG B (moderate disease) domain score and no worsening (<10 % increase)from baseline in PGA.SLEDAI measures disease activity in 9 organ systems, higher scores=more severe disease activity. Each organ system measured as either absent/present within last 30 days and weighted score across systems was utilized to calculate total SLEDAI score(range:0=no symptoms to 105=presence of all defined symptoms). Improvement is defined as reduction in SLEDAI score (BILAG) Index: assessing clinical signs, symptoms,or laboratory parameters related to SLE,divided into 9 domains. Each domain can range from A=new domain activity, B=worse domain activity, C=same domain activity, D=improving domain activity to E=absence of domain activity. PGA assesses disease activity on visual analogue scale from very well(0)-very poor(10). (NCT03517722)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo to Ustekinumab | 56 |
| Ustekinumab | 45.7 |
Percentage of participants achieving at least 50% improvement in CLASI activity score at Week 52 reported in participants with a CLASI activity score of 4 or greater at baseline. The CLASI is an instrument to assess the disease activity and damage caused to the skin for cutaneous lupus erythematosus participants with or without systemic involvement. The CLASI activity score ranges from 0-70 with lower score being improved. Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss, and non-scarring alopecia. (NCT03517722)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo to Ustekinumab | 55.9 |
| Ustekinumab | 40.7 |
Time to flare is defined as the time (in days) post baseline when the first flare occurs. It was calculated with flare defined as either 1 or more BILAG A (severe disease activity) or 2 or more new BILAG B (moderate disease activity) domain scores relative to baseline. BILAG was defined as a measure of alterations or intensification to therapy consisting of 97 questions in 9 domains. Each domain can range from A=new domain activity, B=worse domain activity, C=same domain activity, D=improving domain activity to E=absence of domain activity. BILAG A flare was defined as at least 1 new BILAG A scores. BILAG B flare was defined as at least 2 new BILAG B scores. (NCT03517722)
Timeframe: Up to Week 52
| Intervention | days (Mean) | ||
|---|---|---|---|
| Time to First BILAG Flare | Time to First BILAG A Flare | Time to First BILAG B Flare | |
| Placebo to Ustekinumab | 200.4 | 201.4 | 218.1 |
| Ustekinumab | 204.7 | 203.1 | 208.7 |
Participants' current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented. (NCT03978520)
Timeframe: From Baseline to Week 24
| Intervention | mg (Least Squares Mean) |
|---|---|
| Elsubrutinib Placebo/Upadacitinib Placebo | -0.65 |
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | -0.45 |
| Elsubrutinib Placebo/Upadacitinib 30 mg | -0.62 |
BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment [PhGA], < 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score. (NCT03978520)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Elsubrutinib Placebo/Upadacitinib Placebo | 42.7 |
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | 54.4 |
| Elsubrutinib Placebo/Upadacitinib 30 mg | 58.1 |
LLDAS is a state of low disease activity based on Systemic Lupus Erythematosus Disease Activity Index 2000 score (SLEDAI-2K score ≤4 excluding SLEDAI-2K activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA ≤1), and concomitant medication usage (steroid dose ≤7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses). (NCT03978520)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Elsubrutinib Placebo/Upadacitinib Placebo | 13.3 |
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | 30.9 |
| Elsubrutinib Placebo/Upadacitinib 30 mg | 45.2 |
"SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline:~≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score~No worsening of the overall condition (< 0.3 point increase in Physician's Global Assessment [PhGA])~No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history." (NCT03978520)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Elsubrutinib Placebo/Upadacitinib Placebo | 37.3 |
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | 48.5 |
| Elsubrutinib Placebo/Upadacitinib 30 mg | 54.8 |
"SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline:~≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score~No worsening of the overall condition (< 0.3 point increase in Physician's Global Assessment [PhGA])~No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history." (NCT03978520)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Elsubrutinib Placebo/Upadacitinib Placebo | 38.7 |
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | 54.4 |
| Elsubrutinib Placebo/Upadacitinib 30 mg | 56.5 |
The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity. (NCT03978520)
Timeframe: From Baseline to Week 24
| Intervention | Events per patient-year (Number) | ||
|---|---|---|---|
| Mild/Moderate | Severe | Overall | |
| ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) | 1.39 | 0.26 | 1.65 |
| Elsubrutinib Placebo/Upadacitinib 30 mg | 1.76 | 0.10 | 1.87 |
| Elsubrutinib Placebo/Upadacitinib Placebo | 2.45 | 0.36 | 2.81 |
CLASI-50 Response is defined as a 50% improvement from baseline in CLASI-A score at Week 24. The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Placebo | 42.11 |
| Part A: BIIB059 50 mg | 50 |
| Part A: BIIB059 150 mg | 16.67 |
| Part A: BIIB059 450 mg | 64.10 |
An active joint is defined as a joint with pain and signs of inflammation (e.g., tenderness, swelling or effusion). The 28 Joint Count includes assessment of swelling and tenderness in the shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and knees. The investigator counts how many of the 28 joints are swollen or tender at the given week. (NCT02847598)
Timeframe: Baseline to Week 24
| Intervention | joints (Mean) |
|---|---|
| Part A: Placebo | -12.7 |
| Part A: BIIB059 50 mg | -9.0 |
| Part A: BIIB059 150 mg | -13.0 |
| Part A: BIIB059 450 mg | -14.5 |
The PGA is used to quantify disease activity and is measured using an anchored VAS. The PGA asks the Investigator to assess the participants current disease activity from a score of 0 (none) to 3 (severe), where higher score means severe SLE disease activity. (NCT02847598)
Timeframe: Baseline to Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Part A: Placebo | -2.46 |
| Part A: BIIB059 50 mg | -2.05 |
| Part A: BIIB059 150 mg | -0.12 |
| Part A: BIIB059 450 mg | -2.45 |
The SLEDAI-2K is a reliable, valid, simple, 1-page activity index that measures disease activity and records features of active lupus as present or not. It uses a weighted checklist to assign a numeric score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 28 days. Each symptom present is assigned between 1 and up to 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms), where higher scores representing increased disease activity. (NCT02847598)
Timeframe: Baseline to Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Part A: Placebo | -2.1 |
| Part A: BIIB059 50 mg | -3.0 |
| Part A: BIIB059 150 mg | -1.3 |
| Part A: BIIB059 450 mg | -4.4 |
(NCT02847598)
Timeframe: Baseline up to Week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| Part A: Placebo | 0 |
| Part A: BIIB059 50 mg | 0 |
| Part A: BIIB059 150 mg | 0 |
| Part A: BIIB059 450 mg | 0 |
(NCT02847598)
Timeframe: Baseline up to Week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| Part A: Placebo | 0 |
| Part A: BIIB059 50 mg | 0 |
| Part A: BIIB059 150 mg | 0 |
| Part A: BIIB059 450 mg | 0 |
(NCT02847598)
Timeframe: Baseline up to Week 36
| Intervention | Participants (Count of Participants) |
|---|---|
| Part A: Placebo | 0 |
| Part A: BIIB059 50 mg | 0 |
| Part A: BIIB059 150 mg | 0 |
| Part A: BIIB059 450 mg | 0 |
(NCT02847598)
Timeframe: Baseline up to Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Part A: Placebo | 1 |
| Part A: BIIB059 50 mg | 0 |
| Part A: BIIB059 150 mg | 0 |
| Part A: BIIB059 450 mg | 5 |
An SRI-4 at Week 24 was a categorical response variable (Yes/No) incorporating the following criteria for achievement of responder status (i.e., all criteria must have been met to achieve responder status): A reduction from baseline of ≥4 points in SLEDAI-2K, No new organ system affected, as defined by no new BILAG-2004 Grade A and no more than 1 new BILAG-2004 Grade B, No worsening from baseline in participant's lupus disease activity, defined by a <1-point increase in the PGA (VAS) [on a scale of 0 to 10],No changes to protocol-specified medication rules,as follows (all criteria were required to be met): No initiation or increase of SLE standard of care therapy or other disallowed concomitant therapy; Concomitant corticosteroid dosage at Week 24 to be ≤10 mg/day;Concomitant corticosteroid dosage at Week 24 was no more than at Day 1;No increase in corticosteroid dose between Weeks 17 and 24. The percentage of participants who had responded to each of the 4 criteria was also reported. (NCT02847598)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Placebo | 28.57 |
| Part A: BIIB059 50 mg | 33.33 |
| Part A: BIIB059 150 mg | 16.67 |
| Part A: BIIB059 450 mg | 56.25 |
The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=4-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Placebo | 57.89 |
| Part A: BIIB059 50 mg | 83.66 |
| Part A: BIIB059 150 mg | 16.67 |
| Part A: BIIB059 450 mg | 71.79 |
The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=7-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Placebo | 34.21 |
| Part A: BIIB059 50 mg | 66.67 |
| Part A: BIIB059 150 mg | 16.67 |
| Part A: BIIB059 450 mg | 56.41 |
No new organ system affected, as defined by no new British Isles Lupus Activity Group (BILAG)-2004 A and no more than one new BILAG-2004 B. The BILAG-2004 index categorizes disease activity in each organ system into five different levels from A to E. Grade A represents very active disease, Grade B represents moderate disease activity, Grade C indicates mild stable disease, and grade D implies no disease activity, but suggests the organ system had previously been affected. Grade E indicates no current or previous disease activity. A score is applied to each grade of each organ system using coding scheme of A=12, B=8, C=1, and D/E=0 and is summarized as a total score ranging 0-108. Higher scores indicate more severe disease activity. (NCT02847598)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Placebo | 82.14 |
| Part A: BIIB059 50 mg | 100.00 |
| Part A: BIIB059 150 mg | 50.00 |
| Part A: BIIB059 450 mg | 85.94 |
(NCT02847598)
Timeframe: Baseline up to Week 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Part B: Placebo | 0 |
| Part B: BIIB059 50 mg | 0 |
| Part B: BIIB059 150 mg | 0 |
| Part B: BIIB059 450 mg | 0 |
(NCT02847598)
Timeframe: Baseline up to Week 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Part B: Placebo | 0 |
| Part B: BIIB059 50 mg | 0 |
| Part B: BIIB059 150 mg | 0 |
| Part B: BIIB059 450 mg | 0 |
(NCT02847598)
Timeframe: Baseline up to Week 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Part B: Placebo | 0 |
| Part B: BIIB059 50 mg | 0 |
| Part B: BIIB059 150 mg | 0 |
| Part B: BIIB059 450 mg | 0 |
(NCT02847598)
Timeframe: Baseline up to Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Part B: Placebo | 0 |
| Part B: BIIB059 50 mg | 5 |
| Part B: BIIB059 150 mg | 4 |
| Part B: BIIB059 450 mg | 5 |
The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| Part B: Placebo | -10.73 |
| Part B: BIIB059 50 mg | -38.72 |
| Part B: BIIB059 150 mg | -47.82 |
| Part B: BIIB059 450 mg | -35.25 |
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a clinical tool that quantifies disease activity and damage in cutaneous lupus erythematosus (CLE). The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Baseline to Week 16
| Intervention | percent change (Mean) |
|---|---|
| Part B: Placebo | -15.03 |
| Part B: BIIB059 50 mg | -35.52 |
| Part B: BIIB059 150 mg | -47.11 |
| Part B: BIIB059 450 mg | -41.66 |
Vaccine-related immunoglobulin titers for tetanus and diphtheria were analyzed using international units per milliliter (IU/mL). (NCT02847598)
Timeframe: Baseline to Week 24
| Intervention | IU/mL (Mean) | |||
|---|---|---|---|---|
| C. tetani IgG Antibody: Baseline | C. tetani IgG Antibody: Change at Week 24 | Diphtheria IgG Antibody: Baseline | Diphtheria IgG Antibody: Change at Week 24 | |
| Part A: BIIB059 150 mg | 2.52 | 1.07 | 0.17 | 0.07 |
| Part A: BIIB059 450 mg | 3.30 | -0.70 | 0.33 | -0.07 |
| Part A: BIIB059 50 mg | 1.73 | 0.07 | 0.10 | -0.03 |
| Part A: Placebo | 2.46 | -0.07 | 0.33 | -0.06 |
Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) were analyzed, including 23 types of serotypes (sero). AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 24
| Intervention | milligrams per liter (mg/L) (Mean) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sero 1 IgG AB: Baseline | Sero 1 IgG AB: Change at Week 24 | Sero 2 IgG AB: Baseline | Sero 2 IgG AB: Change at Week 24 | Sero 3 IgG AB: Baseline | Sero 3 IgG AB: Change at Week 24 | Sero 4 IgG AB: Baseline | Sero 4 IgG AB: Change at Week 24 | Sero 5 IgG AB: Baseline | Sero 5 IgG AB: Change at Week 24 | Sero 6 IgG AB: Baseline | Sero 6 IgG AB: Change at Week 24 | Sero 7 IgG AB: Baseline | Sero 7 IgG AB: Change at Week 24 | Sero 8 IgG AB: Baseline | Sero 8 IgG AB: Change at Week 24 | Sero 9N IgG AB: Baseline | Sero 9N IgG AB: Change at Week 24 | Sero 9V IgG AB: Baseline | Sero 9V IgG AB: Change at Week 24 | Sero 10A IgG AB: Baseline | Sero 10A IgG AB: Change at Week 24 | Sero 11A IgG AB: Baseline | Sero 11A IgG AB: Change at Week 24 | Sero 12F IgG AB: Baseline | Sero 12F IgG AB: Change at Week 24 | Sero 14 IgG AB: Baseline | Sero 14 IgG AB: Change at Week 24 | Sero 15B IgG AB: Baseline | Sero 15B IgG AB: Change at Week 24 | Sero 17F IgG AB: Baseline | Sero 17F IgG AB: Change at Week 24 | Sero 18C IgG AB: Baseline | Sero 18C IgG AB: Change at Week 24 | Sero 19A IgG AB: Baseline | Sero 19A IgG AB: Change at Week 24 | Sero 19F IgG AB: Baseline | Sero 19F IgG AB: Change at Week 24 | Sero 20 IgG AB: Baseline | Sero 20 IgG AB: Change at Week 24 | Sero 22F IgG AB: Baseline | Sero 22F IgG AB: Change at Week 24 | Sero 23F IgG AB: Baseline | Sero 23F IgG AB: Change at Week 24 | Sero 33F IgG AB: Baseline | Sero 33F IgG AB: Change at Week 24 | |
| Part A: BIIB059 150 mg | 2.705 | -0.565 | 4.202 | -1.975 | 1.2733 | -0.2067 | 1.317 | -0.795 | 13.507 | -7.322 | 4.458 | -3.083 | 7.0033 | -2.8917 | 2.6183 | -1.5483 | 2.810 | -0.907 | 1.5900 | -0.5750 | 14.040 | 0.100 | 4.095 | -0.782 | 2.077 | -1.220 | 8.167 | -0.798 | 4.332 | -1.607 | 11.952 | -5.898 | 2.980 | -0.915 | 50.3175 | -29.3558 | 8.353 | -3.673 | 21.8742 | -13.0942 | 5.525 | -3.657 | 0.685 | 0.190 | 5.630 | -3.740 |
| Part A: BIIB059 450 mg | 1.495 | 0.475 | 1.626 | -0.011 | 1.6579 | 0.8122 | 0.429 | 0.060 | 4.442 | 0.329 | 1.957 | 0.070 | 3.0983 | 0.3053 | 1.5890 | 0.1281 | 2.337 | 0.499 | 2.2696 | 0.6701 | 7.631 | -0.384 | 2.308 | -0.276 | 0.262 | -0.072 | 5.183 | 0.597 | 3.690 | -0.341 | 4.277 | 1.330 | 2.485 | 0.054 | 14.9554 | 4.0988 | 2.609 | 1.136 | 4.0902 | 1.2437 | 1.138 | 0.087 | 1.797 | 0.125 | 1.800 | 0.066 |
| Part A: BIIB059 50 mg | 3.873 | 0.055 | 5.715 | -1.648 | 2.1450 | -0.2017 | 2.602 | -1.510 | 10.693 | -4.692 | 4.462 | -2.168 | 8.5333 | -1.3283 | 3.1933 | -1.3300 | 2.710 | -1.327 | 1.8300 | -0.0767 | 17.847 | -8.062 | 3.203 | -1.615 | 2.355 | -1.648 | 13.982 | -7.027 | 6.287 | -2.262 | 11.422 | -6.123 | 3.475 | -1.172 | 35.2000 | -18.0750 | 10.857 | -6.447 | 26.7958 | -21.4475 | 5.743 | -4.000 | 1.897 | -0.150 | 6.600 | -5.042 |
| Part A: Placebo | 2.017 | 0.445 | 1.562 | 0.014 | 1.2607 | -0.0886 | 0.734 | -0.025 | 4.921 | 0.813 | 3.348 | -0.448 | 6.4300 | -1.0336 | 3.1978 | 0.0925 | 1.781 | 0.217 | 1.0274 | 0.3963 | 6.443 | 0.502 | 1.768 | 0.241 | 0.852 | 0.060 | 7.910 | -0.635 | 3.926 | 0.603 | 4.817 | 0.427 | 3.229 | -0.096 | 15.2372 | 2.2418 | 4.203 | 0.651 | 5.4506 | 0.0455 | 1.563 | 0.244 | 1.401 | 0.078 | 2.610 | -0.392 |
(NCT02847598)
Timeframe: Baseline up to Week 24
| Intervention | grams per Liter (g/L) (Mean) | |||||
|---|---|---|---|---|---|---|
| Immunoglobulin A (IgA): Baseline | IgA: Change at Week 24 | Immunoglobulin G (IgG): Baseline | IgG: Change at Week 24 | Immunoglobulin M (IgM): Baseline | IgM: Change at Week 24 | |
| Part A: BIIB059 150 mg | 4.080 | -0.057 | 17.620 | -0.790 | 1.242 | -0.150 |
| Part A: BIIB059 50 mg | 3.610 | -0.433 | 15.723 | -0.468 | 1.065 | -0.050 |
(NCT02847598)
Timeframe: Baseline up to Week 24
| Intervention | grams per Liter (g/L) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Immunoglobulin A (IgA): Baseline | IgA: Change at Week 16 | IgA: Change at Week 24 | Immunoglobulin G (IgG): Baseline | IgG: Change at Week 16 | IgG: Change at Week 24 | Immunoglobulin M (IgM): Baseline | IgM: Change at Week 16 | IgM: Change at Week 24 | |
| Part A: BIIB059 450 mg | 3.116 | -0.006 | 0.012 | 14.792 | 0.233 | 0.758 | 1.106 | -0.065 | -0.072 |
| Part A: Placebo | 3.350 | 0.033 | -0.093 | 14.423 | 1.057 | 0.874 | 1.046 | 0.004 | -0.003 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: Results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect. (NCT02847598)
Timeframe: Baseline up to Week 36
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| Part A: BIIB059 150 mg | 6 | 1 |
| Part A: BIIB059 450 mg | 36 | 3 |
| Part A: BIIB059 50 mg | 3 | 0 |
| Part A: Placebo | 38 | 6 |
The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Baseline, Week 12, 16 and 24
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Change at Week 12 | Change at Week 16 | Change at Week 24 | |
| Part A: BIIB059 150 mg | -8.39 | -6.19 | -17.92 |
| Part A: BIIB059 450 mg | -44.36 | -50.20 | -60.59 |
| Part A: BIIB059 50 mg | -29.32 | -41.76 | -58.61 |
| Part A: Placebo | -36.63 | -42.55 | -45.40 |
Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) including 23 types of serotypes (sero), tetanus and diphtheria were analyzed. AB = Antibody (NCT02847598)
Timeframe: Baseline to Week 24
| Intervention | percent change (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sero 1 IgG AB: Change at Week 24 | Sero 2 IgG AB: Change at Week 24 | Sero 3 IgG AB: Change at Week 24 | Sero 4 IgG AB: Change at Week 24 | Sero 5 IgG AB: Change at Week 24 | Sero 6B IgG AB: Change at Week 24 | Sero 7F IgG AB: Change at Week 24 | Sero 8 IgG AB: Change at Week 24 | Sero 9N IgG AB: Change at Week 24 | Sero 9V IgG AB: Change at Week 24 | Sero 10A IgG AB: Change at Week 24 | Sero 11A IgG AB: Change at Week 24 | Sero 12F IgG AB: Change at Week 24 | Sero 14 IgG AB: Change at Week 24 | Sero 15B IgG AB: Change at Week 24 | Sero 17F IgG AB: Change at Week 24 | Sero 18C IgG AB: Change at Week 24 | Sero 19A IgG AB: Change at Week 24 | Sero 19F IgG AB: Change at Week 24 | Sero 20 IgG AB: Change at Week 24 | Sero 22F IgG AB: Change at Week 24 | Sero 23F IgG AB: Change at Week 24 | Sero 33F IgG AB: Change at Week 24 | C.tetani IgG Antibody: Change at Week24 | Diphtheria IgG Antibody: Change at Week 24 | |
| Part A: BIIB059 150 mg | -10.403 | -26.089 | 16.282 | -26.435 | 2.937 | -40.573 | -27.272 | -19.919 | 2.985 | -13.591 | 11.364 | 14.976 | -41.416 | 2.213 | -5.380 | -29.346 | -30.608 | -16.275 | -20.778 | -53.328 | -27.150 | 35.862 | -47.069 | 29.887 | 77.083 |
| Part A: BIIB059 450 mg | 159.298 | 2.207 | 51.000 | 26.481 | 23.064 | 34.204 | 19.827 | 13.552 | 13.703 | 56.445 | 24.321 | 18.956 | -11.447 | 20.278 | 69.305 | 51.187 | 43.454 | 32.146 | 101.397 | 75.407 | 20.048 | 22.329 | 23.533 | -11.895 | -8.842 |
| Part A: BIIB059 50 mg | 2.996 | 17.857 | 530.405 | -15.385 | 81.053 | -7.761 | 1.928 | -14.917 | 22.663 | -3.399 | 101.031 | -16.656 | -5.463 | -31.375 | 17.353 | 1.009 | -14.827 | 44.814 | 5.412 | -37.641 | 23.828 | 18.204 | -3.348 | 39.032 | -50.000 |
| Part A: Placebo | 53.629 | -2.263 | -10.854 | -8.039 | 13.293 | -8.215 | -7.560 | 13.540 | 13.302 | 32.983 | 19.729 | 51.134 | -4.445 | -3.087 | 11.206 | 20.238 | 14.720 | 21.433 | 54.691 | 35.202 | 11.419 | 0.215 | 2.245 | 19.517 | 15.310 |
(NCT02847598)
Timeframe: Baseline up to Week 24
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| IgA: Change at Week 24 | IgG: Change at Week 24 | IgM: Change at Week 24 | |
| Part A: BIIB059 150 mg | -0.10 | -5.88 | -14.99 |
| Part A: BIIB059 50 mg | -15.55 | -2.53 | -6.73 |
(NCT02847598)
Timeframe: Baseline up to Week 24
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| IgA: Change at Week 16 | IgA: Change at Week 24 | IgG: Change at Week 16 | IgG: Change at Week 24 | IgM: Change at Week 16 | IgM: Change at Week 24 | |
| Part A: BIIB059 450 mg | -0.53 | -0.48 | 2.63 | 6.07 | -0.73 | 0.87 |
| Part A: Placebo | 1.50 | -1.51 | 7.30 | 6.86 | 0.96 | 1.86 |
(NCT02847598)
Timeframe: Part A: pre-dose on Days 1, 29, 85 and 113 and post-dose on Days 1, 8, 29, 85, 169, 197 and 253
| Intervention | nanogram per milliliter (ng/mL) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: Pre-dose | Day 1: Post-dose | Day 8 | Day 29: Pre-dose | Day 29: Post-dose | Day 85: Pre-dose | Day 113: Pre-dose | Day 169 | Day 197 | Day 253 | |
| Part A: BIIB059 150 mg | 0.0 | 2.1 | 17.1 | 23.7 | 25.9 | 12.7 | 11.3 | 12.8 | 4.1 | 0.4 |
(NCT02847598)
Timeframe: Part A: pre-dose on Days 1, 29, 85 and 113 and post-dose on Days 1, 8, 29, 85, 169, 197 and 253
| Intervention | nanogram per milliliter (ng/mL) (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: Pre-dose | Day 1: Post-dose | Day 8 | Day 29: Pre-dose | Day 29: Post-dose | Day 85: Pre-dose | Day 85: Post-dose | Day 113: Pre-dose | Day 169 | Day 197 | Day 253 | |
| Part A: BIIB059 450 mg | 0.0 | 1.9 | 45.5 | 53.6 | 52.5 | 34.7 | 36.1 | 34.6 | 32.0 | 12.6 | 2.8 |
(NCT02847598)
Timeframe: Part A: pre-dose on Days 1, 29, 85 and 113 and post-dose on Days 1, 8, 29, 85, 169, 197 and 253
| Intervention | nanogram per milliliter (ng/mL) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 1: Pre-dose | Day 1: Post-dose | Day 8 | Day 29: Pre-dose | Day 29: Post-dose | Day 85: Pre-dose | Day 113: Pre-dose | Day 169 | Day 197 | |
| Part A: BIIB059 50 mg | 0.0 | 0.7 | 5.5 | 7.0 | 7.9 | 3.9 | 3.4 | 3.7 | 0.9 |
Vaccine-related immunoglobulin titers for tetanus and diphtheria were analyzed. (NCT02847598)
Timeframe: Baseline to Week 12
| Intervention | IU/mL (Mean) | |
|---|---|---|
| C. tetani IgG Antibody: Baseline | Diphtheria IgG Antibody: Baseline | |
| Part B: BIIB059 50 mg | 3.00 | 0.10 |
Vaccine-related immunoglobulin titers for tetanus and diphtheria were analyzed. (NCT02847598)
Timeframe: Baseline to Week 12
| Intervention | IU/mL (Mean) | |||
|---|---|---|---|---|
| C. tetani IgG Antibody: Baseline | C. tetani IgG Antibody: Change at Week 12 | Diphtheria IgG Antibody: Baseline | Diphtheria IgG Antibody: Change at Week 12 | |
| Part B: BIIB059 450 mg | 5.04 | 1.20 | 0.74 | 0.06 |
| Part B: Placebo | 4.41 | -0.61 | 0.46 | -0.01 |
Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) were analyzed, including 23 types of serotypes (sero). AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 12
| Intervention | mg/L (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sero 1 IgG AB: Baseline | Sero 2 IgG AB: Baseline | Sero 3 IgG AB: Baseline | Sero 4 IgG AB: Baseline | Sero 5 IgG AB: Baseline | Sero 6B IgG AB: Baseline | Sero 7F IgG AB: Baseline | Sero 8 IgG AB: Baseline | Sero 9N IgG AB: Baseline | Sero 9V IgG AB: Baseline | Sero 10A IgG AB: Baseline | Sero 11A IgG AB: Baseline | Sero 12F IgG AB: Baseline | Sero 14 IgG AB: Baseline | Sero 15B IgG AB: Baseline | Sero 17F IgG AB: Baseline | Sero 18C IgG AB: Baseline | Sero 19A IgG AB: Baseline | Sero 19F IgG AB: Baseline | Sero 20 IgG AB: Baseline | Sero 22F IgG AB: Baseline | Sero 23F IgG AB: Baseline | Sero 33F IgG AB: Baseline | |
| Part B: BIIB059 50 mg | 0.210 | 0.9900 | 0.400 | 0.1000 | 3.3500 | 0.3600 | 0.660 | 0.2300 | 0.1300 | 0.070 | 2.140 | 0.3500 | 0.2700 | 8.9000 | 1.430 | 17.4500 | 0.140 | 13.7700 | 2.0500 | 0.7900 | 0.6700 | 0.5600 | 0.220 |
Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) were analyzed, including 23 types of serotypes (sero). AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 12
| Intervention | mg/L (Mean) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sero 1 IgG AB: Baseline | Sero 1 IgG AB: Change at Week 12 | Sero 2 IgG AB: Baseline | Sero 2 IgG AB: Change at Week 12 | Sero 3 IgG AB: Baseline | Sero 3 IgG AB: Change at Week 12 | Sero 4 IgG AB: Baseline | Sero 4 IgG AB: Change at Week 12 | Sero 5 IgG AB: Baseline | Sero 5 IgG AB: Change at Week 12 | Sero 6B IgG AB: Baseline | Sero 6B IgG AB: Change at Week 12 | Sero 7F IgG AB: Baseline | Sero 7F IgG AB: Change at Week 12 | Sero 8 IgG AB: Baseline | Sero 8 IgG AB: Change at Week 12 | Sero 9N IgG AB: Baseline | Sero 9N IgG AB: Change at Week 12 | Sero 9V IgG AB: Baseline | Sero 9V IgG AB: Change at Week 12 | Sero 10A IgG AB: Baseline | Sero 10A IgG AB: Change at Week 12 | Sero 11A IgG AB: Baseline | Sero 11A IgG AB: Change at Week 12 | Sero 12F IgG AB: Baseline | Sero 12F IgG AB: Change at Week 12 | Sero 14 IgG AB: Baseline | Sero 14 IgG AB: Change at Week 12 | Sero 15B IgG AB: Baseline | Sero 15B IgG AB: Change at Week 12 | Sero 17F IgG AB: Baseline | Sero 17F IgG AB: Change at Week 12 | Sero 18C IgG AB: Baseline | Sero 18C IgG AB: Change at Week 12 | Sero 19A IgG AB: Baseline | Sero 19A IgG AB: Change at Week 12 | Sero 19F IgG AB: Baseline | Sero 19F IgG AB: Change at Week 12 | Sero 20 IgG AB: Baseline | Sero 20 IgG AB: Change at Week 12 | Sero 22F IgG AB: Baseline | Sero 22F IgG AB: Change at Week 12 | Sero 23F IgG AB: Baseline | Sero 23F IgG AB: Change at Week 12 | Sero 33F IgG AB: Baseline | Sero 33F IgG AB: Change at Week 12 | |
| Part B: BIIB059 450 mg | 1.930 | 0.116 | 3.9669 | -0.4734 | 1.133 | 0.307 | 1.2376 | 0.0450 | 5.0124 | 3.4794 | 2.9210 | 0.2738 | 3.030 | 0.796 | 2.6629 | 0.5931 | 2.0848 | 0.5875 | 1.520 | -0.181 | 6.600 | 4.696 | 3.5831 | 0.6431 | 1.2424 | 0.3638 | 11.0210 | -1.0319 | 3.410 | 0.624 | 6.8752 | 1.4531 | 5.630 | 0.077 | 16.5624 | 5.3575 | 3.3800 | 1.2275 | 8.2971 | -1.6638 | 3.8002 | 1.8431 | 1.9957 | 0.2775 | 4.245 | 0.203 |
| Part B: Placebo | 3.538 | 4.193 | 4.7775 | -0.4586 | 3.881 | -1.886 | 3.6185 | 0.0571 | 7.2845 | 4.4443 | 10.7965 | 0.2943 | 2.482 | 4.399 | 3.6820 | 1.5329 | 4.1090 | 3.3407 | 1.104 | -0.001 | 6.760 | 1.833 | 2.1860 | 0.6293 | 2.1680 | 1.1429 | 5.6435 | 1.3686 | 4.717 | 0.209 | 16.0005 | -2.0357 | 4.083 | 8.439 | 24.5485 | 3.4457 | 4.1040 | 2.3893 | 11.5305 | -0.2271 | 5.9930 | -1.8500 | 1.6980 | 1.9964 | 5.500 | -0.281 |
(NCT02847598)
Timeframe: Baseline up to Week 16
| Intervention | g/L (Mean) | |||||
|---|---|---|---|---|---|---|
| IgA: Baseline | IgA: Change at Week 16 | IgG: Baseline | IgG: Change at Week 16 | IgM: Baseline | IgM: Change at Week 16 | |
| Part B: BIIB059 150 mg | 2.900 | -0.016 | 13.700 | -0.084 | 1.095 | -0.045 |
| Part B: BIIB059 50 mg | 3.873 | -0.117 | 14.087 | -0.776 | 0.880 | -0.072 |
(NCT02847598)
Timeframe: Baseline up to Week 16
| Intervention | g/L (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| IgA: Baseline | IgA: Change at Week 12 | IgA: Change at Week 16 | IgG: Baseline | IgG: Change at Week 12 | IgG: Change at Week 16 | IgM: Baseline | IgM: Change at Week 12 | IgM: Change at Week 16 | |
| Part B: BIIB059 450 mg | 3.061 | -0.304 | -0.076 | 14.874 | -1.961 | -0.064 | 0.993 | -0.028 | -0.035 |
| Part B: Placebo | 3.341 | -0.029 | -0.045 | 13.480 | 0.120 | 0.450 | 0.978 | -0.009 | -0.016 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: Results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect. (NCT02847598)
Timeframe: Baseline up to Week 28
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| Part B: BIIB059 150 mg | 15 | 3 |
| Part B: BIIB059 450 mg | 38 | 3 |
| Part B: BIIB059 50 mg | 18 | 1 |
| Part B: Placebo | 22 | 3 |
Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) including 23 types of serotypes (sero), tetanus and diphtheria were analyzed. AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 12
| Intervention | percent change (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sero 1 IgG AB: Change at Week 12 | Sero 2 IgG AB: Change at Week 12 | Sero 3 IgG AB: Change at Week 12 | Sero 4 IgG AB: Change at Week 12 | Sero 5 IgG AB: Change at Week 12 | Sero 6B IgG AB: Change at Week 12 | Sero 7F IgG AB: Change at Week 12 | Sero 8 IgG AB: Change at Week 12 | Sero 9N IgG AB: Change at Week 12 | Sero 9V IgG AB: Change at Week 12 | Sero 10A IgG AB: Change at Week 12 | Sero 11A IgG AB: Change at Week 12 | Sero 12F IgG AB: Change at Week 12 | Sero 14 IgG AB: Change at Week 12 | Sero 15B IgG AB: Change at Week 12 | Sero 17F IgG AB: Change at Week 12 | Sero 18C IgG AB: Change at Week 12 | Sero 19A IgG AB: Change at Week 12 | Sero 19F IgG AB: Change at Week 12 | Sero 20 IgG AB: Change at Week 12 | Sero 22F IgG AB: Change at Week 12 | Sero 23F IgG AB: Change at Week 12 | Sero 33F IgG AB: Change at Week 12 | C. tetani IgG Antibody: Change at Week 12 | Diphtheria IgG Antibody: Change at Week 12 | |
| Part B: BIIB059 450 mg | 4.257 | 15.437 | 40.604 | 32.033 | 68.850 | 43.759 | 25.297 | 41.622 | 19.616 | -0.573 | 60.437 | 29.295 | 62.768 | 18.059 | 27.188 | 19.712 | 8.882 | 44.140 | 46.995 | 0.714 | 38.974 | 16.859 | 26.241 | 27.872 | 28.845 |
| Part B: Placebo | 16.835 | -20.725 | -3.370 | 6.349 | 39.578 | 11.800 | 67.784 | 28.981 | 18.274 | -7.707 | 62.824 | 12.392 | 21.768 | 77.551 | 14.160 | -14.128 | 36.970 | 15.179 | 54.773 | 1.131 | -14.748 | 52.210 | 0.600 | -6.387 | 0.000 |
(NCT02847598)
Timeframe: Baseline up to Week 16
| Intervention | percent change (Mean) | ||
|---|---|---|---|
| Ig A: Change at Week 16 | Ig G: Change at Week 16 | Ig M: Change at Week 16 | |
| Part B: BIIB059 150 mg | 0.19 | 1.05 | -1.25 |
| Part B: BIIB059 50 mg | -1.48 | -3.84 | -7.60 |
(NCT02847598)
Timeframe: Baseline up to Week 16
| Intervention | percent change (Mean) | |||||
|---|---|---|---|---|---|---|
| Ig A: Change at Week 12 | Ig A: Change at Week 16 | Ig G: Change at Week 12 | Ig G: Change at Week 16 | Ig M: Change at Week 12 | Ig M: Change at Week 16 | |
| Part B: BIIB059 450 mg | -5.11 | -2.98 | -8.40 | -0.39 | -1.22 | -0.57 |
| Part B: Placebo | -1.45 | -1.32 | 0.63 | 2.48 | -1.25 | -3.62 |
The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=4-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 12, Week 16
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 12 | Week 16 | |
| Part B: BIIB059 150 mg | 76.00 | 72.00 |
| Part B: BIIB059 450 mg | 47.92 | 55.81 |
| Part B: BIIB059 50 mg | 50.00 | 46.15 |
| Part B: Placebo | 33.33 | 37.50 |
The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=7-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 12, Week 16
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 12 | Week 16 | |
| Part B: BIIB059 150 mg | 40.00 | 48.00 |
| Part B: BIIB059 450 mg | 33.33 | 41.86 |
| Part B: BIIB059 50 mg | 38.46 | 30.77 |
| Part B: Placebo | 18.18 | 21.88 |
CLASI-50 Response is defined as a 50% improvement from baseline in CLASI-A score at Weeks 12 and 16. The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Week 12, Week 16
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 12 | Week 16 | |
| Part B: BIIB059 150 mg | 48.00 | 44.00 |
| Part B: BIIB059 450 mg | 37.50 | 46.51 |
| Part B: BIIB059 50 mg | 38.46 | 38.46 |
| Part B: Placebo | 12.12 | 21.88 |
(NCT02847598)
Timeframe: Part B: pre-dose on Days 1, 29, 85 and post-dose on Days 1, 29, 85, 113, 141, 169 and 197
| Intervention | ng/mL (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: Pre-dose | Day 1: Post-dose | Day 8 | Day 29: Pre-dose | Day 29: Post-dose | Day 85: Pre-dose | Day 85: Post-dose | Day 113 | Day 141 | Day 169 | Day 197 | |
| Part B: BIIB059 150 mg | 0.1 | 1.1 | 13.3 | 16.9 | 17.6 | 11.0 | 11.6 | 12.1 | 4.6 | 2.2 | 1.1 |
| Part B: BIIB059 450 mg | 0.0 | 2.9 | 47.8 | 60.2 | 61.0 | 42.0 | 42.0 | 43.2 | 19.3 | 7.4 | 3.4 |
| Part B: BIIB059 50 mg | 0.0 | 0.4 | 6.8 | 8.3 | 8.7 | 3.8 | 4.1 | 4.6 | 2.5 | 2.4 | 0.8 |
Number of Participants with changes in vital signs, ECGs, Safety laboratory parameters (full blood count including white differential count, clinical chemistry, thyroid hormones, urinalysis, and faecal occult blood test), Development of anti-drug antibodies against BT063 (anti-BT063), Immunological status of potential viral and bacterial infections (HBV, HCV, HIV, tetanus, diphtheria tuberculosis), EBV / CMV Serology, Premature withdrawals. (NCT02554019)
Timeframe: Baseline through End of Trial Visit (Week 14)
| Intervention | Participants (Count of Participants) |
|---|---|
| BT063 50 mg | 0 |
| BT063 100 mg | 0 |
| Placebo | 0 |
Number of Participants with Adverse Events (Including SAEs and AEs leading to discontinuation) from Baseline through End of Trial Visit (Week 14) (NCT02554019)
Timeframe: Baseline through End of Trial Visit (Week 14)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Subjects with TEAEs | Subjects with TEAEs leading to early termination | Subjects with treatment-emergent SAEs | Subjects with drug-related TEAEs | Subjects with severe TEAEs | Subjects with TEAEs leading to death | |
| BT063 100 mg | 8 | 0 | 1 | 2 | 0 | 0 |
| BT063 50 mg | 5 | 1 | 1 | 1 | 0 | 0 |
| Placebo | 8 | 0 | 0 | 0 | 0 | 0 |
"Number of Participants with 50% improvement in Cutaneous Lupus Erythematosus Disease Area and Sensitivity Index (CLASI) Activity score. The CLASI is an assessment over 13 body regions (scalp, ears, nose - including malar area, rest of the face, V-area neck - frontal, post. neck & shoulders, chest, abdomen, back and buttocks, arms, hands, legs, feet) and consists of 2 scores: total activity score and total damage score. Only the activity score was used in this study.~The minimum score possible on this scale is 0 and the maximum score is 70. The higher scores mean a worse outcome." (NCT02554019)
Timeframe: At week14 and week 28
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 50% improvement in CLASI Activity score at week 14 | 50% improvement in CLASI Activity score at week 28 | |
| BT063 100 mg | 5 | 4 |
| BT063 50 mg | 6 | 7 |
| Placebo | 3 | 3 |
Number of Participants with 50% improvement of swollen/tender joints. A total of 66/68 joints was assessed for the swollen/tender joint count. A joint that is normal (no tenderness or swelling), without signs of inflammation will be graded as 0. A joint with tenderness will be graded as 1 for tender joint count and a joint with swelling will be graded as 1 for swollen joint count. Joints suspected or known to have ischemic osteonecrosis are not to be taken into consideration. Higher scores indicate more disease activity. (NCT02554019)
Timeframe: At week14 and week 28
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| 50% improvement in swollen joints at week 14 | 50% improvement in swollen joints at week 28 | 50% improvement in tender joints at week 14 | 50% improvement in tender joints at week 28 | |
| BT063 100 mg | 5 | 4 | 7 | 6 |
| BT063 50 mg | 8 | 7 | 5 | 7 |
| Placebo | 8 | 7 | 6 | 6 |
"Percent changes in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores from baseline SLEDAI-2K score.~The SLEDAI-2K is a global index that measures SLE disease activity. It includes 24 items for the 9 organs/systems. Scores range from 0 to 105; a score of 6 is considered clinically important. The index measures disease activity within the last 10 days. Higher scores mean worse outcome. Negative percent change means reduced disease activity." (NCT02554019)
Timeframe: Baseline to week 14 and at week 28
| Intervention | percentage of change (Mean) | |
|---|---|---|
| Percent changes in SLEDAI-2K scores at week 14 | Percent changes in SLEDAI-2K scores at week 28 | |
| BT063 100 mg | -18.0 | -24.4 |
| BT063 50 mg | -29.3 | -28.9 |
| Placebo | -18.2 | -13.5 |
Change from baseline in number of joints (active joint) with pain and signs of inflammation (tenderness, swelling or effusion) for participants with at least 2 affected joints at baseline were reported. An active joint is defined as a joint with pain and signs of inflammation (e.g., tenderness, swelling or effusion). (NCT02349061)
Timeframe: Baseline, Week 24
| Intervention | Joints (Mean) |
|---|---|
| Placebo | -2.8 |
| Ustekinumab | -4.5 |
PGA was recorded on a visual analogue scale (VAS; 0.0 to 10.0 centimeter [cm]). The scale for the physician's assessment ranges for 'no lupus activity' (0.0) to 'extremely active lupus' (10.0). (NCT02349061)
Timeframe: Baseline, Week 24
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -1.93 |
| Ustekinumab | -2.17 |
The SLEDAI-2K is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE patients in the previous 30 days. It is weighted according to the feature. Features are scored by the assessing physician if present within the last 30 days with more severe features having higher scores, and then simply added to determine the total SLEDAI 2K score, which ranges from 0 to 105, with higher scores representing increased disease activity. (NCT02349061)
Timeframe: Baseline, Week 24
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -3.8 |
| Ustekinumab | -4.4 |
BICLA response defined as participants meeting following criteria: 1. BILAG improvement (all BILAG A scores at baseline improved to either B, C or D and all BILAG B scores at baseline improved to C or D and no worsening in disease activity defined as no new BILAG A scores and <= 1 new BILAG B score) and 2. no worsening of total SLEDAI-2K from baseline 3. < 1 cm increase in PGA and 4. no treatment failure criteria met. BILAG: assesses disease extent, severity (range: A [severe] to E [no disease]). SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). PGA: assesses worsening in participant's general health status (0.0= 'no lupus activity' to 10.0 = 'extremely active lupus'). (NCT02349061)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 14 |
| Ustekinumab | 21 |
SRI-4 response was defined as greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA). Composite response is defined as SRI-4 response in participants who do not meet treatment failure criteria. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from very well (0)-very poor (10). (NCT02349061)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 33.3 |
| Ustekinumab | 61.7 |
The PK model was fitted to the observed serum concentration-time data. The AUC values reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days. (NCT01649765)
Timeframe: 28-days dosing interval at steady state
| Intervention | Micrograms per milliliter (Geometric Mean) |
|---|---|
| Belimumab 10 mg/kg | 3012 |
ParentGA assesses the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale (VAS; 0 - very well, 10 - very poorly). Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. Last Observation Carried Forward (LOCF) was used. Eight participants had a score of zero at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -23.61 |
| Belimumab 10 mg/kg | -53.85 |
The PedsQL is a generic quality of life scale validated for the pediatric population which consists of 23 items, encompassing 4 health domains: Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). From the raw scores of the 23 items, a total summary score and individual domain scores can be calculated. The total and domain scores are each transformed on a 0 to 100 score with higher scores indicating higher quality of life. For Physical Functioning Domain scale, score was from 0 to 100 where, 0 indicates lower quality of life and 100 indicates greater quality of life. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 12.5 |
| Belimumab 10 mg/kg | 10.5 |
The PGA is a 10 centimeter (cm) visual analogue scale (VAS), anchored at 0 (none) and 3 (severe), designed for the physician to indicate the participant's overall disease activity at a particular visit as part of the validated SELENA SLEDAI index. Primary investigator or a subinvestigator scored the PGA for the participant, and same person evaluated the participant each time. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. LOCF was used. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52
| Intervention | Percent change (Mean) |
|---|---|
| Placebo | -48.802 |
| Belimumab 10 mg/kg | -56.525 |
Percent change from Baseline in proteinuria was calculated. The percent change from baseline to Week 52 in 24 hour proteinuria was analyzed using summary statistics and 95% confidence intervals, without any adjustment for covariates. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52
| Intervention | Percent Change (Median) |
|---|---|
| Placebo | 7.0920 |
| Belimumab 10 mg/kg | -2.1277 |
The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. One participant had missing data at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52
| Intervention | Percent change (Mean) |
|---|---|
| Placebo | -38.0 |
| Belimumab 10 mg/kg | -43.3 |
Sustained ParentGA response was defined as having >0.7 improvement at Weeks 44, 48, and 52 compared at Baseline. Data for percentage of participants with a sustained ParentGA response was presented. Thirteen participants had a score of <=0.7 at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Up to 52 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 33.3 |
| Belimumab 10 mg/kg | 59.1 |
Sustained SRI response was defined as having a response on the primary efficacy endpoint at Weeks 44, 48, and 52. Data for percentage of participants with a sustained SRI response was presented. Drop Outs and Treatment Failures were considered Non-Responders. Only those participants with data available at specific time point were analyzed. (NCT01649765)
Timeframe: Up to 52 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 41.0 |
| Belimumab 10 mg/kg | 43.4 |
SRI response is defined as >=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of <0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (<=12 vs. >=13). Percentage of participants with SRI response at Week 52 of Part A were reported. Intent-to-Treat Population comprised of all participants who were randomized and treated with at least one dose of study agent in Part A. One participant had missing data at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Week 52
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 43.6 |
| Belimumab 10 mg/kg | 52.8 |
The pharmacokinetic (PK) population comprised all participants included in the As- Treated population for whom at least one post belimumab treatment PK sample was obtained and analyzed. The PK model was fitted to the observed serum concentration-time data. The maximum (Cmax) and minimum (Cmin) concentrations reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days. (NCT01649765)
Timeframe: 28-days dosing interval at steady state
| Intervention | Micrograms per milliliter (Geometric Mean) | |
|---|---|---|
| Cmax, ss | Cmin, ss | |
| Belimumab 10 mg/kg | 315 | 50 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported. (NCT01649765)
Timeframe: Up to 60 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| Belimumab 10 mg/kg | 42 | 9 |
| Placebo | 33 | 14 |
Percentage of participants meeting PRINTO/ACR Juvenile SLE Response Evaluation criteria for improvement in juvenile SLE using two different PRINTO/ACR Juvenile SLE Response Evaluation definitions of improvement that is Definition 1: At least 50% improvement in any 2 of 5 endpoints below and no more than 1 of the remaining worsening by more than 30% and Definition 2: At least 30% improvement in 3 of 5 endpoints below and no more than 1 of the remaining worsening more than 30%. Endpoints were: 1. Percent change in Parent's Global Assessment (ParentGA) at Week 52, 2. Percent change in PGA at Week 52, 3. Percent change in SELENA SLEDAI score at Week 52, 4. Percent change in Pediatric Quality of Life Inventory (PedsQL) physical functioning domain at Week 52, 5. Percent change in 24 hour proteinuria at Week 52 (gram/24hour equivalent by spot urine protein to creatinine ratio). (NCT01649765)
Timeframe: Week 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Definition 1 | Definition 2 | |
| Belimumab 10 mg/kg | 60.4 | 52.8 |
| Placebo | 35.0 | 27.5 |
The area under the plasma concentration time curve (AUCt) was defined as area under the concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic (PK) blood samples were collected on Day 1 and Day 29 pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.
| Intervention | ng*h/mL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 29 | |
| Part 1: Iberdomide 0.3 mg QD | 11.29 | 15.55 |
| Part 1: Iberdomide 0.3 mg QOD | 10.82 | 13.34 |
| Part 1: Iberdomide 0.6 mg QD | 38.73 | 52.65 |
| Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days | 34.15 | 24.85 |
Joint swelling was noted as present or absent. Forty-four joints were assessed for swelling, including the sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal (MCP), proximal interphalangeal (PIP), knee, ankle, and metatarsophalangeal (MTP) joints were included in this joint count. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Joints (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Week 100 Follow-Up | |
| ATEP: Iberdomide 0.3 mg QD | -1.2 | -1.8 | -2.6 | -2.1 | -3.9 | -3.6 | -2.6 | -4.0 | -4.2 | -3.7 | -3.6 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | -0.4 | -0.6 | -0.3 | 1.2 | -0.2 | 0.6 | 0.4 | 0.7 | 0.0 | 0.0 | -0.4 |
Joint tenderness was noted as present or absent. Forty-four joints were assessed for swelling, including the sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal (MCP), proximal interphalangeal (PIP), knee, ankle, and metatarsophalangeal (MTP) joints were included in this joint count. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Joints (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Week 100 Follow-Up | |
| ATEP: Iberdomide 0.3 mg QD | -0.9 | -0.9 | 0.5 | -3.9 | -5.1 | -5.9 | -5.6 | -6.2 | -7.3 | -7.0 | -4.1 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | -2.5 | -2.0 | -3.7 | -3.6 | -3.8 | -3.0 | -4.4 | -6.7 | 0.0 | 0.0 | -1.4 |
The BILAG-2004 index measures clinical disease activity in systemic lupus erythematosus (SLE). A single alphabetic score (A through E) is used to denote disease severity for each of the 9 domains (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematologic). BILAG A represents the most active disease or severe disease; BILAG B represents intermediate activity or moderate disease; BILAG C represents stable mild disease; BILAG D represents organ system previously affected but now inactive; and BILAG E represents organ system never involved. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 9 domains. The theoretical range spans from 0 (no activity) to 13 active or severe disease activity BILAG. A higher score means more severe disease activity while a lower score means lower disease activity (or no disease activity for score of zero). (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Units on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Global Score Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Follow-Up Week 100 | |
| ATEP: Iberdomide 0.3 mg QD | -0.5 | 2.0 | -2.2 | -6.3 | -7.3 | -6.1 | -6.3 | -7.5 | -7.8 | -0.52 | -6.3 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | 3.3 | 0.7 | 2.0 | 3.0 | 1.6 | 1.4 | 0.4 | 4.3 | -1.0 | -0.20 | -3.9 |
The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and nonscarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the CLASI activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together. Composite scores are calculated by summing the individual component scores. The higher the score, the greater the cutaneous disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Units on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Follow-Up Week 100 | |
| ATEP: Iberdomide 0.3 mg QD | -0.1 | 0.0 | -0.6 | 0.1 | 0.1 | 0.3 | 0.4 | 0.3 | 0.7 | 0.0 | -0.3 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | 0.0 | -1.0 | -0.9 | -2.2 | -2.2 | -2.4 | -2.6 | -0.7 | -1.0 | 0.0 | 0.0 |
"The Fatigue VAS evaluates SLE-related fatigue using a 0 to 100 mm VAS scale. The Fatigue VAS allowed the participant to indicate the degree of SLE-related fatigue by placing an X representing how they feel, along a visual analog line that extends between two extremes (e.g., from not at all tired to extremely tired) over the previous week. A decrease in the fatigue VAS indicates improvement." (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Units on a Scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | |
| ATEP: Iberdomide 0.3 mg QD | -10.0 | -4.1 | -15.9 | -13.6 | -21.1 | -29.9 | -23.0 | -22.8 | -10.3 | -9.8 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | -4.0 | -3.7 | -8.0 | -4.0 | -17.2 | -12.8 | -12.6 | -25.7 | -14.0 | -20.0 |
The SELENA SLEDAI score measures SLE disease activity through assessment of 24 lupus descriptors/manifestations. Each descriptor (clinical or lab values) receives a positive score if it is present over the previous assessment period; a score of '0' indicates inactive disease while a positive score (from 1 to 8 based on the relative importance of each descriptor in the total scoring) indicates disease activity. The SELENA SLEDAI score is the sum of all 24 descriptors' scores for the assessment period. The SELENA SLEDAI score can range from '0' (no SLE disease activity) to a maximum theoretical score of 105 (maximum SLE disease activity). The higher the SELENA SLEDAI score the greater of SLE disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Units on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Week 100 Follow-Up | |
| ATEP: Iberdomide 0.3 mg QD | 0.2 | 0.2 | -1.8 | -2.8 | -3.1 | -2.9 | -2.6 | -3.0 | -3.0 | -2.0 | -1.7 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | -1.0 | -1.7 | -0.9 | -1.2 | 0.3 | -1.0 | -1.8 | -1.3 | -1.0 | 0.0 | 0.3 |
The pericardial/pleuritic pain scale was scored using numerical values of 1 through 10 with 1 representing 'no pain' and 10 representing 'worst possible pain'. These were self-administered by the participants and gauged the severity of their SLE pain related to pericardial and pleuritic discomfort. Any indication from participants or study assessments, aside from pain, which indicated clinically significant pericardial or pleuritic manifestations of SLE was thoroughly investigated; if clinically significant SLE related complications were found, the participants was to be discontinued from the study and entered into the Observational Follow-up Period and treated appropriately. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Units on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Follow-Up Week 100 | |
| ATEP: Iberdomide 0.3 mg QD | -1.0 | -0.8 | -1.1 | -1.0 | -0.7 | -1.4 | -1.1 | 0.2 | 0.2 | -0.2 | -0.6 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | 0.8 | 0.9 | 1.3 | 0.6 | 0.7 | 0.9 | 1.1 | 0.0 | 0.0 | 0.0 | 0.2 |
"The physician's global assessment was administered by the treating physician and was used to gauge the participants overall state of health. The instrument uses a visual analogue scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows:~0 = none~1 = mild disease~2 = moderate disease~3 = severe disease" (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Units on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Follow-Up Week 100 | |
| ATEP: Iberdomide 0.3 mg QD | -0.08 | -0.26 | -0.15 | -0.28 | -0.30 | -0.53 | -0.37 | -0.48 | -0.57 | -0.52 | -0.21 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | -0.10 | -0.17 | -0.31 | -0.20 | -0.36 | -0.26 | -0.24 | -0.23 | -0.30 | -0.20 | 0.10 |
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as nonreversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. Damage is defined for 12 separate organ systems: ocular (range 0-2), neuropsychiatric (0-6), renal (0-3), pulmonary (0-5), cardiovascular (0-6), peripheral vascular (0-5), gastrointestinal (0-6), musculoskeletal (0-7), skin (0-3), endocrine (diabetes) (0-1), gonadal (0-1) and malignancies (0-2). A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 47, and increasing score indicates increasing disease damage severity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Units on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Follow-Up Week 100 | |
| ATEP: Iberdomide 0.3 mg QD | -0.1 | -0.1 | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | 0.0 | -0.1 | -0.1 | -0.2 | -0.2 | -0.2 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic blood samples were collected on Day 1 and Day 29 at pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 29 | |
| Part 1: Iberdomide 0.3 mg QD | 0.64 | 1.09 |
| Part 1: Iberdomide 0.3 mg QOD | 0.90 | 1.02 |
| Part 1: Iberdomide 0.6 mg QD | 2.35 | 3.51 |
| Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days | 2.92 | 2.37 |
A TEAE was defined as any adverse event (AE) that began or worsened on or after the start of IP up to 28 days after the last dose of IP or IP discontinuation date, whichever was later. Each participant was counted once for each applicable category. An IP-related TEAE was defined as a TEAE that the investigator considered to be of suspected relationship to IP. The severity of each adverse event and serious AE (SAE) was assessed by the investigator and graded based on a scale from mild - mild symptoms to severe AEs (non-serious or serious). A serious adverse event (SAE) was any AE which: • Resulted in death • Was life-threatening • Required inpatient hospitalization or prolongation of existing hospitalization • Resulted in persistent or significant disability/incapacity • Was a congenital anomaly/birth defect • Constituted an important medical event. (NCT02185040)
Timeframe: From the start of the first dose of IP until 28 days after the last dose or study discontinuation in Part 1; median treatment duration = 12.0 weeks for the placebo, 0.3 mg QOD and 0.3 mg iberdomide QD arms, 11.9 weeks for the 0.6/0.3 ALT and 0.6 cohorts.
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any IP-related TEAE | Any Severe TEAE | Any Serious TEAE | Any Serious IP-related TEAE | Any TEAE Leading to IP Interruption | Any TEAE Leading to IP Withdrawal | Any TEAE Leading to Death | |
| Part 1: Iberdomide 0.3 mg QD | 7 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Part 1: Iberdomide 0.3 mg QOD | 7 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part 1: Iberdomide 0.6 mg QD | 8 | 6 | 2 | 1 | 1 | 5 | 3 | 0 |
| Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days | 8 | 4 | 1 | 1 | 0 | 1 | 2 | 0 |
| Part 1: Placebo | 5 | 1 | 1 | 2 | 0 | 0 | 1 | 0 |
A TEAE was defined as any adverse event (AE) that began or worsened on or after the start of IP through 28 days after the last dose of IP or IP discontinuation date, whichever was later. Each participant was counted once for each applicable category. An IP-related TEAE was defined as a TEAE that the investigator considered to be of suspected relationship to IP. The severity of each adverse event and serious AE (SAE) was assessed by the investigator and graded based on a scale from mild - mild symptoms to severe AEs (non-serious or serious). A serious adverse event (SAE) was any AE which: • Resulted in death • Was life-threatening • Required inpatient hospitalization or prolongation of existing hospitalization • Resulted in persistent or significant disability/incapacity • Was a congenital anomaly/birth defect • Constituted an important medical event. (NCT02185040)
Timeframe: From the date of the first dose of IP in the ATEP until 28 days after the last dose in the ATEP or study discontinuation; median duration of IP was 95.86 weeks for the 0.3 mg iberdomide QD cohort and 60.64 weeks for the 0.6 mg/0.3 mg ALT QD cohorts.
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any IP-related TEAE | Any Severe TEAE | Any Serious TEAE | Any Serious IP-related TEAE | Any TEAE Leading to IP Interruption | Any TEAE Leading to IP Withdrawal | Any TEAE Leading to Death | |
| ATEP: Iberdomide 0.3 mg QD | 9 | 2 | 0 | 0 | 0 | 2 | 1 | 0 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | 7 | 5 | 5 | 4 | 0 | 5 | 4 | 0 |
The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and nonscarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the CLASI activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together. Composite scores are calculated by summing the individual component scores. The higher the score, the greater the cutaneous disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Percent Change (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Follow-Up Week 100 | |
| ATEP: Iberdomide 0.3 mg QD | -21.40 | -32.13 | -18.42 | 13.54 | -0.56 | -46.97 | -65.64 | -55.13 | -65.71 | -75.38 | -53.04 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | -13.35 | -18.32 | -36.46 | -44.69 | -43.98 | -46.00 | -47.51 | -40.35 | -32.46 | -26.32 | -18.82 |
The SELENA SLEDAI score measures SLE disease activity through assessment of 24 lupus descriptors/manifestations. Each descriptor (clinical or lab values) receives a positive score if it is present over the previous assessment period; a score of '0' indicates inactive disease while a positive score (from 1 to 8 based on the relative importance of each descriptor in the total scoring) indicates disease activity. The SELENA SLEDAI score is the sum of all 24 descriptors' scores for the assessment period. The SELENA SLEDAI score can range from '0' (no SLE disease activity) to a maximum theoretical score of 105 (maximum SLE disease activity). The higher the SELENA SLEDAI score the greater of SLE disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.
| Intervention | Percentage of Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Week 100 Follow-Up | |
| ATEP: Iberdomide 0.3 mg QD | 0.0 | 0.0 | 66.7 | 83.3 | 66.7 | 50.0 | 33.3 | 80.0 | 80.0 | 40.0 | 40.0 |
| ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days | 12.5 | 14.3 | 0.0 | 20.0 | 0.0 | 20.0 | 20.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Terminal phase half-life in plasma, calculated as [(In 2)/λz]. T1/2 half was only calculated when a reliable estimate for λz could be obtained. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic blood samples were collected on Day 1 and Day 29 at pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.
| Intervention | days (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 29 | |
| Part 1: Iberdomide 0.3 mg QD | 10.25 | 11.85 |
| Part 1: Iberdomide 0.3 mg QOD | 7.50 | 8.46 |
| Part 1: Iberdomide 0.6 mg QD | 9.55 | 11.32 |
| Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days | 7.96 | 9.39 |
Time to Cmax, obtained directly from the observed concentration versus time data. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic blood samples were collected on Day 1 and Day 29 at pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.
| Intervention | days (Median) | |
|---|---|---|
| Day 1 | Day 29 | |
| Part 1: Iberdomide 0.3 mg QD | 6.00 | 2.00 |
| Part 1: Iberdomide 0.3 mg QOD | 4.00 | 4.00 |
| Part 1: Iberdomide 0.6 mg QD | 4.01 | 2.02 |
| Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days | 1.92 | 3.00 |
The CLASI consists of two scores the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI score ranges from 0 to 70, with higher scores indicating more severe skin disease. (NCT01753401)
Timeframe: at Week 52
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo/Acthar | 0.4 |
| Acthar/Acthar | 1.3 |
"The Krupp FSS is a scale to rate disability-related fatigue. Respondents use a scale ranging from 1 (completely disagree) to 7 (completely agree) to indicate their agreement with nine statements about fatigue. A visual analogue scale is also included with the scale; respondents are asked to denote the severity of their fatigue over the past 2 weeks by placing a mark on a line extending from no fatigue to fatigue as bad as could be. Higher scores on the scale are indicative of more severe fatigue.~This validated fatigue severity scale measures impact of fatigue with a 9-item questionnaire, with a 7-point Likert scale for each question. Total score ranges from 0 (best possible outcome) to 63 (worst possible fatigue)." (NCT01753401)
Timeframe: at Week 52
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo/Acthar | 4.523 |
| Acthar/Acthar | 4.743 |
The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement. (NCT01753401)
Timeframe: at Week 52
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo/Acthar | 45.272 |
| Acthar/Acthar | 39.700 |
The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement. (NCT01753401)
Timeframe: at Week 52
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo/Acthar | 43.618 |
| Acthar/Acthar | 39.710 |
"Participants are counted as responders based on:~decrease in SELENA-SLEDAI score from 4 to 0 for arthritis and no worsening in other organ systems based on BILAG~OR~decrease in SELENA-SLEDAI score from 2 to 0 for rash and no worsening in other organ systems based on BILAG" (NCT01753401)
Timeframe: at Week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo/Acthar | 4 |
| Acthar/Acthar | 3 |
"Participants are counted as responders based on two SLE indices: the Systemic Lupus Erythematosus Disease Activity Index amended by the SELENA group (SELENA-SLEDAI) and the British Isles Lupus Assessment Group (BILAG) Index.~decrease in SELENA-SLEDAI score from 4 to 0 for the arthritis descriptor (highest possible score is 4) and no worsening in other organ systems based on BILAG~OR~decrease in SELENA-SLEDAI score from 2 to 0 for rash (highest possible score is 2) and no worsening in other organ systems based on BILAG~The BILAG is a transitional index that captures changing severity of clinical manifestations. It has an ordinal scale scoring system by design that produces an overview of disease activity across eight systems. The individual system scores were not intended to be summated into a global score." (NCT01753401)
Timeframe: within 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 3 |
| Acthar | 4 |
"Participants are counted as responders based on:~decrease in SELENA-SLEDAI score from 4 to 0 for arthritis and no worsening in other organ systems based on BILAG~OR~decrease in SELENA-SLEDAI score from 2 to 0 for rash and no worsening in other organ systems based on BILAG" (NCT01753401)
Timeframe: within 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 3 |
| Acthar | 11 |
(NCT01753401)
Timeframe: within 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo/Acthar | 1 |
| Acthar/Acthar | 6 |
The doctor counted the number of tender or swollen joints at Week 52. (NCT01753401)
Timeframe: at Week 52
| Intervention | Tender or Swollen Joints (Mean) |
|---|---|
| Placebo/Acthar | 1.1 |
| Acthar/Acthar | 0.7 |
"SLEDAI was modeled on the basis of clinician global judgment. A participant's SELENA-SLEDAI total score is the sum of all marked SLE-related descriptors on a checklist developed by the SELENA Group (also referred to as hybrid SLEDAI).~The scores of the descriptors range from 0 to 8. A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity." (NCT01753401)
Timeframe: at Week 52
| Intervention | score on a scale (Median) |
|---|---|
| Placebo/Acthar | 3 |
| Acthar/Acthar | 4 |
"The BILAG is a transitional index that captures changing severity of clinical manifestations that produces an overview of disease activity across eight systems.~The 8 systems are scored on a scale from 0=not present to 4=worse, for the 4 week period before the assessment. The lowest possible score is 0, and the highest possible score is 32. A higher score means the symptoms are worse.~Rows: Baseline, Week 4, Week 8" (NCT01753401)
Timeframe: within 8 weeks
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| at Baseline | at Week 4 | at Week 8 | |
| Acthar | 15.7 | 9.2 | 6.8 |
| Placebo | 15.4 | 10.3 | 13.5 |
"The CLASI consists of two scores the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI score ranges from 0 to 70, with higher scores indicating more severe skin disease.~Rows: at Baseline, at Week 4, at Week 8" (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| at Baseline | at Week 4 | at Week 8 | |
| Acthar | 6.4 | 4.8 | 3.7 |
| Placebo | 6.1 | 6.3 | 5.7 |
"The Krupp FSS is a scale to rate disability-related fatigue. Respondents use a scale ranging from 1 (completely disagree) to 7 (completely agree) to indicate their agreement with nine statements about fatigue. A visual analogue scale is also included with the scale; respondents are asked to denote the severity of their fatigue over the past 2 weeks by placing a mark on a line extending from no fatigue to fatigue as bad as could be. Higher scores on the scale are indicative of more severe fatigue.~This validated fatigue severity scale measures impact of fatigue with a 9-item questionnaire, with a 7-point Likert scale for each question. Total score ranges from 0 (best possible outcome) to 63 (worst possible fatigue).~Rows: at Baseline, at Week 4, at Week 8" (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| at Baseline | at Week 4 | at Week 8 | |
| Acthar | 5.648 | 5.298 | 5.152 |
| Placebo | 5.374 | 5.379 | 5.404 |
The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement. (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| at Baseline | at Week 4 | at Week 8 | |
| Acthar | 38.406 | 40.280 | 40.408 |
| Placebo | 41.304 | 38.744 | 39.256 |
"The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement.~Rows: at Baseline, at Week 4, at Week 8" (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| at Baseline | at Week 4 | at Week 8 | |
| Acthar | 31.526 | 35.318 | 35.701 |
| Placebo | 32.927 | 32.831 | 33.310 |
The doctor counted the number of tender or swollen joints at Baseline, at Week 4, and at Week 8 (NCT01753401)
Timeframe: at Baseline, Week 4, and Week 8 (within 8 weeks)
| Intervention | Tender or Swollen Joints (Mean) | ||
|---|---|---|---|
| at Baseline | at Week 4 | at Week 8 | |
| Acthar | 9.6 | 4.5 | 3.5 |
| Placebo | 6.2 | 3.8 | 4.0 |
"SLEDAI was modeled on the basis of clinician global judgment. A participant's SELENA-SLEDAI total score is the sum of all marked SLE-related descriptors on a checklist developed by the SELENA Group (also referred to as hybrid SLEDAI).~The scores of the descriptors range from 0 to 8. A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.~Rows: Week 2, Week 4, Week 6, Week 8" (NCT01753401)
Timeframe: within 8 weeks
| Intervention | score on a scale (Median) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | |
| Acthar | 8.0 | 8.0 | 6.0 | 6.0 |
| Placebo | 10.0 | 9.0 | 8.0 | 9.0 |
Number of days of daily prednisone dose <=7.5 mg/day and/or reduced by 50 percent over time through each scheduled visit during the blinded period were compared between belimumab and placebo using Rank ANCOVA model which was used for comparing belimumab and placebo. The independent variables in the model included treatment group, Baseline prednisone dose level, country, Baseline SELENA SLEDAI score (<=9 vs. >=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). This analysis was perfomed on the participants who used prednisone >7.5 mg/day at Baseline. (NCT01345253)
Timeframe: Week 52
| Intervention | Days (Median) |
|---|---|
| Placebo | 0.0 |
| Belimumab 10 mg/kg | 0.0 |
SRI response is a composite index, defined as the percent of participants with >=4 point reduction from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score and no worsening (increase of < 0.30 points from Baseline) in physicians global assessment (PGA) and no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction). (NCT01345253)
Timeframe: Week 52
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 40.1 |
| Belimumab 10 mg/kg | 53.8 |
The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. The Baseline value of a variable is defined as the value of the variable measured at Day 0 prior to dosing. In case of multiple results on Day 0 prior to dosing, the latest result was used. If a Day 0 value was not available, the last available value prior to Day 0 was used. (NCT01345253)
Timeframe: Baseline (Day 0) and Week 52
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 42.2 |
| Belimumab 10 mg/kg | 55.7 |
SRI7 response is defined as the percent of participants with >=7 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of < 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction). (NCT01345253)
Timeframe: Baseline (Day 0) and Week 52
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 23.5 |
| Belimumab 10 mg/kg | 32.4 |
Time to first severe SLE flare is defined as the number of days from first treatment until the participant had an event (event date-treatement start date +1). If a participant had a severe SFI flare and received protocol restricted medication then the event date was the earliest of the first severe SFI flare date, and the treatment failure date. Analysis of severe SFI flare was performed on the modified SELENA SLEDAI SLE flare index in which the modification excluded severe flares that were triggered only by an increase in SELENA SLEDAI score to >12. Analysis was from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for country, Baseline SELENA SLEDAI score (<=9 vs. >=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). (NCT01345253)
Timeframe: 52 weeks
| Intervention | Days (Median) |
|---|---|
| Placebo | NA |
| Belimumab 10 mg/kg | NA |
SRI response is a composite index, defined as the percent of participants with >=4 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of < 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at time of assessment. Excludes participants with a SELENA SLEDAI score <4 at baseline. Participants randomized to belimumab in double-blinded (DB) phase, Baseline is last available value before first belimumab dose received in DB phase. Participants randomized to placebo in DB phase, Baseline is last available value before receiving first belimumab dose in OL phase. Observed case data are presented.Year 6 Week 48 is the Exit Visit obtained by slotting the Exit Visit to Week 48. A SELENA SLEDAI score of 0 (no lupus activity) and a score of 105 (maximum). PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. (NCT01345253)
Timeframe: Weeks 24 and 48 for Years 2, 3, 4, 5 and 6
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 24, Year 2, n=326 | Week 48, Year 2, n=299 | Week 24, Year 3, n=271 | Week 48, Year 3, n=247 | Week 24, Year 4, n=233 | Week 48, Year 4, n=194 | Week 24, Year 5, n= 156 | Week 48, Year 5, n= 82 | Week 24, Year 6, n= 36 | Week 48, Year 6, n= 5 | |
| Belimumab 10mg/kg (Open-label Phase) | 66.0 | 69.6 | 72.3 | 70.9 | 71.7 | 76.8 | 81.4 | 80.5 | 86.1 | 60.0 |
This is a landmark measure of percentage of patients who meet response criteria. To meet the BICLA response measure a patient must, compared to baseline, have a decrease in all moderate or severe scores on the British Isles Lupus Assessment Group (BILAG) index by at least one severity grade (Severe disease (BILAG A score) must drop to at least moderate (B or better) and B must drop to at least mild (C or not present). Also, there must be no increase in any other BILAG organ scores, no increase in The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and no increase in the physician's global assessment (PGA) by more than 10% of the scale. Furthermore, there may no off protocol medication increases. Note on all scales mentioned a higher score signifies greater disease activity. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76. (NCT01781611)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Release Dipyridamole/Aspirin | 3 |
| Aspirin | 2 |
This is a landmark analysis of percentage of patients who, compared to baseline, have a 4 point drop in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A 4 point decrease signifies a clinically significant decrease in disease activity as reported in many studies and as commonly used as a clinical endpoint in trials. SLEDAI could range 0-105 but is rarely greater than 20. (NCT01781611)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Release Dipyridamole/Aspirin | 4 |
| Aspirin | 2 |
This is a landmark analysis of percentage of patients who meet the following response criteria: Compared to baseline there must be a 4 point decrease in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), no increase in The British Isles Lupus Assessment Group (BILAG) Index score and no more of an increase in Physician's Global Assessment (PGA) than 10% of the scale. As assessed here, there must also be no off protocol increase in medications. All scales signify worsening disease when scores increase. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76. (NCT01781611)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Release Dipyridamole/Aspirin | 3 |
| Aspirin | 2 |
FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.44 |
| 2 mg Baricitinib | 7.46 |
| 4 mg Baricitinib | 7.08 |
The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52
| Intervention | swollen joint count (Least Squares Mean) |
|---|---|
| Placebo | -5.37 |
| 2 mg Baricitinib | -5.67 |
| 4 mg Baricitinib | -5.81 |
The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52
| Intervention | tender joint count (Least Squares Mean) |
|---|---|
| Placebo | -7.50 |
| 2 mg Baricitinib | -7.26 |
| 4 mg Baricitinib | -7.94 |
Participants assessed their worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.62 |
| 2 mg Baricitinib | -1.73 |
| 4 mg Baricitinib | -1.71 |
"The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K <=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where no activity is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the new feature is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), <=1; (4) current prednisolone (or equivalent) dose <=7.5 mg daily." (NCT03616912)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 26.2 |
| 2 mg Baricitinib | 25.7 |
| 4 mg Baricitinib | 29.7 |
"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616912)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.9 |
| 4 mg Baricitinib | 56.7 |
"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616912)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.9 |
| 2 mg Baricitinib | 49.8 |
For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by >=25% from Baseline to <=7.5 mg/day during Weeks 40 through 52. (NCT03616912)
Timeframe: Baseline, Week 40 through Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 30.8 |
| 2 mg Baricitinib | 29.2 |
| 4 mg Baricitinib | 34.0 |
The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations. (NCT03616912)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 49.0 |
| 2 mg Baricitinib | 54.3 |
| 4 mg Baricitinib | 55.8 |
PK: Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) was evaluated using population PK approach. (NCT03616912)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
| Intervention | hour*nanograms per milliliter (h*ng/mL) (Geometric Mean) |
|---|---|
| 2 mg Baricitinib | 256 |
| 4 mg Baricitinib | 502 |
Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) was evaluated using population PK approach. (NCT03616912)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose
| Intervention | nanograms per milliliter (ng/mL) (Geometric Mean) |
|---|---|
| 2 mg Baricitinib | 26.7 |
| 4 mg Baricitinib | 53.0 |
Time to first severe flare was analyzed using a Cox proportional hazards model with treatment group, baseline disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K ] <10; SLEDAI-2K ≥10), baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time. (NCT03616912)
Timeframe: Baseline to Week 52
| Intervention | weeks (Median) |
|---|---|
| Placebo | NA |
| 2 mg Baricitinib | NA |
| 4 mg Baricitinib | NA |
Any medically significant changes from the screening ECG was recorded as TEAEs. An abnormal ECG findings such as QT prolonged were reported as treatment emergent adverse events. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)
| Intervention | Participants (Number) |
|---|---|
| Placebo | 0 |
| Anifrolumab 300 mg | 0 |
| Anifrolumab 1000 mg | 2 |
An SRI (4) responder defined as a participant who had 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of greater than or equal to (>=) 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of >= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index 'A' organ system score and no more than one new or worsening BILAG-2004 Index 'B' organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 [less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1]. SRI was analyzed by a logistic regression model. (NCT01438489)
Timeframe: Day 169
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 17.6 |
| Anifrolumab 300 mg | 34.3 |
| Anifrolumab 1000 mg | 28.8 |
An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of >= 4 points; 2) no worsening of disease from baseline as measured by the MDGA (worsening was defined as an increase of >= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 281 through Day 365 (less than 10 mg/day and less or equal to the dose received on Day 1). SRI was analyzed by a logistic regression model. (NCT01438489)
Timeframe: Day 365
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 25.5 |
| Anifrolumab 300 mg | 51.5 |
| Anifrolumab 1000 mg | 38.5 |
Participants on OCS >=10 mg/day of prednisone or equivalent at baseline who were able to taper to <= 7.5 mg/day at Day 365 were evaluated. (NCT01438489)
Timeframe: Day 365
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 26.6 |
| Anifrolumab 300 mg | 56.4 |
| Anifrolumab 1000 mg | 31.7 |
Type I IFN signature in whole blood assessed by using a 4-gene diagnostic test. The blood samples collected were to be used to prospectively identify participants as IFN test-high or test-low. The results of this test were used to stratify participants. An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of >= 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of >= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 [less than 10 mg/day and less or equal to the dose received on Day 1]. SRI was analyzed by a logistic regression model. (NCT01438489)
Timeframe: Day 169
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 13.2 |
| Anifrolumab 300 mg | 36 |
| Anifrolumab 1000 mg | 28.2 |
Accumulation ratio for maximum plasma concentration (Cmax,AR) of anifrolumab after multiple administration at Day 169 and 337 was calculated. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 169 and 337
| Intervention | Ratio (Median) | |
|---|---|---|
| Day 169 (n=81,86) | Day 337 (n=78,66) | |
| Anifrolumab 1000 mg | 1.43 | 1.76 |
| Anifrolumab 300 mg | 1.36 | 1.56 |
Accumulation ratio for trough concentration (Ctrough,AR) of anifrolumab after multiple administration at Day 169 and 365 was calculated. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 169 and 365
| Intervention | Ratio (Median) | |
|---|---|---|
| Day 169 (n=82,86) | Day 365 (n=79,70) | |
| Anifrolumab 1000 mg | 2.29 | 3.02 |
| Anifrolumab 300 mg | 2.49 | 3.06 |
Maximum plasma concentration (Cmax) was defined as the peak plasma level of anifrolumab, derived from plasma concentration -time data. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 1, 169 and 337
| Intervention | micrograms/milliliter (mcg/mL) (Mean) | ||
|---|---|---|---|
| Day 1 (n=98,104) | Day 169 (n=86,87) | Day 337 (n=83,67) | |
| Anifrolumab 1000 mg | 248 | 375 | 439 |
| Anifrolumab 300 mg | 82.8 | 110 | 127 |
The PD positive and negative gene signature was determined by comparing the expression of type I IFN-inducible genes in a 21-gene panel in study participants relative to pooled normal blood collected from healthy participants. (NCT01438489)
Timeframe: Days 29, 85, 141, 169, 253, 337 (treatment phase), on Days 365, 396, and 422 (follow up period)
| Intervention | Ratio (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 29 (n= 68, 66, 73) | Day 85 (n= 63, 62, 72) | Day 141 (n= 59, 64, 68) | Day 169 (n= 56, 60, 66) | Day 253 (n= 50, 60, 61) | Day 337 (n= 49, 59, 53) | Day 365 (n= 58, 66, 68) | Day 396 (n= 56, 61, 64) | Day 422 (n= 53, 57, 55) | |
| Anifrolumab 1000 mg | 82.056 | 79.350 | 88.569 | 88.126 | 86.099 | 87.811 | 81.115 | 72.291 | 37.532 |
| Anifrolumab 300 mg | 70.194 | 72.639 | 73.662 | 77.364 | 73.972 | 79.363 | 72.796 | 11.510 | -0.836 |
| Placebo | -0.753 | -5.412 | -25.411 | -17.122 | -9.908 | -13.784 | -6.428 | -22.106 | -31.777 |
Any medically significant change in laboratory evaluations were recorded as Treatment emergent adverse events. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutrophil count increased | Leukocytosis | Leukopenia | Neutropenia | Anaemia | Iron deficiency anaemia | Lymphopenia | Microcytic anaemia | Thrombocytosis | White blood cell count increased | Monocyte count increased | Hypochromic anaemia | Hyperglycaemia | Hypokalaemia | Hepatic enzyme increased | Hypocalcaemia | Lipid metabolism disorder | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood creatine phosphokinase increased | Hyperlipidaemia | Hypertriglyceridaemia | Hyponatraemia | Blood alkaline phosphatase increased | Gamma-glutamyltransferase increased | Glomerular filtration rate decreased | Transaminases increased | Dyslipidaemia | Alanine aminotransferase abnormal | Aspartate aminotransferase abnormal | Blood triglycerides abnormal | Glomerular filtration rate increased | |
| Anifrolumab 1000 mg | 3 | 2 | 3 | 3 | 2 | 1 | 2 | 2 | 0 | 1 | 1 | 0 | 1 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Anifrolumab 300 mg | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 3 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
An adverse event (AE) was any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A serious AE (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly (in offspring of participant). AEs may be treatment emergent (TE) [that is, occurring after initial receipt of investigational product] or non-TE. An AESI is one of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by investigator to sponsor. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)
| Intervention | Participants (Number) | ||
|---|---|---|---|
| TEAEs | TESAEs | AESIs | |
| Anifrolumab 1000 mg | 90 | 18 | 15 |
| Anifrolumab 300 mg | 84 | 16 | 10 |
| Placebo | 78 | 19 | 12 |
Vital sign parameters are temperature, blood pressure, respiratory rate, heart rate and weight. Vital signs abnormalities were reported as TEAEs. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hypertension | Pyrexia | Blood pressure increased | Blood pressure decreased | Hypotension | Secondary hypertension | Weight increased | Blood pressure abnormal | Chills | Hypertensive emergency | |
| Anifrolumab 1000 mg | 2 | 3 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Anifrolumab 300 mg | 3 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 7 | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Anti-drug antibody responses to anifrolumab in serum were evaluated. (NCT01438489)
Timeframe: Days 1, 85, 141, 169, 253, 337 (Treatment Phase), 365, 396, and 422 (Follow-up Period)
| Intervention | Percentage of Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=100,98,105) | Day 85 (n=91,93,98) | Day 141 (n=84,94,93) | Day 169 (n=81,89,92) | Day 253 (n=72,86,86) | Day 337 (n=70,87,76) | Day 365 (n=85,96,94) | Day 396 (n=78,88,90) | Day 422 (n=76,86,77) | Any Visit Post Baseline (n= 99,98,102) | |
| Anifrolumab 1000 mg | 1.9 | 0.0 | 2.2 | 1.1 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 2.0 |
| Anifrolumab 300 mg | 1.0 | 0.0 | 0.0 | 0.0 | 1.2 | 1.1 | 1.0 | 2.3 | 5.8 | 5.1 |
| Placebo | 1.0 | 1.1 | 2.4 | 2.5 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 3.0 |
Trough concentration (Ctrough) of anifrolumab at Day 29, 169 and 365 were calculated. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 29, 169 and 365
| Intervention | microgram per milliliter (Mean) | ||
|---|---|---|---|
| Day 29 (n=95,99) | Day 169 (n=87,87) | Day 365 (n=83,71) | |
| Anifrolumab 1000 mg | 46.8 | 110 | 154 |
| Anifrolumab 300 mg | 7.95 | 18.4 | 23.6 |
Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
| Non-Randomized Active Comparator | 0 |
Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Correlation coefficient (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks
| Intervention | Inflammatory markers (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Clinical factors (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 0 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Number of adverse events. (Number) | |
|---|---|---|
| Adverse events (only Level 1 and 2) observed in the study. | Serious adverse events (Level 3 or 4). | |
| Non-Randomized Active Comparator | 2 | 0 |
| Placebo | 188 | 0 |
| Study Drug - Daily Dose | 206 | 0 |
| Study Drug - Weekly Dose | 193 | 0 |
Comparison of baseline and post-treatment Sartorius severity scoring Sartorius scoring: minimum 0, no maximum, higher scores mean a worse outcome (NCT03275870)
Timeframe: 6 months
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline sartorius score | 6 month sartorius score | |
| Hydroxychloroquine Treatment | 23.3 | 17.7 |
Comparison of baseline and post-treatment self-reported quality of life Dermatology Life Quality Index score: minimum 0, maximum 30. higher scores mean worse outcome. (NCT03275870)
Timeframe: 6 months
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline DLQI score | 6 month DLQI score | |
| Hydroxychloroquine Treatment | 14.7 | 6 |
Change in mean systolic BP is modeled using all blood pressure data points collected between baseline and month 12 to provide an average change over time, accounting for repeated values from patients using a mixed linear regression approach. (NCT03325426)
Timeframe: Between baseline and month 12
| Intervention | mmHg (Mean) |
|---|---|
| Usual Care | 0.3 |
| Physical Activity Tracker | -4 |
Weights were measured in clinic using a standardized scale. Z score of 0 represents the population mean. A z-score of +1.96 represents the 95th percentile of weight and -1.96 represents the 5th percentile of weight. Change in weight (z-score) is modeled using all weight data points collected between baseline and month 12 to provide an average change over time accounting for repeated values from patients using a mixed linear regression approach. (NCT03325426)
Timeframe: Months 0-12
| Intervention | Z-score (Mean) |
|---|---|
| Usual Care | -0.20 |
| Physical Activity Tracker | -0.06 |
Rate of study participant retention (NCT03325426)
Timeframe: Months 0-12
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care Arm | 11 |
| Intervention Arm | 18 |
150 reviews available for hydroxychloroquine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
[State of the art: fertility and pregnancy in rheumatic diseases].
Topics: Female; Fertility; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy C | 2021 |
Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.
Topics: Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Neoplasms; Prospective Stu | 2021 |
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis.
Topics: Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic | 2022 |
Efficacy of hydroxychloroquine in the prevention of thromboembolic events: A systematic review and meta-analysis.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2022 |
Recurrent brachial plexopathy as initial presentation of systemic lupus erythematosus: A case report and review of the literature.
Topics: Adult; Brachial Plexus Neuropathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, System | 2022 |
Dilated cardiomyopathy: An unusual and severe condition in juvenile systemic lupus erythematosus.
Topics: Cardiomyopathy, Dilated; Child; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; S | 2022 |
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2022 |
COVID-19 in patients with systemic lupus erythematosus: A systematic review.
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics | 2022 |
Advances in the clinical use of hydroxychloroquine levels.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2022 |
Tailored treatment strategies and future directions in systemic lupus erythematosus.
Topics: Antibodies, Antiphospholipid; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive | 2022 |
Drug monitoring in systemic lupus erythematosus.
Topics: Drug Monitoring; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2022 |
Pregnancy-related complications in systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Systemic; Pregnancy; Pregn | 2022 |
B cell-targeted therapies in systemic lupus erythematosus.
Topics: Autoantibodies; B-Lymphocytes; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lu | 2022 |
How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
Topics: Antirheumatic Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Friends; Humans; Hydroxychloro | 2023 |
Lupus Anticoagulant-Hypoprothrombinemia Syndrome and Pseudotumor Cerebri as an Initial Presentation of Systemic Lupus Erythematosus in a 16-Year-Old Male Patient: A Case Report and Literature Review.
Topics: Adolescent; Adrenal Cortex Hormones; Antiphospholipid Syndrome; Hemorrhage; Humans; Hydroxychloroqui | 2022 |
Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies.
Topics: Antirheumatic Agents; Chloroquine; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2022 |
Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Topics: Exanthema; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Multicenter S | 2023 |
Hydroxychloroquine in nephrology: current status and future directions.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Ne | 2023 |
[What is proven in the treatment of systemic lupus erythematosus?]
Topics: Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis | 2023 |
Update on pregnancy complications in systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Complication | 2019 |
Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis.
Topics: Case-Control Studies; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ris | 2019 |
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.
Topics: Abortion, Habitual; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2020 |
Pregnancy and Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newborn | 2020 |
Preclinical and early systemic lupus erythematosus.
Topics: Biomarkers; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2019 |
Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; | 2020 |
Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; Drug Monitoring; Humans; Hy | 2021 |
[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].
Topics: Antimalarials; Antirheumatic Agents; Child; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2020 |
[Pregnancy with lupus erythematosus-an update].
Topics: Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregna | 2020 |
Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroquine; Lupus Erythem | 2020 |
The history of lupus throughout the ages.
Topics: Antibodies, Antinuclear; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupu | 2022 |
Diversity of neuropsychiatric manifestations in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Autoantibodies; Cytokines; Humans; Hydroxychloroqu | 2020 |
Systemic lupus erythematosus and risk of infection.
Topics: Humans; Hydroxychloroquine; Immunosuppression Therapy; Immunosuppressive Agents; Infection Control; | 2020 |
Aortitis in the setting of catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Ao | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythemat | 2020 |
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Labo | 2020 |
Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
Topics: Antibodies, Antiphospholipid; Antirheumatic Agents; Antiviral Agents; Autoimmune Diseases; COVID-19; | 2020 |
Systemic lupus erythematosus complicated with Castleman disease: a case-based review.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Castleman Disease; Diagnosis, Differential; Female; | 2021 |
[Hydroxychloroquine treatment rarely causes eye damage when used correctly].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Lupus Erythematosus | 2020 |
Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.
Topics: Arthritis, Rheumatoid; Betacoronavirus; Chikungunya Fever; Chikungunya virus; Coronavirus Infections | 2020 |
CD34+CD133+CD309+ circulating angiogenic cell level is reduced but positively related to hydroxychloroquine use in SLE patients-a case-control study and meta-regression analysis.
Topics: AC133 Antigen; Adult; Antigens, CD34; Antirheumatic Agents; Case-Control Studies; Endothelial Progen | 2021 |
Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
Topics: Antiviral Agents; Autoimmune Diseases; Cardiotoxicity; COVID-19 Drug Treatment; Humans; Hydroxychlor | 2021 |
Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Infant, Newborn; | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine | 2021 |
Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Case-Control Studies; Diabetes, Gestational; Female; HE | 2021 |
Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythema | 2021 |
Acute acalculous cholecystitis as the initial manifestation of systemic lupus erythematous: A case report.
Topics: Acalculous Cholecystitis; Acute Disease; Adult; Aged; Antibodies, Antinuclear; Antirheumatic Agents; | 2021 |
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.
Topics: Complement Activation; Complement System Proteins; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2021 |
Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Drug Discov | 2017 |
Systemic Lupus Erythematosus and Pregnancy.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychlo | 2017 |
Neonatal lupus erythematosus.
Topics: Antibodies, Antinuclear; Autoantibodies; Biomarkers; Female; Humans; Hydroxychloroquine; Infant, New | 2017 |
Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?
Topics: Adult; Antiphospholipid Syndrome; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2017 |
Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review.
Topics: Adult; Antibodies, Antiphospholipid; Aspirin; Cardiovascular Diseases; Female; Humans; Hydroxychloro | 2017 |
Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
Topics: Adult; Biomarkers; Down-Regulation; Female; Humans; Hydroxychloroquine; Immunologic Factors; Lipopro | 2018 |
Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs.
Topics: Antimalarials; Autoimmune Diseases; Humans; Hydroxychloroquine; Interferon Type I; Lupus Erythematos | 2018 |
Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Drug Eruptions; | 2018 |
Cutaneous lupus erythematosus: clinico-pathologic correlation.
Topics: Disease Progression; Humans; Hydroxychloroquine; Incidence; Lupus Erythematosus, Cutaneous; Lupus Er | 2018 |
Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis.
Topics: Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Infant, Newborn; | 2018 |
Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.
Topics: Animals; Atherosclerosis; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Oxidative Stres | 2018 |
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineoplastic Agents; Antirheumatic | 2018 |
Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
Topics: Antimalarials; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythema | 2018 |
Hydroxychloroquine: An old drug with new relevance.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythemato | 2018 |
Acquired angioedema in juvenile systemic lupus erythematosus: case-based review.
Topics: Adolescent; Angioedema; Complement C1 Inactivator Proteins; Female; Humans; Hydroxychloroquine; Lupu | 2018 |
Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.
Topics: Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Practic | 2018 |
Primary Sjögren's syndrome.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Hypergammaglobulinemia; | 2018 |
Systemic lupus erythematosus in pregnancy: high risk, high reward.
Topics: Adult; Counseling; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Lupus Erythematosus | 2019 |
Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis.
Topics: Adult; Antimalarials; Chloroquine; Dyslipidemias; Female; Humans; Hydroxychloroquine; Lipids; Lupus | 2019 |
Update on the treatment and outcome of systemic lupus erythematous in children.
Topics: Antirheumatic Agents; Biomarkers; Child; Cytokines; Glucocorticoids; Humans; Hydroxychloroquine; Lup | 2019 |
Autoimmune Hepatitis A Case Report and Literature Review.
Topics: Antirheumatic Agents; Arthralgia; Autoantibodies; Biopsy; Chest Pain; Diagnosis, Differential; Femal | 2019 |
[Application of hydroxychloroquine in children with systemic lupus erythematosus].
Topics: Child; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2019 |
Multifaceted effects of hydroxychloroquine in human disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Lupus Erythematosus, System | 2013 |
Hydrochloroquine retinopathy: characteristic presentation with review of screening.
Topics: Aged; Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroqu | 2013 |
[Treatment of systemic lupus erythematosus: myths, certainties and doubts].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Are systemic lupus erythematosus patients carrying MEFV gene less prone to renal involvement? Report of three cases and review of the literature.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Colchicine; Cytoskeletal Pr | 2013 |
2013 update: Hopkins lupus cohort.
Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc | 2013 |
Systemic lupus erythematosus.
Topics: Glucocorticoids; Humans; Hydroxychloroquine; Immunologic Factors; Immunosuppressive Agents; Lupus Er | 2013 |
Adherence to treatment in systemic lupus erythematosus patients.
Topics: Antirheumatic Agents; Attitude to Health; Biomarkers; Drug Monitoring; Humans; Hydroxychloroquine; L | 2013 |
Adherence to treatment in systemic lupus erythematosus patients.
Topics: Antirheumatic Agents; Attitude to Health; Biomarkers; Drug Monitoring; Humans; Hydroxychloroquine; L | 2013 |
Adherence to treatment in systemic lupus erythematosus patients.
Topics: Antirheumatic Agents; Attitude to Health; Biomarkers; Drug Monitoring; Humans; Hydroxychloroquine; L | 2013 |
Adherence to treatment in systemic lupus erythematosus patients.
Topics: Antirheumatic Agents; Attitude to Health; Biomarkers; Drug Monitoring; Humans; Hydroxychloroquine; L | 2013 |
Pure red cell aplasia as a presenting feature in systemic lupus erythematosus and association with thymoma, hypothyroidism and hypoparathyroidism: a case report and literature review.
Topics: Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroquine; Hypoparathyroidism; Hypot | 2014 |
Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Azathioprine; Cohort Studies; Female; Heart Block; Humans; Hydrox | 2014 |
Hydroxychloroquine: a multifaceted treatment in lupus.
Topics: Antimalarials; Antirheumatic Agents; Biomarkers; Half-Life; Humans; Hydroxychloroquine; Interferon-a | 2014 |
Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Monitoring; Humans; Hydroxychloroquine; Lupus Erythema | 2014 |
The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets.
Topics: Animals; Antigen Presentation; Apoptosis; Autoantibodies; Autoantigens; B-Lymphocytes; Cell Differen | 2014 |
Clinical inquiry. What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus?
Topics: Antirheumatic Agents; Arthritis; Disease Management; Exercise Therapy; Fatigue; Fish Oils; Humans; H | 2014 |
Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Blood Platelets; Erythrocytes; Hum | 2015 |
A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
Topics: Animals; Chloroquine; Drug Dosage Calculations; Eye Diseases; Humans; Hydroxychloroquine; Lupus Eryt | 2015 |
Optimizing the use of existing therapies in lupus.
Topics: Antimetabolites, Antineoplastic; Azathioprine; Cohort Studies; Cyclophosphamide; Dose-Response Relat | 2015 |
Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis.
Topics: Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Methylprednisolone; Pred | 2015 |
Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Glucocorticoids; Humans; Hydroxychloroqui | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Female; Heparin; H | 2016 |
Systemic lupus erythematosus: review of synthetic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Calcineurin Inhibitors; Glucocorticoids; Hum | 2015 |
Endosomal Toll-like receptors in clinically overt and silent autoimmunity.
Topics: Animals; Asymptomatic Diseases; Autoantibodies; Autoimmunity; Endosomes; Heart Block; Humans; Hydrox | 2016 |
[Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Disea | 2016 |
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2016 |
Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus.
Topics: Aged; Antimalarials; Cardiomyopathy, Restrictive; Drug Administration Schedule; Female; Humans; Hydr | 2017 |
Immunomodulators in SLE: Clinical evidence and immunologic actions.
Topics: Adjuvants, Immunologic; B-Lymphocytes; Combined Modality Therapy; Dehydroepiandrosterone; Disease Ma | 2016 |
Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.
Topics: Animals; Calcineurin Inhibitors; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; H | 2017 |
Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management.
Topics: Antirheumatic Agents; Disease Management; Family Practice; Glucocorticoids; Humans; Hydroxychloroqui | 2016 |
[Management of systemic lupus erythematosus].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Combined Modality Therapy; Evidence-Based Medicine; | 2016 |
Hydroxychloroquine in systemic lupus erythematosus (SLE).
Topics: Animals; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pr | 2017 |
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cata | 2017 |
Treatment of preeclampsia with hydroxychloroquine: a review.
Topics: Adjuvants, Pharmaceutic; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2018 |
Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Muscular Di | 2017 |
Systemic lupus erythematosus: an update.
Topics: Antibodies, Monoclonal, Humanized; Biological Therapy; Glucocorticoids; Humans; Hydroxychloroquine; | 2017 |
The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychlor | 2017 |
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Enzyme Inhibitors; Humans; Hydroxychloroqui | 2011 |
Systemic lupus erythematosus: safe and effective management in primary care.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Anti | 2010 |
Lupus and pregnancy: integrating clues from the bench and bedside.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Azathioprine; Counseli | 2011 |
Current and novel therapeutics in the treatment of systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Mono | 2011 |
Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Hydr | 2011 |
TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2011 |
The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus.
Topics: Biomarkers, Pharmacological; Disease Progression; Drug Interactions; France; Humans; Hydroxychloroqu | 2011 |
Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine | 2011 |
Systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Humans; Hydroxychloro | 2009 |
The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Magn | 2012 |
[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 10. Hydroxychloroquine].
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosu | 2011 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
Immunosuppressive drug use in pregnancy.
Topics: Adrenal Cortex Hormones; Azathioprine; Breast Feeding; Cyclophosphamide; Cyclosporine; Female; Fetal | 2003 |
Polymorphic light eruption.
Topics: Arachidonic Acid; Comorbidity; Dermatologic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2003 |
Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Female; Heart; Heart Conduction System; Humans; Hydro | 2004 |
Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age of Onset; Aged; Antirheumatic Agents; Child; Child, | 2004 |
Systemic lupus erythematosus with simultaneous onset of Kikuchi-Fujimoto's disease complicated with antiphospholipid antibody syndrome: a case report and review of the literature.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; An | 2005 |
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
Topics: Antirheumatic Agents; Breast Feeding; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Syste | 2005 |
[Pleading to maintain hydroxychloroquine throughout Lupus pregnancies].
Topics: Antirheumatic Agents; Disease Progression; Female; Humans; Hydroxychloroquine; Lactation; Lupus Eryt | 2005 |
Life-threatening angioedema in a patient with systemic lupus.
Topics: Administration, Oral; Adult; Airway Obstruction; Analgesics; Angioedema; Dose-Response Relationship, | 2006 |
Sjögren syndrome and systemic lupus erythematosus are distinct conditions.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Sjogren's Syndrome | 2006 |
[Systemic lupus erythematosus in children and adolescents].
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Child; Diagnosis, Diff | 2006 |
Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.
Topics: Adolescent; Bile Acids and Salts; Child; Complementary Therapies; Dyslipidemias; Humans; Hydroxychlo | 2007 |
The biology behind the new therapies for SLE.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens; Autoantibodies; B-Lymphocy | 2007 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Femal | 1982 |
Antimalarials and ophthalmologic safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, | 1982 |
Hypergammaglobulinemic purpura of Waldenstrom associated with systemic lupus erythematosus: report of a case and review of the literature.
Topics: Adult; Colchicine; Female; gamma-Globulins; Humans; Hydroxychloroquine; Immunoglobulin G; Immunoglob | 1995 |
Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retin | 1993 |
Antimalarial agents and lupus.
Topics: Antibodies, Antiphospholipid; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Kidney | 1994 |
The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Topics: Animals; Antimalarials; CD8 Antigens; Humans; Hydroxychloroquine; Hypercholesterolemia; Interleukin- | 1993 |
Transverse myelitis complicating systemic lupus erythematosus: treatment including hydroxychloroquine. Case report.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lupus Erythe | 1993 |
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.
Topics: Antirheumatic Agents; Baltimore; Blood Glucose; Cohort Studies; Diabetes Complications; Diabetes Mel | 1996 |
Antimalarial drugs in pregnancy--the North American experience.
Topics: Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus | 1996 |
[Kikuchi syndrome, Hashimoto thyroiditis and lupus serology. Apropos of a case].
Topics: Adolescent; Cortisone; Female; Histiocytosis; Humans; Hydroxychloroquine; Lupus Erythematosus, Syste | 1996 |
Update on immunosuppressive therapy.
Topics: Adult; Arthritis, Juvenile; Azathioprine; Behcet Syndrome; Child; Cladribine; Cyclophosphamide; Cycl | 1998 |
Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist?
Topics: Adult; Azathioprine; Cathartics; Dermatologic Agents; Diagnosis, Differential; Erythema Multiforme; | 1999 |
Human parvovirus B19 infection: its relationship with systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Antinuclear; Antibodies, Viral; Child; Diagnosis, Differential; Drug Therapy | 1999 |
Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort.
Topics: Anti-Inflammatory Agents; Cohort Studies; Coronary Disease; Female; Humans; Hydroxychloroquine; Hypo | 2000 |
Antimalarials--the 'real' advance in lupus.
Topics: Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2001 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
Treatment of systemic lupus erythematosus.
Topics: Azathioprine; Cyclophosphamide; Cyclosporins; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 1986 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
39 trials available for hydroxychloroquine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial.
Topics: Aged; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response.
Topics: Adult; Azathioprine; Child; Cyclophosphamide; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunos | 2023 |
Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.
Topics: Adult; Antirheumatic Agents; Child; Drug Monitoring; Humans; Hydroxychloroquine; Lupus Erythematosus | 2022 |
Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.
Topics: Child; Double-Blind Method; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosu | 2023 |
Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Pr | 2021 |
Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial.
Topics: Child; Clinical Trials as Topic; COVID-19; Drug Monitoring; Humans; Hydroxychloroquine; Lupus Erythe | 2021 |
Improvement of medication adherence in adolescents and young adults with SLE using web-based education with and without a social media intervention, a pilot study.
Topics: Adolescent; Antirheumatic Agents; Education, Distance; Feasibility Studies; Female; Humans; Hydroxyc | 2018 |
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antimalarials; Biomarkers; Disease Progression; Double-B | 2018 |
Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Drug Monitoring; Early Diagnosis; Female; Humans; Hydroxychloroqu | 2013 |
[Long-term effects of hydroxychloroquine on metabolism of serum lipids and left ventricular structure and function in patients of systemic lupus erythematosus].
Topics: Adult; Female; Humans; Hydroxychloroquine; Lipid Metabolism; Lipids; Lupus Erythematosus, Systemic; | 2014 |
Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistanc | 2016 |
Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels.
Topics: Adult; Antirheumatic Agents; Double-Blind Method; Female; France; Humans; Hydroxychloroquine; Linear | 2016 |
Systemic lupus erythematosus complicated with femoral head ischemic necrosis treated by Chinese medicine therapy for activating blood and dredging collaterals method.
Topics: Adolescent; Adult; Blood Circulation; Collateral Circulation; Combined Modality Therapy; Cyclophosph | 2011 |
QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Echocardiography; Electrocardiography; Fema | 2012 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Topics: Adult; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; | 2013 |
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Antimalarials; Drug Therapy, Combinati | 2003 |
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
Topics: Antirheumatic Agents; Birth Weight; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hydr | 2003 |
Utility of red amsler grid screening in a rheumatology clinic.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; False Positive Reactions; Female; Humans; Hydroxychloro | 2004 |
[Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
Topics: Adult; Aged; Algorithms; Antimalarials; Case-Control Studies; Chloroquine; Drug Therapy, Combination | 2004 |
[Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions].
Topics: Adult; Advertising; Antimalarials; Autoimmune Diseases; Female; Humans; Hydroxychloroquine; Lupus Er | 2004 |
The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Topics: Adult; Antibodies, Anticardiolipin; Antirheumatic Agents; Azathioprine; B-Cell Activating Factor; Ca | 2006 |
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Topics: Adult; Biomarkers; Chromatography, High Pressure Liquid; Disease Progression; Female; Humans; Hydrox | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Child; Cholesterol; Drug Therapy, Combination; Female; F | 1995 |
Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus.
Topics: Adult; Double-Blind Method; Female; Humans; Hydroxychloroquine; Joint Diseases; Lupus Erythematosus, | 1994 |
Hydroxychloroquine, dosage parameters and retinopathy.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Lupus | 1993 |
The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; CD4 Antigens; CD8 Antigens; Female; Humans; Hydroxychloroquine; Interleukin-6; Lu | 1994 |
Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Topics: Antimalarials; Child, Preschool; Contraindications; Female; Fetus; Follow-Up Studies; Hearing Disord | 1996 |
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo | 1998 |
The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients.
Topics: Adult; Antimalarials; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; H | 2000 |
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
Topics: Adult; Antimalarials; Double-Blind Method; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2001 |
Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Therap | 2001 |
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Danazol; Drug Administration Routes; Dru | 2002 |
[Crug formulation and liberation of the active ingredient in of chloroquine phosphate].
Topics: Chloroquine; Clinical Trials as Topic; Delayed-Action Preparations; Dosage Forms; Female; Humans; Hu | 1975 |
Hydroxychloroquine in systemic lupus erythematosus.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1991 |
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lupus Ery | 1991 |
Therapy for systemic lupus erythematosus.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1991 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine.
Topics: Adolescent; Adult; Arthritis, Juvenile; Child; Child, Preschool; Chloroquine; Clinical Trials as Top | 1974 |
815 other studies available for hydroxychloroquine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Clinically effective concentration and risk of hydroxychloroquine retinopathy in systemic lupus erythematosus: walking on a thin line. Comment on the article by Garg et al.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Diseases; W | 2022 |
Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antibodies | 2021 |
A rare case of a patient with systemic lupus erythematosus who presented with Rowell syndrome responding to treatment with hydroxychloroquine and prednisone with 1 year of relapse-free survival on belimumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, S | 2022 |
Late-Onset Systemic Lupus Erythematosus Associated with Autoimmune Hemolytic Anemia and Sixth Cranial Nerve Palsy.
Topics: Abducens Nerve Diseases; Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Antinuclear; Female; Human | 2021 |
Which interventions are effective for cutaneous disease in systemic lupus erythematosus? A Cochrane Review summary with commentary.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Impact of Structural Changes on Multifocal Electroretinography in Patients With Use of Hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Humans; Hydro | 2021 |
Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal.
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newbor | 2021 |
Use of hydroxychloroquine in dermatology: A multicenter retrospective study in Korea.
Topics: Dermatology; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, System | 2022 |
Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study.
Topics: Adult; China; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; M | 2021 |
75-Year-Old Man With Fever and Malaise.
Topics: Acute Kidney Injury; Aged; Antirheumatic Agents; Diagnosis, Differential; Humans; Hydroxychloroquine | 2021 |
Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Topics: BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Drug-Related Side Effects and Adverse Reactions; Humans | 2022 |
Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding.
Topics: Antirheumatic Agents; Cardiomyopathy, Restrictive; Echocardiography; Female; Gastroplasty; Heart; Hu | 2021 |
Utilization of glucocorticoids among White and Black patients with systemic lupus erythematosus: Observations from the enrollment visit of a prospective registry.
Topics: Adult; Antirheumatic Agents; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Syste | 2021 |
Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus.
Topics: Diabetes, Gestational; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2022 |
Hydroxychloroquine versus tacrolimus for the treatment of persistently active systemic lupus erythematosus.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retrospective Studi | 2022 |
Combined treatment of prednisone and hydroxychloroquine may improve outcomes of frozen embryo transfer in antinuclear antibody-positive patients undergoing IVF/ICSI treatment.
Topics: Abortion, Spontaneous; Antibodies, Antinuclear; Embryo Transfer; Female; Fertilization in Vitro; Hum | 2021 |
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Topics: Adult; Antirheumatic Agents; Drug Tapering; Female; Follow-Up Studies; Humans; Hydroxychloroquine; L | 2022 |
Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; British Columbia; Case-Control Studies; Humans; Hydroxy | 2023 |
Prenatal predisposing factors associated with neonatal lupus erythematosus.
Topics: Antibodies, Antinuclear; Case-Control Studies; Causality; Female; Humans; Hydroxychloroquine; Infant | 2022 |
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Skin Diseases | 2022 |
Hydroxychloroquine and lupus flare: a good drug, but we need to do better.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Randomized Controll | 2022 |
Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; | 2022 |
Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.
Topics: Antibodies, Antiphospholipid; Azathioprine; Female; Glucocorticoids; Humans; Hydroxychloroquine; Inf | 2022 |
Systemic Lupus Erythematosus Increases the Risk of Gestational Diabetes: Truth or Illusion?
Topics: Antirheumatic Agents; Diabetes, Gestational; Female; Humans; Hydroxychloroquine; Illusions; Lupus Er | 2022 |
Broadening the spectrum of the neurological complications in systemic lupus erythematosus: A patient with meningoradiculitis.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Middl | 2022 |
Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.
Topics: Antirheumatic Agents; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug-Related Side Effe | 2022 |
RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; British Columbia; Cohort Studies; Humans; Hydrox | 2022 |
Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study.
Topics: Adrenal Cortex Hormones; Alcoholism; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male | 2022 |
Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus.
Topics: Biomarkers; Cell Adhesion Molecules; E-Selectin; Humans; Hydroxychloroquine; Intercellular Adhesion | 2022 |
Comparison of hydroxychloroquine titers measured in frozen/thawed serum and whole blood obtained from lupus patients.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2022 |
Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
Topics: Adult; Aged; Case-Control Studies; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychlo | 2022 |
Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; COVID-19; COVID-19 Drug Treatment; Humans; Hydro | 2022 |
Antihypertensive effects of immunosuppressive therapy in autoimmune disease.
Topics: Antihypertensive Agents; Female; Humans; Hydroxychloroquine; Hypertension; Immunosuppression Therapy | 2023 |
Hydroxychloroquine Therapy and Serum Immunoglobulin Levels in Women with IgG Subclass Deficiency and Systemic Lupus Erythematosus, Sjögren Syndrome, and Rheumatoid Arthritis: A Retrospective Study.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; IgG Deficiency; Immunoglobulin A; | 2022 |
Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study.
Topics: Adult; Anticoagulants; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ly | 2022 |
Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.
Topics: Adult; Glucocorticoids; Goals; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Prednisone | 2022 |
Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients.
Topics: Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroq | 2022 |
Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean.
Topics: Adult; Antiphospholipid Syndrome; Cyclophosphamide; Female; Humans; Hydroxychloroquine; Immunoglobul | 2022 |
Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials.
Topics: Antimalarials; Granzymes; Humans; Hydroxychloroquine; Immunosuppressive Agents; Interferon Regulator | 2022 |
[Should HCQ be administered in SLE patients dependent on hemodialysis?]
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Renal Dialysis | 2022 |
Hydroxychloroquine induces apoptosis of myeloid-derived suppressor cells via up-regulation of CD81 contributing to alleviate lupus symptoms.
Topics: Animals; Antirheumatic Agents; Apoptosis; Hydroxychloroquine; Lupus Erythematosus, Systemic; Mice; M | 2022 |
Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus.
Topics: Chemokine CCL3; Cytokines; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; In | 2022 |
Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus.
Topics: Adolescent; Antirheumatic Agents; Child; Child, Preschool; Hospitalization; Humans; Hydroxychloroqui | 2022 |
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine.
Topics: Adolescent; Antirheumatic Agents; Azathioprine; Child; Female; Humans; Hydroxychloroquine; Lupus Ery | 2023 |
Effect of Hydroxychloroquine on Influenza Prevention.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Influenza, Human; Lupus Ery | 2022 |
Macular and peripapillary vessel density alterations in a large series of patients with systemic lupus erythematosus without ocular involvement.
Topics: Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Macula Lutea; Re | 2022 |
Effectiveness of anti-interleukin-17-receptor antibody for hydroxychloroquine-induced generalized pustular psoriasis in a patient with systemic lupus erythematosus.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Psoriasis; Receptors, Interleukin-17; Ski | 2022 |
Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre.
Topics: Antimalarials; Drug-Related Side Effects and Adverse Reactions; Female; Glycoproteins; Humans; Hydro | 2022 |
Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
Topics: Adipokines; Adiponectin; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Atherosclerosis; Cyto | 2022 |
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Medication Adherenc | 2022 |
A case of palmoplantar pustular psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Psoriasis; Quality of Life | 2022 |
Quantitative Proteomics Explore the Potential Targets and Action Mechanisms of Hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Galectins; Humans; Hydroxychloroquine; Lupus Erythemato | 2022 |
Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atrial Fibrillation; British Columbia; Humans; Hydroxyc | 2023 |
[Lupus nephritis].
Topics: Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Lupus Erythem | 2023 |
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Wei | 2023 |
The association between hydroxychloroquine use and future development of systemic lupus erythematosus in patients with primary Sjögren's syndrome.
Topics: Case-Control Studies; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Sjo | 2022 |
A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article.
Topics: Aged; Antibodies, Monoclonal; Breast Neoplasms; Female; Glycoproteins; Humans; Hydrocortisone; Hydro | 2022 |
Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares.
Topics: Antirheumatic Agents; Dose-Response Relationship, Drug; Eye Diseases; Humans; Hydroxychloroquine; Lu | 2022 |
Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.
Topics: Antirheumatic Agents; East Asian People; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; | 2023 |
Interstitial lung disease in patients with systemic lupus erythematosus: a cohort study.
Topics: Carbon Monoxide; Cohort Studies; Humans; Hydroxychloroquine; Lung; Lung Diseases, Interstitial; Lupu | 2022 |
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study.
Topics: Cross-Sectional Studies; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupu | 2022 |
Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.
Topics: Aged; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Carotid Artery Diseases; Case-Contr | 2022 |
Development and Initial Validation of a Systemic Lupus Erythematosus-Specific Measure of the Extent of and Reasons for Medication Nonadherence.
Topics: Adult; Fatigue; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Medication | 2022 |
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
Topics: Antibodies, Viral; Autoimmune Diseases; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Imm | 2022 |
Unilateral periorbital lupus erythematosus tumidus mimicking heliotrope rash.
Topics: Exanthema; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; | 2023 |
Association of Hydroxychloroquine Dose With Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Heart Failure; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Stro | 2023 |
Hydroxychloroquine dose: balancing toxicity and SLE flare risk.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Sys | 2023 |
Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Topics: Adult; Antirheumatic Agents; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2022 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Cesarean Section; Child; Di | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Aspirin; Cytokines; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Cross-Sectional St | 2023 |
Unilateral lupus mastitis.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lu | 2023 |
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Sys | 2023 |
Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study.
Topics: Antirheumatic Agents; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ret | 2023 |
The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report.
Topics: COVID-19; Cross-Sectional Studies; Humans; Hydroxychloroquine; Immunosuppression Therapy; Lupus Eryt | 2023 |
Consequences of medication unavailability on patient anxiety: the example of the 2020 hydroxychloroquine availability crisis for patients with SLE - 18 months later.
Topics: Antirheumatic Agents; Anxiety; Anxiety Disorders; Humans; Hydroxychloroquine; Lupus Erythematosus, S | 2023 |
Hydroxychloroquine Dose and Risk of Systemic Lupus Erythematosus Flares-Reply.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Risk; Symptom Flare Up | 2023 |
Hydroxychloroquine Dose and Risk of Systemic Lupus Erythematosus Flares.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Risk; Symptom Flare Up | 2023 |
KLRG1 is reduced on NK cells in SLE patients, inversely correlates with disease activity and is modulated by hydroxychloroquine
Topics: Flow Cytometry; Humans; Hydroxychloroquine; Killer Cells, Natural; Lectins, C-Type; Leukocytes, Mono | 2023 |
Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration.
Topics: Antirheumatic Agents; Glomerular Filtration Rate; Humans; Hydroxychloroquine; Immunosuppressive Agen | 2023 |
Association between cumulative dose of hydroxychloroquine and electrocardiographic abnormalities in patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Multivariate Analys | 2023 |
Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Humans; Hydroxychloroquine; Immunosuppression Therapy; Immunosuppressive Ag | 2023 |
Analysis of choroidal thickness in juvenile systemic lupus erythematosus and its correlation with laboratory tests.
Topics: Choroid; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Refraction, Ocular; Tomography, | 2023 |
Systemic Lupus Erythematosus: Diagnosis and Treatment.
Topics: Abortion, Spontaneous; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; | 2023 |
Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Body Weight; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retina | 2023 |
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review.
Topics: Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quality Indicators, Heal | 2023 |
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.
Topics: Animals; Autoimmune Diseases; Humans; Hydroxychloroquine; Interferons; Lupus Erythematosus, Systemic | 2023 |
Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study.
Topics: Adult; Colombia; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; | 2023 |
Systemic lupus erythematosus presenting as lupus erythematosus tumidus and lupus nephritis: a case report.
Topics: Adult; Female; Humans; Hydroxychloroquine; Kidney; Lupus Erythematosus, Discoid; Lupus Erythematosus | 2023 |
Systemic lupus erythematosus associated with development of macrophage activation syndrome and disseminated aspergillosis.
Topics: Adrenal Cortex Hormones; Adult; Aspergillosis; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2023 |
Systemic lupus erythematosus: An approach to pharmacologic interventions.
Topics: Antimalarials; Biological Factors; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Ag | 2023 |
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort.
Topics: Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; P | 2023 |
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards.
Topics: Decision Support Techniques; Health Literacy; Humans; Hydroxychloroquine; Lupus Erythematosus, Syste | 2023 |
Breastfeeding in women with systemic lupus erythematosus: results from a Norwegian quality register.
Topics: Breast Feeding; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregna | 2023 |
Protective effect of hydroxychloroquine on infections in patients with systemic lupus erythematosus: an observational study using the LUNA registry.
Topics: Adult; Female; Glucocorticoids; Hospitalization; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Trends and practices following the 2016 hydroxychloroquine screening guidelines.
Topics: Academies and Institutes; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
In vitro evaluation of the potential immunosuppressive effect of panobinostat on cultured lymphocytes retrieved from childhood systemic lupus erythematosus patients.
Topics: Annexin A5; Child; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lymphocytes; Panobinos | 2023 |
Association of patient copayment and medication adherence in systemic lupus erythematosus.
Topics: Adult; Aged; Azathioprine; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Eryth | 2023 |
The co-occurrence of Kikuchi-Fujimoto disease and systemic lupus erythematosus: a case report.
Topics: Female; Fever; Histiocytic Necrotizing Lymphadenitis; Humans; Hydroxychloroquine; Lupus Erythematosu | 2023 |
Clinical efficacy of plasma exchange in systemic lupus erythematosus during pregnancy.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Plasma Exch | 2023 |
Case Report: Tuberculosis lymphadenitis with systemic lupus erythematosus in a young woman: a case report.
Topics: Adult; Antitubercular Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lym | 2023 |
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE.
Topics: Antirheumatic Agents; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; East Asian People; Genotype; | 2023 |
Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus.
Topics: Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosu | 2023 |
Belimumab treatment in rhupus: A case report with severe skin involvement.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Drug Therap | 2019 |
Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs.
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, S | 2020 |
Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity.
Topics: Biopsy; Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Electrocardiography; Female; Humans; | 2019 |
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
Topics: Adult; Age Factors; Antirheumatic Agents; Body Mass Index; Female; Humans; Hydroxychloroquine; Lupus | 2020 |
[Drug-induced Sweet's syndrome related to hydroxychloroquine: About 2 cases].
Topics: Adrenal Cortex Hormones; Adult; Diagnosis, Differential; Drug Substitution; Female; Humans; Hydroxyc | 2020 |
Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Clinical Protocols; Cyclophosphamide; Dose-Respo | 2019 |
Successful hydroxychloroquine treatment for familial Mediterranean fever in a Japanese patient with concurrent systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Asian People; Colchicine; Cytokines; Familial Mediterranean Fever; Fema | 2020 |
Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
Topics: Adrenal Cortex Hormones; Age Factors; Antirheumatic Agents; Comorbidity; Cost of Illness; Female; He | 2020 |
Drugs for Lupus While Breastfeeding.
Topics: Biological Products; Breast Feeding; Drug Monitoring; Female; Glucocorticoids; Humans; Hydroxychloro | 2019 |
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cyclosporine; Deprescriptions; Female; Hum | 2020 |
Structural Retinal Assessment Using Optical Coherence Tomography and Fundus Fluorescein Angiography in Systemic Lupus Erythematosus Patients.
Topics: Adult; Antirheumatic Agents; Correlation of Data; Early Diagnosis; Female; Fluorescein Angiography; | 2021 |
Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).
Topics: Adult; Antibodies, Antinuclear; Black or African American; Disease Progression; Female; Humans; Hydr | 2019 |
Chilblains in a Patient with Systemic Lupus Erythematosus: Another Manifestation of the Great Masquerader.
Topics: Antirheumatic Agents; Autoantibodies; Biopsy; Chilblains; Glucocorticoids; Humans; Hydroxychloroquin | 2019 |
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI.
Topics: Adult; Aged; Antimalarials; Biopsy; Cardiomyopathies; Cardiotoxicity; Chloroquine; Diagnosis, Differ | 2020 |
Myocarditis as a lupus challenge: two case reports.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus | 2019 |
Plaque-like Cutaneous Lupus Mucinosis as the First Sign of Systemic Lupus Erythematosus.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Biopsy; Diagnosis, Differential; Female; Glucocor | 2020 |
Hydroxychloroquine Ocular Toxicity: Lessons Learned.
Topics: Antirheumatic Agents; Female; Fundus Oculi; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2019 |
Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry.
Topics: Adult; Antirheumatic Agents; Autoimmune Diseases; Autoimmunity; Cross-Sectional Studies; Female; Hum | 2020 |
Acute generalized exanthematous pustulosis induced by hydroxychloroquine successfully treated with etretinate.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antirheumatic Agents; Biopsy; Etretinate; Female; | 2020 |
Organising pneumonia in Rhupus syndrome.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis; Cough; Diagnosis, Differential; Drug Ther | 2019 |
Unexpectedly, low hydroxychloroquine concentration enhances DNA-induced immune stimulation
Topics: Adjuvants, Immunologic; Cells, Cultured; CpG Islands; DNA; Dose-Response Relationship, Drug; Humans; | 2020 |
Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies?
Topics: Adult; Antirheumatic Agents; California; Female; Humans; Hydroxychloroquine; Logistic Models; Lupus | 2020 |
What every nephrologist needs to know about hydroxychloroquine toxicity
.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Kidney; Lupus Erythematosus, System | 2020 |
Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; | 2020 |
Targetoid-like Lesions in the Setting of Systemic Lupus Erythematosus: A Case of Rowell Syndrome.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Diagnosis, Differential; Erythema Multiforme; | 2020 |
The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lupus Er | 2020 |
Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study.
Topics: Adult; Antifungal Agents; Antirheumatic Agents; Case-Control Studies; Female; Glucocorticoids; Human | 2020 |
New onset weakness in the face and arm.
Topics: Adult; Arm; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Vasculitis, Cen | 2020 |
Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance.
Topics: Animals; Atherosclerosis; Dendritic Cells; Disease Models, Animal; Disease Progression; Female; Hydr | 2020 |
Sudden visual loss in a patient with systemic lupus erythematosus caused by a combination of the disease itself and drug toxicity.
Topics: Blindness; Cataract Extraction; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus E | 2020 |
[Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer].
Topics: Adult; China; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Neoplasms; Ris | 2020 |
[New and Established Therapeutic Options for the Treatment of Systemic Lupus Erythematosus].
Topics: Antimalarials; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythema | 2020 |
Patterns and predictors of recurrent acute care use among Medicaid beneficiaries with systemic lupus erythematosus.
Topics: Adult; Aged; Comorbidity; Hospitalization; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2020 |
Placenta accrete after a frozen-thawed embryo transfer in a systemic lupus erythematosus patient treated with hydroxychloroquine.
Topics: Adult; Blastocyst; Cesarean Section; Cryopreservation; Embryo Transfer; Female; Freezing; Humans; Hy | 2020 |
Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fear; Human | 2020 |
SLE patients are not immune to covid-19: importance of sending the right message across.
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV- | 2021 |
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Topics: Adult; Aged; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2020 |
[A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials].
Topics: Antimalarials; Asthenia; Biopsy; Cardiotoxicity; Diagnosis, Differential; Humans; Hydroxychloroquine | 2020 |
Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Hyperpigmen | 2020 |
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.
Topics: Adult; Aged; Antirheumatic Agents; Betacoronavirus; Case-Control Studies; Coronavirus Infections; CO | 2020 |
A positive PYP scan: Thinking beyond amyloid.
Topics: Antirheumatic Agents; Cardiomyopathies; Cardiotoxicity; Female; Humans; Hydroxychloroquine; Lupus Er | 2021 |
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Azathioprine; Betacoronavirus; Clinical Labora | 2020 |
No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit.
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV- | 2021 |
Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.
Topics: Aged; Antirheumatic Agents; British Columbia; Case-Control Studies; Databases, Factual; Female; Huma | 2021 |
Hydroxychloroquine reduces IL-6 and pro-thrombotic status.
Topics: Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroquine; Inflammation; Interleukin-6; Lup | 2020 |
Lupus Erythematosus Tumidus with Pseudolymphomatous Infiltrates: A Case Report.
Topics: Adult; Antigens, CD20; B-Lymphocytes; CD3 Complex; Female; Humans; Hydroxychloroquine; Interleukin-3 | 2020 |
Clinical Features of Systemic Lupus Erythematosus in Tunisian Males.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male | 2020 |
Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Renal Insufficiency, Chronic | 2022 |
Hydroxychloroquine shortages during the COVID-19 pandemic.
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Syst | 2021 |
Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Renal Insufficiency, Chr | 2022 |
Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Comorbidity; Disease Progression; Female; Huma | 2020 |
Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Medic | 2020 |
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
Topics: Adult; Antirheumatic Agents; Case-Control Studies; Female; Humans; Hydroxychloroquine; Lupus Erythem | 2020 |
Are patients with systemic lupus erythematosus at increased risk for COVID-19?
Topics: Coronavirus; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV-2 | 2021 |
Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV-2 | 2021 |
Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'.
Topics: Coronavirus; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Eryt | 2021 |
Response to: 'Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour
Topics: Coronavirus; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Eryt | 2021 |
Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.
Topics: Adult; Aged; Betacoronavirus; Chromatography, Liquid; Coronavirus Infections; COVID-19; Drug Monitor | 2020 |
Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, | 2021 |
Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long-Term Care; Lupus Erythematosus, Systemic | 2021 |
Patients with lupus with COVID-19: University of Michigan experience.
Topics: Arthritis, Rheumatoid; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
A Sensitive and Optimized HPLC-FLD Method for the Simultaneous Quantification of Hydroxychloroquine and Its Two Metabolites in Blood of Systemic Lupus Erythematosus Patients.
Topics: Adult; Chloroquine; Chromatography, High Pressure Liquid; Female; Humans; Hydroxychloroquine; Linear | 2020 |
Ocular flare-up in patients with systemic lupus erythematosus following discontinuation of hydroxychloroquine.
Topics: Aged; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Retinal | 2020 |
Response to: 'COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics; Rheumatic Diseases; | 2021 |
[Proximal myopathy and fulminant heart failure in a 57 year-old female patient with lupus erythematosus].
Topics: Biopsy; Cardiomyopathies; Echocardiography; Fatal Outcome; Female; Heart; Heart Failure; Humans; Hyd | 2020 |
Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak.
Topics: COVID-19; Disease Outbreaks; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Response to: 'Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak' by Holubar
Topics: COVID-19; Disease Outbreaks; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
Topics: Adult; Antirheumatic Agents; Biomarkers; Dose-Response Relationship, Drug; Female; Humans; Hydroxych | 2020 |
Altered microvascular density in patients with systemic lupus erythematosus treated with hydroxychloroquine-an optical coherence tomography angiography study.
Topics: Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Microvascular De | 2020 |
Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Arthritis, Rheumatoid; Computer Simulation; COVID- | 2021 |
The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2020 |
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Health Services Accessibility; Humans; Hydroxychloroq | 2021 |
Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments.
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, | 2021 |
[Reticular erythematous mucinosis-A special subtype of cutaneous lupus erythematosus?]
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; M | 2020 |
Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
Topics: Acoustic Impedance Tests; Adult; Antimalarials; Audiometry, Pure-Tone; Chloroquine; Cross-Sectional | 2021 |
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Az | 2020 |
Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics | 2021 |
Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey.
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics | 2021 |
Autoimmune Conditions: Systemic Lupus Erythematosus.
Topics: Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quality of Life; Severit | 2020 |
Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female | 2020 |
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
Topics: Adult; Aged; Antimalarials; Antiviral Agents; Arthritis, Rheumatoid; COVID-19; Drug Administration S | 2021 |
Hereditary C1 inhibitor deficiency associated with systemic lupus erythematosus.
Topics: Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Family; Female; Humans; Hydroxychloroquine | 2020 |
Adverse pregnancy outcomes among multi-ethnic systemic lupus erythematosus patients in Malaysia.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Mala | 2020 |
Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics | 2021 |
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India.
Topics: COVID-19; Humans; Hydroxychloroquine; India; Lupus Erythematosus, Systemic; Pandemics; SARS-CoV-2 | 2021 |
Lentiform fork sign in a patient with systemic lupus erythematosus.
Topics: Aged; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; | 2021 |
Immunomodulatory Medication Use in Newly Diagnosed Youth With Systemic Lupus Erythematosus.
Topics: Administrative Claims, Healthcare; Adolescent; Antirheumatic Agents; Child; Drug Prescriptions; Drug | 2021 |
Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV-2 | 2021 |
COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine.
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; SARS-CoV-2 | 2021 |
Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hydroxychloroquine; India; Infant, Newborn; Lupus Eryt | 2020 |
Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idio | 2021 |
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, | 2021 |
Differential approach to peripheral blood cell ratios in patients with systemic lupus erythematosus and various manifestations.
Topics: Adult; Biomarkers; Blood Sedimentation; Disease Progression; Female; Glucocorticoids; Humans; Hydrox | 2020 |
Implications of SARS-CoV-2 infection for patients with rheumatic disease.
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Rheumatic Diseases; SARS-CoV-2 | 2022 |
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agen | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Topics: Aged; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroqu | 2020 |
The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Cross Infection; Databases, Factual; Female; Humans; Hydroxychloroquine | 2020 |
The multi-targets mechanism of hydroxychloroquine in the treatment of systemic lupus erythematosus based on network pharmacology.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Molecular Docking Simulation; Phosphatidy | 2020 |
Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig
Topics: Chloroquine; COVID-19; COVID-19 Drug Treatment; France; Hospitalization; Humans; Hydroxychloroquine; | 2023 |
Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathi
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Syst | 2022 |
Response to 'Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic' by Chuah
Topics: COVID-19; Hospitalization; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics; Ter | 2022 |
Zebra bodies without Fabry disease or hydroxychloroquine.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Fabry Disease; Humans; Hydroxychloroquine | 2021 |
COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.
Topics: Adult; Antirheumatic Agents; Betacoronavirus; Clinical Laboratory Techniques; Communicable Disease C | 2020 |
Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth With Systemic Lupus Erythematosus.
Topics: Adolescent; Adolescent Behavior; Age Factors; Antirheumatic Agents; Child; Child Behavior; Comorbidi | 2021 |
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Antirheu | 2020 |
Rowell's syndrome: a rare but distinct entity in rheumatology.
Topics: Adolescent; Antibodies, Antinuclear; Antipyretics; Arthralgia; Drug Therapy, Combination; Erythema M | 2020 |
Comment on: Successful hydroxychloroquine treatment for familial Mediterranean fever in a Japanese patient with concurrent systemic lupus erythematosus.
Topics: Familial Mediterranean Fever; Humans; Hydroxychloroquine; Japan; Lupus Erythematosus, Systemic; Pyri | 2020 |
Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Patient Compliance; | 2020 |
SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus.
Topics: Adult; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Dyspnea; | 2020 |
Lupus erythematosus tumidus in an adolescent with beta thalassemia minor successfully controlled with hydroxychloroquine.
Topics: Adolescent; beta-Thalassemia; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Eryt | 2020 |
Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Graft Rejection; Graf | 2020 |
Pediatric catastrophic antiphospholipid syndrome patient evolving to systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Antinuclear; Antiphospholipid Syndrome; Catastrophic Illness; Female; Hepari | 2021 |
Comment on: Successful hydroxychloroquine treatment for familial Mediterranean fever in a Japanese patient with concurrent systemic lupus erythematosus: reply.
Topics: Familial Mediterranean Fever; Humans; Hydroxychloroquine; Japan; Lupus Erythematosus, Systemic; Pyri | 2020 |
Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Atrial Fibrillation; Female; Humans; Hydroxychloroquine; Incidenc | 2021 |
Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
Topics: Adult; Antimalarials; China; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxyc | 2021 |
Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
Topics: Adult; Autoantibodies; Biomarkers; Complement System Proteins; Disease Progression; DNA; Enzyme Inhi | 2020 |
Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; B-Cell Activating Factor; Humans; Hydroxychloroquine; Interferons; Lupus Eryth | 2021 |
The effect of long-term hydroxychloroquine use on the corneal endothelium in patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Endothelium, Corneal; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2021 |
Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring - A Danish population-based study.
Topics: Academic Performance; Adolescent; Adolescent Development; Adult; Child; Child Development; Denmark; | 2021 |
Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Biomarkers; Case-Control Studies; Complement | 2020 |
[Therapeutic de-escalation in systemic lupus erythematosus in remission].
Topics: Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Mainten | 2020 |
Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroq
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Syst | 2022 |
New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre.
Topics: Adult; Cohort Studies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Malaysia; | 2020 |
A 6-step rapid desensitization protocol to hydroxychloroquine.
Topics: Adult; Desensitization, Immunologic; Drug Eruptions; Female; Humans; Hydroxychloroquine; Lupus Eryth | 2021 |
Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine.
Topics: Adolescent; Antirheumatic Agents; Child; Female; Hospitals, Pediatric; Humans; Hydroxychloroquine; I | 2021 |
[Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine].
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; COVID- | 2021 |
Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; COVID | 2021 |
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |
Evaluation of corneal safety in systemic lupus erythematosus patients undergoing long-term hydroxychloroquine treatment.
Topics: Aberrometry; Adolescent; Adult; Cornea; Corneal Diseases; Corneal Pachymetry; Cross-Sectional Studie | 2021 |
Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision-Making in Systemic Lupus Erythematosus Treatment?
Topics: Adult; Antirheumatic Agents; Canada; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Ery | 2022 |
Hydroxychloroquine, TTP, COVID-19, and SLE
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Purpura, Thrombo | 2021 |
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Chromatography, Liquid; Female; Fingers; Gangrene; Humans; Hydroxychlor | 2021 |
"Protenuria in SLE: Is it always lupus?"
Topics: Antirheumatic Agents; Biopsy; Diagnosis, Differential; Enzyme Replacement Therapy; Fabry Disease; Fe | 2021 |
[Toxic hydroxychloroquine-induced cardiomyopathy complicating systemic lupus treatment].
Topics: Aged; Biopsy; Cardiomyopathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2021 |
Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
Topics: COVID-19; COVID-19 Drug Treatment; Disease Progression; Humans; Hydroxychloroquine; Lupus Erythemato | 2023 |
Non-central serous chorioretinopathy in a patient with systemic lupus erythematosus and hydroxychloroquine retinopathy.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Disease Progression; Drug Therapy, Combination | 2021 |
Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cause of Death; Cohort Studies; | 2021 |
QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Topics: Antirheumatic Agents; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; Lupus Eryth | 2021 |
Moyamoya angiopathy unmasking systemic lupus erythematosus.
Topics: Albuminuria; Angiography, Digital Subtraction; Antibodies, Antinuclear; Anticonvulsants; Antirheumat | 2021 |
Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retr | 2021 |
Predictors of Initial Hydroxychloroquine Receipt Among Medicaid Beneficiaries With Incident Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Syst | 2022 |
Subacute cutaneous lupus erythematosus triggered after measles vaccination.
Topics: Antirheumatic Agents; Drug Therapy, Combination; Female; Folic Acid; Follow-Up Studies; Glucocortico | 2021 |
Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris.
Topics: Dermatomyositis; Humans; Hydroxychloroquine; Lichen Planus; Lupus Erythematosus, Cutaneous; Lupus Er | 2021 |
Breastfeeding in women affected by systemic lupus erythematosus: Rate, duration and associated factors.
Topics: Adult; Breast Feeding; Cesarean Section; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2021 |
Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan.
Topics: Cohort Studies; Cyclophosphamide; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus Erythem | 2022 |
Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Cross-Sectional Studies; D | 2021 |
Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study.
Topics: Adult; Cohort Studies; Databases, Factual; Disease Management; Disease Progression; Female; Glucocor | 2021 |
Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review.
Topics: Adolescent; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Vision, Low; Visual A | 2021 |
Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Blood Platelets; Female; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
Macula pigment optical densitometry changes in hydroxychloroquine use.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Densitom | 2021 |
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence.
Topics: Adult; Antirheumatic Agents; Europe; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, System | 2021 |
Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, P | 2021 |
Hydroxychloroquine-related hyperpigmentation.
Topics: Adult; Antirheumatic Agents; Cheek; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Leg; Lupu | 2022 |
Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety.
Topics: Antirheumatic Agents; Anxiety; Civil Defense; Community Pharmacy Services; COVID-19; COVID-19 Drug T | 2021 |
Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
Topics: COVID-19; COVID-19 Drug Treatment; Disease Progression; Humans; Hydroxychloroquine; Lupus Erythemato | 2023 |
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy-a tertiary centre experience in an Appalachian state.
Topics: Appalachian Region; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Kentucky; Lupus Ery | 2021 |
A novel KCNV2 mutation in a patient taking hydroxychloroquine associated with cone dystrophy with supernormal rod response.
Topics: Adult; Antirheumatic Agents; Consanguinity; Electroretinography; Female; Frameshift Mutation; Geneti | 2021 |
Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Complement Hemolytic Activity Assay; Female; G | 2021 |
Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study.
Topics: Antirheumatic Agents; Arrhythmias, Cardiac; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2021 |
Visual Impact of Early Hydroxychloroquine-Related Retinal Structural Changes in Patients with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2021 |
Case of annular pustular psoriasis/circinate erythematous psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus: Possible association with CARD-14 mutation.
Topics: Erythema; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Mutation; Psoriasis | 2021 |
Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study.
Topics: Adolescent; Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; China; Cohort Studies; Female | 2021 |
Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus | 2021 |
Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New-Onset End-Stage Renal Disease.
Topics: Adolescent; Aged; Antirheumatic Agents; Glucocorticoids; Humans; Hydroxychloroquine; Kidney Failure, | 2022 |
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Aspirin; Drug Tapering; Europe; Fema | 2021 |
Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies.
Topics: Animals; Antibodies, Antinuclear; Cell Line, Tumor; Cell Survival; Cells, Cultured; Enzyme Inhibitor | 2021 |
Hydroxychloroquine might reduce risk of incident endometriosis in patients with systemic lupus erythematosus: A retrospective population-based cohort study.
Topics: Antirheumatic Agents; Cohort Studies; Endometriosis; Female; Humans; Hydroxychloroquine; Lupus Eryth | 2021 |
Ophthalmologic manifestations in patients with antiphospholipid antibodies: Beware of iatrogenic complications.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Eye Disease | 2021 |
Does hydroxychloroquine improve patient reported outcomes in patients with lupus?
Topics: Adult; Antirheumatic Agents; Cross-Sectional Studies; Databases, Factual; Female; Humans; Hydroxychl | 2021 |
Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients.
Topics: Cohort Studies; Drug Tapering; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Ery | 2022 |
Lupus-related protein-losing enteropathy associated with pseudo-pseudo Meigs' syndrome and successfully treated with hydroxychloroquine.
Topics: Ascites; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Meigs Syndrome; Protein- | 2022 |
Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia.
Topics: Antidepressive Agents; Antirheumatic Agents; Drug Therapy, Combination; Electrocardiography; Fibromy | 2021 |
Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
Topics: COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunologic Factors; Lupus Erythematosus, Syste | 2021 |
Immune-mediated Coombs negative intravascular haemolysis in systemic lupus erythematosus (SLE).
Topics: Adult; Coombs Test; Female; Hemolysis; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pr | 2021 |
Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases.
Topics: Adult; Anticoagulants; Antimalarials; Antirheumatic Agents; Cross-Sectional Studies; Female; Humans; | 2017 |
Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Asian People; China; Databases, Factual; Female; Glucocorticoids; Human | 2017 |
[Association between myasthenia gravis and systemic lupus erythematosus: is it safe to use hydroxychloroquine?]
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myasthenia Gravis; Retrosp | 2017 |
Systemic lupus erythematosus with Degos disease: role of dermatoscopy in diagnosis.
Topics: Adolescent; Aspirin; Biopsy, Needle; Dermoscopy; Drug Therapy, Combination; Female; Humans; Hydroxyc | 2017 |
[Young patient diagnosed with hydroxychloroquine intoxication].
Topics: Adult; Antirheumatic Agents; Coma; Female; Glasgow Coma Scale; Humans; Hydroxychloroquine; Lupus Ery | 2017 |
High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Che | 2017 |
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Aspirin; Cardiovascular Diseases; Drug Synergism; Drug Therapy, Combina | 2017 |
Antimalarial drug retinopathy: A typical « Bull's eyes » appearance of fundus.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2018 |
Breastfeeding initiation, duration, and reasons for weaning in patients with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Breast Feeding; Cross-Sectional Studies; Femal | 2017 |
Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.
Topics: Anemia, Hemolytic; Antirheumatic Agents; Black or African American; Clinical Decision-Making; Female | 2018 |
Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
Topics: Adult; Antirheumatic Agents; Chloroquine; Female; Health Status; Humans; Hydroxychloroquine; Immunos | 2018 |
Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cesarean Section; Female; Ges | 2018 |
The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report.
Topics: Acetazolamide; Administration, Oral; Antirheumatic Agents; Carbonic Anhydrase Inhibitors; Dose-Respo | 2017 |
The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Case-Control Studies; Cyclophosphamide; DNA; F | 2017 |
Hydroxychloroquine inhibits CD154 expression in CD4
Topics: Adult; Antirheumatic Agents; CD4-Positive T-Lymphocytes; CD40 Ligand; Cells, Cultured; Female; Human | 2017 |
Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
Topics: Antineoplastic Agents, Immunological; Antirheumatic Agents; Diagnosis, Differential; Etoposide; Fema | 2017 |
Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Electroretinography; | 2017 |
Choroidal Thinning Associated With Hydroxychloroquine Retinopathy.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Choroid; Female; Humans; Hydro | 2017 |
Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Desensitization, Immunologic; Drug Administ | 2018 |
Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
Topics: Adolescent; Adult; Antirheumatic Agents; Databases, Factual; Female; Follow-Up Studies; Humans; Hydr | 2017 |
Systemic Lupus Erythematosus Presenting as Acute Lupus Pneumonitis.
Topics: Acute Disease; Aged; Chest Pain; Diagnosis, Differential; Dyspnea; Emergencies; Female; Fever; Human | 2018 |
Chloroquine Autophagic Inhibition Rebalances Th17/Treg-Mediated Immunity and Ameliorates Systemic Lupus Erythematosus.
Topics: Adult; Animals; Antimalarials; Autophagy; Cells, Cultured; Chloroquine; Female; Humans; Hydroxychlor | 2017 |
More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Chi-Square Distribution; Chloroquine; Female; Follow-Up Studies; Humans; Hydro | 2018 |
Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
Topics: Administration, Oral; Adolescent; Adult; Aged; Asian People; Child; Drug Administration Schedule; Fe | 2018 |
Familial Mediterranean Fever Imitating Lupus Flare: A Rare Coexistence of an Autoimmune Disease With an Autoinflammatory Disease.
Topics: Adult; Antirheumatic Agents; Colchicine; Familial Mediterranean Fever; Female; Humans; Hydroxychloro | 2018 |
Hydroxychloroquine-Induced Reversible Hypomnesis in Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reaction | 2018 |
Response to risk of hydroxychloroquine retinopathy is not related to systemic lupus erythematosus or rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2018 |
Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infan | 2017 |
Baseline Retinal Examinations in Patients With Systemic Lupus Erythematosus Newly Initiating Hydroxychloroquine Treatment in a US Medicaid Systemic Lupus Erythematosus Population, 2000-2010.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2018 |
Therapeutic adherence in patients with systemic lupus erythematosus: a cross-sectional study.
Topics: Adolescent; Adult; Age of Onset; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Secti | 2018 |
Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.
Topics: Adolescent; Adult; Arthritis; Case-Control Studies; Female; Hospitalization; Humans; Hydroxychloroqu | 2018 |
Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Databases, Factual; Female; Humans; Hydroxychloroquin | 2018 |
Effect of pregnancy on disease flares in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Antirheumatic Agents; Cohort Studies; Female; Humans; Hydroxychloroquine; Lupus E | 2018 |
Improvement of Libman-Sacks Endocarditis With Combined Hydroxychloroquine-Vitamin K Antagonist Therapy in a Primary Antiphospholipid Syndrome Patient.
Topics: Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Drug Therapy, Combination; Endocard | 2018 |
[Antimalarial drug retinopathy].
Topics: Adult; Antimalarials; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythemato | 2018 |
Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
Topics: Adult; Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Cell Differentiation; Female; Flow C | 2018 |
Differences in the diagnosis and management of systemic lupus erythematosus by primary care and specialist providers in the American Indian/Alaska Native population.
Topics: Adult; Alaskan Natives; Female; Humans; Hydroxychloroquine; Indians, North American; Lupus Erythemat | 2018 |
Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Topics: Adult; Antimalarials; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressi | 2018 |
Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality.
Topics: Adult; Bacterial Infections; Candidiasis; Enzyme Inhibitors; Female; Herpes Zoster; Hospitalization; | 2018 |
Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice.
Topics: Animals; Antibodies; B-Lymphocytes; Cell Movement; Cells, Cultured; Female; Humans; Hydroxychloroqui | 2018 |
Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood.
Topics: Antirheumatic Agents; Chromatography, High Pressure Liquid; Humans; Hydroxychloroquine; Limit of Det | 2018 |
Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016.
Topics: Antirheumatic Agents; Drug Dosage Calculations; Female; Guideline Adherence; Humans; Hydroxychloroqu | 2018 |
A successful treatment of severe systemic lupus erythematosus caused by occult pulmonary infection-associated with hemophagocytic syndrome: A case report.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Blood Cell Count; Bone Marrow Examination; Cilas | 2018 |
Inhibition of Cyclic GMP-AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1-Deficient Mice.
Topics: Aminoacridines; Animals; Antimalarials; Chemokine CXCL10; Chromatography, Liquid; Cytokines; Exodeox | 2018 |
Effect of topical dorzolamide therapy on cystoid macular edema in hydroxychloroquine retinopathy.
Topics: Administration, Topical; Adult; Aged; Antirheumatic Agents; Carbonic Anhydrase Inhibitors; Female; F | 2018 |
Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization.
Topics: Aged, 80 and over; Antiphospholipid Syndrome; Clinical Protocols; Desensitization, Immunologic; Drug | 2019 |
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |
Evidence for the Detection of Subclinical Retinal Involvement in Systemic Lupus Erythematosus and Sjögren Syndrome: A Potential Association with Therapies.
Topics: Antirheumatic Agents; Case-Control Studies; Female; Humans; Hydroxychloroquine; Immunosuppressive Ag | 2018 |
Hydroxychloroquine ototoxicity in a patient with systemic lupus erythematosus.
Topics: Antimalarials; Antirheumatic Agents; Arthritis; Female; Hearing Loss, Sensorineural; Humans; Hydroxy | 2018 |
Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Databases, Factual; Female; Follow-Up Studies; Humans; Hydroxychloroqui | 2018 |
Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus.
Topics: Antimalarials; Endosomes; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; NADPH Oxidases | 2019 |
Response to: 'Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus' by Wang
Topics: Antibodies, Antiphospholipid; Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, System | 2019 |
Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
Topics: Adult; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Longitudinal Studies; Lupus E | 2018 |
Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Topics: Adult; Aged; Antirheumatic Agents; Body Mass Index; Body Weight; Drug Dosage Calculations; Female; H | 2018 |
Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Biomarkers; Case-Control Studies; Cohort Studi | 2018 |
Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysis.
Topics: Adult; Calcifediol; Female; Humans; Hydroxychloroquine; Longitudinal Studies; Lupus Erythematosus, S | 2018 |
Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.
Topics: Adolescent; Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Insurance Benefits; Lup | 2019 |
Hydroxychloroquine-Induced Psoriasis-form Erythroderma in a Patient with Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Dermatitis, Exfoliative; Humans; Hydroxychloroquine; Lupus Erythematosus, Syst | 2018 |
Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.
Topics: Adult; Antimalarials; Antirheumatic Agents; Biological Products; Canada; Cardiovascular Diseases; Fe | 2018 |
Bilateral Severe Decreased Vision With Normal Examination Findings.
Topics: Adult; Antibiotics, Antineoplastic; Antirheumatic Agents; Autoimmune Diseases; Cataract; Cystic Fibr | 2018 |
Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye | 2018 |
Lemierre's Syndrome in an Aseptic Patient with Systemic Lupus Erythematosus.
Topics: Adult; Anticoagulants; Enzyme Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Hydroxychlo | 2018 |
Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Diarrhea; Drug Eruptions; Female; Humans; Hydroxychlo | 2018 |
Hydroxychloroquine-induced mimic of renal Fabry disease.
Topics: Adult; Antirheumatic Agents; Biopsy; Diagnosis, Differential; Fabry Disease; Female; Humans; Hydroxy | 2018 |
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch | 2019 |
Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Cardiovascular D | 2019 |
Type IV allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus.
Topics: Adult; Antimanic Agents; Chloroquine; Drug Eruptions; Female; Humans; Hydroxychloroquine; Lupus Eryt | 2019 |
Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosu | 2019 |
Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.
Topics: Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; | 2018 |
Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Hum | 2019 |
[Spectral Domain Optical Coherence Tomographic Findings in Systemic Lupus erythematosus in Patients Treated with Chloroquine].
Topics: Chloroquine; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ret | 2019 |
Left Ventricular noncompaction in a patient with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Cardiomyopathies; Echocardiography; Electrocardiography; Female; Humans; Hy | 2019 |
Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
Topics: Adult; Calcineurin Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoi | 2019 |
Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine.
Topics: Color; Female; Hemorrhage; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Syste | 2019 |
En Face Optical Coherence Tomography Imaging of the Photoreceptor Layers in Hydroxychloroquine Retinopathy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fluorescein Angiography; Humans; H | 2019 |
Hydroxychloroquine-induced retinal toxicity in systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Eryt | 2018 |
Commonly used medication for Lupus.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Disease Management; | 2018 |
Bilateral Sequential Acute Proptosis in a Woman With No History of Trauma.
Topics: Acute Disease; Adult; Antirheumatic Agents; Drug Therapy, Combination; Enzyme Inhibitors; Exophthalm | 2019 |
Intentional overdose in an adolescent with depression: Important considerations when prescribing for adolescents.
Topics: Adolescent; Combined Modality Therapy; Depression; Directive Counseling; Drug Overdose; Emergency Se | 2019 |
Comment on: Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2020 |
Woman in grey: hydroxychloroquine-induced hyperpigmentation.
Topics: Aged, 80 and over; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupu | 2018 |
Systemic lupus erythematosus-associated neutrophilic dermatosis manifesting as an acneiform eruption and foot pain.
Topics: Acneiform Eruptions; Antirheumatic Agents; Female; Foot; Glucocorticoids; Humans; Hydroxychloroquine | 2019 |
Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucoc | 2019 |
Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment.
Topics: Antibodies, Antiphospholipid; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Glycopro | 2019 |
Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Antirheumatic Agents; Autoimmune Disease | 2019 |
Revealing a retinal facilitatory effect with the multifocal ERG.
Topics: Adolescent; Adult; Antirheumatic Agents; Child; Child, Preschool; Electroretinography; Female; Healt | 2019 |
Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; California; Female; Humans; Hydroxychloroquine | 2019 |
Hydroxychloroquine: do we all see eye to eye? A single-site analysis of hydroxychloroquine dosing compared with the 2016 Revision of the American Academy of Ophthalmology guidelines.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Practice Guidelines | 2019 |
Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Cohort Studies; Female; Follow-Up Studies; Hospitals, University; | 2019 |
Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus.
Topics: Antirheumatic Agents; Calibration; Chloroquine; Chromatography, High Pressure Liquid; Drug Monitorin | 2019 |
Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Cryopreservation; Cyclophosphamide; Female; | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Topics: Biological Products; Comorbidity; Disease Management; Evidence-Based Medicine; Glucocorticoids; Huma | 2019 |
Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment.
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cross-Sectional Studies; Female; Headache; | 2020 |
Hydroxychloroquine - How Much Is Too Much?
Topics: Antimalarials; Cardiomyopathies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Personal | 2019 |
[The flying saucer sign in toxic hydroxychloroquine retinopathy].
Topics: Female; Fundus Oculi; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Multim | 2019 |
Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Infant, Newborn; L | 2019 |
Hydroxychloroquine Retinal Toxicity.
Topics: Antirheumatic Agents; Color Vision Defects; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2019 |
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Topics: Adolescent; Antibodies, Antinuclear; Asian People; Class I Phosphatidylinositol 3-Kinases; Complemen | 2019 |
Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Biomarkers; Calgranulin A; Calgranulin B; Female; Humans; Hydroxychloro | 2019 |
Hydroxychloroquine-Associated Hyperpigmentation in Chilblain Lupus Erythematosus.
Topics: Chilblains; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Cutaneous; Lupus Ery | 2020 |
Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
Topics: Adult; Aged; Antirheumatic Agents; Chromatography, High Pressure Liquid; Cohort Studies; Drug Admini | 2019 |
A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Arthralgia; Female; Humans; Hydroxychloroquine; Japan; Leukapheresis; L | 2019 |
Kikuchi-Fujimoto disease associated with systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Bone Marrow; Glucocortico | 2019 |
Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2020 |
Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
Topics: Adult; Aged; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppre | 2019 |
Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2020 |
Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age Factors; Aged; Aging; Antirheumatic Agents; Baltimore; Black or African Ameri | 2020 |
Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden.
Topics: Adrenal Cortex Hormones; Adult; Blood Pressure; Case-Control Studies; Comorbidity; Cyclophosphamide; | 2019 |
A rare case of laparoscopy towards SLE with lupus mesenteric vasculitis induced ascites.
Topics: Abdomen, Acute; Administration, Intravenous; Administration, Oral; Antirheumatic Agents; Ascites; Fe | 2019 |
[Atypical hydroxychloroquine maculopathy in an Asian woman with lupus].
Topics: Adult; Asian People; Female; Genetic Predisposition to Disease; Humans; Hydroxychloroquine; Laos; Lu | 2019 |
Response to: 'Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine' by Michaud
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2020 |
Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts.
Topics: Administration, Oral; Adult; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug | 2019 |
A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Cross-Sectional Studies; Female; Humans; Hydroxychlor | 2013 |
Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Arthritis; Black People; Child; Data Collection; Diabete | 2013 |
A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry.
Topics: Chemical Precipitation; Chromatography, Liquid; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2013 |
Myopathy complicating lupus pregnancy.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Biopsy; Drug Therapy, Combination; Female; Hum | 2013 |
[Connective tissue diseases: news in therapy, role of biologics agents].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Connective Tissue Diseases | 2013 |
Hydroxychloroquine-induced phospholipidosis in a case of SLE: the wolf in zebra clothing.
Topics: Adult; Antirheumatic Agents; Cyclophosphamide; Female; Glucocorticoids; Humans; Hydroxychloroquine; | 2013 |
The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Case-Control Studies; Female; Humans; Hydroxychloroquine; Lupus Erythem | 2013 |
Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Birth Weight; Crohn | 2013 |
Hydroxychloroquine alone for severe immune thrombocytopenic purpura associated with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Purp | 2013 |
Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report.
Topics: Adrenal Cortex Hormones; Chemical and Drug Induced Liver Injury; Contraindications; Diphosphonates; | 2013 |
Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients.
Topics: Adult; Aged; Antimalarials; Arthritis, Rheumatoid; Case-Control Studies; Cell Count; Cells, Cultured | 2013 |
Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Topics: Adult; Antirheumatic Agents; Case-Control Studies; Contusions; Ecchymosis; Female; Humans; Hydroxych | 2013 |
Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lupus Erythematos | 2013 |
Hydroxychloroquine-induced hyperpigmentation.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Sy | 2013 |
Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Fluorescein A | 2013 |
Commentary on "The risky business of studying prognosis".
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans; Hydro | 2013 |
Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.
Topics: Animals; B-Lymphocytes; Cell Line; Cells, Cultured; Cytokines; Female; Hydroxychloroquine; Immunoglo | 2013 |
Systemic lupus erythematosus and granulomatous lymphadenopathy.
Topics: Antibodies, Antinuclear; Child; Connective Tissue Diseases; Diagnosis, Differential; Disease Progres | 2013 |
Drs. Lim and Feldman reply.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans; Hydro | 2013 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.
Topics: Adult; Antimalarials; Bipolar Disorder; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus | 2014 |
Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-De | 2014 |
Hydroxycholoroquine-induced hyperpigmentation.
Topics: Antirheumatic Agents; Female; Foot; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematos | 2013 |
Pulmonary hemorrhage in a patient initially presenting with discoid lupus.
Topics: Adult; Anti-Bacterial Agents; Biopsy; Bronchopneumonia; Diagnostic Errors; Disease Progression; Dysp | 2013 |
An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine.
Topics: Bromocriptine; Female; Granulomatous Mastitis; Hormone Antagonists; Humans; Hydroxychloroquine; Lupu | 2014 |
Systemic lupus erythematosus and psoriasis: a new case.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Eryt | 2013 |
Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.
Topics: Anti-Inflammatory Agents; Biomarkers; Chemokine CCL2; Chemokine CXCL10; Humans; Hydroxychloroquine; | 2014 |
Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.
Topics: Adult; Arthritis; Cohort Studies; Congenital Abnormalities; Female; Fetal Death; Follow-Up Studies; | 2014 |
Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study.
Topics: Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydro | 2014 |
Immunoregulation therapy changes the frequency of interleukin (IL)-22+ CD4+ T cells in systemic lupus erythematosus patients.
Topics: Adolescent; Adult; CD4 Antigens; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Lineage; Cyc | 2014 |
Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus.
Topics: Adult; ATP Binding Cassette Transporter 1; Biomarkers; Blood Pressure; Body Mass Index; Cardiovascul | 2014 |
Papulonodular mucinosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immunosuppr | 2014 |
Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus.
Topics: Acute Kidney Injury; Animals; Blood Pressure; Disease Models, Animal; Endothelium, Vascular; Enzyme | 2014 |
[Prospective study of efficacy and safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Compl | 2014 |
Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.
Topics: Aged; Ambulatory Care; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Color Perception Te | 2014 |
Dynamic changes in the numbers of different subsets of peripheral blood NK cells in patients with systemic lupus erythematosus following classic therapy.
Topics: Adolescent; Adult; Child; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Huma | 2014 |
Validation of the colour difference plot scoring system analysis of the 103 hexagon multifocal electroretinogram in the evaluation of hydroxychloroquine retinal toxicity.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; False Pos | 2014 |
Association of systemic lupus erythematosus with uranium exposure in a community living near a uranium-processing plant: a nested case-control study.
Topics: Adult; Aged; Air Pollutants; Antirheumatic Agents; Case-Control Studies; Environmental Exposure; Fem | 2014 |
Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; | 2015 |
Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Biomarkers; Case-Control Studies; Creatinine; | 2016 |
Retinal toxicity found in a patient with systemic lupus erythematosus prior to 5 years of treatment with hydroxychloroquine.
Topics: Antirheumatic Agents; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychlor | 2014 |
The influence of therapy on CD4+CD25(high)FOXP3+ regulatory T cells in systemic lupus erythematosus patients: a prospective study.
Topics: Adult; Azathioprine; CD4 Antigens; Cyclophosphamide; Female; Flow Cytometry; Forkhead Transcription | 2015 |
Short desensitization in an adolescent with hydroxychloroquine anaphylaxis.
Topics: Adolescent; Allergens; Anaphylaxis; Clinical Protocols; Desensitization, Immunologic; Drug Hypersens | 2014 |
Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; China; Cohort Studies; Cross-Sectional Studies | 2015 |
Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Cohort Studies; Comorbidity; Databases, | 2015 |
Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Apgar Score; Female; Fetal Growth Retardation; Follow-Up Studies; Human | 2015 |
Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus.
Topics: Adult; Antirheumatic Agents; Blood Vessels; Facial Dermatoses; Fatal Outcome; Female; Humans; Hydrox | 2014 |
Successful treatment of massive ascites due to lupus peritonitis with hydroxychloroquine in old- onset lupus erythematosus.
Topics: Age of Onset; Aged; Ascites; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Peri | 2014 |
Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report.
Topics: Abdomen, Acute; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Chemical and D | 2015 |
[SD-OCT As screening test for hydroxychloroquine retinopathy: The «flying saucer» sign].
Topics: Adolescent; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fluorescein Angiography; Fovea Cent | 2015 |
Subjective and objective screening tests for hydroxychloroquine toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Diagnostic Technique | 2015 |
Papulonodular mucinosis in a suspected systemic lupus erythematosus patient.
Topics: Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Leg; Lupus Er | 2014 |
Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
Topics: Adolescent; Adult; Antirheumatic Agents; Cohort Studies; Diabetes Mellitus; Dose-Response Relationsh | 2015 |
[Systemic lupus erythematosus and a medical history of deep vein thrombosis in a 27-year-old pregnant woman].
Topics: Adult; Antirheumatic Agents; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Hyd | 2015 |
Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Anemia, Hemolytic; Autoantibodies; Fatigue; Female; Headache | 2015 |
Etanercept in refractory lupus arthritis: An observational study.
Topics: Adult; Antirheumatic Agents; Arthritis; Autoantibodies; Cohort Studies; Etanercept; Female; Glucocor | 2015 |
Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis.
Topics: Adolescent; Adult; Antirheumatic Agents; Black or African American; Cohort Studies; Female; Glucocor | 2015 |
Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eye Diseases; Follow-Up | 2015 |
Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Cardiotoxicity; Dose-Response Relationship, D | 2015 |
Multimodal imaging in a severe case of hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Atrophy; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxy | 2015 |
[Recurrent diffuse alveolar hemorrhage in systemic lupus erytematosus treated with rituximab and immunoglobulins].
Topics: Cyclophosphamide; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxychloroquine; Immunoglobulins | 2015 |
Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Humans; Hydroxychloroquine; Logistic Models; Lupu | 2015 |
Early Lupus Project - A multicentre Italian study on systemic lupus erythematosus of recent onset.
Topics: Adult; Age of Onset; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Arthritis; Female; Human | 2015 |
Assessment of parafoveal cone density in patients taking hydroxychloroquine in the absence of clinically documented retinal toxicity.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Count; Electroretinography; Female; Fovea C | 2015 |
Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Body Mass Index; Creatinine; Female; Humans; H | 2015 |
Taenia solium in a patient with systemic lupus erythematosus: do parasites protect against autoimmune diseases.
Topics: Adult; Animals; Antibodies, Antinuclear; Antirheumatic Agents; Autoimmunity; Confusion; Digestive Sy | 2015 |
Lupus or syphilis? That is the question!
Topics: Adrenal Cortex Hormones; Cyclophosphamide; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lup | 2015 |
Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Gluc | 2015 |
[Systemic lupus erythematosus presenting as Stevens-Johnson syndrome].
Topics: Adult; Anemia; Arthralgia; Autoantibodies; Complement C3; Critical Care; Facial Dermatoses; Female; | 2015 |
Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study.
Topics: Electroretinography; Female; Functional Laterality; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2015 |
Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Antirheumatic Agents; Chi-Square Distribution; Databases, Factual; Emergency Serv | 2015 |
Confirmed False Positive Proteinuria in Patients with Systemic Lupus Erythematosus Taking Hydroxychloroquine: a Spot Sample Measurement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; False Positive Reactions; F | 2015 |
Toxocara canis infection: Unusual trigger of systemic lupus erythematosus.
Topics: Albendazole; Animals; Antibodies, Antinuclear; Antiprotozoal Agents; Child; Female; Glucocorticoids; | 2015 |
Potentially Beneficial Effect of Hydroxychloroquine in a Patient with a Novel Mutation in Protein Kinase Cδ Deficiency.
Topics: Antirheumatic Agents; Autoimmune Lymphoproliferative Syndrome; B-Lymphocytes; Child, Preschool; Cyto | 2015 |
Glucocorticoid receptor genetic polymorphisms is associated with improvement of health-related quality of life in Chinese population with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Gluco | 2015 |
Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy.
Topics: Adult; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immuno | 2015 |
Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Asian People; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; | 2016 |
[Juvenile systemic lupus erythematosus with unusual manifestation of lupus-associated panniculitis].
Topics: Adolescent; Anti-Inflammatory Agents; Diagnosis, Differential; Drug Therapy, Combination; Humans; Hy | 2015 |
Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Cardiovascular Diseases; Cross-Sectional | 2016 |
Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Connective Tissue | 2015 |
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
Topics: Academic Medical Centers; Adult; Age Factors; Analysis of Variance; Cohort Studies; Dose-Response Re | 2015 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus.
Topics: Animals; Antioxidants; Antirheumatic Agents; Disease Models, Animal; Endothelium, Vascular; Female; | 2015 |
Nonleaking Cystoid Macular Edema as a Presentation of Hydroxychloroquine Retinal Toxicity.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Capillary Permeability; Female; Fluorescein Angio | 2016 |
Garre's sclerosing osteomyelitis caused by salmonella group D in a patient with systemic lupus erythematosus: an unusual complication.
Topics: Adult; Anti-Bacterial Agents; Antiphospholipid Syndrome; Ceftazidime; Doxycycline; Femur; Humans; Hy | 2015 |
Routine Hydroxychloroquine Blood Concentration Measurement in Systemic Lupus Erythematosus Reaches Adulthood.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Medication Adherence | 2015 |
Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2016 |
Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Body Weight; Chromatography, High Pressure Liquid; | 2016 |
Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; B | 2016 |
Systemic lupus erythaematosus presenting as spontaneous splenic rupture.
Topics: Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle A | 2015 |
HELMINTHS AND AUTOIMMUNITY: THE PECULIAR CASE OF TAENIA SOLIUM.
Topics: Animals; Glucocorticoids; Humans; Hydroxychloroquine; Intestine, Small; Lupus Erythematosus, Systemi | 2015 |
To the Editor.
Topics: Animals; Glucocorticoids; Humans; Hydroxychloroquine; Intestine, Small; Lupus Erythematosus, Systemi | 2015 |
Diagnostic and Therapeutic Challenges.
Topics: Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematos | 2016 |
Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Female; Humans; Hydroxychloroquine; Longitudinal Studie | 2016 |
Coexistence of systemic lupus erythematosus and familial Mediterranean fever in a pediatric patient.
Topics: Adolescent; Colchicine; Cyclophosphamide; Familial Mediterranean Fever; Female; Humans; Hydroxychlor | 2016 |
Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007.
Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Chronic Disease; Female; Finland; Humans; Hydroxych | 2016 |
Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lipoproteins; Longitudinal Studies; | 2016 |
The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice.
Topics: Animals; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Mast Cel | 2016 |
Myasthenia gravis due to hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myas | 2015 |
Breastfeeding in mothers with systemic lupus erythematosus.
Topics: Adult; Azathioprine; Breast Feeding; Databases, Factual; Decision Making; Female; Humans; Hydroxychl | 2016 |
Hydroxychloroquine-related skin discoloration.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Hypopigmentation; Lupus Erythematosus, Systemic; M | 2017 |
Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Databases, Factual; Female; Humans; Hydroxychloroquine; | 2016 |
Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease.
Topics: Adult; Aged; Drug Prescriptions; Female; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus | 2016 |
Severe vitamin D deficiency increases the risk for moderate to severe disease activity in Chinese patients with SLE.
Topics: Adult; Calcifediol; China; Cross-Sectional Studies; Female; Humans; Hydroxychloroquine; Lupus Erythe | 2016 |
Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
Topics: Administration, Intravenous; Administration, Oral; Adrenal Cortex Hormones; Adult; Azathioprine; Cas | 2016 |
Development of Systemic Lupus Erythematosus Following Interferon-α Therapy for Hepatitis C Infection.
Topics: Adrenal Cortex Hormones; Female; Hepatitis C; Humans; Hydroxychloroquine; Immunologic Factors; Inter | 2016 |
Hydroxychloroquine-Induced Retinal Toxicity.
Topics: Antirheumatic Agents; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2016 |
Heart Involvement in a Woman Treated with Hydroxychloroquine for Systemic Lupus Erythematosus Revealing Fabry Disease.
Topics: Biopsy, Needle; Cardiomyopathies; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Ad | 2016 |
Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes.
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Female; Humans; Hydroxy | 2016 |
Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Chromatography, High Pressure Liquid; Cross-Secti | 2017 |
CHOROIDAL THICKNESS IN MULTISYSTEMIC AUTOIMMUNE DISEASES WITHOUT OPHTHALMOLOGIC MANIFESTATIONS.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Choroid; Cross-Sectional St | 2017 |
Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Guideline Adherence; Humans; Hydroxychloroquine; Israel | 2017 |
Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus.
Topics: Aged; Antimalarials; Cardiomyopathies; Disease Progression; Echocardiography; Female; Humans; Hydrox | 2016 |
Relationship between health-related quality of life, disease activity and disease damage in a prospective international multicenter cohort of childhood onset systemic lupus erythematosus patients.
Topics: Adolescent; Age of Onset; Child; Child, Preschool; Cyclophosphamide; Female; Health Status; Humans; | 2017 |
Beneficial effect of hydroxychloroquine on cutaneous vasculitis in a Japanese patient with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lup | 2017 |
Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use.
Topics: Antiphospholipid Syndrome; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 2016 |
[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Drug Monitoring; France; Humans; Hydr | 2017 |
[Hydroxychloroquine-induced hearing loss: First case of positive rechallenge and analysis of the French pharmacovigilance database].
Topics: Adult; Antirheumatic Agents; Databases, Factual; Female; France; Hearing Loss; Humans; Hydroxychloro | 2017 |
Juvenile systemic lupus erythematosus in Nigeria.
Topics: Adolescent; Antibodies, Antinuclear; Antirheumatic Agents; Azathioprine; Child; Female; Hospitals, T | 2017 |
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Disease Progression; Drug Therapy, Combinati | 2017 |
Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs.
Topics: Adult; Algorithms; Cohort Studies; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lup | 2017 |
Joint ultrasound baseline abnormalities predict a specific long-term clinical outcome in systemic lupus erythematosus patients.
Topics: Adult; Antirheumatic Agents; Arthralgia; Case-Control Studies; Female; Follow-Up Studies; Hand; Huma | 2017 |
Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients.
Topics: Adolescent; Child; Cohort Studies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2017 |
The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Autoantibodies; CD4-Positive T-Lymphocytes; Complement C | 2016 |
Hydroxychloroquine-Induced Erythema Multiforme.
Topics: Adult; Antirheumatic Agents; Diagnosis, Differential; Erythema Multiforme; Female; Humans; Hydroxych | 2017 |
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Anticardiolipin; Antirheumatic Agents; B-Cell Activating | 2017 |
Thrombotic thrombocytopenic purpura in a new onset lupus patient?
Topics: Adult; Anemia, Hemolytic; Autoantibodies; Blood Platelets; Codeine; Cyclophosphamide; Female; Humans | 2017 |
Psoriasis in systemic lupus erythematosus: a single-center experience.
Topics: Adolescent; Adult; Antirheumatic Agents; Azathioprine; Cohort Studies; Female; Humans; Hydroxychloro | 2017 |
Hydroxychloroquine retinopathy: an emerging problem.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Early Diagnosis; Electroretinography; Fema | 2017 |
Interferon-stimulated gene 15 expression in systemic lupus erythematosus : Diagnostic value and association with lymphocytopenia.
Topics: Adult; Aged; Anemia; Case-Control Studies; Connective Tissue Diseases; Correlation of Data; Cytokine | 2018 |
Treatment Satisfaction in Systemic Lupus Erythematosus: Development of a Patient-Reported Outcome Measure.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hyd | 2017 |
Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?
Topics: Abdominal Pain; Antirheumatic Agents; Dysgeusia; Dyspepsia; Humans; Hydroxychloroquine; Incidence; L | 2017 |
Value of Microperimetry in Detecting Early Retinal Toxicity of Hydroxychloroquine in Children with Juvenile Systemic Lupus Erythematosus.
Topics: Adolescent; Antirheumatic Agents; Child; Cross-Sectional Studies; Early Diagnosis; Electroretinograp | 2017 |
Adherence to medications in systemic lupus erythematosus.
Topics: Academic Medical Centers; Adult; Antirheumatic Agents; Cross-Sectional Studies; Female; Humans; Hydr | 2008 |
Chloroquine psychosis masquerading as PCP: a case report.
Topics: Adolescent; Antimalarials; Catatonia; Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxyc | 2008 |
Reversible ageusia as an adverse effect of hydroxychloroquine treatment.
Topics: Adult; Ageusia; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregna | 2009 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2008 |
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; California; Child; Female; Humans; Hydroxyc | 2009 |
Systemic lupus erythematosus presenting as pyoderma gangrenosum in two cases.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Antiphospholipi | 2009 |
[Blepharitis--rare in systemic lupus erythematosus].
Topics: Adolescent; Adult; Antimalarials; Blepharitis; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2008 |
42-year-old man with discoid lupus and progressive weakness.
Topics: Adult; Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Micros | 2009 |
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antirheuma | 2009 |
Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Biopsy; Celecoxib; Female; Follow | 2009 |
[Antimalarial's retinopaty remains a current threat].
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cohort Studies; Dose-Response Relationship, Drug; | 2009 |
The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine.
Topics: Antimalarials; Chloroquine; Drug Interactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Syst | 2009 |
Restrictive cardiomyopathy secondary to hydroxychloroquine therapy.
Topics: Antirheumatic Agents; Cardiomyopathy, Restrictive; Echocardiography; Female; Heart; Humans; Hydroxyc | 2009 |
Case records of the Massachusetts General Hospital. Case 5-2009. A 47-year-old woman with a rash and numbness and pain in the legs.
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Aspirin; Biopsy; Diagnosis, Differential; Dry Eye Syn | 2009 |
Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Opht | 2009 |
A case of SLE with bilateral osteonecrosis of femoral heads and bone infarct in distal of femur.
Topics: Antirheumatic Agents; Drug Therapy, Combination; Female; Femur; Femur Head Necrosis; Humans; Hydroxy | 2010 |
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Topics: Adult; Antimalarials; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2009 |
Systemic lupus erythematosus in a patient with primary MALT lymphoma of the larynx.
Topics: Adult; Female; Glucocorticoids; Humans; Hydroxychloroquine; Laryngeal Neoplasms; Lupus Erythematosus | 2009 |
Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Azathioprine; Cyclosporine; Dose-Response Relationship, Drug; Drug Thera | 2009 |
Central variant of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: new associations?
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythemato | 2010 |
Impending cardiac tamponade as the initial presentation of thymoma in a systemic lupus erythematosus patient.
Topics: Antirheumatic Agents; Cardiac Tamponade; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2010 |
Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?
Topics: Antirheumatic Agents; Drug Monitoring; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ri | 2010 |
Therapy: Hydroxychloroquine in SLE: old drug, new perspectives.
Topics: Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2010 |
Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.
Topics: Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematos | 2009 |
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middl | 2010 |
Enhanced adhesive properties of endothelial progenitor cells (EPCs) in patients with SLE.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cell Adhesion; Cells, Cultured; Colony-Forming Units Assa | 2011 |
[Acute generalized exanthematous pustulosis included by hydroxychloroquine during lupus].
Topics: Antirheumatic Agents; Drug Eruptions; Exanthema; Female; Humans; Hydroxychloroquine; Lupus Erythemat | 2010 |
Systemic lupus erythematosus pregnancies: the Sarawak experience and review of lupus pregnancies in Asia.
Topics: Adult; Antirheumatic Agents; Asia; Cesarean Section; Cross-Sectional Studies; Disease Progression; F | 2011 |
Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; California; Female; Humans; Hydroxychloroquine; Interviews as Topic; Lo | 2010 |
Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.
Topics: Adult; Antirheumatic Agents; Black or African American; Disease Progression; Female; Hispanic or Lat | 2010 |
Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.
Topics: Antirheumatic Agents; Contrast Sensitivity; Disease Progression; Electroretinography; Female; Fluore | 2010 |
[Skin pigmentation in a patient with systemic lupus erythematosus].
Topics: Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Systemic | 2010 |
Changing cytokine patterns in systemic lupus: a prospective longitudinal study.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antigen-Antibody Complex; Cells, Cultured; Cytoki | 2010 |
Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Cross-Sectional Studies; Diabetes Mellit | 2010 |
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.
Topics: Antirheumatic Agents; Autoantibodies; Autoantigens; Case-Control Studies; Female; Heart Diseases; Hu | 2010 |
Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Hydroxy | 2010 |
GI vasculitis associated with systemic lupus erythematosus.
Topics: Administration, Oral; Anti-Inflammatory Agents; Colon; Colonic Diseases; Colonoscopy; Diagnosis, Dif | 2010 |
Erythema elevatum diutinum in systemic lupus erythematosus.
Topics: Adult; Biopsy; Dapsone; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lupus Erythem | 2011 |
[Childhood onset systemic lupus erythematosus: how does it must be treated in 2010?].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Child; Evide | 2010 |
Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Arthritis, Rheumatoid; Chi-Square Distribution; Chloroquine; | 2010 |
Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Diabetes Mellitus; Female; Glycate | 2010 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Dose-Response Relationship, Drug; | 2010 |
Successful desensitization for hydroxychloroquine anaphylaxis.
Topics: Anaphylaxis; Antirheumatic Agents; Desensitization, Immunologic; Humans; Hydroxychloroquine; Lupus E | 2010 |
Acquired thrombotic thrombocytopenic purpura: puzzles, curiosities and conundrums.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Antirheumatic Agents; Autoantibodies; Humans; Hydroxychloroq | 2011 |
Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al.
Topics: Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Thrombosis | 2010 |
[Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome].
Topics: Annexin A5; Antiphospholipid Syndrome; Antirheumatic Agents; Biomarkers; Enzyme Inhibitors; Evidence | 2010 |
[Narcolepsy associated with systemic lupus erythematosus].
Topics: Adult; Aspirin; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Lup | 2011 |
Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Contrast Sensitivity | 2011 |
Pediatric systemic lupus erythematosus in Thammasat University Hospital.
Topics: Adolescent; Adrenal Cortex Hormones; Age of Onset; Antibodies, Monoclonal, Murine-Derived; Antirheum | 2010 |
Hydroxychloroquine-induced ototoxicity in a child with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Child; Female; Hearing Loss, Sensorineural; Humans; Hydroxychloroquine; Lupus | 2011 |
Rituximab and lupus interstitial lung disease: friend or foe?
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Drug Therapy, Combination; Dysp | 2011 |
[Renal infarction in systemic lupus with antiphospholipid syndrome: role of hydroxychloroquine withdrawal? Comment on the article by Szymezak et al].
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antinuclear; Anticoagulants; Antiphospholipid Syndro | 2011 |
Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases.
Topics: Adult; Antibodies, Antinuclear; Azathioprine; Biopsy; Enzyme-Linked Immunosorbent Assay; Female; Hep | 2011 |
Hydroxychloroquine-induced cardiomyopathy: a case report.
Topics: Biopsy; Cardiac Resynchronization Therapy; Cardiomyopathies; Cardiovascular Agents; Defibrillators, | 2011 |
Interferon-α induced lupus in a patient with chronic hepatitis C virus.
Topics: Antirheumatic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyd | 2011 |
Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure.
Topics: Antirheumatic Agents; Biomarkers; Cardiomyopathies; Diagnosis, Differential; Echocardiography; Elect | 2011 |
Kikuchi fujimoto disease and systemic lupus erythematosus--a rare association.
Topics: Adult; Female; Folic Acid; Histiocytic Necrotizing Lymphadenitis; Humans; Hydroxychloroquine; Lupus | 2010 |
Catatonia as the presenting symptom in systemic lupus erythematosus.
Topics: Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Catatonia; Diagnosis, Diffe | 2011 |
Fetopathy probably associated to self-medication with a blocker of the renin-angiotensin system.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antimalarials; Cesarean | 2011 |
Lamotrigine-induced lupus: a case report.
Topics: Adolescent; Anticonvulsants; Antirheumatic Agents; Arthralgia; Epilepsy; Female; Humans; Hydroxychlo | 2011 |
Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
Topics: Adult; Antirheumatic Agents; Arthralgia; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2012 |
[A case of bullous lupus in black skin].
Topics: Comoros; Complement C3; Dermis; Epidermis; Fluorescent Antibody Technique; Humans; Hydroxychloroquin | 2011 |
Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus.
Topics: Adolescent; Ambulatory Care Facilities; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lu | 2012 |
Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus.
Topics: Adolescent; Ambulatory Care Facilities; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lu | 2012 |
Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus.
Topics: Adolescent; Ambulatory Care Facilities; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lu | 2012 |
Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus.
Topics: Adolescent; Ambulatory Care Facilities; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lu | 2012 |
Impact of smoking in cutaneous lupus erythematosus.
Topics: Adult; Antimalarials; Cohort Studies; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combinatio | 2012 |
Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Antiphospholipid; Antirheumatic Agents; Biom | 2012 |
Comparison of screening procedures in hydroxychloroquine toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnostic Techniques, Ophthalmological; E | 2012 |
Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.
Topics: Adult; Antimalarials; Arthralgia; Asian People; Female; Humans; Hydroxychloroquine; Japan; Lipids; L | 2012 |
A case of minimal change disease treated successfully with mycophenolate mofetil in a patient with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; | 2011 |
[Haemophagocytic syndrome as a complication of acute pancreatitis during systemic lupus erythematosus].
Topics: Abdomen, Acute; Autoantibodies; Female; Gingival Hemorrhage; Humans; Hydroxychloroquine; Lupus Eryth | 2012 |
Subendocardial ischemia and myocarditis in systemic lupus erythematosus detected by cardiac magnetic resonance imaging.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Biphenyl Compounds; Chest Pain; Coronary Angiography; Coro | 2012 |
[The safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy Compl | 2011 |
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort.
Topics: Adolescent; Adult; Antirheumatic Agents; Biomarkers; CD40 Ligand; Chemokine CCL2; Chemokine CXCL10; | 2012 |
[Chorea, lupus and antiphospholipid antibodies].
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Biomarkers; Child; Chorea; Drug Therapy, | 2012 |
Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus.
Topics: Alemtuzumab; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Drug Th | 2012 |
Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus.
Topics: Cross-Sectional Studies; Down-Regulation; Female; HeLa Cells; Humans; Hydroxychloroquine; Lupus Eryt | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect.
Topics: Adult; Antimalarials; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Hu | 2012 |
Rituximab-responsive nephrotic syndrome due to minimal change disease in systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Diuretics; Drug Therapy, C | 2012 |
Use of hydroxychloroquine in Japan.
Topics: Antirheumatic Agents; Clinical Protocols; Clinical Trials as Topic; Health Services Accessibility; H | 2012 |
Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus.
Topics: Antirheumatic Agents; Dendritic Cells; Female; Flow Cytometry; Humans; Hydroxychloroquine; Interfero | 2012 |
Methimazole-induced bullous systemic lupus erythematosus: a case report.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Antithyroid Agents; Blister; Drug Therapy, Co | 2012 |
Intestinal vasculitis and renal infarction in a lupus patient with antiphospholipid syndrome.
Topics: Adolescent; Antiphospholipid Syndrome; Comorbidity; Drug Therapy, Combination; Female; Humans; Hydro | 2012 |
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans | 2013 |
Hydroxychloroquine: a treatable cause of cardiomyopathy.
Topics: Antirheumatic Agents; Biopsy; Cardiomyopathies; Coronary Angiography; Diagnosis, Differential; Dyspn | 2012 |
[Incidence of metabolic syndrome in systemic lupus erythematosus and its influence by glucocorticoids].
Topics: Adolescent; Adult; Case-Control Studies; Female; Glucocorticoids; Humans; Hydroxychloroquine; Incide | 2012 |
Evidence for risk of cardiomyopathy with hydroxychloroquine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiomyopathies; Dose- | 2012 |
Fatal antimalarial-induced cardiomyopathy: report of 2 cases.
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Cardiomyopathies; Chloroquine; Fatal Outcome; Female; H | 2012 |
Symptoms of shrinking lung syndrome reveal systemic lupus erythematosus in a 12-year-old girl.
Topics: Chest Pain; Child; Cyclophosphamide; Diaphragm; Dyspnea; Female; Humans; Hydroxychloroquine; Immunos | 2013 |
The risky business of studying prognosis.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans; Hydro | 2013 |
Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice.
Topics: Academies and Institutes; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthriti | 2013 |
Auricular chondritis and thrombotic microangiopathy: an unusual combination revealing systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Cartilage Diseases; Comorbidity; Drug Therapy, Combination; Ear Cart | 2013 |
Disseminated tuberculosis in a patient with antinuclear antibody-negative systemic lupus erythematosus: a rare association.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Antitubercular Agents; Female; Humans; Hydroxy | 2013 |
Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important.
Topics: Adult; Antirheumatic Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hy | 2013 |
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Ag | 2002 |
[Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Azathioprine; Dermatologic Agents; Femal | 2003 |
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Stud | 2003 |
[Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antirheumatic Agents; Azathioprine; Coumarins; Cycloph | 2003 |
Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort.
Topics: Adult; Antimalarials; Antirheumatic Agents; Chloroquine; Cohort Studies; Drug Monitoring; Female; Gu | 2003 |
Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil.
Topics: Adolescent; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Hemorrhage; H | 2003 |
Discoid lupus erythematosus treated with plaquenil.
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1956 |
Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report.
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1956 |
Plaquenil in the treatment of lupus erythematosus.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1956 |
Plaquenil sulfate in treatment of lupus erythematosus and light-sensitivity eruptions.
Topics: Chloroquine; Exanthema; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Syste | 1957 |
Plaquenil sulfate in treatment of lupus erythematosus and light-sensitivity eruptions.
Topics: Chloroquine; Exanthema; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Syste | 1957 |
Plaquenil sulfate in treatment of lupus erythematosus and light-sensitivity eruptions.
Topics: Chloroquine; Exanthema; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Syste | 1957 |
Plaquenil sulfate in treatment of lupus erythematosus and light-sensitivity eruptions.
Topics: Chloroquine; Exanthema; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Syste | 1957 |
Treatment of chronic lupus erythematosus: effectiveness of plaquenil and APA (Aralen 65 mg., plaquenil 50 mg., Atabrine 25 mg.) as compared with Aralen, with observations on side-reactions and toxicity; report and presentation of unusual cases.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythema | 1958 |
Plaquenil in the treatment of cutaneous lupus erythematosus.
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus | 1958 |
Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1959 |
[Hydroxychloroquine sulfate in chronic lupus erythematosus (discoid)].
Topics: Chloroquine; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic | 1958 |
[Hydroxychloroquine in the treatment of chronic erythematosus].
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1961 |
[Treatment of chronic lupus erythematosus with hydroxychloroquine].
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1961 |
Hydroxychloroquine (plaquenil) in the treatment of lupus erythematosus.
Topics: Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1959 |
[Plaquenil treatment of discord lupus erythematosus and polymorphous photodermatitis].
Topics: Chloroquine; Dermatitis; Hydroxychloroquine; Lupus Erythematosus, Systemic; Photosensitivity Disorde | 1960 |
[Treatment of discoid lupus erythematosus, polymorphous photodermatosis and rosacea with Triquin--a combination of 3 anti-malarials].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythema | 1962 |
PIGMENTATION FROM ANTIMALARIAL THERAPY. ITS POSSIBLE RELATIONSHIP TO THE OCULAR LESIONS.
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Cornea; Eye; Eye Manifestations; Histo | 1963 |
POLYMORPHOUS LIGHT ERUPTION. A TEN-YEAR FOLLOW-UP AND EVALUATION.
Topics: Chloroquine; Dermatitis, Phototoxic; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus Erythemato | 1963 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyosit | 1963 |
[CHRONIC DISCOID ERYTHEMATOSUS (REPORT ON 69 CASES OVER A PERIOD OF 6 YEARS FROM THE VIEWPOINT OF OPTIMUM THERAPY)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythema | 1963 |
INDIVIDUAL TOXIC REACTIONS TO MUSHROOMS.
Topics: Agaricales; Foodborne Diseases; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosu | 1964 |
WHAT'S NEW AND WHAT'S TRUE OF WHAT'S NEW IN DERMATOLOGY.
Topics: Amodiaquine; Dermatology; Humans; Hydroxychloroquine; Keratoacanthoma; Lupus Erythematosus, Discoid; | 1964 |
SYSTEMIC LUPUS ERYTHEMATOSUS: TREATMENT WITH ANTIMALARIAL DRUGS.
Topics: Antimalarials; Chloroquine; Dexamethasone; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 1964 |
LYMPHOCYTIC INFILTRATION OF THE SKIN.
Topics: Black People; Chloroquine; Dermatology; Diagnosis, Differential; Humans; Hydroxychloroquine; Lupus E | 1964 |
CHILBLAIN LUPUS ERYTHEMATOSUS.
Topics: Chilblains; Chloroquine; Fluocinolone Acetonide; Frostbite; Humans; Hydroxychloroquine; Hypothyroidi | 1964 |
[EVALUATION OF LONG-TERM THERAPY WITH CHLOROQUINE AND HYDROXYCHLOROQUINE IN RHEUMATOLOGY].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therapy; Humans; Hydrarthrosis; Hydroxychloroqui | 1964 |
[OUR PRESENT EXPERIENCE IN DIAGNOSIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS].
Topics: Adolescent; Adrenocorticotropic Hormone; Aspirin; Chloroquine; Cortisone; Diagnosis; Drug Therapy; H | 1964 |
ISOLATION AND CHARACTERIZATION OF MYCOPLASMAS (PPLO) FROM PATIENTS WITH RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS AND REITER'S SYNDROME.
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Reactive; Arthritis, Rheumatoid; Aspirin; Com | 1965 |
BONE MARROW DEPRESSION AFTER DRUG THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
Topics: Adolescent; Agranulocytosis; Anemia; Anemia, Aplastic; Anti-Bacterial Agents; Bone Marrow; Bone Marr | 1965 |
CHRONIC DISSEMINATED LUPUS ERYTHEMATOSUS AND CALCINOSIS CUTIS.
Topics: Calcinosis; Diagnosis; Humans; Hydroxychloroquine; Keratosis; Lupus Erythematosus, Systemic; Patholo | 1965 |
DISCOID LUPUS ERYTHEMATOSUS. IS SYSTEMIC TREATMENT NECESSARY?
Topics: Bandages; Chloroquine; Drug Therapy; Fluocinolone Acetonide; Humans; Hydrocortisone; Hydroxychloroqu | 1965 |
THE VALUE OF HYDROXYCHLOROQUINE (PLAQUENIL) FOR THE TREATMENT OF CHRONIC DISCOID LUPUS ERYTHEMATOSUS; A DOUBLE BLIND TRIAL.
Topics: Biomedical Research; Double-Blind Method; Drug Therapy; Humans; Hydroxychloroquine; Lupus Erythemato | 1965 |
[THE VALUE OF HYDROXYCHLOROQUINE (PLAQUENIL) THERAPY IN CHRONIC DISCOID LUPUS ERYTHEMATOSUS].
Topics: Drug Therapy; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemi | 1965 |
Bilateral cytomegalovirus retinitis in a patient with systemic lupus erythematosus and end-stage renal disease.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cytomegalovirus Retinitis; Female; HIV Seronegativity; Hu | 2003 |
Lupus erythematosus tumidus in systemic lupus erythematosus: novel association and possible role of early treatment in prevention of discoid lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Diagnosis, Differential; Female; Humans; Hydro | 2004 |
Assessing hydroxychloroquine toxicity by the multifocal ERG.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Electrooculography; Electroretinography; Humans; | 2004 |
The effect of race on disease activity in systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Blood Sedimentation; C-Reactive Protein; Cohort Studies; Female; Glucoc | 2004 |
Ophthalmologic monitoring for antimalarial toxicity.
Topics: Antimalarials; Arthritis, Rheumatoid; Drug Monitoring; Greece; Humans; Hydroxychloroquine; Lupus Ery | 2004 |
[Analysis of 925 patients on long-term hydroxychloroquine or chloroquine treatment: results of ophthalmological screening].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus | 2004 |
Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Color Perception Tests; Dermatologic Agent | 2004 |
Hyperkeratotic nail discoid lupus erythematosus evolving towards systemic lupus erythematosus: therapeutic difficulties.
Topics: Dermatologic Agents; Diagnosis, Differential; Drug Therapy, Combination; Fingers; Hand Dermatoses; H | 2004 |
[Systemic lupus erythematosus therapy. Antimalarials in inflammatory diseases].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Quinacrine | 2004 |
Lupus cystitis in association with severe gastrointestinal manifestations in an adolescent.
Topics: Adolescent; Antirheumatic Agents; Azathioprine; Cystitis, Interstitial; Drug Therapy, Combination; F | 2005 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
Nonlupus nephritis in an adolescent with systemic lupus erythematosus.
Topics: Adolescent; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; | 2005 |
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.
Topics: Adult; Black People; Female; Hispanic or Latino; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2005 |
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.
Topics: Antibodies, Antiphospholipid; Antirheumatic Agents; Epidemiologic Methods; Female; Humans; Hydroxych | 2005 |
Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction.
Topics: Cardiomyopathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Ve | 2005 |
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.
Topics: Adult; Antibiotics, Antineoplastic; Black or African American; Drug Administration Schedule; Drug Th | 2006 |
Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Humans; Hydroxychlo | 2005 |
A 39-year-old man with sudden onset of chest pain.
Topics: Acute Disease; Adult; Antirheumatic Agents; Chest Pain; Diagnosis, Differential; Drug Therapy, Combi | 2005 |
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
Topics: Adult; Aged; Antibodies, Viral; Azathioprine; Case-Control Studies; Female; Hemagglutination Inhibit | 2006 |
Shrinking lung syndrome as a presenting manifestation of systemic lupus erythematosus in a female Kuwaiti.
Topics: Adult; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Female; Glucocorticoids; Humans; | 2006 |
[Subcutaneous calcifications in systemic lupus erythematosus].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Calcinosis; Dermatologic Agents; Female; Human | 2006 |
[Pericardial effusion in a 21-year-old employee].
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Antirheumatic Agents; Autoantibodies; Depres | 2006 |
Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.
Topics: Aged; Antirheumatic Agents; Electrocardiography; Female; Humans; Hydroxychloroquine; Long QT Syndrom | 2006 |
Hydroxychloroquine-induced pigmentation in two patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pigmentatio | 2006 |
The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis.
Topics: Antimalarials; Azathioprine; Cyclophosphamide; Cyclosporine; Disease Progression; Drug Therapy, Comb | 2007 |
Annular erythema of Sjögren's syndrome.
Topics: Adult; Dermatologic Agents; Erythema; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Syste | 2006 |
[Is it necessary to monitor blood hydroxychloroquine concentrations in patients with systemic lupus erythematosus?].
Topics: Chromatography, High Pressure Liquid; Double-Blind Method; Humans; Hydroxychloroquine; Lupus Erythem | 2006 |
Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.
Topics: Adult; Aged; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional | 2006 |
Antimalarial agents: closing the gate on Toll-like receptors?
Topics: Antimalarials; Disease Progression; Humans; Hydroxychloroquine; Interferon-alpha; Lupus Erythematosu | 2006 |
Asymptomatic sensorineural hearing loss in patients with systemic lupus erythematosus.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antirheumatic Agents; Audiometry, | 2006 |
Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL).
Topics: Black or African American; Cohort Studies; Demography; Female; Hispanic or Latino; Humans; Hydroxych | 2006 |
Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.
Topics: Adolescent; Adult; Aged; Antimalarials; Antirheumatic Agents; Bundle-Branch Block; Connective Tissue | 2007 |
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Attitude to Health; Biomarkers; Drug Monitoring; Female; Follow-Up Stud | 2007 |
Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Child; Cros | 2007 |
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).
Topics: Adolescent; Adult; Antirheumatic Agents; Case-Control Studies; Ethnicity; Female; Humans; Hydroxychl | 2007 |
Missing the forest for the trees.
Topics: Abdominal Pain; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gluco | 2007 |
Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Chilblains; Child; Cohort St | 2007 |
Hydroxychloroquine in systemic lupus erythematosus.
Topics: Dermatologic Agents; Half-Life; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2007 |
Corticosteroids in preventing severe lupus flares: do all patients have the same risk? Comment on the article by Tseng et al.
Topics: Adrenal Cortex Hormones; Antibodies, Anti-Idiotypic; Antirheumatic Agents; DNA; Dose-Response Relati | 2007 |
High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Fe | 2007 |
[Hydroxychloroquine and systemic lupus: a reappraisal].
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic | 2008 |
A case of acute pericarditis with hemophagocytic syndrome, cytomegalovirus infection and systemic lupus erythematosus.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Cytomegalovirus Infections; Gastrointestinal Hemorrh | 2008 |
[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; Child; Chloroquine; Dose-Response Relat | 2007 |
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibody Specificity; Autoantibodies; Disease Progre | 2007 |
Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male | 2007 |
Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arteries; Diabetes Mellitus; Elasticity; Female; Huma | 2007 |
Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients.
Topics: Adult; Antirheumatic Agents; CD4-Positive T-Lymphocytes; Cell Differentiation; Chromatography, High | 2007 |
New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases.
Topics: Aged; Antirheumatic Agents; Cardiomyopathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosu | 2007 |
Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Treatment Refusal | 2008 |
Progressive multifocal leukoencephalopathy in a minimally immunosuppressed patient with systemic lupus erythematosus treated with dapsone.
Topics: Dapsone; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunocompromised Host; Immu | 2008 |
Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences.
Topics: Adult; Age Factors; Antirheumatic Agents; Calcifediol; Cross-Sectional Studies; Fatigue; Female; Hum | 2008 |
Hydroxychloroquine: the cornerstone of lupus therapy.
Topics: Antimalarials; Humans; Hydroxychloroquine; Immunity, Cellular; Lupus Erythematosus, Systemic; Treatm | 2008 |
Tjalma's or pseudo-pseudo-Meigs' syndrome: a case report.
Topics: Adult; Ascites; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Female; Human | 2008 |
Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Inflammation; Informed Consent; Lupu | 2007 |
Systemic lupus erythematosus, celiac disease and antiphospholipid antibody syndrome: a rare association.
Topics: Adult; Antiphospholipid Syndrome; Antirheumatic Agents; Celiac Disease; Diet, Gluten-Free; Female; H | 2008 |
Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Cornea; Eye Diseases; Female; Fluoresceins; H | 1967 |
Static perimetry in chloroquine retinopathy. Perifoveal patterns of visual field depression.
Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 1984 |
Cutaneous mucinosis associated with lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Mid | 1984 |
Non-organic non-psychotic psychopathology (NONPP) in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Biopsy; Blood Sedimentation; Central Nervous Syste | 1981 |
Safety of hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Vision, Ocular | 1982 |
Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Blood Sedimentation; Chronic Disease; Female; Huma | 1982 |
Systemic lupus erythematosus: important considerations in the adolescent.
Topics: Adolescent; Alopecia; Anxiety; Chronic Disease; Depression; Female; Humans; Hydroxychloroquine; Lupu | 1982 |
Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Cohort Studies; Drug Therapy, Combination; Female; Foll | 1995 |
Systemic lupus erythematosus: nephritis, dilated cardiomyopathy, and extensive cutaneous depigmentation responsive to hydroxychloroquine.
Topics: Adult; Cardiomyopathy, Dilated; Humans; Hydroxychloroquine; Hypopigmentation; Lupus Erythematosus, S | 1995 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1995. A 66-year-old man with a history of rheumatoid arthritis treated with adrenocorticosteroids, with the development of aphasia and right-sided weakness.
Topics: Aged; Aphasia; Arthritis, Rheumatoid; Diagnosis, Differential; Fatal Outcome; Hemiplegia; Humans; Hy | 1995 |
Bullous rash and brown urine in a systemic lupus erythematosus patient treated with hydroxychloroquine.
Topics: Adult; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; P | 1995 |
Chromonychia with systemic lupus erythematosus.
Topics: Child; Color; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Nail Diseases; Pred | 1994 |
Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Eye; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 1994 |
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis.
Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Coronary Disease; Female; Humans; Hydroxychloroquin | 1994 |
Lupus and its management.
Topics: Adolescent; Antibiotics, Antineoplastic; Autoantibodies; Azathioprine; Cyclophosphamide; Dose-Respon | 1993 |
Therapy for childhood rheumatic diseases. Have we been doing enough?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Child, Pr | 1993 |
The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Cholesterol, VLDL; Cohort Studies; | 1993 |
Acquired C1 inhibitor deficiency revealing systemic lupus erythematosus.
Topics: Angioedema; Complement C1 Inactivator Proteins; Female; Humans; Hydroxychloroquine; Immunologic Defi | 1993 |
Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 1995 |
Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Follo | 1996 |
Aplastic anemia as the sole presentation of systemic lupus erythematosus.
Topics: Adult; Anemia, Aplastic; Bone Marrow; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Syste | 1996 |
Retinal toxicity in long term hydroxychloroquine treatment.
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Female; Fluorescein Angiography; Humans; Hydroxychloroq | 1996 |
Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.
Topics: Adult; Antirheumatic Agents; Drug Administration Schedule; Female; Humans; Hydroxychloroquine; Lupus | 1996 |
The use of hydroxychloroquine in lupus pregnancy: the British experience.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Disc | 1996 |
Pneumocystis carinii pneumonia after discontinuation of hydroxychloroquine in 2 patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Drug Utilization; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 1996 |
Electronic mail. A physician extender?
Topics: Adult; Computer Communication Networks; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus | 1997 |
Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine.
Topics: Antirheumatic Agents; Apoptosis; Cell Survival; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 1997 |
Should patients on hydroxychloroquine have their eyes examined regularly?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Corneal Diseases; Diagnostic Tests, Routine; Dose-Respo | 1997 |
[The therapy of systemic lupus erythematosus].
Topics: Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retina | 1997 |
Chloroquine and cytokines.
Topics: Biomarkers; Cytokines; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Macrophages; T-Lym | 1997 |
Hydroxychloroquine: past, present, future.
Topics: Antimalarials; Antirheumatic Agents; Clinical Trials as Topic; Humans; Hydroxychloroquine; Lupus Ery | 1998 |
Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
Topics: Adult; Antimalarials; Chloroquine; Data Collection; Female; Humans; Hydroxychloroquine; Lupus Erythe | 1998 |
Hydroxychloroquine myopathy.
Topics: Aged; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myopa | 1998 |
Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloroquine; Female; F | 1998 |
The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Cholesterol; Dose-Response Relationship, Drug; Dru | 1999 |
Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Topics: Adult; Antimalarials; Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Re | 1999 |
[Discoloration of hair under the effect of hyroxychloroquine].
Topics: Adult; Female; Hair; Hair Diseases; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pigme | 1999 |
["Let's walk in the woods"].
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Complement C4; Diagnosis, Differential; Enzyme | 1999 |
Hydroxychloroquine-induced pruritus.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Prur | 1999 |
Hydroxychloroquine overdose: toxicokinetics and management.
Topics: Adolescent; Antimalarials; Area Under Curve; Chromatography, High Pressure Liquid; Drug Overdose; El | 1999 |
Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Apolipoproteins; China; Female; Humans; Hydro | 2000 |
Effect of systemic lupus erythematosus (SLE) treatment drugs on GI-101A breast tumor cell growth.
Topics: Breast Neoplasms; Enzyme Activation; Enzyme Inhibitors; Humans; Hydroxychloroquine; Lupus Erythemato | 2000 |
Crossing of antinuclear antibodies and anti-leishmania antibodies.
Topics: Adult; Antibodies, Antinuclear; Antibodies, Protozoan; Antiphospholipid Syndrome; Antirheumatic Agen | 2000 |
Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus.
Topics: Adolescent; Antirheumatic Agents; Contraindications; Female; Humans; Hydroxychloroquine; Lupus Eryth | 2000 |
Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.
Topics: Absorptiometry, Photon; Activities of Daily Living; Adolescent; Adult; Aged; Bone Density; Child; Co | 2001 |
Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy.
Topics: Adolescent; Adult; Antirheumatic Agents; Female; Heart Block; Humans; Hydroxychloroquine; Lupus Eryt | 2001 |
Sensorineural hearing loss in conjunction with aortic insufficiency in systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Aortic Valve Insufficiency; Female; Glucocorticoids; Hearing Loss, Sens | 2001 |
Middermal elastolysis in two patients with lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Celecoxib; Cutis Laxa; Derm | 2001 |
Reversible blindness resulting from optic chiasmitis secondary to systemic lupus erythematosus.
Topics: Blindness; Color Perception; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosu | 2001 |
Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus.
Topics: Acridine Orange; Adult; Apoptosis; Cell Separation; Cell Survival; Dose-Response Relationship, Drug; | 2001 |
Early hydroxychloroquine macular toxicity.
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Macular Degeneration | 2001 |
Systemic lupus erythematosus: current management.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase | 2001 |
Leflunomide for the treatment of systemic lupus erythematosus: comment on the article by McMurray.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Humans; Hydroxychloroqui | 2001 |
Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia.
Topics: Adolescent; Adult; Aged; Dietary Supplements; Drug Antagonism; Female; Fibromyalgia; Humans; Hydroxy | 2001 |
How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy?
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Dis | 2002 |
Phototoxic maculopathy following uneventful cataract surgery in a predisposed patient.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Macu | 2002 |
[Eye toxicity of antimalarial agents].
Topics: Adult; Antimalarials; Chloroquine; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythemat | 2002 |
Long-term course of chloroquine retinopathy after cessation of medication.
Topics: Adult; Aged; Chloroquine; Color Perception Tests; Female; Fluorescein Angiography; Follow-Up Studies | 1979 |
[Transverse myelopathy and systemic lupus erythematosus. Report of a case and review of the literature].
Topics: Adolescent; Demyelinating Diseases; Dexamethasone; Drug Therapy, Combination; Female; Humans; Hydrox | 1979 |
Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset.
Topics: Adult; Aged; Cyclophosphamide; Diagnosis, Differential; Evaluation Studies as Topic; Female; Fluocin | 1979 |
[Simultaneous incidence of psoriasis and lupus erythematosus and their treatment].
Topics: Adult; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Psoriasis | 1977 |
Porphyria precipitated by hydroxychloroquine treatment of systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Porphyrias | 1976 |
[Lupus nephropathy. Treatment with the indomethacin-hydroxychloroquine combination and comparison with corticoids].
Topics: Adolescent; Adult; Antibodies; Complement System Proteins; Drug Synergism; Drug Therapy, Combination | 1975 |
[Lupus, sicca syndrome and chronic interstitial nephritis. Apropos of a case].
Topics: Adult; Female; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus Erythematosus, Systemic; N | 1992 |
Drug therapy in the rheumatic diseases.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Gold; Huma | 1992 |
Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Drug Administration Schedule; Female; Humans; Hydroxychloroquine; Lupu | 1992 |
Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience.
Topics: Adult; Female; Humans; Hydroxychloroquine; Kidney; Lupus Erythematosus, Systemic; Maryland; Middle A | 1991 |
Hydroxychloroquine retinopathy.
Topics: Electroretinography; Female; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquine; Lupu | 1991 |
Pregnancy outcome following first trimester exposure to chloroquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Arthritis, Rheumatoid; Chloro | 1991 |
Acquired Brown's syndrome in systemic lupus erythematosus: another ocular manifestation.
Topics: Adult; Diclofenac; Diplopia; Fever; Humans; Hydroxychloroquine; Ibuprofen; Lupus Erythematosus, Syst | 1990 |
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Cholesterol; Cholesterol, H | 1990 |
Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus.
Topics: Adult; Chorea; Contraceptives, Oral; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, System | 1989 |
Effect of in vitro ultraviolet radiation on the binding capacity of anti-DNA and DNA in systemic lupus erythematosus.
Topics: Antibodies, Antinuclear; Antibody Affinity; Chromosome Aberrations; DNA; Enzyme-Linked Immunosorbent | 1989 |
Cardiac tamponade in systemic lupus erythematosus.
Topics: Adult; Cardiac Tamponade; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Naproxen; | 1988 |
Antimalarial drugs, systemic lupus erythematosus and pregnancy.
Topics: Abortion, Spontaneous; Antimalarials; Chloroquine; Female; Fetal Death; Humans; Hydroxychloroquine; | 1988 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1988. A 58-year-old woman with fever, sweats, congestive heart failure, and lymphadenopathy after treatment for a diagnosis of systemic lupus erythematosus.
Topics: Bone Marrow; Cardiomyopathies; Diagnosis, Differential; Female; Hodgkin Disease; Humans; Hydroxychlo | 1988 |
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Thrombo | 1987 |
Hydroxychloroquine therapy in massive total doses without retinal toxicity.
Topics: Adult; Arthritis, Rheumatoid; Color Perception; Female; Humans; Hydroxychloroquine; Lupus Erythemato | 1987 |
Keratopathy with low dose chloroquine therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Chemical Phenomena; Chemistry; Chloroquine; Corneal Diseases; Fe | 1986 |
Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy.
Topics: Biopsy; Cardiomyopathies; Chloroquine; Endocardium; Female; Humans; Hydroxychloroquine; Lupus Erythe | 1987 |
Cutaneous lupus erythematosus. Recognition of its many forms.
Topics: Adrenal Cortex Hormones; Adult; Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroq | 1986 |
[Disseminated lupus erythematosus, induced by estrogens. Viral inclusions revealed by renal biopsy].
Topics: Adult; Biopsy; Contraceptives, Oral; Ethinyl Estradiol; Female; Fluorescent Antibody Technique; Huma | 1971 |
Systemic lupus erythematosus with signs of retroperitoneal fibrosis.
Topics: Adolescent; Beta-Globulins; Complement System Proteins; Cyclophosphamide; Female; Glomerulonephritis | 1974 |
The inhibition of antigen-antibody reaction by quinoline derivatives.
Topics: Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Antigen-Antibody Reactions; Arthritis, R | 1974 |
The management of keratoconjuctivitis sicca.
Topics: Anesthetics; Autoimmune Diseases; Bicarbonates; Chloramphenicol; Cysteine; Dextrans; Heparin; Herpes | 1965 |
Auto-immune annular erythema. A variant of lupus erythematosus?
Topics: Antibodies, Antinuclear; Autoimmune Diseases; Biopsy; Blood Protein Electrophoresis; Complement Fixa | 1973 |
Nasal septal perforation in systemic lupus erythematosus.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Epistaxis; Female; Fluorescent Ant | 1974 |
[Acute lupus erythematosus with total absence of the C4 fraction of complement].
Topics: Adolescent; Complement System Proteins; Cortisone; Female; Fluorescent Antibody Technique; Humans; H | 1974 |
Nitroblue tetrazolium dye reduction by peripheral leukocytes from rheumatoid arthritis and systemic lupus erythematosus patients measured by a histochemical and spectrophotometric method.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Histocytochemistry; Humans; Hydroxychloroquine; In V | 1973 |
[Plaquenil in treatment of systemic lupus erythematosus].
Topics: Adolescent; Adult; Drug Evaluation; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 1973 |
[Chloroquine and hydroxychloroquine dosage in juvenile rheumatoid arthritis].
Topics: Administration, Oral; Adolescent; Arthritis, Juvenile; Child; Child, Preschool; Chloroquine; Corneal | 1974 |
Ocular damage in chloroquine therapy.
Topics: Adult; Arthritis, Rheumatoid; Child; Chloroquine; Color Perception Tests; Color Vision Defects; Corn | 1967 |
Immunofluorescent "band" test for lupus erythematosus. II. Employing skin lesions.
Topics: Antibodies, Antinuclear; Basement Membrane; Chloroquine; Collagen Diseases; Fluorescent Antibody Tec | 1970 |
Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine.
Topics: Antibodies, Antinuclear; Autoantibodies; Chloroquine; DNA; Erythema; Humans; Hydralazine; Hydroxychl | 1967 |
Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Color Perception Tests; Electroretinography; Eye Diseases; Eye Movements; Hum | 1970 |
Lupus erythematosus presenting as panniculitis.
Topics: Adult; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; P | 1971 |
Ocular toxicity of antimalarial drugs. Long-term follow-up.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Electrooculography; Electror | 1968 |
Lupus erythematosus and calcinosis cutis.
Topics: Adult; Calcinosis; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; P | 1969 |
[Transitory retinopathy caused by prolonged treatment with hydroxychloroquine sulfate].
Topics: Antimalarials; Arthritis, Rheumatoid; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythe | 1965 |
Drug-induced systemic lupus erythematosus. Primidone as a possible cause.
Topics: Electroencephalography; Epilepsy; Female; Humans; Hydralazine; Hydroxychloroquine; Lupus Erythematos | 1966 |